abstract_id,session_title,abstract_title,ground_truth_raw,ground_truth,approach_3_indication_response,approach_3_success,approach_3_selected_source,approach_3_reasoning,approach_3_rules_retrieved,approach_3_components_identified,approach_3_llm_calls
147482,Myeloproliferative Neoplasms - Clinical,Overall And Progression-Free Survival In Patients Treated With Fedratinib As First-Line Myelofibrosis (Mf) Therapy And After Prior Ruxolitinib (Rux): Results From The Jakarta And Jakarta2 Trials,First-Line;;Myelofibrosis,First-Line Myelofibrosis,First-Line Myelofibrosis;;Previously Treated Myelofibrosis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains a more specific disease term, 'Myelofibrosis (Mf)', compared to the broader 'Myeloproliferative Neoplasms' in the session title. This adheres to the single-source principle.

2.  **Component Identification**: The abstract title contains two distinct patient populations for the disease 'Myelofibrosis':
    *   Patients receiving therapy as 'First-Line'.
    *   Patients treated 'After Prior Ruxolitinib'.

3.  **Rule Retrieval and Application**:
    *   For the 'First-Line' component, I retrieved rules for 'Line of treatment'. The rules (e.g., ID: 198, 200) state that when 'first-line' modifies a therapy or disease concept (as in 'First-Line Myelofibrosis...Therapy'), it should be retained, standardized to 'First-Line', and placed at the beginning of the indication. This leads to the first indication: `First-Line Myelofibrosis`.
    *   For the 'After Prior Ruxolitinib' component, this phrase describes a patient's treatment history. This is a specific instance of a 'Previously Treated' patient subgroup. Rules for 'Treatment Status' confirm that such descriptors should be included. Therefore, this cohort is normalized to `Previously Treated Myelofibrosis`.

4.  **Indication Construction**: The title explicitly separates these two populations with 'And', indicating two distinct groups are being analyzed. Therefore, two separate indications are generated and combined using the ';;' delimiter as required.

5.  **Final Quality Check**: Generic rules were applied. The disease term 'Myelofibrosis' is singular and in Title Case. Procedural details like drug names ('Fedratinib', 'Ruxolitinib') and trial names ('Jakarta', 'Jakarta2') were correctly excluded. The final output accurately reflects the two clinically distinct patient populations described in the abstract title.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly handle the 'First-Line' descriptor and determine if it should be included in the final indication.""}]","[{'component': 'First-Line Myelofibrosis (Mf) Therapy', 'type': 'Disease with Line of Treatment', 'normalized_form': 'First-Line Myelofibrosis', 'rule_applied': ""Rule ID: 200 - Standardize 'first line' to 'First-Line' and place at the beginning of the indication.""}, {'component': 'After Prior Ruxolitinib', 'type': 'Patient Subgroup (Treatment Status)', 'normalized_form': 'Previously Treated', 'rule_applied': 'Generic rule for normalizing specific treatment history to a standard patient subgroup descriptor.'}, {'component': 'Myelofibrosis (Mf)', 'type': 'Disease', 'normalized_form': 'Myelofibrosis', 'rule_applied': 'Generic rule for singular form and title case.'}]",2
180260,"Clonal Hematopoiesis, Aging and Inflammation: Poster I",Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis,RUNX1-Familial Platelet Disorder;;Myeloid Malignancies,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy,RUNX1-Familial Platelet Disorder;;Myeloid Malignancy;;Clonal Hematopoiesis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Genomic Landscape of RUNX1-Familial Platelet Disorder with Myeloid Malignancies Reveals Rising Clonal Hematopoiesis') was chosen over the session title because it contains specific, multiple disease entities, making it the more informative source, adhering to the single-source principle.
2.  **Component Identification**: Three distinct clinical entities were identified in the abstract title:
    a. 'RUNX1-Familial Platelet Disorder'
    b. 'Myeloid Malignancies'
    c. 'Clonal Hematopoiesis'
3.  **Rule Retrieval**: Rules were retrieved for handling multiple diseases, familial qualifiers, and gene names.
    - `Patient with two different Disease`: No specific rule for the connector 'with' was found, defaulting to the generic rule of separating distinct diseases with ';;'.
    - `Patient Sub-Group` for 'Familial': The rules confirm that 'Familial' should be retained as a prefix to the disease it modifies.
    - `Gene Name` for 'RUNX1': The rules indicate that a gene name alone is insufficient, but here 'RUNX1' is an integral part of the specific disorder's name ('RUNX1-Familial Platelet Disorder'), not a standalone biomarker, so it must be retained.
4.  **Rule Application and Construction**:
    - **Indication 1**: 'RUNX1-Familial Platelet Disorder' was kept as is, correctly formatted in Title Case with the gene name preserved.
    - **Indication 2**: 'Myeloid Malignancies' was processed using the generic rule for singularization, converting 'Malignancies' to 'Malignancy', resulting in 'Myeloid Malignancy'.
    - **Indication 3**: 'Clonal Hematopoiesis' was identified as a distinct, well-formed indication and extracted directly.
5.  **Final Assembly**: The three extracted indications were combined into a single string, separated by the required ';;' delimiter, resulting in the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To determine how to handle multiple diseases connected by 'with'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Familial'], 'reason': ""To correctly process the 'Familial' qualifier.""}, {'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To verify the correct formatting for the 'RUNX1' gene name as part of a disease.""}]","[{'component': 'RUNX1-Familial Platelet Disorder', 'type': 'Disease', 'normalized_form': 'RUNX1-Familial Platelet Disorder', 'rule_applied': ""Gene Name rule (retained as part of disease name); Patient Sub-Group rule for 'Familial'.""}, {'component': 'Myeloid Malignancies', 'type': 'Disease', 'normalized_form': 'Myeloid Malignancy', 'rule_applied': 'Generic rule: Singular Form.'}, {'component': 'Clonal Hematopoiesis', 'type': 'Disease', 'normalized_form': 'Clonal Hematopoiesis', 'rule_applied': 'Generic rule: Title Case.'}]",2
262190,Chronic lymphocytic leukemia and related disorders - Clinical,"Nemtabrutinib (Mk-1026), A Non-Covalent Inhibitor Of Wild-Type And C481S Mutated Bruton Tyrosine Kinase For B-Cell Malignancies: Efficacy And Safety Of The Phase 2 Dose-Expansion Bellwave-001 Study",B-Cell Malignancies,B-Cell Malignancy,Wild-Type Bruton Tyrosine Kinase B-Cell Malignancy;;C481S-Mutated Bruton Tyrosine Kinase B-Cell Malignancy,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease term ('B-Cell Malignancies'), making it the preferred source over the session title, according to the single-source principle.
2.  **Component Identification**: The abstract title identifies the core disease as 'B-Cell Malignancies' and specifies two distinct patient subgroups based on genetic status: 'Wild-Type' and 'C481S Mutated Bruton Tyrosine Kinase'.
3.  **Rule Application & Normalization**:
    *   **Disease Term**: The plural 'Malignancies' was converted to its singular form 'Malignancy' as per the generic formatting rules.
    *   **Genetic Status**: The study targets two separate, clinically significant cohorts for the same disease. Therefore, two distinct indications are generated.
    *   The term 'Mutated' is standardized to the hyphenated form '-Mutated' when combined with the specific mutation ('C481S-Mutated').
    *   'Wild-Type' is a standard descriptor and is retained as a prefix.
4.  **Indication Construction**: The genetic status descriptors are prefixed to the normalized disease term to create two precise indications: 'Wild-Type Bruton Tyrosine Kinase B-Cell Malignancy' and 'C481S-Mutated Bruton Tyrosine Kinase B-Cell Malignancy'.
5.  **Final Formatting**: The two distinct indications are separated by the required ';;' delimiter.","[{'category': 'Gene type', 'subcategories': ['Gene Mutation', 'Gene Mutant', 'Gene Mutated'], 'reason': ""To check for specific rules on formatting gene mutations like 'C481S Mutated'. No specific rules were found, so standard formatting was applied.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To check for rules regarding 'Wild-Type' status. No specific rules were found, so the term was kept as is.""}]","[{'component': 'B-Cell Malignancies', 'type': 'Disease', 'normalized_form': 'B-Cell Malignancy', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Wild-Type Bruton Tyrosine Kinase', 'type': 'Patient Subgroup (Genetic Status)', 'normalized_form': 'Wild-Type Bruton Tyrosine Kinase', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'C481S Mutated Bruton Tyrosine Kinase', 'type': 'Patient Subgroup (Genetic Status)', 'normalized_form': 'C481S-Mutated Bruton Tyrosine Kinase', 'rule_applied': 'Standard formatting for gene mutations.'}]",3
327732,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Tandem Duplications of the UBTF gene in Adult AML: A Rare but Recurrent Alteration Associated with Myelodysplasia and Poor Outcome,Adult;;AML,Adult Acute Myeloid Leukemia,Adult UBTF Tandem Duplication Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains a more specific description of the patient population and disease, including the age group, gene, and specific alteration. This adheres to the single-source principle of using the most detailed source.
2.  **Component Identification**: I identified the following key components in the abstract title: 'Adult' (age group), 'AML' (disease), 'Tandem Duplications of the UBTF gene' (genetic alteration), and 'Myelodysplasia' (associated condition).
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category to correctly handle the 'Adult' descriptor.
4.  **Component Analysis and Normalization**:
    *   **Disease**: 'AML' was expanded to its full form 'Acute Myeloid Leukemia' and converted to singular Title Case.
    *   **Age Group**: Based on the retrieved 'Adult' rule (ID: 289), the term 'Adult' was prepended to the indication.
    *   **Genetic Alteration**: 'Tandem Duplications of the UBTF gene' was standardized to 'UBTF Tandem Duplication'. The gene symbol 'UBTF' is kept in its original uppercase form, and the alteration is formatted in Title Case. This component acts as a primary qualifier for the disease.
    *   **Associated Condition**: 'Myelodysplasia' was considered. However, the phrasing 'Associated with Myelodysplasia' indicates it is a characteristic or outcome of the primary disease cohort (Adult AML with UBTF duplication) rather than a separate, parallel indication being studied. Therefore, it was excluded from the final indication string to maintain focus on the core patient group.
    *   **Occurrence**: The term 'Recurrent Alteration' was identified. This describes the nature of the genetic finding itself (i.e., it is a commonly recurring mutation in the population) rather than the patient's disease status (e.g., relapsed/refractory). Thus, it was not included as a disease state qualifier like 'Recurrent'.
5.  **Indication Construction**: The normalized components were assembled in the standard order: Age Group + Genetic Qualifier + Disease. This resulted in 'Adult UBTF Tandem Duplication Acute Myeloid Leukemia'.
6.  **Final Quality Check**: The final indication was checked against all generic rules, including Title Case, singular form, spacing, and exclusion of non-indicative terms ('rare', 'poor outcome'). The output is a single, concise, and clinically accurate indication.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult' patient subgroup descriptor.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Rule ID: 289 - Prepend 'Adult' as the leading age-group descriptor.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule - Expand abbreviation and use singular form.'}, {'component': 'Tandem Duplications of the UBTF gene', 'type': 'Gene Alteration', 'normalized_form': 'UBTF Tandem Duplication', 'rule_applied': 'Generic Rule - Standardize gene alteration format, keeping gene symbol in uppercase.'}, {'component': 'Myelodysplasia', 'type': 'Associated Condition', 'normalized_form': 'N/A (Excluded)', 'rule_applied': 'Generic Rule - Exclude non-diagnostic items. The term was identified as an associated feature, not the primary disease of the study cohort.'}]",2
147511,Stem Cell Transplantation - Clinical,Narsoplimab (Oms721) Treatment Contributes To Improvements In Organ Function In Adult Patients With High-Risk Transplant-Associated Thrombotic Microangiopathy,,,Adult High-Risk Transplant-Associated Thrombotic Microangiopathy,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Transplant-Associated Thrombotic Microangiopathy'), whereas the session title is a broad category.
2. **Component Identification**: The key components identified in the abstract title were 'Adult Patients', 'High-Risk', and 'Transplant-Associated Thrombotic Microangiopathy'.
3. **Rule Retrieval**: I retrieved rules for 'Age Group' (for 'Adult'), 'Risk' (for 'High-Risk'), and 'Treatment Set-up' (to verify handling of 'Transplant-Associated').
4. **Rule Application**:
   - **Age Group**: The rule for 'Adult' (ID: 289) directs to prepend the capitalized term 'Adult' to the indication.
   - **Risk**: The rule for 'High-Risk' (ID: 122) directs to normalize the term to 'High-Risk' and place it before the disease name.
   - **Disease Name**: 'Transplant-Associated Thrombotic Microangiopathy' is a specific clinical syndrome. The qualifier 'Transplant-Associated' is integral to the disease name and is not a simple procedural qualifier to be excluded. Therefore, it was retained as part of the core indication.
   - **Generic Rules**: Title Case was applied, and the disease term was confirmed to be in singular form.
5. **Indication Construction**: The components were assembled in the standard order: Age Group -> Risk -> Disease. This resulted in 'Adult High-Risk Transplant-Associated Thrombotic Microangiopathy'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult Patients' descriptor.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To standardize the 'High-Risk' descriptor.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine if 'Transplant-Associated' should be excluded as a procedural qualifier. It was determined to be integral to the disease name.""}]","[{'component': 'Adult Patients', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule ID: 289'}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule ID: 122'}, {'component': 'Transplant-Associated Thrombotic Microangiopathy', 'type': 'Disease', 'normalized_form': 'Transplant-Associated Thrombotic Microangiopathy', 'rule_applied': 'Generic rule: Retain integral disease qualifiers. Title Case.'}]",2
213047,Geriatric Urological Society (GUS),Parkinson's Disease and the Impact on Urologic Health in Older Adults,Parkinson's Disease;;Older Adults,Elderly Parkinson's Disease,Older Adult Parkinson's Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Parkinson's Disease and the Impact on Urologic Health in Older Adults') was chosen because it contains a specific disease ('Parkinson's Disease'), which is preferred over the session title ('Geriatric Urological Society (GUS)').
2. **Component Identification**: The selected title contains the disease 'Parkinson's Disease' and the patient subgroup 'Older Adults'. The phrase 'Urologic Health' was identified as a general physiological area, not a specific disease, and was excluded per the 'Non-Diagnostic Items' rule.
3. **Rule Retrieval**: To standardize the age group descriptor 'Older Adults', I retrieved rules for the 'Age Group' category, specifically for 'Elderly' and related terms.
4. **Rule Application**: The retrieved rule (ID: 331) for 'Older adult' specifies normalizing the term to the capitalized, singular form 'Older Adult' and placing it at the beginning of the indication. Generic rules for Title Case and singular form were also applied.
5. **Indication Construction**: The normalized patient subgroup 'Older Adult' was prepended to the disease 'Parkinson's Disease' to form the final indication.
6. **Quality Check**: The final indication adheres to the single-source principle, correctly applies formatting rules, includes the relevant patient subgroup, and excludes non-diagnostic information, ensuring clinical accuracy.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To find the correct standardization for the term 'Older Adults'.""}]","[{'component': ""Parkinson's Disease"", 'type': 'Disease', 'normalized_form': ""Parkinson's Disease"", 'rule_applied': 'Generic Casing Rule'}, {'component': 'Older Adults', 'type': 'Age Group', 'normalized_form': 'Older Adult', 'rule_applied': ""Age Group Rule (ID: 331) for 'Older adult' and Generic Singular Form Rule.""}, {'component': 'Urologic Health', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items.'}]",2
327741,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITDhighbut Not FLT3-ITDlow and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age,NPM1;;Mutant;;AML,NPM1-Mutant Acute Myeloid Leukemia,NPM1-Mutated Acute Myeloid Leukemia;;FLT3-ITD-High Acute Myeloid Leukemia;;FLT3-ITD-Low Acute Myeloid Leukemia;;FLT3-TKD-Mutated Acute Myeloid Leukemia;;Elderly Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title because it contains more specific information about the disease, including genetic mutations and patient subgroups (NPM1, FLT3, age), making it the primary source according to the single-source principle.
2.  **Component Identification**: The abstract title was parsed to identify the core disease and several distinct patient subgroups:
    *   Core Disease: 'AML' (Acute Myeloid Leukemia).
    *   Genetic Subgroup 1: 'NPM1 Mutant'.
    *   Genetic Subgroup 2: 'FLT3-ITDhigh'.
    *   Genetic Subgroup 3: 'FLT3-ITDlow'.
    *   Genetic Subgroup 4: 'FLT3-TKD'.
    *   Age Subgroup: 'Patients over 60 Years of Age'.
3.  **Rule Retrieval**: To standardize these components, rules were retrieved for 'Gene type' (to handle mutations like 'Mutant', 'high', 'low') and 'Age Group' (to handle 'over 60').
4.  **Rule Application and Normalization**:
    *   'AML' was expanded to its full name 'Acute Myeloid Leukemia' and standardized to Title Case.
    *   'NPM1 Mutant' was normalized to 'NPM1-Mutated' based on the 'Gene Mutant' rule (ID: 31).
    *   'FLT3-ITDhigh' was normalized to 'FLT3-ITD-High' based on the 'Gene High' rule (ID: 34).
    *   'FLT3-ITDlow' was normalized to 'FLT3-ITD-Low' based on the 'Gene Low' rule (ID: 33).
    *   'FLT3-TKD' refers to a Tyrosine Kinase Domain mutation and was standardized to 'FLT3-TKD-Mutated' for clinical clarity and consistency.
    *   'over 60 Years of Age' was normalized to 'Elderly' based on the 'Above 60' age group rule (ID: 303).
5.  **Indication Construction**: Each identified subgroup was combined with the core disease to form a distinct, clinically valid indication. The title discusses these as separate cohorts or factors of interest within the AML patient population.
6.  **Final Formatting**: The multiple distinct indications were formatted in Title Case, using the singular form for the disease, and separated by the required ';;' delimiter, resulting in the final generated output.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the genetic markers 'NPM1 Mutant', 'FLT3-ITDhigh', and 'FLT3-ITDlow'.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To standardize the age descriptor 'over 60 Years of Age'.""}]","[{'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Disease Normalization'}, {'component': 'NPM1 Mutant', 'type': 'Gene Mutation', 'normalized_form': 'NPM1-Mutated', 'rule_applied': ""Gene type rule (ID: 31) for 'Gene Mutant'""}, {'component': 'FLT3-ITDhigh', 'type': 'Gene Expression', 'normalized_form': 'FLT3-ITD-High', 'rule_applied': ""Gene type rule (ID: 34) for 'Gene High'""}, {'component': 'FLT3-ITDlow', 'type': 'Gene Expression', 'normalized_form': 'FLT3-ITD-Low', 'rule_applied': ""Gene type rule (ID: 33) for 'Gene Low'""}, {'component': 'FLT3-TKD', 'type': 'Gene Mutation', 'normalized_form': 'FLT3-TKD-Mutated', 'rule_applied': 'Standardization for Tyrosine Kinase Domain mutations'}, {'component': 'over 60 Years of Age', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule (ID: 303) for 'Above 60'""}]",2
294973,MSD - Navigating through the rapidly evolving treatment landscape for GI Cancers - A Clinical & Patient Centric Approach towards implementing Immunotherapy,Changing GEC Patient Care with IO plus Chemotherapy in First-Line,GI Cancers;;First-Line,First-Line Gastrointestinal Cancer,First-Line Gastroesophageal Cancer,True,abstract_title,"Step 1: The abstract title ('Changing GEC Patient Care with IO plus Chemotherapy in First-Line') was chosen as the source because it contains a specific disease term ('GEC'), taking precedence over the session title ('GI Cancers') as per the single-source principle.
Step 2: The components identified in the abstract title were the disease 'GEC' and the treatment context 'First-Line'.
Step 3: Rules for 'Line of treatment' were retrieved to correctly handle 'First-Line'. Rule 200 dictates that 'First-Line' should be standardized and placed at the beginning of the indication when it describes the treatment setting for the disease, rather than a specific drug.
Step 4: The abbreviation 'GEC' was expanded to its full clinical term 'Gastroesophageal Cancer'.
Step 5: Generic formatting rules were applied, converting the final indication to Title Case and ensuring singular form.
Step 6: The final indication was constructed by combining the standardized treatment line with the normalized disease name, resulting in 'First-Line Gastroesophageal Cancer'.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine the correct handling and formatting of the 'First-Line' keyword.""}]","[{'component': 'GEC', 'type': 'Disease', 'normalized_form': 'Gastroesophageal Cancer', 'rule_applied': 'Standard medical abbreviation expansion.'}, {'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Rule 200 for 'First-Line' treatment context.""}]",2
147521,Thrombosis And Vascular Biology - Biology & Translational Research,Thrombophilia As Risk Factor For Asparaginase Related Venous Thromboembolism In Pediatric And Young Adult Patients Affected By Acute Lymphoblastic Leukemia,Venous Thromboembolism;;Pediatric;;Young Adult,Pediatric Young Adult Venous Thromboembolism,Pediatric Acute Lymphoblastic Leukemia;;Young Adult Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains specific disease terms ('Thrombophilia', 'Venous Thromboembolism', 'Acute Lymphoblastic Leukemia'), making it the definitive source over the more general session title.
2.  **Component Identification**: The abstract title identifies a primary disease and patient subgroups. The core disease the patients are 'affected by' is 'Acute Lymphoblastic Leukemia'. The patient population is specified as 'Pediatric And Young Adult'. 'Thrombophilia' is identified as a risk factor and 'Venous Thromboembolism' as a treatment-related complication, not the primary indications defining the patient cohort.
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' to handle 'Pediatric' and 'Young Adult'. The rules confirm that age-group qualifiers should be prepended to the disease name.
4.  **Indication Construction**: Based on the analysis, the core indication is the primary disease qualified by the distinct age groups. This results in two separate indications:
    *   'Pediatric' + 'Acute Lymphoblastic Leukemia' -> 'Pediatric Acute Lymphoblastic Leukemia'
    *   'Young Adult' + 'Acute Lymphoblastic Leukemia' -> 'Young Adult Acute Lymphoblastic Leukemia'
5.  **Formatting**: The two indications are combined using the required ';;' separator. All terms are converted to Title Case, and disease names are in singular form as per generic rules.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine how to handle the multiple conditions mentioned (Thrombophilia, VTE, ALL).'}, {'category': 'Age Group', 'subcategories': ['Pediatric', 'Young Adult'], 'reason': ""To correctly format the age group descriptors 'Pediatric' and 'Young Adult'.""}]","[{'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule: Use as primary disease.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule: Prepend to the disease name.'}, {'component': 'Young Adult', 'type': 'Age Group', 'normalized_form': 'Young Adult', 'rule_applied': 'Age Group rule: Prepend to the disease name.'}, {'component': 'Thrombophilia', 'type': 'Risk Factor', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-primary disease/risk factors.'}, {'component': 'Venous Thromboembolism', 'type': 'Complication', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude complications/adverse effects.'}]",2
180300,Bone Marrow Failure: Poster I,Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry,Adult;;Late-Onset;;Telomere Biology Disorders,Adult Late-Onset Telomere Biology Disorder,Adult Late Onset Telomere Biology Disorder,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Clinical Presentation of Patients with Adult Late-Onset Telomere Biology Disorders - Results from the Aachen Telomeropathy Registry') was chosen over the session title ('Bone Marrow Failure: Poster I') because it contains a more specific and complete disease description, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were the age group 'Adult', the onset qualifier 'Late-Onset', and the disease term 'Telomere Biology Disorders'. The term 'Telomeropathy' was noted but identified as describing the registry, not the specific patient condition being presented.
3. **Rule Retrieval**: To ensure correct formatting, rules for 'Age Group' (specifically 'Adult') and 'Onset' (specifically 'Onset by Time' for 'Late-Onset') were retrieved using the `get_indication_rules` tool.
4. **Rule Application**:
   - **Generic Rules**: The plural 'Disorders' was converted to its singular form 'Disorder'. The final output was formatted to Title Case.
   - **Age Group Rule (ID: 289)**: Confirmed that 'Adult' should be used as a capitalized prefix.
   - **Onset Rule (ID: 287)**: Confirmed that 'Late-Onset' should be normalized to 'Late Onset' (hyphen removed, Title Case).
5. **Indication Construction**: The identified and normalized components were combined in the correct order (Age Group -> Onset -> Disease) to form the final indication: 'Adult Late Onset Telomere Biology Disorder'.
6. **Exclusion**: Non-diagnostic information such as 'Clinical Presentation of Patients with' and 'Results from the Aachen Telomeropathy Registry' was excluded as per the generic rules.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To validate the formatting and placement of the 'Adult' age group descriptor.""}, {'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To correctly normalize and format the 'Late-Onset' term.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group Rule ID: 289'}, {'component': 'Late-Onset', 'type': 'Onset Qualifier', 'normalized_form': 'Late Onset', 'rule_applied': 'Onset Rule ID: 287'}, {'component': 'Telomere Biology Disorders', 'type': 'Disease', 'normalized_form': 'Telomere Biology Disorder', 'rule_applied': 'Generic Rule: Singular Form'}]",2
327760,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies,Newly Diagnosed;;IDH;;TP53;;Co-Mutated;;AML,Newly Diagnosed IDH-Mutated TP53-Mutated Acute Myeloid Leukemia,Newly Diagnosed IDH/TP53 Co-Mutated Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('AML') and provides more detailed patient subgroup information than the session title, following the single-source principle.
2. **Component Identification**: The following components were identified in the abstract title: 'Newly Diagnosed' (diagnosis status), 'IDH/TP53 Co-Mutated' (genetic markers), and 'AML' (disease).
3. **Rule Retrieval**: I retrieved rules for 'Diagnosis Status' to handle 'Newly Diagnosed' and for 'Gene type' to understand the standard formatting for mutations.
4. **Rule Application and Normalization**:
   - **Disease**: The abbreviation 'AML' was expanded to its full form 'Acute Myeloid Leukemia' based on common clinical knowledge, which is also supported by the session title. The generic rule for singularization was applied.
   - **Diagnosis Status**: The rule for 'Newly Diagnosed' (Rule ID: 193) was applied, which specifies prefixing this term to the indication.
   - **Genetic Markers**: The term 'IDH/TP53 Co-Mutated' was identified as a key patient subgroup. While specific rules for 'Co-Mutated' were not present, the general principle from 'Gene type' rules is to preserve clinically significant mutation details. The term was retained, and Title Case was applied, keeping the gene symbols 'IDH' and 'TP53' in their original uppercase form as per casing rules.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order: Diagnosis Status + Genetic Markers + Disease. This resulted in 'Newly Diagnosed IDH/TP53 Co-Mutated Acute Myeloid Leukemia'.
6. **Quality Check**: The final indication was checked against all generic rules. It adheres to the single-source principle, uses Title Case, is in singular form, and correctly includes all relevant patient subgroup information without incorporating any excluded terms.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly handle the 'Newly Diagnosed' component.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To understand the standard formatting for genetic mutations like 'Co-Mutated'.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule 193 for 'Newly Diagnosed' from 'Treatment based' category.""}, {'component': 'IDH/TP53 Co-Mutated', 'type': 'Gene Mutation', 'normalized_form': 'IDH/TP53 Co-Mutated', 'rule_applied': 'Generic Title Case rule and preservation of specific clinical terminology for co-mutations.'}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and singularization rule.'}]",2
311376,"Abstracts: RA - Diagnosis, Manifestations, and Outcomes I: Pre- and Early Disease",Sputum RA-Associated Autoantibodies Independently Associate with Future Development of Classified RA in an At-Risk Cohort of Individuals with Systemic Anti-CCP Positivity,RA ,Rheumatoid Arthritis,Anti-CCP-Positive Rheumatoid Arthritis,True,abstract_title,"The abstract title was chosen as the source because it contains the specific disease 'RA' (Rheumatoid Arthritis) and a key patient subgroup defined by a biomarker. The term 'RA' was expanded to 'Rheumatoid Arthritis'. The patient subgroup 'Individuals with Systemic Anti-CCP Positivity' was identified and normalized to the standard clinical format 'Anti-CCP-Positive'. The term 'At-Risk Cohort' was excluded as it describes the study population rather than being a part of the clinical indication itself. The final indication combines the biomarker status with the disease name, adhering to standard formatting rules.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine how to handle the term 'At-Risk'. The rules confirmed it is not a standard clinical risk stratification, leading to its exclusion.""}]","[{'component': 'RA', 'type': 'Disease', 'normalized_form': 'Rheumatoid Arthritis', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'At-Risk Cohort', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic study cohort descriptors.'}, {'component': 'Systemic Anti-CCP Positivity', 'type': 'Biomarker', 'normalized_form': 'Anti-CCP-Positive', 'rule_applied': 'Standard normalization for biomarker positivity status.'}]",2
229467,Vaccines and Immunity against Bacteria and Parasites,"The novel adjuvant, ADA-1, restores age-associated defects in the adaptive immune response to Clostridioides difficile infection and vaccination in an aging mouse model",Clostridioides difficile infection,Clostridioides Difficile Infection,Elderly Clostridioides Difficile Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Clostridioides difficile infection', whereas the session title is general.
2. **Component Identification**: The abstract title contains the disease 'Clostridioides difficile infection' and the patient subgroup context 'age-associated' and 'aging mouse model'.
3. **Rule Retrieval**: Rules for 'Age Group' were retrieved to standardize the age-related terms. The term 'aging' is conceptually similar to keywords like 'Older' or 'Advanced age' which map to the standardized term 'Elderly'.
4. **Component Analysis & Normalization**:
   - The disease 'Clostridioides difficile infection' was normalized to 'Clostridioides Difficile Infection' using Title Case, as per generic formatting rules.
   - The context 'age-associated' and 'aging' was interpreted as representing an elderly patient population. Based on the pattern from retrieved rules for similar terms, this was standardized to the prefix 'Elderly'.
   - The phrase 'mouse model' was excluded as it refers to the study methodology (a pre-clinical model) and not a clinically valid human indication.
5. **Indication Construction**: The standardized age group 'Elderly' was prepended to the normalized disease name to form the final indication.
6. **Final Quality Check**: The resulting indication 'Elderly Clostridioides Difficile Infection' adheres to all formatting and content rules. It is singular, in Title Case, and correctly represents the clinical condition and patient subgroup described in the source.","[{'category': 'Age Group', 'subcategories': ['Elderly', 'Young', 'Adult', 'Pediatric', 'Adolescent', 'Childhood', 'Juvenile', 'Non-Elderly'], 'reason': ""To standardize the terms 'age-associated' and 'aging' into a recognized clinical age group.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for any rules related to disease characterization that might apply.'}]","[{'component': 'Clostridioides difficile infection', 'type': 'Disease', 'normalized_form': 'Clostridioides Difficile Infection', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'age-associated, aging', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule pattern (mapping terms like 'Older', 'Advanced age' to 'Elderly')""}, {'component': 'mouse model', 'type': 'Methodology', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude non-diagnostic items (study methodologies)'}]",2
213104,Quality Improvement Summit: Laying the Foundation for Primary Palliative Care in Urology,What Clinical Innovations and Other Interventions Are Needed?,,,Urologic Disease,True,session_title,"Step 1: The abstract title 'What Clinical Innovations and Other Interventions Are Needed?' contains no disease or condition terms. 
Step 2: The session title 'Quality Improvement Summit: Laying the Foundation for Primary Palliative Care in Urology' contains the therapeutic area 'Urology'.
Step 3: According to the Single-Source Extraction Principle, the session title is selected as the source.
Step 4: The generic rule for 'Therapeutic Area Fallback' is applied. The therapeutic area 'Urology' is converted to the overarching disease 'Urologic Disease'.
Step 5: Formatting rules (Title Case, singular form) are applied, resulting in the final indication 'Urologic Disease'.",[],"[{'component': 'Urology', 'type': 'Therapeutic Area', 'normalized_form': 'Urologic Disease', 'rule_applied': 'Therapeutic Area Fallback'}]",1
229493,Vaccination and immunotherapy against COVID-19,Pan-coronavirus neutralizing S2 human monoclonal antibodies and utility of direct respiratory administration as combination therapy with S1 antibodies against SARS-CoV-2,SARS-CoV-2,SARS-CoV-2 Infection,COVID-19,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title mentions ""SARS-CoV-2"" and the session title mentions ""COVID-19"". Both refer to the same disease entity.
2. **Select Source**: Following the single-source principle, the abstract title is selected as it contains a specific disease-related term (""SARS-CoV-2"").
3. **Identify Components**: The key component identified in the abstract title is the pathogen ""SARS-CoV-2"". No patient subgroups or other qualifiers are present.
4. **Retrieve Rules**: No specific category rules were required. The extraction relies on general knowledge and generic rules.
5. **Apply Rules & Construct Indication**: The pathogen name ""SARS-CoV-2"" is normalized to its corresponding clinical disease name, ""COVID-19"", which is standard practice for creating medical indications. The session title helps confirm this context. The generic rule for Title Case is applied, resulting in ""COVID-19"".
6. **Quality Check**: The final indication is clinically accurate, follows formatting rules, and is correctly derived from the selected source.",[],"[{'component': 'SARS-CoV-2', 'type': 'Pathogen', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic Rule: Normalization of pathogen name to the corresponding disease name for clinical indication.'}]",2
393337,Germ Cell (Testicular) Cancer And Penile Cancer,Efficacy And Safety Of High-Dose Chemotherapy As Second Or Subsequent Salvage Therapy In Relapsed Or Refractory Germ Cell Cancer Patients: A Multicentric Analysis,Relapsed;;Refractory;;Germ Cell Cancer,Relapsed or Refractory Germ Cell Cancer,Second-Line Relapsed/Refractory Germ Cell Cancer;;Later-Line Relapsed/Refractory Germ Cell Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title as it contains a more specific description of the patient population and disease state, adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were the disease ('Germ Cell Cancer'), the disease state ('Relapsed or Refractory'), and the treatment context ('Second or Subsequent Salvage Therapy').
3.  **Rule Retrieval**: Rules for 'Occurrence' (specifically 'Relapsed' and 'Refractory') and 'Treatment Set-up' (specifically 'Line of treatment') were retrieved to guide standardization.
4.  **Rule Application & Standardization**:
    *   **Disease**: 'Germ Cell Cancer Patients' was converted to its singular form, 'Germ Cell Cancer'.
    *   **Occurrence**: The phrase 'Relapsed or Refractory' was standardized to the combined form 'Relapsed/Refractory' based on common clinical terminology and the principles in the retrieved rules.
    *   **Line of Treatment**: The phrase 'Second Or Subsequent' indicates two distinct treatment settings. Following the pattern of rules like Rule 204 (for 'Third- or later-line'), this was split into two separate indications. 'Second' was standardized to 'Second-Line', and 'Subsequent' was standardized to the more common term 'Later-Line'.
    *   **Exclusion**: The term 'Salvage Therapy' was excluded as it describes a procedural/temporal context rather than being a core part of the indication itself, similar to how 'adjuvant' or 'neoadjuvant' are excluded.
5.  **Indication Construction**: The standardized components were assembled into two distinct indications to accurately capture the full scope of the patient cohort: 'Second-Line Relapsed/Refractory Germ Cell Cancer' and 'Later-Line Relapsed/Refractory Germ Cell Cancer'.
6.  **Final Formatting**: The two indications were joined using the required ';;' separator, and all terms were formatted in Title Case.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Relapse', 'Refractory'], 'reason': ""To correctly handle and standardize the terms 'Relapsed or Refractory'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly handle and standardize the treatment context 'Second Or Subsequent Salvage Therapy'.""}]","[{'component': 'Germ Cell Cancer', 'type': 'Disease', 'normalized_form': 'Germ Cell Cancer', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Relapsed Or Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for combining relapsed and refractory states.'}, {'component': 'Second Or Subsequent', 'type': 'Line of treatment', 'normalized_form': 'Second-Line;;Later-Line', 'rule_applied': 'Treatment Set-up rule for handling multiple lines of therapy (e.g., Rule 204 pattern).'}, {'component': 'Salvage Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of procedural/temporal qualifiers.'}]",2
376961,Acute myeloid leukemia - Clinical,Lifetime Clinical Outcomes Of Cpx-351 Versus 7+3 Modeled From The 5-Year Results Of A Randomized Phase 3 Trial For Older Adults With Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia,Older Adults;;Newly Diagnosed;;High-Risk;;Secondary;;Acute Myeloid Leukaemia,Elderly Newly Diagnosed High-Risk Secondary Acute Myeloid Leukaemia,Elderly Newly Diagnosed High-Risk Acute Myeloid Leukemia;;Elderly Newly Diagnosed Secondary Acute Myeloid Leukemia,True,abstract_title,"The abstract title was chosen as the source because it contains more specific information than the session title. The title describes a study in 'Older Adults with Newly Diagnosed High-Risk Or Secondary Acute Myeloid Leukaemia'. The 'or' indicates two distinct patient populations, leading to the extraction of two separate indications. I identified the following components: 'Older Adults' (age group), 'Newly Diagnosed' (diagnosis status), 'High-Risk' (risk level), 'Secondary' (disease origin), and 'Acute Myeloid Leukaemia' (disease). I retrieved rules for each component to ensure proper normalization. 'Older Adults' was standardized to 'Elderly' and placed at the beginning. 'High-Risk' and 'Secondary' were treated as distinct qualifiers for 'Acute Myeloid Leukemia'. The two resulting indications were combined using the ';;' separator as required.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To normalize the term 'Older Adults'.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To confirm the handling of 'Newly Diagnosed'.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To standardize the term 'High-Risk'.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To determine the correct handling of 'Secondary' as a disease qualifier.""}]","[{'component': 'Older Adults', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule for 'Older' (ID: 302) standardizes 'older adults' to 'Elderly'.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Treatment based rule for 'Newly Diagnosed' (ID: 193) confirms its inclusion.""}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': ""Risk rule for 'High-Risk' (ID: 122) confirms its format.""}, {'component': 'Secondary', 'type': 'Disease State', 'normalized_form': 'Secondary', 'rule_applied': ""Generic rule for 'Secondary' indicates inclusion when part of the disease name.""}, {'component': 'Acute Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for singular form and standardized spelling.'}]",2
295042,Proffered Paper session: Policy and preventive strategies,Invited Discussant 1312O and 1313O,,,,True,none,"Neither the abstract title ('Invited Discussant 1312O and 1313O') nor the session title ('Proffered Paper session: Policy and preventive strategies') contains any specific disease, condition, or therapeutic area. The titles are administrative and do not provide any clinical information from which to extract a medical indication.",[],[],1
311433,"Abstracts: SLE - Diagnosis, Manifestations, and Outcomes II: Complications",Overall and Post-vaccination Prevalence of Severe COVID-19-related Events Among Commercially Insured Patients with Systemic Lupus Erythematosus and the General U.S. Population,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Severe COVID-19;;Systemic Lupus Erythematosus,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title contains 'Severe COVID-19' and 'Systemic Lupus Erythematosus'. The session title contains 'SLE' (Systemic Lupus Erythematosus). Both titles contain valid disease terms.
2. **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred as it contains the disease terms. The session title is therefore ignored.
3. **Identify Components**: From the abstract title, two distinct medical conditions were identified: 'Severe COVID-19' and 'Systemic Lupus Erythematosus'. Other descriptors like 'Post-vaccination', 'Commercially Insured Patients', and 'General U.S. Population' were identified as exclusions based on generic rules (procedural/temporal, non-clinical, and sociodemographic).
4. **Retrieve Rules**: I retrieved rules for 'Risk' (subcategory 'severe') and 'Occurrence' (subcategory 'Disease State/Severity') to confirm how to handle the term 'Severe'. I also checked for rules regarding multiple diseases ('Patient with two different Disease') but found none, defaulting to the generic rule.
5. **Apply Rules & Construct Indication**: 
   - The generic rule for multiple diseases was applied, requiring both conditions to be extracted and separated by ';;'.
   - For 'Severe COVID-19', 'Severe' is a valid clinical descriptor of the disease state and was retained. The term was already in correct Title Case.
   - For 'Systemic Lupus Erythematosus', the term was already in correct Title Case and singular form.
   - The two indications were combined using the ';;' separator.
6. **Quality Check**: The final output adheres to all formatting and exclusion rules. It correctly captures the two distinct conditions from the source title without mixing information from the session title.","[{'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To validate the handling of the term 'Severe' as a disease qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for rules related to disease severity descriptors like 'Severe'.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on how to handle multiple diseases mentioned in the same context.'}]","[{'component': 'Severe COVID-19', 'type': 'Disease', 'normalized_form': 'Severe COVID-19', 'rule_applied': 'Generic Rule: Title Case, Multiple Diseases'}, {'component': 'Systemic Lupus Erythematosus', 'type': 'Disease', 'normalized_form': 'Systemic Lupus Erythematosus', 'rule_applied': 'Generic Rule: Title Case, Multiple Diseases'}, {'component': 'Post-vaccination', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}, {'component': 'Commercially Insured Patients', 'type': 'Non-clinical descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}, {'component': 'General U.S. Population', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule'}]",2
311449,Abstracts: SLE - Treatment,Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus,Systemic Lupus Erythematosus Flare,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizations for Systemic Lupus Erythematosus Flares'. The session title is 'Abstracts: SLE - Treatment'.
2. **Select Source**: The abstract title contains the full disease name 'Systemic Lupus Erythematosus', making it the preferred source over the session title which uses the abbreviation 'SLE'.
3. **Identify Components**: The core disease identified is 'Systemic Lupus Erythematosus'. The term 'Flares' is identified as a descriptor of the disease state or severity.
4. **Retrieve Rules**: I retrieved rules for 'Disease State/Severity' to see if 'Flares' had a specific handling rule. No specific rule was found for 'Flares', so I proceeded with generic rules.
5. **Apply Rules & Construct Indication**: 
   - The core disease is 'Systemic Lupus Erythematosus'.
   - The qualifier 'Flares' is a clinically significant descriptor of the disease state.
   - Applying the 'Singular Form' generic rule, 'Flares' is converted to 'Flare'.
   - Applying the 'Title Case' generic rule, the components are capitalized correctly.
   - Information about drug dosing ('Hydroxychloroquine Dosing Less Than 5 Mg/kg/day') and outcomes ('Increased Hospitalizations') are excluded as they are not part of the core indication.
   - The final indication is constructed by combining the disease and the state: 'Systemic Lupus Erythematosus Flare'.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.","[{'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for specific rules on handling disease state descriptors like 'Flares'.""}]","[{'component': 'Systemic Lupus Erythematosus', 'type': 'Disease', 'normalized_form': 'Systemic Lupus Erythematosus', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Flares', 'type': 'Disease State', 'normalized_form': 'Flare', 'rule_applied': 'Generic Rule: Singular Form'}]",2
409754,Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases,Audience Q&A,,,Complement-Mediated Kidney Disease,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title 'Audience Q&A' contains no medical information. The session title 'Regulating the Regulator: Exploring the Therapeutic Landscape for Complement-Mediated Kidney Diseases' contains a clear disease term.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the session title is selected as the source because the abstract title lacks a disease term.
3.  **Identify Components**: The key phrase identified in the session title is 'Complement-Mediated Kidney Diseases'. 'Complement-Mediated' is a clinically significant characterization of the disease.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to check for any specific handling of this type of descriptor. No specific rule applied directly to 'Complement-Mediated', so I proceeded with generic rules.
5.  **Apply Generic Rules**:
    *   **Singular Form**: The plural 'Diseases' was converted to its singular form, 'Disease'.
    *   **Title Case**: The phrase was already in proper Title Case.
    *   **Exclusion Rules**: No terms for exclusion (e.g., sociodemographic, procedural) were present.
6.  **Construct Indication**: The components were combined according to the rules, resulting in 'Complement-Mediated Kidney Disease'.
7.  **Quality Check**: The final indication is clinically accurate, correctly formatted, and derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if any specific rules apply to disease characterizations like 'Complement-Mediated'.""}]","[{'component': 'Complement-Mediated Kidney Diseases', 'type': 'Disease', 'normalized_form': 'Complement-Mediated Kidney Disease', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}]",2
393371,Gynaecological Cancers,Ccne1 Amplification Defines A Good Prognostic Subgroup Among Brcawt/Hrdneg Advanced High-Grade Ovarian Cancer (Hgoc),Advanced;;High-Grade;;Ovarian Cancer,Advanced High-Grade Ovarian Cancer,CCNE1-Amplified BRCA Wild-Type HRD-Negative Advanced High Grade Ovarian Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Ccne1 Amplification Defines A Good Prognostic Subgroup Among Brcawt/Hrdneg Advanced High-Grade Ovarian Cancer (Hgoc)' was chosen as it contains a specific disease ('Ovarian Cancer'), which is more precise than the session title 'Gynaecological Cancers'.
2. **Component Identification**: I identified several key components in the abstract title: a gene amplification ('Ccne1 Amplification'), genetic/biomarker statuses ('Brcawt' for BRCA wild-type, 'Hrdneg' for HRD-negative), a stage descriptor ('Advanced'), a grade descriptor ('High-Grade'), and the disease ('Ovarian Cancer').
3. **Rule Retrieval**: I retrieved rules for Gene Name, Biomarker, Stage, and Grade to ensure correct normalization and formatting.
4. **Rule Application and Normalization**:
   - **Gene**: Based on Gene Name rules (e.g., Rule 27), 'Ccne1 Amplification' was normalized to 'CCNE1-Amplified', using the standard uppercase gene symbol and hyphenated qualifier.
   - **Biomarkers**: 'Brcawt' was interpreted and normalized to 'BRCA Wild-Type'. 'Hrdneg' was normalized to 'HRD-Negative'. The slash in 'Brcawt/Hrdneg' indicates a combined subgroup, which I've represented as two distinct qualifiers.
   - **Stage**: 'Advanced' was kept as a standard stage descriptor, formatted in Title Case.
   - **Grade**: Based on Grade Rule 115, 'High-Grade' was normalized to 'High Grade' (no hyphen).
   - **Disease**: 'Ovarian Cancer' was used in its singular form as required.
5. **Indication Construction**: The normalized components were assembled in the standard order of [Gene/Biomarker Statuses] [Stage] [Grade] [Disease]. This resulted in the final indication, which precisely defines the patient subgroup described in the title.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To correctly format the 'Ccne1 Amplification' component.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To understand how to handle biomarker statuses like 'Brcawt' (BRCA wild-type) and 'Hrdneg' (HRD-negative).""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To confirm the handling of the 'Advanced' stage descriptor.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'High-Grade' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': 'To check for rules regarding complex genetic patient subgroups.'}]","[{'component': 'Ccne1 Amplification', 'type': 'Gene Amplification', 'normalized_form': 'CCNE1-Amplified', 'rule_applied': ""Gene Name Rule 27: Format as '<GeneSymbol>-<Qualifier>'.""}, {'component': 'Brcawt', 'type': 'Biomarker Status', 'normalized_form': 'BRCA Wild-Type', 'rule_applied': 'Standard clinical nomenclature for BRCA status.'}, {'component': 'Hrdneg', 'type': 'Biomarker Status', 'normalized_form': 'HRD-Negative', 'rule_applied': 'Standard clinical nomenclature for HRD status.'}, {'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule: Include stage descriptors in Title Case.'}, {'component': 'High-Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade Rule 115: Standardize to 'High Grade' without a hyphen.""}, {'component': 'Ovarian Cancer', 'type': 'Disease', 'normalized_form': 'Ovarian Cancer', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}]",2
262300,"Hematopoiesis, stem cells and microenvironment",Monoallelic And Biallelic Germline Mutations Affecting The Transcription Factor Helios Cause Pleiotropic Defects Of Immunity,,,Helios-Mutated Germline Pleiotropic Defect of Immunity,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Monoallelic And Biallelic Germline Mutations Affecting The Transcription Factor Helios Cause Pleiotropic Defects Of Immunity' was chosen as it contains a specific disease/disorder ('Pleiotropic Defects Of Immunity'), whereas the session title 'Hematopoiesis, stem cells and microenvironment' is a broad therapeutic area without a specific disease.

2.  **Component Identification**: The selected title contains several key components:
    *   Disease: 'Pleiotropic Defects Of Immunity'
    *   Gene/Factor: 'Transcription Factor Helios'
    *   Genetic Origin: 'Germline'
    *   Mutation Type: 'Mutations'
    *   Allelic Status: 'Monoallelic', 'Biallelic'

3.  **Rule Retrieval & Application**:
    *   **Allelic Status**: Rules for 'Patient Sub-Group' -> 'Genetic Status' were retrieved for 'Biallelic'. Rule ID 466 explicitly states to exclude allelic zygosity descriptors like 'Biallelic'. By extension, 'Monoallelic' was also excluded as it falls under the same category of non-standard descriptors.
    *   **Genetic Origin**: Rules for 'Occurrence' -> 'Genetic Origin' were retrieved for 'Germline'. Rule ID 180 specifies retaining 'Germline' and placing it after the standardized gene-mutation token (e.g., '<Gene>-Mutated Germline').
    *   **Gene Mutation**: Following standard gene mutation rules, 'Mutations Affecting... Helios' is normalized to 'Helios-Mutated'.
    *   **Disease Normalization**: The disease term 'Pleiotropic Defects Of Immunity' was processed according to generic rules: converted to singular ('Defect') and formatted in Title Case ('Pleiotropic Defect of Immunity').

4.  **Indication Construction**: The identified and normalized components were assembled in the standard order: Gene-Mutation -> Genetic Origin -> Disease.
    *   'Helios-Mutated' + 'Germline' + 'Pleiotropic Defect of Immunity' results in the final indication.

5.  **Quality Check**: The final indication adheres to the single-source principle, correctly applies formatting rules (Title Case, singular form), includes the patient subgroup defined by the germline mutation, and excludes non-standard descriptors ('Biallelic', 'Monoallelic').","[{'category': 'Occurrence', 'subcategories': ['Genetic Origin'], 'reason': ""To determine how to handle the term 'Germline'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To determine how to handle the term 'Biallelic'.""}]","[{'component': 'Germline Mutations Affecting The Transcription Factor Helios', 'type': 'Gene Mutation with Genetic Origin', 'normalized_form': 'Helios-Mutated Germline', 'rule_applied': ""Rule 180 for 'Germline' positioning and standard rules for gene mutation formatting.""}, {'component': 'Pleiotropic Defects Of Immunity', 'type': 'Disease', 'normalized_form': 'Pleiotropic Defect of Immunity', 'rule_applied': 'Generic rules for singular form and Title Case.'}, {'component': 'Monoallelic And Biallelic', 'type': 'Genetic Status', 'normalized_form': '', 'rule_applied': ""Rule 466 explicitly excludes 'Biallelic', and by extension 'Monoallelic', as non-standard allelic zygosity descriptors.""}]",2
393379,Gynaecological Cancers,Correlation Between Chemotherapy Response Score (Crs) And Germline Brca1/2 (Gbrca) Status In Women Diagnosed With Figo Stage Iiic/Iv High-Grade Serous Ovarian Cancer (Hgsoc),Stage Iiic/Iv;;High-Grade;;Serous Ovarian Cancer,Stage IIIc/IV High-Grade Serous Ovarian Cancer,Stage IIIC/IV High Grade Serous Ovarian Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease ('High-Grade Serous Ovarian Cancer'), so it was chosen as the source over the more general session title ('Gynaecological Cancers'), following the single-source principle.
2.  **Component Identification**: The abstract title contains the following components: a disease ('High-Grade Serous Ovarian Cancer'), a stage ('Figo Stage Iiic/Iv'), a grade ('High-Grade'), and a patient descriptor ('Women'). It also mentions a genetic status ('Germline Brca1/2 (Gbrca) Status') as a correlative factor, not as a defining characteristic of the patient cohort.
3.  **Rule Retrieval**: Rules were retrieved for Stage, Grade, and Gene type to ensure proper formatting.
4.  **Rule Application & Normalization**:
    *   **Disease**: 'High-Grade Serous Ovarian Cancer (Hgsoc)' was normalized. The abbreviation '(Hgsoc)' was removed. 'Cancer' is already in singular form. 'Serous' is a key histological subtype and was retained.
    *   **Grade**: Based on the retrieved 'Grade' rules (e.g., ID 115), 'High-Grade' was normalized to 'High Grade'.
    *   **Stage**: 'Figo Stage Iiic/Iv' was standardized. The staging system 'Figo' was dropped in favor of the standard format. The Roman numerals were capitalized and combined, resulting in 'Stage IIIC/IV', consistent with staging rules.
    *   **Exclusions**: The sociodemographic descriptor 'Women' was excluded as per generic rules. The phrase 'Diagnosed With' was excluded as a procedural qualifier. 'Germline Brca1/2 (Gbrca) Status' was excluded because the title indicates it's a variable being correlated *within* the patient group, not a defining inclusion criterion for the cohort itself.
5.  **Indication Construction**: The normalized components were assembled in the standard clinical order: [Stage] [Grade] [Histology] [Disease]. This resulted in the final indication: 'Stage IIIC/IV High Grade Serous Ovarian Cancer'.
6.  **Final Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately represents the patient population described in the abstract title.","[{'category': 'Stage', 'subcategories': ['Stage number', 'Stage Type'], 'reason': ""To correctly format the stage 'Figo Stage Iiic/Iv'.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To standardize the term 'High-Grade'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To evaluate how to handle 'Germline Brca1/2 (Gbrca) Status'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To handle the '/' in the stage 'Iiic/Iv'.""}]","[{'component': 'Figo Stage Iiic/Iv', 'type': 'Stage', 'normalized_form': 'Stage IIIC/IV', 'rule_applied': ""Stage number rules for Roman numerals and Connectors rule for '/'.""}, {'component': 'High-Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade rule ID 115 for standardizing 'High Grade'.""}, {'component': 'Serous Ovarian Cancer', 'type': 'Disease', 'normalized_form': 'Serous Ovarian Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'Women', 'type': 'Gender', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors.'}, {'component': 'Germline Brca1/2 (Gbrca) Status', 'type': 'Analyte', 'normalized_form': '', 'rule_applied': 'Excluded as it is a factor being studied for correlation, not a defining characteristic of the patient cohort.'}]",2
213157,Society for the Study of Male Reproduction (SSMR),Society for the Study of Male Reproduction (SSMR),,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. Both titles, 'Society for the Study of Male Reproduction (SSMR)', refer to a field of study or a professional society, not a specific disease, disorder, or condition. The term 'Male Reproduction' describes a physiological process, which is listed as a non-diagnostic item to be excluded according to the generic rules. Therefore, no indication can be extracted.",[],"[{'component': 'Male Reproduction', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items (Physiologic processes)'}]",1
344232,Intercepting Molecular Residual Disease in the Clinic,Chair Introduction,,,Molecular Residual Disease,True,session_title,"Step 1: The abstract title 'Chair Introduction' contains no medical terms. The session title 'Intercepting Molecular Residual Disease in the Clinic' contains the term 'Molecular Residual Disease'.
Step 2: Following the single-source principle, the session title is selected for extraction.
Step 3: The term 'Molecular Residual Disease' is identified as the core medical concept.
Step 4: The verb 'Intercepting' and the location qualifier 'in the Clinic' are identified for exclusion based on generic rules.
Step 5: Generic formatting rules are applied. The term is already in Title Case and singular form.
Step 6: The final indication is constructed by taking the core medical concept and applying the necessary formatting and exclusions, resulting in 'Molecular Residual Disease'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules regarding disease state characterizations like 'Molecular Residual Disease'. No specific rule was found to be directly applicable, so generic rules were used.""}]","[{'component': 'Molecular Residual Disease', 'type': 'Disease', 'normalized_form': 'Molecular Residual Disease', 'rule_applied': 'Generic rule: Use Title Case and singular form.'}, {'component': 'Intercepting', 'type': 'Action Verb', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude non-diagnostic items and study methodologies.'}, {'component': 'in the Clinic', 'type': 'Location Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude procedural/temporal qualifiers.'}]",2
180390,Acute Myeloid Leukemias: Clinical and Epidemiological: Poster I,Clinical Characteristics Associated with Venous Thromboembolism in Patients with Non-APL Acute Myeloid Leukemia,Venous Thromboembolism;;Acute Myeloid Leukemia,Venous Thromboembolism;;Acute Myeloid Leukemia,Venous Thromboembolism;;Non-APL Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains specific disease terms ('Venous Thromboembolism', 'Non-APL Acute Myeloid Leukemia'), following the single-source principle.
2. **Component Identification**: Two distinct medical conditions were identified in the abstract title: 'Venous Thromboembolism' and 'Non-APL Acute Myeloid Leukemia'. 'Non-APL' (Non-Acute Promyelocytic Leukemia) is a clinically significant patient subgroup of Acute Myeloid Leukemia.
3. **Rule Retrieval**: Rules for handling multiple diseases were considered. The generic rule specifies separating distinct diseases with ';;'. Rules for patient subgroups ('Disease Characterisation') were also considered, confirming that clinically relevant subgroups like 'Non-APL' should be retained.
4. **Rule Application**: 
   - The generic rule for multiple diseases was applied, leading to the extraction of both conditions.
   - The generic formatting rule for Title Case was applied to both indications.
   - The generic rule for using singular form was applied; both terms were already singular.
   - No terms met the criteria for exclusion.
5. **Indication Construction**: The two identified and normalized indications were combined using the ';;' separator, resulting in the final output.
6. **Quality Check**: The final indication adheres to all formatting and clinical accuracy guidelines. It correctly captures the two distinct clinical entities mentioned in the source title.","[{'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': 'To determine the correct procedure for handling titles that mention two distinct diseases.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify how to handle the 'Non-APL' qualifier for Acute Myeloid Leukemia.""}]","[{'component': 'Venous Thromboembolism', 'type': 'Disease', 'normalized_form': 'Venous Thromboembolism', 'rule_applied': 'Generic rule for disease identification and Title Case.'}, {'component': 'Non-APL Acute Myeloid Leukemia', 'type': 'Disease with Patient Subgroup', 'normalized_form': 'Non-APL Acute Myeloid Leukemia', 'rule_applied': 'Generic rule for retaining clinically significant patient subgroups and Title Case.'}]",2
180403,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Updated Results from a Phase II Study of Hyper-CVAD with Sequential Blinatumomab in Adults with Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,Adults;;Newly Diagnosed;;Philadelphia Chromosome;;Negative;;B-Cell Acute Lymphoblastic Leukemia,Adult Newly Diagnosed Ph-Negative B-Cell Acute Lymphoblastic Leukemia,Adult Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia'), making it more informative than the session title ('Acute Lymphoblastic Leukemias'). This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The following components were identified in the abstract title:
    *   Age Group: 'Adults'
    *   Diagnosis Status: 'Newly Diagnosed'
    *   Genetic Status: 'Philadelphia Chromosome-Negative'
    *   Cell Type: 'B-Cell'
    *   Core Disease: 'Acute Lymphoblastic Leukemia'
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' (Adult), 'Treatment based' (Diagnosis Status), and 'Patient Sub-Group' (Genetic Status) to ensure correct formatting and inclusion.
4.  **Rule Application and Construction**:
    *   The 'Age Group' rule for 'Adult' was applied, normalizing 'Adults' to 'Adult' and placing it as a prefix.
    *   The 'Treatment based' rule for 'Newly Diagnosed' was applied, placing it as a prefix after the age group.
    *   'Philadelphia Chromosome-Negative' was identified as a key genetic descriptor and included.
    *   'B-Cell' was identified as an essential cell lineage specifier for the leukemia.
    *   The core disease 'Acute Lymphoblastic Leukemia' was kept in its singular form.
    *   Generic rules for Title Case and single spacing were applied.
5.  **Final Assembly**: The components were assembled in the standard clinical order: Age Group -> Diagnosis Status -> Genetic Status -> Cell Type -> Core Disease. This resulted in the final indication: 'Adult Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adults' patient subgroup.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To handle the 'Newly Diagnosed' descriptor.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To confirm the handling of genetic descriptors like 'Philadelphia Chromosome-Negative'.""}]","[{'component': 'Adults', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Rule ID: 289 - 'Adult' keyword rule.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - 'Newly Diagnosed' keyword rule.""}, {'component': 'Philadelphia Chromosome-Negative', 'type': 'Genetic Status', 'normalized_form': 'Philadelphia Chromosome-Negative', 'rule_applied': 'Generic rule for including genetic patient subgroups.'}, {'component': 'B-Cell', 'type': 'Cell Type', 'normalized_form': 'B-Cell', 'rule_applied': 'Generic rule for including cell lineage as part of the disease name.'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for singular form and Title Case.'}]",2
327859,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Robust Validation of the UKALL High Hyperdiploid Risk Profile Using Individual Patient Data Collected By the Harmony Alliance,ALL,Acute Lymphoblastic Leukemia,High Hyperdiploid Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title. While the session title explicitly names 'Acute Lymphoblastic Leukemias', the abstract title contains 'UKALL', a well-known acronym for 'United Kingdom Acute Lymphoblastic Leukaemia', and provides a more specific patient subgroup, 'High Hyperdiploid'. According to the single-source principle, the more specific title containing the disease (or a direct acronym) is preferred.
2.  **Component Identification**: From the abstract title, the key components identified were 'UKALL' (disease) and 'High Hyperdiploid' (patient subgroup/genetic status).
3.  **Rule Retrieval**: Rules for 'Risk' and 'Patient Sub-Group' were retrieved to understand how to handle descriptors like 'High' and genetic statuses like 'Hyperdiploid'.
4.  **Rule Application and Construction**:
    *   The disease 'UKALL' was expanded to its full, standardized name: 'Acute Lymphoblastic Leukemia'.
    *   The descriptor 'High Hyperdiploid' was identified as a specific, clinically significant patient subgroup that defines the type of leukemia. It is not a generic risk level but a distinct genetic profile.
    *   The term 'Risk Profile' was determined to be part of the study's methodology ('Validation of the... Risk Profile') and not a part of the patient's actual diagnosis, so it was excluded.
    *   Generic formatting rules were applied: The final indication was converted to Title Case and singular form.
5.  **Final Indication Assembly**: The components were combined to form the final indication: 'High Hyperdiploid Acute Lymphoblastic Leukemia'.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Risk Types'], 'reason': ""To correctly handle the term 'High' and 'Risk Profile' found in the abstract title.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To determine how to classify and format the genetic descriptor 'Hyperdiploid'.""}]","[{'component': 'UKALL', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Standardization of acronym to full disease name.'}, {'component': 'High Hyperdiploid', 'type': 'Patient Sub-Group (Genetic Status)', 'normalized_form': 'High Hyperdiploid', 'rule_applied': 'Inclusion of a specific genetic profile as a prefix to the disease.'}, {'component': 'Risk Profile', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Exclusion of non-diagnostic items (Generic Rule 3).'}]",2
393400,Gynaecological Cancers,Tumor-Informed Ctdna Detection As A Predictive Marker For Postoperative Residual Disease In Epithelial Ovarian Cancer: A Feasibility Study,Epithelial Ovarian Cancer,Epithelial Ovarian Cancer,Residual Epithelial Ovarian Cancer,True,abstract_title,"Step 1: The abstract title was selected as the source because it contains a specific disease, 'Epithelial Ovarian Cancer', which is more precise than the broader category 'Gynaecological Cancers' in the session title.
Step 2: The components identified in the abstract title were the core disease 'Epithelial Ovarian Cancer' and the potential qualifiers 'Postoperative' and 'Residual Disease'.
Step 3: Rules for 'Treatment Set-up' (specifically 'Operative Status') were retrieved to handle the term 'Postoperative'.
Step 4: Based on the retrieved rules (specifically Rule ID 255), 'Postoperative' was excluded as it is a procedural/temporal qualifier not included in the final indication.
Step 5: The term 'Residual Disease' was identified as a clinically significant disease state that defines the patient population. It was therefore included as a qualifier.
Step 6: The final indication was constructed by combining the qualifier 'Residual' with the core disease 'Epithelial Ovarian Cancer' and applying Title Case and singular form rules. Other non-diagnostic parts of the title, such as 'Tumor-Informed Ctdna Detection', were excluded.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status'], 'reason': ""To determine how to handle the term 'Postoperative'.""}, {'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To check for rules regarding disease states like 'Residual Disease'.""}]","[{'component': 'Epithelial Ovarian Cancer', 'type': 'Disease', 'normalized_form': 'Epithelial Ovarian Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Postoperative', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Rule ID 255 from 'Operative Status' category, which mandates exclusion.""}, {'component': 'Residual Disease', 'type': 'Disease State', 'normalized_form': 'Residual', 'rule_applied': 'Inclusion as a clinically significant patient subgroup qualifier based on general principles.'}]",2
327866,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III",The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia,Relapse;;KMT2A;;rearranged;;Infant;;Childhood;;Leukemia,Relapsed KMT2A-Rearranged Infant Childhood Leukemia,Infant Relapsed KMT2A-Rearranged Leukemia;;Childhood Relapsed KMT2A-Rearranged Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease and patient subgroup information ('KMT2A-rearranged Infant and Childhood Leukemia'), which is more detailed than the session title ('Acute Lymphoblastic Leukemias'). The single-source principle mandates using the abstract title exclusively.
2. **Component Identification**: The key components identified in the abstract title are:
    - Disease: 'Leukemia'
    - Gene Information: 'KMT2A-rearranged'
    - Age Groups: 'Infant' and 'Childhood'
    - Occurrence Status: 'Relapse'
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Gene type' (for 'KMT2A-rearranged'), 'Age Group' (for 'Infant' and 'Childhood'), and 'Occurrence' (for 'Relapse').
4. **Rule Application and Normalization**:
    - **Disease**: The term 'Leukemia' is already in singular form and was converted to Title Case.
    - **Gene Information**: The term 'KMT2A-rearranged' was normalized to 'KMT2A-Rearranged' based on the retrieved 'Gene Rearranged' rule (ID 48), which specifies the format '<Gene>-Rearranged'.
    - **Age Groups**: The terms 'Infant' and 'Childhood' were identified as distinct patient subgroups. The retrieved 'Age Group' rules (ID 291, 292) state that these descriptors should be placed at the beginning of the indication.
    - **Occurrence Status**: The term 'Relapse' was converted to 'Relapsed' as per the 'Relapse' occurrence rule (ID 144), which standardizes the term to its adjectival form and places it before the disease name.
5. **Indication Construction**: The components were assembled for each age group, creating two distinct indications. The structure followed is [Age Group] [Occurrence] [Gene Info] [Disease].
    - For 'Infant': 'Infant' + 'Relapsed' + 'KMT2A-Rearranged' + 'Leukemia' -> 'Infant Relapsed KMT2A-Rearranged Leukemia'.
    - For 'Childhood': 'Childhood' + 'Relapsed' + 'KMT2A-Rearranged' + 'Leukemia' -> 'Childhood Relapsed KMT2A-Rearranged Leukemia'.
6. **Final Output Formatting**: The two resulting indications were combined and separated by the mandatory ';;' delimiter, resulting in the final generated indication.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To handle the 'KMT2A-rearranged' genetic marker.""}, {'category': 'Age Group', 'subcategories': ['Infant', 'Childhood'], 'reason': ""To correctly format the 'Infant' and 'Childhood' patient subgroups.""}, {'category': 'Occurrence', 'subcategories': ['Relapse'], 'reason': ""To standardize the disease occurrence status 'Relapse'.""}]","[{'component': 'Leukemia', 'type': 'Disease', 'normalized_form': 'Leukemia', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}, {'component': 'KMT2A-rearranged', 'type': 'Gene Rearrangement', 'normalized_form': 'KMT2A-Rearranged', 'rule_applied': ""get_indication_rules(category='Gene type', subcategories=['Gene type']) - Rule ID 48""}, {'component': 'Infant', 'type': 'Age Group', 'normalized_form': 'Infant', 'rule_applied': ""get_indication_rules(category='Age Group', subcategories=['Infant'])""}, {'component': 'Childhood', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': ""get_indication_rules(category='Age Group', subcategories=['Childhood']) - Rule ID 291""}, {'component': 'Relapse', 'type': 'Occurrence', 'normalized_form': 'Relapsed', 'rule_applied': ""get_indication_rules(category='Occurrence', subcategories=['Relapse']) - Rule ID 144""}]",2
393407,Gynaecological Cancers,Mental And Socioeconomic Burden In Co-Parents And Children Of Patients With Endometrial And Cervical Cancer: A Swedish Population-Based Study,Children;;Endometrial;;Cervical Cancer,Childhood Endometrial Cancer;;Childhood Cervical Cancer,Endometrial Cancer;;Cervical Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease names ('Endometrial And Cervical Cancer'), which is preferred over the broader term in the session title ('Gynaecological Cancers').
Step 2: Two distinct diseases were identified in the abstract title: 'Endometrial Cancer' and 'Cervical Cancer'.
Step 3: According to the generic rule for multiple diseases, both were extracted and separated by ';;'.
Step 4: Generic formatting rules were applied. The disease names were already in singular form and Title Case, so no changes were needed.
Step 5: Non-diagnostic and sociodemographic information such as 'Mental And Socioeconomic Burden' and 'Swedish Population-Based Study' were excluded as per the exclusion rules.",[],"[{'component': 'Endometrial Cancer', 'type': 'Disease', 'normalized_form': 'Endometrial Cancer', 'rule_applied': 'Generic rule for multiple diseases'}, {'component': 'Cervical Cancer', 'type': 'Disease', 'normalized_form': 'Cervical Cancer', 'rule_applied': 'Generic rule for multiple diseases'}]",1
229586,Neonatal and Fetal Mucosal Immunity,Microbiota drive concomitant expression of IL-17 and the inhibitory receptor PD-1 to regulate effector functions of gd17 cells in the intestine,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title describes a basic science research finding related to cellular functions in the intestine, and the session title refers to a broad area of immunology ('Mucosal Immunity') within a specific age group ('Neonatal and Fetal'). Neither names a disease or disorder that can be extracted as an indication.",[],[],1
377049,Acute myeloid leukemia - Biology & Translational Research,"Therapeutic Potential And Strategies Of Pim447, A Pan-Pim Inhibitor, Targeting Refractory Myeloid Leukemia With Kit-Driven T(8/21)",Refractory;;Myeloid Leukemia,Refractory Myeloid Leukemia,KIT-Driven t(8;21) Refractory Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Myeloid Leukemia') and detailed patient subgroups, making it more informative than the session title, in accordance with the single-source principle.
2. **Component Identification**: The following components were identified in the abstract title: 'Refractory' (disease state), 'Myeloid Leukemia' (core disease), 'Kit-Driven' (genetic driver), and 'T(8/21)' (chromosomal abnormality).
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' to handle 'Refractory', 'Gene type' for 'Kit-Driven', and 'Chromosome type' for 'T(8/21)'.
4. **Rule Application and Normalization**:
   - **Refractory**: The term was standardized to 'Refractory' in Title Case as per Occurrence Rule ID 143.
   - **Kit-Driven**: Based on Gene type Rule ID 50 ('Gene Driven'), this was normalized to 'KIT-Driven', capitalizing the official gene symbol 'KIT' and standardizing the format.
   - **T(8/21)**: This was identified as a specific chromosomal translocation. While no explicit rule existed for this format, it was normalized to the standard cytogenetic notation 't(8;21)' to ensure clinical accuracy and represent this critical patient subgroup.
   - **Myeloid Leukemia**: The core disease was formatted to 'Myeloid Leukemia' using Title Case and singular form as required by generic rules.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order, starting with the most specific genetic and cytogenetic characteristics, followed by the disease state and the core disease. This resulted in the final, precise indication.","[{'category': 'Occurrence', 'subcategories': ['Refractory'], 'reason': ""To correctly format the disease state 'Refractory'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find the rule for handling 'Kit-Driven' and normalize the gene name and format.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To check for rules on handling chromosomal translocations like 'T(8/21)'.""}]","[{'component': 'Refractory', 'type': 'Disease State', 'normalized_form': 'Refractory', 'rule_applied': 'Occurrence Rule ID 143'}, {'component': 'Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Myeloid Leukemia', 'rule_applied': 'Generic Rules (Title Case, Singular Form)'}, {'component': 'Kit-Driven', 'type': 'Gene Driver', 'normalized_form': 'KIT-Driven', 'rule_applied': 'Gene type Rule ID 50'}, {'component': 'T(8/21)', 'type': 'Chromosomal Translocation', 'normalized_form': 't(8;21)', 'rule_applied': 'Normalization to standard clinical cytogenetic notation for accuracy, as no specific rule was found.'}]",2
180442,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I","Aspacytarabine (BST-236) As Monotherapy Is Safe, Well-Tolerated and Effective for the Treatment of Adults with Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy. Results of a Phase 2 Study",Adults;;Newly Diagnosed;;Acute Myeloid Leukemia,Adult Newly Diagnosed Acute Myeloid Leukemia,Adult Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title as it contains a more specific description of the disease and patient population, adhering to the single-source principle.
2.  **Component Identification**: The following components were identified in the abstract title: 'Adults' (Age Group), 'Newly Diagnosed' (Diagnosis Status), 'Acute Myeloid Leukemia' (Disease), and 'Unfit for Intensive Therapy' (Patient Subgroup).
3.  **Rule Retrieval**: Rules were retrieved for 'Age Group' ('Adult'), 'Treatment based' ('Diagnosis Status'), and 'Patient Sub-Group'.
4.  **Rule Application & Construction**:
    *   The generic rule for singularization was applied to 'Leukemias' from the session title, although the abstract title already used the singular 'Leukemia'.
    *   The generic rule for Title Casing was applied to all components.
    *   The specific rule for 'Adult' (ID: 289) was applied, placing 'Adult' as a leading descriptor.
    *   The specific rule for 'Newly Diagnosed' (ID: 193) was applied, placing it as a prefix before the disease.
    *   'Unfit for Intensive Therapy' was identified as a critical, clinically valid patient subgroup that defines the study population and was included in Title Case.
5.  **Final Assembly**: The components were assembled in a clinically logical order, reflecting the phrasing in the source title: Age Group -> Diagnosis Status -> Disease -> Subgroup. This resulted in the final indication: 'Adult Newly Diagnosed Acute Myeloid Leukemia Unfit for Intensive Therapy'.
6.  **Quality Check**: The final indication was verified against all generic and specific rules, ensuring it is correctly formatted, clinically accurate, and derived from a single source.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To handle the 'Adults' patient descriptor.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To handle the 'Newly Diagnosed' descriptor.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding patient fitness status like 'Unfit for Intensive Therapy'.""}]","[{'component': 'Adults', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group Rule ID: 289 - Prepend 'Adult' in title case.""}, {'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Treatment based Rule ID: 193 - Prepend 'Newly Diagnosed' in title case.""}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case and Singular Form.'}, {'component': 'Unfit for Intensive Therapy', 'type': 'Patient Subgroup', 'normalized_form': 'Unfit for Intensive Therapy', 'rule_applied': 'Generic Rule: Inclusion of clinically valid patient subgroups and applying Title Case.'}]",2
180445,"Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster I",Updated Survival and Response Analyses from a Phase 1 Study of Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation,Newly Diagnosed;;AML;;IDH1;;IDH2 Mutation,IDH1-Mutated IDH2-Mutated Newly Diagnosed Acute Myeloid Leukemia,Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia;;Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease (AML) and patient subgroups, which is preferred over the session title.
2. **Component Identification**: The key components identified in the abstract title are 'Newly Diagnosed', 'AML' (Acute Myeloid Leukemia), and 'IDH1 or IDH2 Mutation'.
3. **Rule Retrieval**: Rules for 'Diagnosis Status' (Newly Diagnosed) and 'Gene type' (Mutation) were retrieved to ensure correct formatting.
4. **Rule Application and Normalization**:
   - 'AML' was expanded to its full form 'Acute Myeloid Leukemia' and converted to Title Case.
   - The 'Diagnosis Status' rule (ID: 193) was applied to prefix 'Newly Diagnosed' to the disease.
   - The 'Gene Mutation' rule (ID: 30) was applied to format 'IDH1 Mutation' and 'IDH2 Mutation' into 'IDH1-Mutated' and 'IDH2-Mutated' respectively.
   - The presence of 'or' between 'IDH1' and 'IDH2' indicates two distinct patient populations. Therefore, two separate indications were generated.
5. **Indication Construction**: The normalized components were combined to form two distinct indications: 'Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia' and 'Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia'.
6. **Final Formatting**: The two indications were joined using the required ';;' separator as per the generic formatting rules.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To correctly format the 'Newly Diagnosed' qualifier.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'IDH1' and 'IDH2' mutations.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'IDH1 Mutation', 'type': 'Gene Mutation', 'normalized_form': 'IDH1-Mutated', 'rule_applied': 'Rule ID: 30 - Format as <GENE>-Mutated.'}, {'component': 'IDH2 Mutation', 'type': 'Gene Mutation', 'normalized_form': 'IDH2-Mutated', 'rule_applied': 'Rule ID: 30 - Format as <GENE>-Mutated.'}]",2
409825,Winning Team: The Nephrology Workforce for the 21st Century,Advocacy and Policy: What Can Nephrologists and National Organizations Do?,,,Kidney Disease,True,session_title,"Step 1: The abstract title 'Advocacy and Policy: What Can Nephrologists and National Organizations Do?' does not contain a specific disease, but rather a professional role. Step 2: The session title 'Winning Team: The Nephrology Workforce for the 21st Century' contains the therapeutic area 'Nephrology'. Step 3: According to the generic rules (Therapeutic Area Fallback), when a title only names a therapeutic area, the corresponding overarching disease should be used. For 'Nephrology', the standard overarching disease is 'Kidney Disease'. Step 4: The indication is formatted to 'Kidney Disease' following Title Case and singular form rules.",[],"[{'component': 'Nephrology', 'type': 'Therapeutic Area', 'normalized_form': 'Kidney Disease', 'rule_applied': 'Therapeutic Area Fallback'}]",1
147689,Acute Myeloid Leukemia - Clinical,Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd,Aml,Acute Myeloid Leukemia,Persistent MRD Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The session title is 'Acute Myeloid Leukemia - Clinical'. The abstract title is 'Induced Systemic T-Cell Specific Responses To Multiple Tumor-Associated Antigens After Allogenic Leukemia-Derived Dendritic Cell Vaccine Dcp-001 In Aml Patients With Persistent Mrd'.
2.  **Select Source**: Both titles contain a disease term ('Acute Myeloid Leukemia' and its abbreviation 'Aml'). According to the single-source principle, the abstract title is preferred as it is more specific.
3.  **Identify Components**: From the abstract title, I identified the core disease 'Aml' and a specific patient subgroup 'Patients With Persistent Mrd'. 'Aml' is the standard abbreviation for 'Acute Myeloid Leukemia'. 'MRD' stands for 'Minimal Residual Disease', and 'Persistent MRD' is a clinically significant descriptor of the disease state, defining a specific patient cohort.
4.  **Retrieve Rules**: I retrieved rules for the 'Patient Sub-Group' category with the 'Disease Characterisation' subcategory to check for guidance on terms like 'Persistent'. While no specific rule for 'Persistent' or 'MRD' was found, the general principle is to include clinically significant descriptors that define a subgroup.
5.  **Apply Rules & Construct Indication**: 
    *   The disease 'Aml' was expanded to its full name: 'Acute Myeloid Leukemia'.
    *   The patient subgroup 'Persistent Mrd' was identified as a key qualifier.
    *   Generic formatting rules were applied: The qualifier is placed before the disease name. The connector 'With' is removed. The final string is converted to Title Case, keeping the acronym 'MRD' in its original uppercase form.
    *   Procedural details ('After Allogenic Leukemia-Derived Dendritic Cell Vaccine') and general terms ('Patients') were excluded as per the generic exclusion rules.
6.  **Quality Check**: The final indication 'Persistent MRD Acute Myeloid Leukemia' is derived solely from the abstract title, is in the correct format (Title Case, singular), includes the specific patient subgroup, and excludes irrelevant information. It is a clinically valid and accurate representation of the patient population described.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules governing disease state qualifiers like 'Persistent'.""}]","[{'component': 'Aml', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Standard medical abbreviation expansion.'}, {'component': 'Patients With Persistent Mrd', 'type': 'Patient Sub-Group', 'normalized_form': 'Persistent MRD', 'rule_applied': ""Inclusion of clinically significant disease state qualifier. Kept 'MRD' as an uppercase acronym.""}]",2
409842,Collagen IV Conundrums: Genetic Variants and Clinical Management,Do All Collagen Variants Cause Glomerular Disease?,,,Collagen Variant Glomerular Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Do All Collagen Variants Cause Glomerular Disease?') was chosen as the source because it contains a specific disease term ('Glomerular Disease'), which is preferred over the session title according to the single-source principle.
2. **Component Identification**: I identified two key components in the abstract title: the core disease, 'Glomerular Disease', and the patient subgroup qualifier, 'Collagen Variants'.
3. **Rule Retrieval**: I retrieved rules for 'Gene type' and 'Patient Sub-Group' to determine the correct formatting for genetic qualifiers. Although no specific rule for 'Variant' was found, I applied the general principles of standardization derived from similar rules.
4. **Rule Application**: I applied the generic rules. The 'Singular Form' rule was applied to the qualifier 'Variants', converting it to 'Variant'. The 'Title Case' rule was applied to format the final indication.
5. **Indication Construction**: The patient subgroup qualifier was prepended to the core disease name, following the standard structure for indications (e.g., 'KRAS-Mutated Cancer'). This resulted in the final indication: 'Collagen Variant Glomerular Disease'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To check for rules regarding genetic patient characteristics like 'variants'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find rules on how to format genetic alterations, which is analogous to 'variants'.""}]","[{'component': 'Collagen Variants', 'type': 'Patient Subgroup (Genetic)', 'normalized_form': 'Collagen Variant', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Glomerular Disease', 'type': 'Disease', 'normalized_form': 'Glomerular Disease', 'rule_applied': 'Generic Rule: Title Case'}]",2
164086,LBA01: Late-breaking Abstract I - Benign,Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments,,,Chronic Residual Fragment,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Randomized control trial of ultrasonic propulsion to facilitate clearance of chronic residual fragments'. The session title is 'LBA01: Late-breaking Abstract I - Benign'.
2. **Select Source**: According to the single-source principle, the abstract title is preferred as it contains a specific medical condition ('chronic residual fragments'). The session title's term 'Benign' is too generic and lacks a specific disease context.
3. **Identify Components**: The key phrase identified in the abstract title is 'chronic residual fragments'.
4. **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' and 'Disease Characterisation' to check for any specific guidance on terms like 'residual' or 'chronic'. The generic rules for 'Chronic' are most relevant.
5. **Apply Rules**: 
   - **Generic Rule (Chronic)**: The term 'chronic' is included as it is part of the condition's name, describing its persistent nature, not the duration of a treatment.
   - **Generic Rule (Singular Form)**: The plural 'fragments' is converted to its singular form, 'Fragment'.
   - **Generic Rule (Title Case)**: The final indication is formatted in Title Case.
6. **Construct Indication**: Combining the components after applying the rules results in 'Chronic Residual Fragment'.
7. **Quality Check**: The final indication is derived from a single source, correctly formatted, and accurately represents the clinical condition targeted by the intervention in the study.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding disease characterization terms like 'residual' or 'chronic'.""}]","[{'component': 'chronic residual fragments', 'type': 'Condition', 'normalized_form': 'Chronic Residual Fragment', 'rule_applied': 'Generic Rule (Chronic), Generic Rule (Singular Form), Generic Rule (Title Case)'}]",2
180478,"Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I",Duplex-Sequencing Uncovers Low-Frequency Mutations in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,KMT2A-Rearranged;;Infant;;Acute Lymphoblastic Leukemia,KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia,Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Duplex-Sequencing Uncovers Low-Frequency Mutations in KMT2A-Rearranged Infant Acute Lymphoblastic Leukemia') was chosen over the session title because it contains a more specific and complete description of the disease and patient population, adhering to the single-source principle.
2.  **Component Identification**: The following components were identified in the abstract title:
    *   Disease: 'Acute Lymphoblastic Leukemia'
    *   Gene Rearrangement: 'KMT2A-Rearranged'
    *   Age Group: 'Infant'
    *   Research Finding (to be excluded): 'Low-Frequency Mutations'
3.  **Rule Retrieval**: Rules for 'Gene type' and 'Age Group' were retrieved to ensure correct formatting.
    *   The 'Gene type' rule for rearrangements (ID: 47, 48) confirms that the format '<Gene>-Rearranged' is correct. 'KMT2A-Rearranged' already adheres to this.
    *   No specific rule was found for 'Infant', so the generic rule to include explicit patient subgroups was applied.
4.  **Rule Application & Construction**: 
    *   The generic exclusion rule was applied to remove 'Low-Frequency Mutations' as it describes a research finding, not a defining characteristic of the indication.
    *   The generic formatting rules for Title Case and singular form were applied. 'Leukemia' is already singular.
    *   The components were assembled in a clinically logical order: Age Group + Gene Rearrangement + Disease Name.
5.  **Final Indication**: The final indication was constructed as 'Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia'.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To validate the formatting for the 'KMT2A-Rearranged' component.""}, {'category': 'Age Group', 'subcategories': ['Infant'], 'reason': ""To check for specific rules regarding the 'Infant' age group qualifier.""}]","[{'component': 'KMT2A-Rearranged', 'type': 'Gene Rearrangement', 'normalized_form': 'KMT2A-Rearranged', 'rule_applied': 'Gene type rule for rearrangements (ID: 47, 48)'}, {'component': 'Infant', 'type': 'Age Group', 'normalized_form': 'Infant', 'rule_applied': 'Generic rule to include patient subgroups.'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
377088,Infections in hematology (incl. supportive care/therapy),Clinical Characteristics Of Patients With Prolonged Viral Shedding Of Omicron Variant In Haematological Disease,Haematological Disease,Haematological Disease,VIRTUAL_ASSISTANT_API_CALL-get_indication_rules{category:<ctrl46>Patient with two different Disease<ctrl46>},True,,,[],[],1
311555,Adult Thieves Market Poster,Itchy Rash and Starry Eyed,,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. The abstract title 'Itchy Rash and Starry Eyed' describes symptoms or non-clinical observations, not a specific disease. The session title 'Adult Thieves Market Poster' is non-medical. According to the guidelines, an indication cannot be extracted from symptoms alone.",[],"[{'component': 'Itchy Rash', 'type': 'Symptom', 'normalized_form': 'Itchy Rash', 'rule_applied': 'Exclusion Rules: Isolated symptoms are excluded.'}]",1
344332,"Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials",Chair Introduction,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Chair Introduction', contains no medical or disease-related terms and is therefore unsuitable for extraction.
Step 2: I then evaluated the session title, 'Clinical Trial Design in a Diverse World, Part 3: Biomarkers in Clinical Trials'. This title describes study methodology and the use of biomarkers, but it does not mention a specific disease, disorder, or even a broad therapeutic area (like 'Oncology' or 'Cardiology').
Step 3: According to the generic exclusion rules, 'Study methodologies' and 'Non-Diagnostic Items' should be excluded. 'Biomarkers' in this context is a non-diagnostic item, not a disease itself.
Step 4: Since neither title contains a valid disease term, no indication can be extracted, as per the Single-Source Extraction Principle.",[],"[{'component': 'Biomarkers', 'type': 'Non-Diagnostic Item', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items'}]",1
180501,Lymphomas: Translational-Non-Genetic: Poster I,Differential Gene Expression in Circulating T-Cells in Long-Term Adolescent/Young Adult Hodgkin Lymphoma (AYAHL) Survivors and Their Unaffected Twins,Adolescent/;;oung;;Adult Hodgkin Lymphoma,Adolescent/Young Adult Hodgkin Lymphoma,Adolescent Hodgkin Lymphoma;;Young Adult Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Hodgkin Lymphoma', making it more informative than the session title's broader 'Lymphomas'.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Hodgkin Lymphoma' and the patient subgroup 'Adolescent/Young Adult'. The term 'Long-Term Survivors' was identified as a temporal patient status to be excluded based on generic rules.
3. **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Age Group' category with subcategories 'Adolescent' and 'Young' to determine how to handle the compound age group 'Adolescent/Young Adult'.
4. **Rule Application**: Based on the retrieved rules (specifically the precedent set by Rule ID 314 for 'Children Adolescent'), a slash-separated age group should be split into two distinct indications. 'Adolescent/Young Adult' was therefore processed to create two separate patient subgroups: 'Adolescent' and 'Young Adult'.
5. **Indication Construction**: The disease 'Hodgkin Lymphoma' was combined with each age group qualifier separately. The term 'Long-Term Survivors' was excluded as it describes a post-treatment state, not a primary indication qualifier.
6. **Formatting**: The two resulting indications were formatted in Title Case, kept in singular form, and joined with the required ';;' separator, resulting in the final output.","[{'category': 'Age Group', 'subcategories': ['Adolescent', 'Young'], 'reason': ""To determine the correct formatting for the compound age group 'Adolescent/Young Adult'.""}]","[{'component': 'Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Hodgkin Lymphoma', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Adolescent/Young Adult', 'type': 'Age Group', 'normalized_form': 'Adolescent;;Young Adult', 'rule_applied': 'Rule ID 314 precedent, which suggests splitting compound age groups connected by a separator into distinct indications.'}, {'component': 'Long-Term Survivors', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
311577,Adult Thieves Market: Show Me Your Best Cases,Q&A,,,,True,none,"Neither the abstract title ('Q&A') nor the session title ('Adult Thieves Market: Show Me Your Best Cases') contains any identifiable medical disease, condition, or therapeutic area. The term 'Cases' is too generic to be considered a valid indication. Therefore, no indication can be extracted.",[],[],1
377121,Stem cell transplantation - Clinical,Single Nucleotide Polymorphisms In Patients With Endothelial Damage After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation,,,Pediatric Endothelial Damage,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific medical condition ('Endothelial Damage'), whereas the session title only mentions a procedure ('Stem cell transplantation').
2. **Component Identification**: The selected abstract title contains the condition 'Endothelial Damage', the age group 'Pediatric', and a procedural context 'After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation'.
3. **Rule Retrieval**: Rules for 'Age Group' (specifically 'Pediatric') and 'Treatment Set-up' (specifically 'Transplant Status') were retrieved to handle the identified components.
4. **Rule Application**:
   - The 'Pediatric' age group rule (ID: 295, 296) directs to retain 'Pediatric' as a leading qualifier for the indication.
   - The generic exclusion rules and the specific 'Transplant Status' rules (ID: 232, 233 for 'Post-Transplant') mandate the exclusion of procedural and temporal qualifiers. The phrase 'After...Transplantation' falls into this category and is therefore removed.
5. **Indication Construction**: The age group 'Pediatric' is prepended to the core condition 'Endothelial Damage'. The procedural context is excluded as per the rules.
6. **Final Formatting**: The final indication 'Pediatric Endothelial Damage' is formatted to Title Case and checked for compliance with all generic rules.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the phrase 'After...Transplantation', which is a post-procedural state.""}]","[{'component': 'Endothelial Damage', 'type': 'Disease/Condition', 'normalized_form': 'Endothelial Damage', 'rule_applied': 'Generic rule: Identify core disease term.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295, 296): Retain 'Pediatric' as a leading qualifier.""}, {'component': 'After Pediatric Allogeneic Hematopoietic Stem Cell Transplantation', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule & Treatment Set-up rule (ID: 232, 233): Exclude post-procedural context.'}]",2
229667,Immuneregulation-Innate Immune Responses,The biological mechanisms of metformin effects on aging-associated inflammation in obesity,,,Aging-Associated Inflammation;;Obesity,True,abstract_title,"Step 1: The abstract title contains specific medical conditions ('inflammation', 'obesity'), while the session title describes a biological process. Therefore, the abstract title was selected as the source.
Step 2: Two distinct medical conditions were identified in the abstract title: 'aging-associated inflammation' and 'obesity'.
Step 3: According to the generic rules for multiple diseases, both conditions must be extracted and separated by ';;'.
Step 4: The terms were converted to Title Case ('Aging-Associated Inflammation', 'Obesity') and kept in their singular form.
Step 5: The final indication was constructed by combining the two normalized disease terms with the ';;' separator.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check the correct formatting for co-occurring conditions like inflammation and obesity.'}]","[{'component': 'aging-associated inflammation', 'type': 'Disease', 'normalized_form': 'Aging-Associated Inflammation', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'obesity', 'type': 'Disease', 'normalized_form': 'Obesity', 'rule_applied': 'Generic Rule: Title Case'}]",2
311607,Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes,"UTI Biofilms, Amyloid, and Lupus Flares",,,Urinary Tract Infection;;Amyloidosis;;Lupus,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('UTI Biofilms, Amyloid, and Lupus Flares') was selected over the session title ('Bacterial Autoimmune Sequellae: Common and Newly Recognized Clinical Syndromes') because it contains specific, extractable disease terms, whereas the session title refers to broad categories.
2. **Component Identification**: The abstract title lists three distinct clinical concepts: 'UTI Biofilms', 'Amyloid', and 'Lupus Flares'.
3. **Indication Extraction & Normalization**:
   - **'UTI Biofilms'**: 'UTI' is a standard abbreviation for 'Urinary Tract Infection', which is a valid disease. 'Biofilms' is a microbiological process, not a patient subgroup or part of the disease name, and was excluded based on the generic rule to exclude non-diagnostic items.
   - **'Amyloid'**: In a clinical context alongside other diseases, 'Amyloid' is interpreted as the disease 'Amyloidosis'.
   - **'Lupus Flares'**: 'Lupus' is a valid disease. 'Flares' describes a temporary state of disease activity and is not a standard qualifier for a clinical indication. Therefore, it was excluded, and the core disease 'Lupus' was extracted.
4. **Rule Application & Formatting**: The three extracted diseases are distinct. Following the 'Multiple Diseases' rule, they are separated by ';;'. The 'Formatting Rules' for Title Case and singular form were applied to each indication.",[],"[{'component': 'UTI', 'type': 'Disease', 'normalized_form': 'Urinary Tract Infection', 'rule_applied': 'Generic rule: Abbreviation expansion and singular form.'}, {'component': 'Biofilms', 'type': 'Excluded', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude non-diagnostic items/physiologic processes.'}, {'component': 'Amyloid', 'type': 'Disease', 'normalized_form': 'Amyloidosis', 'rule_applied': 'Clinical interpretation of a substance as its corresponding disease in context.'}, {'component': 'Lupus', 'type': 'Disease', 'normalized_form': 'Lupus', 'rule_applied': 'Generic rule: Direct extraction of disease name.'}, {'component': 'Flares', 'type': 'Excluded', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude temporary disease states/symptoms.'}]",2
377144,Clinical updates in ALL,A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab For Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup Analysis From A Phase Ii Study,Newly Diagnosed;;Philadelphia Chromosome;;Positive;;Acute Lymphoblastic Leukemia,Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia,Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab For Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Subgroup Analysis From A Phase Ii Study') contains a specific disease and patient subgroup. The session title ('Clinical updates in ALL') is more general. Based on the single-source principle, the abstract title is selected for extraction as it is more detailed.
2. **Identify Components**: The key components identified in the abstract title are 'Newly Diagnosed' (Diagnosis Status), 'Philadelphia Chromosome-Positive' (Genetic Marker), and 'Acute Lymphoblastic Leukemia' (Disease).
3. **Retrieve Relevant Rules**: I retrieved rules for the 'Diagnosis Status' component. The call `get_indication_rules(category='Treatment based', subcategories=['Diagnosis Status'])` returned Rule 193, which specifies that 'Newly Diagnosed' should be used as a prefix to the main disease. I attempted to find a specific rule for 'Philadelphia Chromosome-Positive' under the 'Chromosome type' category but none was found, so I will proceed with generic formatting rules.
4. **Apply Rules**: 
   - **Rule 193**: Applied to prefix 'Newly Diagnosed' to the indication.
   - **Generic Casing Rule**: Applied Title Case to 'Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia'.
   - **Generic Singular Form Rule**: 'Leukemia' is already in singular form.
   - **Generic Exclusion Rule**: The phrase 'For Patients With' and details about the study design and treatment ('A Chemotherapy-Free Combination Of Ponatinib And Blinatumomab', 'Subgroup Analysis From A Phase Ii Study') were excluded as they are not part of the core indication.
5. **Construct Indication**: The components were assembled in the correct clinical order: Diagnosis Status + Genetic Marker + Disease Name.
6. **Quality Check**: The final indication 'Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia' is clinically accurate, adheres to all formatting rules, and is derived from a single source.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct formatting and placement of the 'Newly Diagnosed' keyword.""}, {'category': 'Chromosome type', 'subcategories': ['General'], 'reason': ""To check for specific formatting rules for 'Philadelphia Chromosome-Positive', though no specific rule was found.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule 193: Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Philadelphia Chromosome-Positive', 'type': 'Genetic Marker', 'normalized_form': 'Philadelphia Chromosome-Positive', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Title Case'}]",3
327998,Lymphomas: Translational-Non-Genetic: Poster III,"Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma",Second-Line;;Relapsed;;Refractory;;Classical Hodgkin Lymphoma,Second-Line Relapsed or Refractory Classical Hodgkin Lymphoma,Second-Line Relapsed/Refractory Classical Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease ('Classical Hodgkin Lymphoma'), making it the primary source over the more general session title ('Lymphomas').
2.  **Component Identification**: I identified three key components in the abstract title: the disease ('Classical Hodgkin Lymphoma'), a disease state ('Relapsed or Refractory'), and a treatment line ('Second-Line Therapy').
3.  **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Line of treatment' and 'Recurrent/Refractory' categories.
4.  **Rule Application**: 
    *   **Treatment Line**: Based on the retrieved 'Line of treatment' rules (specifically Rule ID 199 and 202), the phrase 'Second-Line Therapy for...' indicates that 'Second-Line' modifies the disease context, not a specific drug. Therefore, it must be retained and normalized to 'Second-Line'.
    *   **Disease State**: The phrase 'Relapsed or Refractory' is a standard patient subgroup descriptor. It is normalized to 'Relapsed/Refractory' with a slash, following common clinical terminology standards.
    *   **Disease Name**: 'Classical Hodgkin Lymphoma' is already in the correct singular and Title Case format.
5.  **Indication Construction**: The components are assembled in the standard order: Treatment Line -> Disease State -> Disease. This results in 'Second-Line Relapsed/Refractory Classical Hodgkin Lymphoma'.
6.  **Quality Check**: The final indication adheres to all generic rules: it's from a single source, uses Title Case, is in singular form, and excludes non-indication elements like drug names.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'Second-Line Therapy' component.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly format the 'Relapsed or Refractory' disease state.""}]","[{'component': 'Second-Line Therapy', 'type': 'Line of treatment', 'normalized_form': 'Second-Line', 'rule_applied': ""Treatment Set-up Rule ID 202: Normalize to 'Second-Line' and prepend to the disease name.""}, {'component': 'Relapsed or Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard normalization for recurrent/refractory disease states.'}, {'component': 'Classical Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Classical Hodgkin Lymphoma', 'rule_applied': 'Generic rules for Casing and Singular Form.'}]",2
328003,Lymphomas: Translational-Non-Genetic: Poster III,Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH Reveals Activation of T Cells and Reduced T Cell Exhaustion,High Grade;;B Cell Lymphoma,High Grade B Cell Lymphoma,Double and Triple Hit High Grade B Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Immune Profiling of Double and Triple Hit High Grade B Cell Lymphoma Patients Treated with DA-EPOCH...') was chosen over the session title ('Lymphomas: Translational-Non-Genetic: Poster III') because it contains a more specific and complete disease description, adhering to the single-source principle.
2. **Component Identification**: Key clinical components identified in the abstract title were 'Double and Triple Hit', 'High Grade', and 'B Cell Lymphoma'. The term 'Patients' and the treatment context 'Treated with DA-EPOCH' were identified for exclusion.
3. **Rule Retrieval**: Rules for the 'Grade' category were retrieved to handle 'High Grade'. Rules for 'Patient Sub-Group' were retrieved to check for handling of descriptors like 'Double and Triple Hit'.
4. **Rule Application**:
   - The retrieved rule for 'High Grade' (ID: 115) confirmed its standardization and placement before the disease name.
   - No specific rule was found for 'Double and Triple Hit', so it was retained as an essential clinical descriptor defining the patient subgroup.
   - Generic exclusion rules were applied to remove 'Patients' (sociodemographic) and 'Treated with DA-EPOCH' (procedural qualifier).
   - Generic formatting rules were applied: Title Case for clinical terms ('Double', 'Triple', 'Hit', 'High', 'Grade', 'B', 'Cell', 'Lymphoma') and lowercase for the conjunction 'and'. The disease term 'Lymphoma' is already in its singular form.
5. **Indication Construction**: The identified and standardized components were combined in the correct clinical order (subgroup -> grade -> disease) to form the final indication: 'Double and Triple Hit High Grade B Cell Lymphoma'. This phrase represents a single, clinically recognized high-risk lymphoma entity, not multiple separate diseases, so no ';;' separator was used.
6. **Quality Check**: The final indication was verified for adherence to all generic and specific rules, clinical accuracy, and proper formatting.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'High Grade' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding 'Double Hit' or 'Triple Hit' lymphoma characterizations.""}]","[{'component': 'Double and Triple Hit', 'type': 'Patient Sub-Group', 'normalized_form': 'Double and Triple Hit', 'rule_applied': 'Generic rule: Retain essential clinical descriptors. Title Case formatting.'}, {'component': 'High Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Rule ID: 115 - Standardize to 'High Grade' and place before the disease name.""}, {'component': 'B Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'B Cell Lymphoma', 'rule_applied': 'Generic rule: Title Case and singular form.'}, {'component': 'Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic descriptors.'}, {'component': 'Treated with DA-EPOCH', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",2
147782,Bleeding Disorders (Congenital And Acquired),Investigation Of Preterm Intraventricular Hemorrhage-Induced Inflammatory Response And Microrna Levels In Human Choroid Plexus Epithelial Cells,Congenital;;Acquired;;Bleeding Disorder,Congenital Bleeding Disorder;;Acquired Bleeding Disorder,Preterm Intraventricular Hemorrhage,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: Both the session title ('Bleeding Disorders') and the abstract title ('Preterm Intraventricular Hemorrhage') contain valid medical conditions. According to the single-source principle, the abstract title is prioritized.
2. **Component Identification**: From the abstract title, the core disease identified is 'Intraventricular Hemorrhage' and the patient subgroup qualifier is 'Preterm'. Other phrases like 'Inflammatory Response' and 'Microrna Levels' are identified as physiological processes or measurements, not primary diseases, and are therefore excluded based on the generic exclusion rules.
3. **Rule Retrieval**: I retrieved rules for 'Onset' to understand how to handle 'Preterm' and for 'Patient with two different Disease' to correctly handle the multiple potential conditions. The 'Onset' rules confirmed that such qualifiers should be included, and the lack of specific rules for the second potential condition confirmed that 'Inflammatory Response' should be treated as a secondary process, not a separate indication.
4. **Rule Application & Construction**: The qualifier 'Preterm' is prepended to the core disease 'Intraventricular Hemorrhage'. Generic rules for Title Casing and singular form are applied. All non-diagnostic and procedural terms ('Investigation Of', '-Induced Inflammatory Response', 'In Human Choroid Plexus Epithelial Cells') are excluded.
5. **Final Indication**: The components are combined and formatted to produce the final indication: 'Preterm Intraventricular Hemorrhage'.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To check how to handle the term 'Preterm' as a temporal qualifier for the disease.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': ""To determine if 'Intraventricular Hemorrhage' and 'Inflammatory Response' should be treated as two separate indications.""}]","[{'component': 'Preterm', 'type': 'Onset Qualifier', 'normalized_form': 'Preterm', 'rule_applied': 'Generic rule for patient subgroup inclusion.'}, {'component': 'Intraventricular Hemorrhage', 'type': 'Disease', 'normalized_form': 'Intraventricular Hemorrhage', 'rule_applied': 'Generic rule for disease extraction and Title Casing.'}, {'component': 'Inflammatory Response', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items.'}]",2
328014,Lymphomas: Translational-Non-Genetic: Poster I,Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader,Lymphomas,Lymphoma,Cutaneous T-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title contains the disease acronym 'CTCL', so it is selected as the source according to the single-source principle.
Step 2: The component 'CTCL' is identified as the core disease. The phrase 'Pre-Clinical Animal Model' is identified as a study methodology and marked for exclusion based on generic rules.
Step 3: The primary task is to standardize the acronym 'CTCL'. No specific rules were needed from the tool for this common acronym.
Step 4: The acronym 'CTCL' is expanded to its full name, 'Cutaneous T-Cell Lymphoma'.
Step 5: Generic formatting rules are applied. The expanded name is converted to Title Case, resulting in 'Cutaneous T-Cell Lymphoma'. The excluded components ('Pre-Clinical Animal Model') are removed.
Step 6: A final quality check confirms the indication is correctly formatted, singular, and derived from a single source.",[],"[{'component': 'CTCL', 'type': 'Disease', 'normalized_form': 'Cutaneous T-Cell Lymphoma', 'rule_applied': 'Standard medical acronym expansion and Title Case formatting rule.'}, {'component': 'Pre-Clinical Animal Model', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Non-Diagnostic Items/Study Methodologies.'}]",2
409966,Dyslipidemia in Pediatric CKD: Risk for Stiff Vessels?,Controversies in the Management of Dyslipidemia in Children with CKD,Dyslipidemia;;Children,Childhood Dyslipidemia,Childhood Dyslipidemia;;Childhood CKD,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Controversies in the Management of Dyslipidemia in Children with CKD', was chosen as it clearly contains the diseases and patient population, aligning with the single-source principle.
2.  **Component Identification**: I identified two distinct medical conditions, 'Dyslipidemia' and 'CKD' (Chronic Kidney Disease), and one patient subgroup descriptor, 'Children'.
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category, specifically for the keyword 'Children'. The rules (e.g., ID 293, 294) mandate replacing 'Children' with the prefix 'Childhood' and placing it before the associated disease names.
4.  **Rule Application**: 
    *   Applying the age group rule, 'Dyslipidemia in Children' was transformed into 'Childhood Dyslipidemia'.
    *   The context '...in Children with CKD' links the age group to CKD as well, resulting in 'Childhood CKD'.
    *   The generic rule for multiple diseases was applied, which requires listing all distinct indications separated by ';;'.
    *   The generic rule for casing was applied, ensuring 'Childhood', 'Dyslipidemia', and 'Chronic Kidney Disease' (implied by CKD) are in Title Case, while the acronym 'CKD' remains in its original uppercase form.
    *   Non-diagnostic terms like 'Controversies in the Management of' were excluded as per the generic exclusion rules.
5.  **Indication Construction**: The individual components were combined to form the final output: `Childhood Dyslipidemia;;Childhood CKD`.
6.  **Quality Check**: The final indication adheres to all formatting, separation, and content rules. It accurately reflects the two core conditions present in the specified pediatric patient group.","[{'category': 'Age Group', 'subcategories': ['Childhood'], 'reason': ""To correctly handle the 'Children' patient subgroup descriptor.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': 'To check for specific rules on handling multiple diseases in the same title, though none were found, defaulting to the generic rule.'}]","[{'component': 'Dyslipidemia', 'type': 'Disease', 'normalized_form': 'Dyslipidemia', 'rule_applied': 'Generic disease identification'}, {'component': 'CKD', 'type': 'Disease', 'normalized_form': 'CKD', 'rule_applied': 'Generic disease identification; Acronym casing rule'}, {'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': 'Age Group rule (ID: 293/294)'}]",2
262522,Myelodysplastic syndromes - Clinical,Runx1 Variants With High Variant Allele Frequency In Myeloid Neoplasms. Germline Or Not?,Myeloid Neoplasms,Myeloid Neoplasm,Runx1-Mutated Myeloid Neoplasm,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease term ('Myeloid Neoplasms'), so it is selected as the source according to the single-source principle, and the session title is disregarded.
2.  **Component Identification**: The selected title contains the components 'Runx1 Variants' (a genetic descriptor) and 'Myeloid Neoplasms' (a disease).
3.  **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Gene type' category to determine how to handle 'Variants'. While no explicit rule for 'Variant' exists, the rule for 'Gene Mutation' (ID: 30) provides the closest and most clinically appropriate standardization, which is to convert genetic variations into the format '<GENE>-Mutated'.
4.  **Rule Application**: 
    *   The genetic component 'Runx1 Variants' is normalized to 'Runx1-Mutated' based on the logic of the Gene Mutation rule.
    *   The disease term 'Myeloid Neoplasms' is converted to its singular form, 'Myeloid Neoplasm', as per the generic formatting rules.
    *   The phrase 'With High Variant Allele Frequency' is excluded as it describes a technical measurement detail rather than a standard clinical subgroup.
    *   The question 'Germline Or Not?' is excluded as it is part of the study's research question, not the indication itself.
5.  **Indication Construction**: The normalized components are combined to form the final indication: 'Runx1-Mutated Myeloid Neoplasm'.
6.  **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, proper gene formatting) and exclusion criteria.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find the correct formatting for the genetic component 'Runx1 Variants'.""}]","[{'component': 'Runx1 Variants', 'type': 'Gene Variant', 'normalized_form': 'Runx1-Mutated', 'rule_applied': ""Applied logic from 'Gene Mutation' rule (ID: 30) as the closest standard for 'Variants'.""}, {'component': 'Myeloid Neoplasms', 'type': 'Disease', 'normalized_form': 'Myeloid Neoplasm', 'rule_applied': 'Generic Rule: Singular Form'}]",2
164220,Society for Pediatric Urology (SPU),Panel Discussion,,,Pediatric Urological Disease,True,session_title,"Step-by-step extraction process:
1.  **Analyze Titles**: The `abstract_title` ('Panel Discussion') contains no medical terms. The `session_title` ('Society for Pediatric Urology (SPU)') contains the terms 'Pediatric' and 'Urology'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the `session_title` is selected as it is the only source containing relevant medical information.
3.  **Identify Components**: The components identified are the age group 'Pediatric' and the therapeutic area 'Urology'.
4.  **Retrieve Rules**: I retrieved rules for the 'Age Group' category and 'Pediatric' subcategory to handle the age qualifier. I also applied the generic rule for Therapeutic Area Fallback.
5.  **Apply Rules**: 
    - The generic rule for Therapeutic Area Fallback was applied to convert 'Urology' into a standard disease term, 'Urological Disease'.
    - The retrieved 'Pediatric' age group rule (ID: 295, 296) dictates that 'Pediatric' should be used as a prefix to the disease name.
    - Generic formatting rules (Title Case, singular form) were applied.
6.  **Construct Indication**: The components were combined according to the rules: the age group 'Pediatric' was prepended to the normalized disease 'Urological Disease'.
7.  **Final Indication**: The resulting indication is 'Pediatric Urological Disease'.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' age group qualifier found in the session title.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295) - Retain 'Pediatric' as a leading qualifier.""}, {'component': 'Urology', 'type': 'Therapeutic Area', 'normalized_form': 'Urological Disease', 'rule_applied': 'Generic Rule: Therapeutic Area Fallback - Convert TA to an overarching disease.'}]",2
409986,A Rocky Course: Bones and Stones Through the Life Span,Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1,Cystinuria;;PH1;;Genetic Stone Disease,Cystinuria;;Primary Hyperoxaluria Type 1;;Genetic Stone Disease,Cystinuria;;PH1,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title ('Novel Therapies in the Management of Genetic Stone Disease: Cystinuria and PH1') contains specific disease names, while the session title ('A Rocky Course: Bones and Stones Through the Life Span') is more general. Based on the Single-Source Extraction Principle, the abstract title is selected.
2.  **Identify Components**: The abstract title explicitly lists two distinct diseases: 'Cystinuria' and 'PH1' (Primary Hyperoxaluria Type 1), which are presented as specific types of 'Genetic Stone Disease'. The most precise indications are the specific diseases mentioned.
3.  **Retrieve Relevant Rules**: No specific category rules were needed as the extraction relies on identifying multiple diseases and applying generic formatting rules.
4.  **Apply Rules**: The generic rule for multiple diseases is applied, which requires separating each distinct disease with a ';;' delimiter. The Casing Rules are applied to ensure 'Cystinuria' is in Title Case, and the acronym 'PH1' is preserved in its original form.
5.  **Construct Indication**: The two identified diseases are combined using the specified delimiter.
6.  **Quality Check**: The final indication 'Cystinuria;;PH1' is checked for adherence to all formatting and content rules. It accurately reflects the specific diseases discussed in the abstract title and follows all formatting requirements.",[],"[{'component': 'Cystinuria', 'type': 'Disease', 'normalized_form': 'Cystinuria', 'rule_applied': 'Generic rule for disease identification and Title Case.'}, {'component': 'PH1', 'type': 'Disease', 'normalized_form': 'PH1', 'rule_applied': 'Generic rule for disease identification and preserving acronyms.'}]",2
311696,Development of Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO),Proposed ACR/EULAR Classification Criteria for CNO,Pediatric;;Chronic Nonbacterial Osteomyelitis,Pediatric Chronic Nonbacterial Osteomyelitis,Pediatric Chronic Nonbacterial Osteomyelitis;;Chronic Recurrent Multifocal Osteomyelitis,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The session title is 'Development of Proposed Classification Criteria for Pediatric Chronic Nonbacterial Osteomyelitis (CNO) and Chronic Recurrent Multifocal Osteomyelitis (CRMO)'. The abstract title is 'Proposed ACR/EULAR Classification Criteria for CNO'.
2. **Select Source**: The session title is chosen as the source because it contains the full, unabbreviated names of the medical conditions, providing more specific information than the abstract title which only uses the abbreviation 'CNO'.
3. **Identify Components**: Two distinct diseases are identified in the session title:
    - Disease 1: 'Pediatric Chronic Nonbacterial Osteomyelitis (CNO)' which includes an age group ('Pediatric') and the disease name.
    - Disease 2: 'Chronic Recurrent Multifocal Osteomyelitis (CRMO)' which includes an occurrence qualifier ('Recurrent') and the disease name.
4. **Retrieve Rules**: Rules for 'Age Group' (specifically 'Pediatric') and 'Occurrence' (specifically 'Recurrence-Related Terms') were retrieved to ensure correct formatting.
5. **Apply Rules & Construct Indication**:
    - **Generic Rules**: The non-diagnostic phrase 'Development of Proposed Classification Criteria for' and the parenthetical abbreviations '(CNO)' and '(CRMO)' are excluded. The final indications are formatted in Title Case and singular form.
    - **Age Group Rule**: The 'Pediatric' rule (ID: 295) confirms that 'Pediatric' should be retained as a leading qualifier for the first disease.
    - **Occurrence Rule**: The 'Recurrent' rule (ID: 139) confirms that 'Recurrent' should be kept as a qualifier for the second disease.
    - **Construction**: The two distinct indications are extracted and combined using the ';;' separator as required by the formatting rules.
6. **Quality Check**: The final output adheres to the single-source principle, correctly identifies and separates both diseases, applies Title Case, and removes excluded elements, resulting in a high-quality, clinically accurate indication.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To validate the handling of the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms'], 'reason': ""To ensure the correct formatting of the 'Recurrent' disease qualifier.""}]","[{'component': 'Pediatric Chronic Nonbacterial Osteomyelitis', 'type': 'Disease with Age Group', 'normalized_form': 'Pediatric Chronic Nonbacterial Osteomyelitis', 'rule_applied': ""Age Group rule for 'Pediatric' and Generic Title Case rule.""}, {'component': 'Chronic Recurrent Multifocal Osteomyelitis', 'type': 'Disease with Occurrence', 'normalized_form': 'Chronic Recurrent Multifocal Osteomyelitis', 'rule_applied': ""Occurrence rule for 'Recurrent' and Generic Title Case rule.""}]",2
344465,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,Chairperson,,,Tumor,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The `abstract_title` ('Chairperson') contains no medical or disease terms. The `session_title` ('Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention') contains the term 'Tumor'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the `session_title` is selected as it is the only one containing a potential disease term.
3.  **Identify Components**: The key components in the selected title are 'Tumor', 'Immune Suppression', and 'Immunotherapy Resistance'.
4.  **Retrieve Rules**: To correctly handle 'Immunotherapy Resistance', I retrieved rules for the 'Occurrence' category, specifically the 'Resistance' subcategory.
5.  **Apply Rules**: 
    - The retrieved rules (ID 164, 165) state that resistance descriptors (e.g., 'Drug-Resistant') should not be included in the final indication as they represent a treatment-response status, not a distinct clinical entity. I extended this principle to 'Immunotherapy Resistance' and excluded it.
    - 'Immune Suppression' is a physiological process/complication, not a primary disease, and is excluded under the 'Non-Diagnostic Items' generic rule.
    - The term 'Tumor' is identified as the core disease.
    - The generic rule for singular form is applied, but 'Tumor' is already singular.
    - The generic rule for Title Case is applied.
6.  **Construct Indication**: After applying all rules and exclusions, the only remaining valid component is 'Tumor'.
7.  **Quality Check**: The final indication 'Tumor' adheres to all formatting and content rules. It is derived from a single source and is clinically valid.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the term 'Immunotherapy Resistance' found in the session title.""}]","[{'component': 'Tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic rule: Title Case, Singular form.'}, {'component': 'Immune Suppression', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and physiologic processes.'}, {'component': 'Immunotherapy Resistance', 'type': 'Treatment Status', 'normalized_form': '', 'rule_applied': 'Retrieved Rule (ID 164/165): Exclude resistance descriptors as they represent treatment-response status, not a distinct indication.'}]",2
344467,Contributions of the Tumor Glycome to Immune Suppression and Immunotherapy Resistance and Opportunities for Therapeutic Intervention,Reprogramming the tumor-immune microenvironment by targeting galectin-glycan interactions,,,Tumor,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains the disease term 'tumor', following the single-source extraction principle.
Step 2: The term 'tumor' was identified as the sole medical indication component in the title. The surrounding text describes biological mechanisms and therapeutic strategies, not patient subgroups or disease characteristics.
Step 3: The generic rules for formatting were applied. The term 'tumor' was converted to Title Case to become 'Tumor'. The term was already in singular form.
Step 4: No other specific patient subgroups, biomarkers, or disease stages were mentioned in the selected title, resulting in the final concise indication.",[],"[{'component': 'tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic Rule - Casing'}]",1
393639,Investigational Immunotherapy,Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database,,,,True,none,"The abstract title 'Analysis Of Pulmonary Adverse Events Associated With Immune Checkpoint Inhibitors Based On Faers And Vigibase Database' focuses on adverse events (side effects) related to a class of drugs (Immune Checkpoint Inhibitors) and does not mention the primary disease or condition being treated. The session title 'Investigational Immunotherapy' describes a broad therapeutic area, not a specific medical indication. Since neither source contains a valid disease or disorder, no indication can be extracted.",[],"[{'component': 'Pulmonary Adverse Events', 'type': 'Adverse Event', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Complications or adverse effects should be excluded.'}]",1
262567,Myeloma and other monoclonal gammopathies - Clinical,Efficacy And Safety Of Daratumumab Monotherapy In Newly Diagnosed Patients With Stage 3B Light Chain Amyloidosis: A Phase 2 Study By The European Myeloma Network,Newly Diagnosed;;Stage 3B;;Light Chain Amyloidosis,Newly Diagnosed Stage 3B Light Chain Amyloidosis,Newly Diagnosed Stage IIIB Light Chain Amyloidosis,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Light Chain Amyloidosis'), which is preferred over the broader categories in the session title ('Myeloma', 'monoclonal gammopathies') per the single-source principle.
2. **Component Identification**: From the abstract title, I identified the following components: the core disease 'Light Chain Amyloidosis', a diagnosis status 'Newly Diagnosed', and a disease stage 'Stage 3B'.
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Stage number' and 'Diagnosis Status'.
4. **Rule Application**:
   - The rule for 'Diagnosis Status' (ID: 193) confirmed that 'Newly Diagnosed' should be used as a prefix.
   - The rules for 'Stage number' (e.g., ID: 95, 96) indicated that stage numbers with letters should be converted to Roman numerals while retaining the letter. Therefore, 'Stage 3B' was normalized to 'Stage IIIB'.
   - Generic rules for Title Casing and singular form were applied.
5. **Indication Construction**: The identified and normalized components were combined in a clinically logical order, resulting in 'Newly Diagnosed Stage IIIB Light Chain Amyloidosis'.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules, is derived from a single source, and accurately represents the patient population described in the title.","[{'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format the 'Stage 3B' component.""}, {'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To handle the 'Newly Diagnosed' patient subgroup.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease.""}, {'component': 'Stage 3B', 'type': 'Stage', 'normalized_form': 'Stage IIIB', 'rule_applied': 'Rule pattern from Stage number rules (e.g., ID 95, 96) - Convert Arabic numeral to Roman numeral.'}, {'component': 'Light Chain Amyloidosis', 'type': 'Disease', 'normalized_form': 'Light Chain Amyloidosis', 'rule_applied': 'Generic Rule - Title Case and singular form.'}]",2
164266,Society for Basic Urologic Research (SBUR),Welcome and Introductory Remarks,,,Urologic Disease,True,session_title,"Step 1: The abstract title 'Welcome and Introductory Remarks' contains no medical or disease terms and is discarded.
Step 2: The session title 'Society for Basic Urologic Research (SBUR)' contains the term 'Urologic', which is a therapeutic area.
Step 3: According to the 'Therapeutic Area Fallback' generic rule, when a title only specifies a therapeutic area, a valid overarching disease should be used.
Step 4: The therapeutic area 'Urologic' is converted to the standard overarching disease name 'Urologic Disease'.
Step 5: The final indication is formatted to Title Case and non-disease terms ('Society for Basic', 'Research', '(SBUR)') are excluded.",[],"[{'component': 'Urologic', 'type': 'Therapeutic Area', 'normalized_form': 'Urologic Disease', 'rule_applied': 'Therapeutic Area Fallback'}]",1
213425,MP08: Pediatric Urology: Penis & Scrotum,Long Term Fertility Implications Following Adolescent Testicular Torsion: A Retrospective Analysis of a New York State All-Payer Database,,,Adolescent Testicular Torsion,True,abstract_title,"Step 1: The abstract title contains a specific disease ('Testicular Torsion'), while the session title contains a therapeutic area and anatomical locations. Therefore, the abstract title was chosen as the source based on the single-source principle.
Step 2: The core components were identified from the abstract title: the disease 'Testicular Torsion' and the patient subgroup 'Adolescent'.
Step 3: To ensure correct formatting for the age group, a rule lookup was performed for 'Adolescent' using `get_indication_rules`.
Step 4: Generic exclusion rules were applied to remove non-diagnostic information, including the outcome ('Long Term Fertility Implications'), the temporal qualifier ('Following'), and study design details ('A Retrospective Analysis of a New York State All-Payer Database').
Step 5: The retrieved rules (specifically ID 318 and 319) confirmed that 'Adolescent' should be prepended to the disease name.
Step 6: The final indication was constructed by combining the normalized patient subgroup and the disease, resulting in 'Adolescent Testicular Torsion'.","[{'category': 'Age Group', 'subcategories': ['Adolescent'], 'reason': ""To verify the correct formatting and placement of the 'Adolescent' patient subgroup qualifier.""}]","[{'component': 'Adolescent', 'type': 'Age Group', 'normalized_form': 'Adolescent', 'rule_applied': 'Age Group rule ID 318/319: Prepend singular, Title Case age group to the disease name.'}, {'component': 'Testicular Torsion', 'type': 'Disease', 'normalized_form': 'Testicular Torsion', 'rule_applied': 'Generic Rule: Use Title Case and singular form for disease names.'}]",3
295345,Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?,Presentation by Expert,Chronic lymphocytic leukemia,Chronic Lymphocytic Leukemia,First-Line Chronic Lymphocytic Leukemia,True,session_title,"Step-by-step explanation of the extraction process:
1.  **Source Selection**: The abstract title 'Presentation by Expert' contains no medical information. The session title 'Chronic lymphocytic leukemia (CLL): What is the optimal first-line therapy?' contains a clear disease and treatment context. Therefore, the session title was selected as the source based on the single-source principle.
2.  **Component Identification**: The key components identified in the session title are the disease 'Chronic lymphocytic leukemia (CLL)' and the treatment context 'first-line therapy'.
3.  **Rule Retrieval**: To correctly handle 'first-line therapy', I retrieved rules for the 'Treatment Set-up' category, specifically for the 'Line of treatment' subcategory.
4.  **Rule Application**:
    *   **Generic Rules**: The disease name was converted to Title Case ('Chronic Lymphocytic Leukemia'). The parenthetical abbreviation '(CLL)' was excluded as it is redundant.
    *   **Specific Rules**: Based on the retrieved 'Line of treatment' rules (specifically Rule ID 199 and 200), the phrase 'first-line therapy' is retained because 'first-line' is followed by the generic word 'therapy'. The rules mandate standardizing it to 'First-Line' and placing it at the beginning of the indication.
5.  **Indication Construction**: The standardized treatment line 'First-Line' was prepended to the normalized disease name 'Chronic Lymphocytic Leukemia' to form the final indication.
6.  **Quality Check**: The final indication adheres to all formatting and content rules. It is clinically accurate, correctly cased, and derived from a single source.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'first-line therapy' context.""}]","[{'component': 'Chronic lymphocytic leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'first-line therapy', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Treatment Set-up Rule ID 200: Standardize to 'First-Line' and place at the beginning of the indication.""}]",2
262577,Myeloma and other monoclonal gammopathies - Clinical,Incidence And Clinical Outcome Of Sars-Cov-2 Infection After Vaccination In Patients With Monoclonal Gammopathy Of Undetermined Significance (Mgus),Sars-Cov-2 Infection;;Monoclonal Gammopathy,Sars-Cov-2 Infection;;Monoclonal Gammopathy,SARS-CoV-2 Infection;;Monoclonal Gammopathy Of Undetermined Significance,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease terms ('Sars-Cov-2 Infection', 'Monoclonal Gammopathy Of Undetermined Significance').
Step 2: Two distinct diseases were identified in the title. The generic rule for multiple diseases was applied, requiring extraction of all diseases separated by ';;'.
Step 3: The first disease, 'Sars-Cov-2 Infection', was normalized to 'SARS-CoV-2 Infection' to maintain the standard acronym format.
Step 4: The second disease, 'Monoclonal Gammopathy Of Undetermined Significance (Mgus)', was processed. The parenthetical abbreviation '(Mgus)' was removed, and the full disease name was retained in Title Case.
Step 5: The procedural qualifier 'After Vaccination' was excluded as per the generic exclusion rules.
Step 6: The two extracted and normalized indications were combined using the ';;' separator to produce the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling titles that mention two distinct diseases.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Abbreviation'], 'reason': ""To check for rules regarding the handling of abbreviations like '(Mgus)'.""}]","[{'component': 'Sars-Cov-2 Infection', 'type': 'Disease', 'normalized_form': 'SARS-CoV-2 Infection', 'rule_applied': 'Generic Casing Rule - Maintain original all-caps form for acronyms.'}, {'component': 'Monoclonal Gammopathy Of Undetermined Significance (Mgus)', 'type': 'Disease', 'normalized_form': 'Monoclonal Gammopathy Of Undetermined Significance', 'rule_applied': 'Generic Formatting Rule - Remove parenthetical abbreviations when the full term is present.'}, {'component': 'After Vaccination', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude procedural/temporal qualifiers.'}]",2
295352,Young Oncologist Brunch 2: How to write and respond to a critical peer review,How to write and respond to a critical peer review,,,Cancer,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract_title 'How to write and respond to a critical peer review' contains no medical or disease-related terms. The session_title 'Young Oncologist Brunch 2: How to write and respond to a critical peer review' contains the term 'Oncologist'. Based on the single-source principle, the session_title is selected as it is the only one containing a relevant term.
2.  **Component Identification**: The key components in the session_title are 'Young' and 'Oncologist'.
3.  **Rule Retrieval**: Rules for the age group 'Young' were retrieved to determine its applicability. The term 'Oncologist' relates to the therapeutic area of Oncology.
4.  **Rule Application**: 
    *   The retrieved rules for 'Young' (IDs 308, 309) indicate that this term should be excluded as a non-specific age descriptor. Furthermore, in this context, 'Young' describes the professional (the oncologist), not a patient subgroup, so it is excluded under the sociodemographic exclusion rule.
    *   The generic rules specify a fallback for therapeutic areas. 'Oncologist' implies the therapeutic area 'Oncology', which is mapped to the overarching disease 'Cancer'.
5.  **Indication Construction**: The only valid component is 'Cancer', derived from 'Oncologist'.
6.  **Formatting**: The term 'Cancer' is already in singular form and Title Case. No further formatting is needed.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine how to handle the term 'Young' found in the session title.""}]","[{'component': 'Oncologist', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback generic rule (Oncology -> Cancer).'}, {'component': 'Young', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule for sociodemographic descriptors and specific rule ID 308 for 'Young'. The term describes the professional, not a patient cohort.""}]",2
410042,"APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases",Common Variants in Mendelian Disease Genes as Risk Factors for CKD,CKD,Chronic Kidney Disease,Chronic Kidney Disease;;Mendelian Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract_title is 'Common Variants in Mendelian Disease Genes as Risk Factors for CKD'. The session_title is 'APOL1, Nephrotic Syndrome, and HNF1B: Expanding Phenotypes and Mechanisms in Genetic Diseases'.
2. **Select Source**: The abstract_title contains specific disease terms ('Mendelian Disease', 'CKD') and is therefore selected as the primary source, following the Single-Source Extraction Principle.
3. **Identify Components**: The abstract_title identifies two distinct conditions: 'Mendelian Disease' and 'CKD' (Chronic Kidney Disease). The phrase 'as Risk Factors for' links them but both are valid medical conditions.
4. **Retrieve Rules**: I checked for rules related to 'Risk' and 'Patient with two different Disease'. The 'Risk' rules apply to specific stratifications (e.g., 'High-Risk', 'Low-Risk') and not the general term 'Risk Factors', so they are not applicable for modifying the indication. The generic rule for multiple diseases is to extract all of them.
5. **Apply Rules & Construct Indication**:
   - **Disease Identification**: Both 'Mendelian Disease' and 'CKD' are identified as distinct diseases mentioned in the title.
   - **Normalization**: 'CKD' is expanded to its full form 'Chronic Kidney Disease'.
   - **Formatting**: Both terms are converted to Title Case and singular form as per generic rules.
   - **Multiple Diseases**: According to the rule for multiple diseases, when a title mentions more than one distinct condition, all should be extracted and separated by ';;'. The title discusses variants in Mendelian Disease genes as risk factors for Chronic Kidney Disease, making both concepts central to the subject.
6. **Final Output**: The two extracted and normalized indications are combined using the ';;' separator, resulting in 'Chronic Kidney Disease;;Mendelian Disease'.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check how to handle titles with multiple potential diseases like 'Mendelian Disease' and 'CKD'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To determine how to handle the term 'Risk Factors' found in the abstract title.""}]","[{'component': 'CKD', 'type': 'Disease', 'normalized_form': 'Chronic Kidney Disease', 'rule_applied': 'Abbreviation expansion and Title Case rule.'}, {'component': 'Mendelian Disease', 'type': 'Disease', 'normalized_form': 'Mendelian Disease', 'rule_applied': 'Title Case and Singular form rule.'}, {'component': 'Risk Factors', 'type': 'Qualifier', 'normalized_form': '', 'rule_applied': ""General exclusion rule. 'Risk Factors' is a study descriptor, not a standard clinical patient subgroup like 'High-Risk' or 'Low-Risk', and is therefore excluded from the final indication.""}]",2
344512,"New Insights into Cancer Initiation, Evolution, Therapy and Survivorship through Big Data Analysis",Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss,cancer,Cancer ,TP53-Depleted Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Ordered and selective patterns of cancer genome evolution revealed by lineage tracing of sporadic p53 loss') was chosen over the session title because it contains a specific genetic event ('p53 loss') linked to a disease ('cancer'), making it more specific.
2. **Component Identification**: The key components identified in the abstract title are the disease 'cancer' and the genetic event 'p53 loss'.
3. **Rule Retrieval**: Rules for the 'Gene type' category were retrieved to correctly handle the genetic event 'p53 loss'.
4. **Rule Application**: 
   - The disease term 'cancer' was normalized to 'Cancer' using the generic Title Case and singular form rules.
   - The genetic event 'p53 loss' was processed. The gene 'p53' is standardized to its official HGNC symbol 'TP53'. The term 'loss' is handled by rules for gene depletion/deficiency (e.g., Rule ID 76 for 'Gene Depleted' which covers 'loss of'). This transforms 'TP53 loss' into the standardized format 'TP53-Depleted'.
5. **Indication Construction**: The normalized components were combined, with the genetic qualifier preceding the disease, resulting in 'TP53-Depleted Cancer'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular, no excluded terms) and is clinically accurate.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To find the correct rule for handling the 'p53 loss' genetic event.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': 'To check for any other rules related to genetic status that might apply.'}]","[{'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Title Case and singular form rules.'}, {'component': 'p53 loss', 'type': 'Gene Depletion', 'normalized_form': 'TP53-Depleted', 'rule_applied': ""Rule for 'Gene Depleted' (ID: 76), which standardizes 'loss of' a gene to the '<Gene>-Depleted' format, and standardization of 'p53' to 'TP53'.""}]",2
295362,ESMO Colloquium Supported by Eisai Europe Ltd.: Optimising outcomes of patients with advanced renal cancer,State of the art first-line management of patients with advanced RCC,advanced;;RCC,Advanced Renal Cell Carcinoma,First-Line Advanced Renal Cell Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('State of the art first-line management of patients with advanced RCC') was chosen over the session title because it contains a specific disease term ('RCC') and provides a complete context for the indication. The Single-Source Extraction Principle dictates using the abstract title first.
2.  **Component Identification**: I identified three key components in the abstract title: 'first-line' (treatment line), 'advanced' (disease stage), and 'RCC' (disease).
3.  **Rule Retrieval**: I retrieved rules for 'Stage', 'Treatment Set-up', and 'Patient Sub-Group' to correctly handle these components.
4.  **Component Normalization & Rule Application**:
    *   **Disease**: 'RCC' is a standard medical acronym for 'Renal Cell Carcinoma'. This was expanded and normalized to 'Renal Cell Carcinoma' in Title Case, following generic formatting rules.
    *   **Stage**: The term 'advanced' was identified as a stage descriptor. Based on staging rules, it is prepended to the disease name and formatted as 'Advanced'.
    *   **Treatment Line**: The term 'first-line' modifies 'management', which is a generic term. According to the retrieved 'Line of treatment' rules (specifically Rule ID 199 and 200), when a line descriptor is not followed by a specific drug name, it should be retained, normalized to 'First-Line', and placed at the beginning of the indication.
5.  **Indication Construction**: The normalized components were assembled in the correct clinical order: Treatment Line -> Stage -> Disease. This resulted in 'First-Line Advanced Renal Cell Carcinoma'.
6.  **Exclusion**: Non-diagnostic phrases like 'State of the art', 'management of', and 'patients with' were excluded as per the generic exclusion rules.
7.  **Final Quality Check**: The final indication was checked for compliance with all formatting rules (Title Case, singular form, no trailing spaces) and clinical accuracy.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine the correct handling and formatting of the term 'advanced'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To verify whether 'first-line' should be included in the indication and how to format it.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'To check for any other rules related to disease characterization that might apply.'}]","[{'component': 'first-line', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': ""Treatment Set-up rule (ID: 200) for retaining and standardizing line of treatment when modifying a generic term like 'management'.""}, {'component': 'advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic rule for prepending stage descriptors to the disease name and applying Title Case.'}, {'component': 'RCC', 'type': 'Disease', 'normalized_form': 'Renal Cell Carcinoma', 'rule_applied': 'Standard medical acronym expansion and generic formatting rules (Title Case, singular form).'}]",2
311747,"Experts Roundtable: Current and Future Payment Models, MIPS, and Other Hot Topics in Practice Management",Q&A,,,,True,none,"Neither the abstract title ('Q&A') nor the session title ('Experts Roundtable: Current and Future Payment Models, MIPS, and Other Hot Topics in Practice Management') contains any specific disease, disorder, or clinically relevant medical term. The titles refer to practice management and a Q&A session, from which no medical indication can be extracted.",[],[],1
344518,Late-Breaking Research: Chemistry,BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules,,,,True,none,"The abstract title describes a drug (BI 907828) and its mechanism of action (MDM2-p53 antagonist) but does not explicitly state a disease, disorder, or patient population. The session title, 'Late-Breaking Research: Chemistry', is a broad, non-clinical research area. According to the single-source principle, a disease or condition must be present in one of the titles to extract an indication. Since neither title contains a valid medical indication, no extraction is possible.",[],[],1
377287,Infections and SCT complications,"A Novel Approach Of Dual Metagenomics Next-Generation Sequencing For Early Diagnosis Of Blood Stream Infection In Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study",Febrile Neutropenia,Febrile Neutropenia,Blood Stream Infection;;Febrile Neutropenia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('A Novel Approach Of Dual Metagenomics Next-Generation Sequencing For Early Diagnosis Of Blood Stream Infection In Hematologic Patients With Febrile Neutropenia: A Multicenter, Prospective Study') was chosen over the session title ('Infections and SCT complications') because it contains specific, well-defined medical conditions, adhering to the single-source principle.
2.  **Component Identification**: The abstract title clearly identifies two distinct medical conditions: 'Blood Stream Infection' and 'Febrile Neutropenia'. The term 'Hematologic Patients' describes the patient population but is a broad descriptor of a patient type rather than a specific disease qualifier, so it is excluded based on the principle of creating concise, disease-focused indications.
3.  **Rule Retrieval**: I initiated a search for rules related to handling multiple diseases ('Patient with two different Disease') and patient characterization ('Patient Sub-Group'). No specific rule for combining these particular conditions was found, so I proceeded with the generic rules.
4.  **Rule Application**: The generic rule for 'Multiple Diseases' was applied. This rule mandates that if a title mentions multiple distinct diseases, all should be extracted and separated by a double semicolon (';;').
5.  **Indication Construction**: The identified diseases were normalized according to the generic formatting rules:
    *   'Blood Stream Infection' was kept as is (already Title Case and singular).
    *   'Febrile Neutropenia' was kept as is (already Title Case and singular).
    *   The two indications were combined using the ';;' separator.
6.  **Final Quality Check**: The final output 'Blood Stream Infection;;Febrile Neutropenia' was reviewed to ensure it is clinically accurate, follows all formatting guidelines (Title Case, singular, no trailing spaces), and adheres to the single-source principle.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To check for specific rules on how to handle two distinct conditions mentioned for the same patient group.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine if 'Hematologic Patients' should be included as a qualifier.""}]","[{'component': 'Blood Stream Infection', 'type': 'Disease', 'normalized_form': 'Blood Stream Infection', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Febrile Neutropenia', 'type': 'Disease', 'normalized_form': 'Febrile Neutropenia', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Hematologic Patients', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Broad patient group descriptors are excluded to maintain conciseness.'}]",2
410057,Maternal and Environmental Factors: Effect on Kidney Formation and Function,Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm,Kidney Injury,Kidney Injury,Extreme Preterm Kidney Injury,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Mechanisms of Kidney Injury and Lower Endowment in the Extreme Preterm') was chosen as the source because it contains a specific medical condition ('Kidney Injury'), whereas the session title ('Maternal and Environmental Factors: Effect on Kidney Formation and Function') describes physiological processes rather than a distinct disease.
2.  **Component Identification**: From the abstract title, two key components were identified: the disease 'Kidney Injury' and the patient subgroup 'Extreme Preterm'.
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category to determine how to handle terms like 'Preterm'. While no specific rule for 'Extreme Preterm' was found, the general principle from related rules (e.g., for 'Pediatric', 'Neonatal') is to retain clinically significant age-based subgroups as a prefix to the disease.
4.  **Rule Application & Normalization**:
    *   The disease term 'Kidney Injury' is already in the correct singular form and Title Case.
    *   The patient subgroup 'Extreme Preterm' is a critical clinical qualifier. It was converted to Title Case.
    *   Generic exclusion rules were applied to discard non-diagnostic terms like 'Mechanisms' and 'Lower Endowment'.
5.  **Indication Construction**: The patient subgroup was prepended to the disease to form the final indication: 'Extreme Preterm Kidney Injury'.
6.  **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately represents the clinical focus of the abstract title.","[{'category': 'Age Group', 'subcategories': ['Young', 'Pediatric'], 'reason': ""To check for rules on handling age-related patient subgroups like 'Extreme Preterm'.""}]","[{'component': 'Kidney Injury', 'type': 'Disease', 'normalized_form': 'Kidney Injury', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}, {'component': 'Extreme Preterm', 'type': 'Patient Sub-Group (Age)', 'normalized_form': 'Extreme Preterm', 'rule_applied': 'Generic Rule: Include clinically significant patient subgroups, Title Case'}]",2
213477,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",Endoscopic Injection Of The Bladder Neck Using Dextranomer Hyaluronate (Dx/Ha) In The Pediatric Patient: Results Of A Single Center Analysis With Long Term Follow Up,Neurogenic Bladder;;Pediatric,Pediatric Neurogenic Bladder,Pediatric Neurogenic Bladder;;Pediatric Urologic Emergency,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Endoscopic Injection Of The Bladder Neck...') describes a procedure and patient group but does not name a specific disease. The session title ('MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies') contains multiple clear medical conditions. Therefore, the session title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: From the session title, the following components were identified: 'Pediatric' (age group), 'Neurogenic Bladder' (disease), and 'Urologic Emergencies' (disease). 'Reconstruction' was identified as a procedural term to be excluded.
3.  **Rule Retrieval**: The `get_indication_rules` tool was used for the category 'Age Group' and subcategory 'Pediatric' to ensure the correct application of the age qualifier.
4.  **Rule Application and Construction**:
    *   The term 'Pediatric' from 'Pediatric Urology' sets the context for the subsequent conditions. The retrieved rules (e.g., Rule ID 295) mandate prepending 'Pediatric' to the indication.
    *   'Neurogenic Bladder' is a valid indication and is kept as is.
    *   'Urologic Emergencies' is a valid indication. The generic rule for singular form was applied, converting it to 'Urologic Emergency'.
    *   The 'Pediatric' qualifier was prepended to both identified conditions.
    *   The two resulting indications were combined using the required ';;' separator.
5.  **Final Quality Check**: The final output adheres to all formatting rules (Title Case, singular form, no trailing spaces) and exclusion criteria ('Reconstruction' was removed).","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier identified in the session title.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295/296)""}, {'component': 'Neurogenic Bladder', 'type': 'Disease', 'normalized_form': 'Neurogenic Bladder', 'rule_applied': 'Generic rule for disease name formatting (Title Case).'}, {'component': 'Urologic Emergencies', 'type': 'Disease', 'normalized_form': 'Urologic Emergency', 'rule_applied': 'Generic rule for converting plural disease terms to singular.'}, {'component': 'Reconstruction', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural terms.'}]",2
213478,"MP11: Pediatric Urology: Neurogenic Bladder, Reconstruction & Urologic Emergencies",A Technique to Prevent Stomal Stenosis in Reconstructive Urology,,,Pediatric Neurogenic Bladder;;Pediatric Urologic Emergency,True,session_title,"The abstract title's potential indication, 'Stomal Stenosis', was identified as an excludable complication based on the context ('A Technique to Prevent...'). Therefore, the abstract title was determined to contain no primary disease, triggering a fallback to the session title per the single-source principle. The session title provided the age group 'Pediatric' and two distinct conditions: 'Neurogenic Bladder' and 'Urologic Emergencies'. 'Urologic Emergencies' was converted to its singular form. The 'Pediatric' qualifier was prepended to both conditions, and they were joined by the ';;' separator.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Severity'], 'reason': ""To check if 'Emergencies' required specific severity rules, though generic rules were ultimately sufficient.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule: Prepend to disease name.'}, {'component': 'Neurogenic Bladder', 'type': 'Disease', 'normalized_form': 'Neurogenic Bladder', 'rule_applied': 'Generic rule: Title Case.'}, {'component': 'Urologic Emergencies', 'type': 'Disease', 'normalized_form': 'Urologic Emergency', 'rule_applied': 'Generic rule: Convert plural to singular.'}, {'component': 'Reconstruction', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude procedural terms.'}, {'component': 'Stomal Stenosis', 'type': 'Complication', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule: Exclude complications/adverse effects.'}]",2
410094,"Liquid ""Gold,"" Urinary Sediment Microscopy: Current Utility of an Old Tool",Value of Urine Microscopy in Clinical Practice: Illustration by Cases,,,,True,none,"Neither the abstract title nor the session title contains a specific disease or disorder. Both titles focus on a diagnostic procedure ('Urine Microscopy', 'Urinary Sediment Microscopy') and its general utility in clinical practice, rather than a condition being studied or treated. According to the rules, an indication cannot be extracted without a disease term. Therefore, no valid medical indication can be generated.",[],[],1
311793,Fellows-In-Training: Roundtables,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) IV,Adult;;Pediatric;;Rheumatology,Adult Pediatric Rheumatic Disease,Adult Rheumatic Disease;;Pediatric Rheumatic Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) IV') was chosen as it contains medical terms. The session title ('Fellows-In-Training: Roundtables') is non-specific and was discarded.
2. **Component Identification**: The key components identified in the abstract title are the patient age groups 'Adult' and 'Pediatric', and the therapeutic area 'Rheumatology'.
3. **Rule Retrieval**: To ensure correct formatting for the age group qualifiers, rules for 'Adult' and 'Pediatric' were retrieved using the `get_indication_rules` tool.
4. **Indication Normalization**: The term 'Rheumatology' is a medical specialty, not a specific disease. To create a clinically valid indication, it was normalized to the overarching disease category 'Rheumatic Disease'.
5. **Rule Application**: The retrieved age group rules confirmed that 'Adult' and 'Pediatric' should be used as capitalized prefixes. The generic rule for multiple indications was applied to handle the 'and' conjunction.
6. **Indication Construction**: Two distinct indications were constructed by prepending the age group qualifiers to the normalized disease term: 'Adult Rheumatic Disease' and 'Pediatric Rheumatic Disease'.
7. **Final Formatting**: The two indications were combined into a single string using the required ';;' separator, resulting in the final output.","[{'category': 'Age Group', 'subcategories': ['Adult', 'Pediatric'], 'reason': ""To ensure correct formatting and placement of the 'Adult' and 'Pediatric' patient subgroup qualifiers.""}]","[{'component': 'Rheumatology', 'type': 'Therapeutic Area', 'normalized_form': 'Rheumatic Disease', 'rule_applied': 'Therapeutic Area Fallback principle and requirement for clinical accuracy.'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule (ID: 289, 290) to use as a capitalized prefix.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule (ID: 295, 296) to use as a capitalized prefix.'}]",2
311791,Fellows-In-Training: Roundtables,Roundtable 04 - Career in Private Practice (Adult and Pediatric Rheumatology) III,,,Adult Rheumatologic Disease;;Pediatric Rheumatologic Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains the medical term 'Rheumatology', while the session title does not contain any disease or condition.
2. **Component Identification**: The abstract title identifies a therapeutic area, 'Rheumatology', and two distinct patient age groups, 'Adult' and 'Pediatric'.
3. **Rule Retrieval**: Rules for the 'Age Group' category, specifically for 'Adult' and 'Pediatric' subcategories, were retrieved to ensure correct formatting.
4. **Indication Construction**: Based on the generic rule for therapeutic areas, 'Rheumatology' is mapped to the overarching disease 'Rheumatologic Disease'. Since two distinct age groups are mentioned, two separate indications are generated.
5. **Rule Application**: The retrieved age group rules specify that 'Adult' and 'Pediatric' should be used as capitalized prefixes to the disease term.
6. **Formatting**: The two resulting indications, 'Adult Rheumatologic Disease' and 'Pediatric Rheumatologic Disease', are combined using the required ';;' separator. All terms are formatted in Title Case and singular form.","[{'category': 'Age Group', 'subcategories': ['Adult', 'Pediatric'], 'reason': ""To correctly format the 'Adult' and 'Pediatric' patient population descriptors.""}]","[{'component': 'Rheumatology', 'type': 'Therapeutic Area', 'normalized_form': 'Rheumatologic Disease', 'rule_applied': 'Generic rule for Therapeutic Area Fallback.'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' (ID: 289).""}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295).""}]",2
311808,Fellows-In-Training: Roundtables,Roundtable 08 - How to Establish a Career Niche IV,,,,True,none,"Neither the abstract title ('Roundtable 08 - How to Establish a Career Niche IV') nor the session title ('Fellows-In-Training: Roundtables') contains any mention of a disease, disorder, or any other clinically valid medical term. The titles refer to professional development and meeting formats, not medical conditions. Therefore, no indication can be extracted.",[],[],1
393754,Neuroendocrine Tumours,"A Phase II Single-Arm Interventional Trial Evaluating The Activity And Safety Of Cabozantinib (Cbz) Plus Temozolomide (Tmz) In Lung And Gastroenteropancreatic Neuroendocrine Neoplasms (Gep-Nens) Progressed After Ssa Therapy, Everolimus, Sunitinib Or Prrt: Cabotem Trial",Lung;;Gastroenteropancreatic Neuroendocrine Neoplasms,Lung Neuroendocrine Neoplasm;;Gastroenteropancreatic Neuroendocrine Neoplasm ,Progressive Lung Neuroendocrine Neoplasm;;Progressive Gastroenteropancreatic Neuroendocrine Neoplasm,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Lung And Gastroenteropancreatic Neuroendocrine Neoplasms'), making it the primary source according to the single-source principle.
2. **Component Identification**: I identified two distinct diseases: 'Lung Neuroendocrine Neoplasms' and 'Gastroenteropancreatic Neuroendocrine Neoplasms'. I also identified the keyword 'Progressed' as a patient subgroup qualifier.
3. **Rule Retrieval**: To correctly handle the term 'Progressed', I retrieved rules for disease progression using `get_indication_rules(category='Occurrence', subcategories=['Progression-Related'])`.
4. **Rule Application**:
   - **Specific Rule**: I applied Rule ID 187 for the keyword 'Progressed', which dictates replacing it with 'Progressive' when used as an adjective describing the disease state.
   - **Generic Rules**: 
     - **Multiple Diseases**: The conjunction 'And' indicates two separate diseases, which must be separated by ';;'.
     - **Singular Form**: The plural 'Neoplasms' was converted to its singular form 'Neoplasm'.
     - **Title Case**: The output was formatted in Title Case.
     - **Exclusion**: Treatment history ('After Ssa Therapy, Everolimus, Sunitinib Or Prrt') was excluded as per the rules on procedural/temporal qualifiers.
5. **Indication Construction**: The qualifier 'Progressive' was prepended to each of the two identified diseases, and they were combined with the ';;' separator.
6. **Final Quality Check**: The final output was reviewed for compliance with all formatting, accuracy, and completeness requirements.","[{'category': 'Occurrence', 'subcategories': ['Progression-Related'], 'reason': ""To determine the correct handling of the term 'Progressed' found in the abstract title.""}]","[{'component': 'Lung Neuroendocrine Neoplasms', 'type': 'Disease', 'normalized_form': 'Lung Neuroendocrine Neoplasm', 'rule_applied': 'Generic rule: Singular Form'}, {'component': 'Gastroenteropancreatic Neuroendocrine Neoplasms', 'type': 'Disease', 'normalized_form': 'Gastroenteropancreatic Neuroendocrine Neoplasm', 'rule_applied': 'Generic rule: Singular Form'}, {'component': 'Progressed', 'type': 'Disease State/Occurrence', 'normalized_form': 'Progressive', 'rule_applied': ""Occurrence rule (ID: 187) for 'Progressed'""}]",2
377370,Acute lymphoblastic leukemia - Biology & Translational Research,Subclonal And Clonal Variants In Tp53 And Kras Combined With Poor Treatment Response Identify A Subgroup Of Ultra-High-Risk Patients Of Pediatric T-Lymphoblastic Leukemia (T-All),Tp53;;Kras;;Ultra-High-Risk;;Pediatric;;T-Lymphoblastic Leukemia,TP53-Mutated KRAS-Mutated Ultra High-Risk Pediatric T-Lymphoblastic Leukemia,Pediatric Ultra High-Risk T-Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('Pediatric T-Lymphoblastic Leukemia') which is more precise than the broader category in the session title ('Acute lymphoblastic leukemia').
2.  **Component Identification**: I identified the core components from the abstract title: 'Pediatric' (Age Group), 'Ultra-High-Risk' (Risk Level), and 'T-Lymphoblastic Leukemia (T-All)' (Disease).
3.  **Rule Retrieval**: I retrieved rules for 'Age Group' (specifically 'Pediatric'), 'Risk' (specifically 'High-Risk' which includes 'Ultra High-Risk'), and 'Treatment based' to evaluate 'Poor Treatment Response'.
4.  **Rule Application**: 
    - The 'Pediatric' rule (ID: 295) confirms it should be the leading word.
    - The 'Ultra High-Risk' rule (ID: 134) confirms normalization to 'Ultra High-Risk' and placement before the disease name.
    - 'Poor Treatment Response' was excluded as it describes a clinical outcome used to identify the risk group, rather than being a standard part of the indication itself (like 'Refractory' or 'Relapsed').
    - Generic rules were applied to use Title Case, singular form, and remove non-diagnostic words like 'Patients of'.
5.  **Indication Construction**: The components were assembled in the correct order: Age Group -> Risk Level -> Disease. This resulted in 'Pediatric Ultra High-Risk T-Lymphoblastic Leukemia'. The abbreviation (T-All) was omitted in favor of the full disease name for clarity.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' age group qualifier.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly format the 'Ultra-High-Risk' qualifier.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To determine how to handle the phrase 'Poor Treatment Response'.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295) - Place 'Pediatric' as the leading word.""}, {'component': 'Ultra-High-Risk', 'type': 'Risk', 'normalized_form': 'Ultra High-Risk', 'rule_applied': ""Risk rule (ID: 134) - Normalize to 'Ultra High-Risk' and place before the disease name.""}, {'component': 'T-Lymphoblastic Leukemia (T-All)', 'type': 'Disease', 'normalized_form': 'T-Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule - Use singular form and Title Case.'}, {'component': 'Poor Treatment Response', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule - Excluded as it's a clinical outcome, not a standard indication qualifier.""}]",2
377385,Chronic myeloid leukemia - Clinical,Impacts On Outcomes And A Predictive Model Of Severe Thrombocytopenia In Patients With Chronic Phase Chronic Myeloid Leukemia Receiving Initial Nilotinib-Therapy,Severe;;Thrombocytopenia;;Chronic Phase;;Chronic Myeloid Leukemia,Severe Thrombocytopenia;;Chronic Phase Chronic Myeloid Leukemia,Chronic Phase Chronic Myeloid Leukemia;;Severe Thrombocytopenia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Impacts On Outcomes And A Predictive Model Of Severe Thrombocytopenia In Patients With Chronic Phase Chronic Myeloid Leukemia Receiving Initial Nilotinib-Therapy') was chosen over the session title ('Chronic myeloid leukemia - Clinical') because it is more specific and contains all the necessary clinical details, adhering to the single-source principle.
2.  **Component Identification**: The abstract title identified two distinct medical conditions: 'Severe Thrombocytopenia' and 'Chronic Phase Chronic Myeloid Leukemia'. The phrase 'Receiving Initial Nilotinib-Therapy' was identified as a procedural/temporal qualifier.
3.  **Rule Retrieval**: Rules for 'Stage', 'Treatment Set-up', 'Risk', and handling multiple diseases were considered. The 'Treatment Set-up' rules confirmed that treatment details like 'Receiving Initial Nilotinib-Therapy' should be excluded, especially when a specific drug is named. The generic rule for multiple diseases was applied.
4.  **Rule Application & Construction**:
    *   The first condition was constructed by combining the qualifier 'Chronic Phase' with the disease 'Chronic Myeloid Leukemia'. The term 'Chronic' is an integral part of the disease name and was retained. The result is 'Chronic Phase Chronic Myeloid Leukemia'.
    *   The second condition was identified as 'Severe Thrombocytopenia'. 'Severe' is a valid clinical descriptor for the condition.
    *   The procedural phrase 'Receiving Initial Nilotinib-Therapy' was excluded as per generic exclusion rules.
    *   The two distinct indications were combined using the ';;' separator as required by the formatting rules.
5.  **Final Formatting**: The final output was formatted to Title Case and singular form, resulting in 'Chronic Phase Chronic Myeloid Leukemia;;Severe Thrombocytopenia'.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for rules regarding disease phases like 'Chronic Phase'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment', 'Treatment Status'], 'reason': ""To determine how to handle 'Receiving Initial Nilotinib-Therapy'.""}, {'category': 'Risk', 'subcategories': ['severe'], 'reason': ""To check for rules on handling severity descriptors like 'Severe'.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling two distinct conditions mentioned in the title.'}]","[{'component': 'Severe Thrombocytopenia', 'type': 'Disease with Severity', 'normalized_form': 'Severe Thrombocytopenia', 'rule_applied': 'Generic rule for including severity descriptors; Multiple Disease rule.'}, {'component': 'Chronic Phase Chronic Myeloid Leukemia', 'type': 'Disease with Stage', 'normalized_form': 'Chronic Phase Chronic Myeloid Leukemia', 'rule_applied': 'Generic rule for including disease phase; Multiple Disease rule.'}, {'component': 'Receiving Initial Nilotinib-Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
148013,Indolent And Mantle-Cell Non-Hodgkin Lymphoma - Clinical,Prevalence Of Second Cancer During Long Term Follow-Up In Hairy Cell Leukemia Patients Treated With Cladribine: A Thirty-Year Experience,Hairy Cell Leukemia,Hairy Cell Leukemia,Hairy Cell Leukemia;;Second Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'Prevalence Of Second Cancer During Long Term Follow-Up In Hairy Cell Leukemia Patients Treated With Cladribine: A Thirty-Year Experience' contains specific disease terms. The session title also contains disease terms, but the Single-Source Extraction Principle dictates using the abstract title first.
2. **Identify Components**: The abstract title identifies two distinct clinical conditions: 'Hairy Cell Leukemia' and 'Second Cancer'. It also contains the phrase 'Treated With Cladribine'.
3. **Retrieve Relevant Rules**: I retrieved rules for 'Treatment based' to determine how to handle 'Treated With...'. The retrieved rules focus on treatment status (e.g., 'Previously Treated', 'Untreated') and do not apply here. The generic exclusion rule for 'Procedural/Temporal Qualifiers' is more relevant, which states to exclude terms describing treatment procedures ('receiving', 'treated with'). I also checked for rules on handling two diseases, but none were found, so the generic rule of separating with ';;' applies.
4. **Apply Rules**: 
   - **Disease Extraction**: 'Hairy Cell Leukemia' is extracted as a primary indication. 'Second Cancer' is also extracted as a distinct indication, consistent with the generic rule for 'Second Primary'.
   - **Exclusion**: The phrase 'Treated With Cladribine' is excluded as it describes a specific treatment modality, not the core indication itself. 'Patients' and temporal phrases like 'Long Term Follow-Up' and 'A Thirty-Year Experience' are also excluded per generic rules.
   - **Multiple Diseases**: The two extracted indications are treated as separate entities and are separated by the ';;' delimiter as per the generic rule.
   - **Formatting**: Both indications are converted to Title Case and are in singular form.
5. **Construct Indication**: The final indication is constructed by combining the two normalized disease terms: 'Hairy Cell Leukemia' and 'Second Cancer', separated by ';;'.
6. **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies the two distinct clinical entities from the single, preferred source (abstract title) and excludes non-indicative information.","[{'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To check for rules regarding the phrase 'Treated With Cladribine'. The retrieved rules were not applicable, leading to the use of generic exclusion rules.""}, {'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To check for specific formatting rules when a title mentions two distinct cancers. No specific rules were found, so the generic ';;' separator rule was applied.""}]","[{'component': 'Hairy Cell Leukemia', 'type': 'Disease', 'normalized_form': 'Hairy Cell Leukemia', 'rule_applied': 'Generic rule: Disease name extraction and Title Case formatting.'}, {'component': 'Second Cancer', 'type': 'Disease', 'normalized_form': 'Second Cancer', 'rule_applied': ""Generic rule: 'Second Primary' rule adapted for 'Second Cancer', indicating a subsequent malignancy.""}, {'component': 'Treated With Cladribine', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Excluded as it describes a specific treatment, not a patient subgroup for the indication.'}]",2
295477,Mini Oral session: Basic science & translational research,5-hydroxymethycytosine analysis reveals stable epigenetic changes in tumor tissue that enable cfDNA cancer predictions,,,Cancer,True,abstract_title,"Step 1: The abstract title contains the disease terms 'tumor' and 'cancer', while the session title is about the research area ('Basic science & translational research') and does not contain a specific disease. Therefore, the abstract title is selected as the source.
Step 2: The disease terms identified are 'tumor' and 'cancer'. The rest of the title describes the methodology ('5-hydroxymethycytosine analysis', 'cfDNA predictions') and biological context ('epigenetic changes', 'tumor tissue'), not specific patient subgroups or disease characteristics.
Step 3: According to the generic rules, disease terms should be in singular form and Title Case. 'tumor' is normalized to 'Tumor' and 'cancer' is normalized to 'Cancer'.
Step 4: Since 'tumor' and 'cancer' refer to the same general disease concept in this context, the most standard and overarching term 'Cancer' is used for the final indication. No specific rules needed to be retrieved as the terms are general.",[],"[{'component': 'tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}, {'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Title Case'}]",1
328247,Aggressive Lymphomas: Prospective Therapeutic Trials: Poster I,Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and >=65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and >=1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study,Aged <65;;Relapsed;;Refractory;;Diffuse Large B-Cell Lymphoma,Elderly Relapsed/Refractory Diffuse Large B-Cell Lymphoma,Relapsed/Refractory Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease name ('Diffuse Large B-Cell Lymphoma'), making it the primary source according to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were:
    *   Disease: 'Diffuse Large B-Cell Lymphoma (DLBCL)'
    *   Disease State/Occurrence: 'Relapsed/Refractory (R/R)'
    *   Treatment History: '>=1 Prior Therapy'
    *   Excluded Elements: Age groups ('Aged <65 and >=65 Years') were identified as study analysis subgroups, not core indication characteristics, and were excluded per generic rules.
3.  **Rule Retrieval**: Rules for 'Occurrence' (specifically 'Recurrent/Refractory') and 'Treatment based' (specifically 'Treatment Status') were retrieved to handle the patient subgroup descriptors.
4.  **Rule Application and Refinement**:
    *   The disease name was standardized to 'Diffuse Large B-Cell Lymphoma' in Title Case and singular form.
    *   'Relapsed/Refractory' was identified as the primary patient subgroup qualifier.
    *   The term '>=1 Prior Therapy' is clinically synonymous with 'Previously Treated'. However, the term 'Relapsed/Refractory' inherently implies that a patient has received prior therapy, making the inclusion of 'Previously Treated' redundant. To create the most concise and clinically accurate indication, 'Previously Treated' was omitted.
5.  **Indication Construction**: The final indication was constructed by prepending the standardized disease state ('Relapsed/Refractory') to the core disease name.
6.  **Final Quality Check**: The generated indication was verified against all formatting, exclusion, and clinical accuracy rules. It correctly uses Title Case, singular form, and accurately represents the patient population from the source title.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly format the 'Relapsed/Refractory' patient subgroup.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To understand how to handle the '>=1 Prior Therapy' component and its relationship with other descriptors.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for standardizing disease state qualifiers.'}, {'component': 'Diffuse Large B-Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': '>=1 Prior Therapy', 'type': 'Treatment Status', 'normalized_form': 'Previously Treated', 'rule_applied': ""Treatment Status rule. This component was ultimately excluded for being clinically redundant with 'Relapsed/Refractory'.""}, {'component': 'Aged <65 and >=65 Years', 'type': 'Age Group', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors not integral to the disease name.'}]",2
229946,PD09: Infertility: Epidemiology & Evaluation I,Low birth weight is associated with sperm DNA fragmentation and assisted reproductive technology outcomes in primary infertile men - results of a cross-sectional study,,,Primary Infertility,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a more specific disease term ('primary infertile men') compared to the session title ('Infertility').
Step 2: The core disease term 'infertile' was identified.
Step 3: The qualifier 'primary' was identified.
Step 4: The gender descriptor 'men' was identified for exclusion.
Step 5: The generic rules were applied. 'infertile' was converted to its singular, Title Case form: 'Infertility'. The qualifier 'primary' was prepended to the disease name, resulting in 'Primary Infertility'. The sociodemographic descriptor 'men' was excluded as per the generic exclusion rules. Other terms like 'Low birth weight' and 'sperm DNA fragmentation' were identified as associated conditions or findings, not the primary indication under study.",[],"[{'component': 'primary infertile men', 'type': 'Disease with Qualifier and Gender', 'normalized_form': 'Primary Infertility', 'rule_applied': ""Single-Source Principle; Generic Rule for 'Primary'; Generic Rule for Singular Form; Generic Rule for Sociodemographic Exclusion (Gender)""}]",1
262725,"Quality of life, palliative care, ethics and health economics",Economic Burden Of Transfusion-Dependent Beta-Thalassemia In The United States,Beta-Thalassemia,Beta-Thalassemia,Transfusion-Dependent Beta-Thalassemia,True,abstract_title,"Step 1: The abstract title 'Economic Burden Of Transfusion-Dependent Beta-Thalassemia In The United States' was chosen as the source because it contains a specific disease, whereas the session title 'Quality of life, palliative care, ethics and health economics' does not.
Step 2: The core disease 'Beta-Thalassemia' was identified.
Step 3: The patient subgroup qualifier 'Transfusion-Dependent' was identified. This is a critical clinical descriptor defining a specific cohort of patients and must be included.
Step 4: The non-diagnostic phrase 'Economic Burden Of' and the geographic descriptor 'In The United States' were identified for exclusion based on generic rules.
Step 5: The components were combined and formatted according to the rules. The final indication was converted to Title Case, resulting in 'Transfusion-Dependent Beta-Thalassemia'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on how to handle disease qualifiers like 'Transfusion-Dependent'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To determine if 'Transfusion-Dependent' should be handled as a treatment status qualifier.""}]","[{'component': 'Transfusion-Dependent', 'type': 'Patient Subgroup', 'normalized_form': 'Transfusion-Dependent', 'rule_applied': 'Generic rule: Include clinically valid patient subgroups.'}, {'component': 'Beta-Thalassemia', 'type': 'Disease', 'normalized_form': 'Beta-Thalassemia', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}, {'component': 'In The United States', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic descriptors.'}]",2
311878,Fellows-In-Training: Roundtables,Roundtable 24 - Salivary Lip Biopsies in Practice IV,,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. The abstract title, 'Roundtable 24 - Salivary Lip Biopsies in Practice IV', refers to a medical procedure (biopsy), not a disease or disorder. The session title, 'Fellows-In-Training: Roundtables', describes the audience and format of the session. According to the exclusion rules, procedural terms without an associated disease are not considered valid indications. Therefore, no indication can be extracted.",[],"[{'component': 'Salivary Lip Biopsies', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Exclusion Rules - Procedural/Temporal Qualifiers'}]",1
344653,Diagnostic and Prognostic Biomarkers 1,Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma,malignant;;uterine leiomyosarcoma,Malignant Uterine Leiomyosarcoma,Malignant Uterine Leiomyosarcoma;;Benign Leiomyoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma', contains specific disease terms. The session title, 'Diagnostic and Prognostic Biomarkers 1', is generic. Therefore, the abstract title was selected as the source based on the single-source principle.
2.  **Component Identification**: The abstract title explicitly mentions two distinct clinical entities: 'malignant uterine leiomyosarcoma' and 'benign leiomyoma'. The core task described is differentiating between these two.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to check for specific handling of terms like 'malignant' and 'benign'. No specific rules were found, so I proceeded with generic rules.
4.  **Rule Application & Construction**:
    *   **Multiple Diseases**: The title presents two distinct conditions being compared. Both must be extracted as separate indications, delimited by ';;'.
    *   **First Indication**: 'malignant uterine leiomyosarcoma' was processed. 'Malignant' is a critical disease characteristic and must be retained. 'Uterine' is an essential anatomical specifier. Applying Title Case and singular form (already singular) results in 'Malignant Uterine Leiomyosarcoma'.
    *   **Second Indication**: 'benign leiomyoma' was processed. 'Benign' is a critical disease characteristic and must be retained. Applying Title Case and singular form (already singular) results in 'Benign Leiomyoma'.
    *   **Combination**: The two indications are combined using the ';;' separator.
5.  **Quality Check**: The final output adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately reflects the two distinct clinical conditions mentioned in the source title.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules regarding the handling of disease characterization keywords like 'malignant' and 'benign'.""}]","[{'component': 'malignant uterine leiomyosarcoma', 'type': 'Disease', 'normalized_form': 'Malignant Uterine Leiomyosarcoma', 'rule_applied': ""Generic Rule: Title Case, Generic Rule: Retain essential clinical characteristics ('Malignant').""}, {'component': 'benign leiomyoma', 'type': 'Disease', 'normalized_form': 'Benign Leiomyoma', 'rule_applied': ""Generic Rule: Title Case, Generic Rule: Retain essential clinical characteristics ('Benign').""}]",2
328274,Aggressive Lymphomas: Clinical and Epidemiological: Poster II,Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemiafrom a Low-Middle Income Country: An Experience from Hematology Cancer Consortium,Adolescent;;Adult;;Burkitt Lymphoma;;Leukemia,Adolescent Adult Burkitt Lymphoma;;Adolescent Adult Leukemia,Adolescent Burkitt Lymphoma;;Adult Burkitt Lymphoma;;Adolescent Leukemia;;Adult Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Prognostic Factors and Outcomes of Adolescent and Adult Burkitt Lymphoma and Leukemia...') was chosen over the session title ('Aggressive Lymphomas...') because it contains more specific disease names ('Burkitt Lymphoma', 'Leukemia') and patient subgroups, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were:
    - Age Groups: 'Adolescent' and 'Adult'.
    - Diseases: 'Burkitt Lymphoma' and 'Leukemia'.
    - Excludable terms: 'Prognostic Factors and Outcomes', 'Low-Middle Income Country', 'Experience from Hematology Cancer Consortium' were identified as study methodology or geographic descriptors and marked for exclusion per generic rules.
3. **Rule Retrieval**: To ensure correct formatting for the age groups, the `get_indication_rules` tool was used for the category 'Age Group' with subcategories 'Adolescent' and 'Adult'.
4. **Rule Application**: 
    - The retrieved rules (e.g., Rule ID 289 for 'Adult', Rule ID 318 for 'Adolescent') confirmed that the age group should be a capitalized prefix to the disease name (e.g., 'Adult Gastric Cancer').
    - The structure 'Adolescent and Adult Burkitt Lymphoma and Leukemia' implies that both age groups apply to both diseases. This requires creating all four possible combinations.
    - Generic rules were applied: diseases were kept in singular form, Title Case was used, and excluded terms were removed.
5. **Indication Construction**: The components were combined to form four distinct indications, separated by the ';;' delimiter as required for multiple diseases/subgroups: 'Adolescent Burkitt Lymphoma', 'Adult Burkitt Lymphoma', 'Adolescent Leukemia', and 'Adult Leukemia'.
6. **Quality Check**: The final output was verified against all rules: single source used, all diseases and subgroups included, correct formatting and separators applied, and non-clinical information excluded.","[{'category': 'Age Group', 'subcategories': ['Adolescent', 'Adult'], 'reason': ""To verify the correct formatting and application of the 'Adolescent' and 'Adult' patient subgroups identified in the abstract title.""}]","[{'component': 'Adolescent', 'type': 'Age Group', 'normalized_form': 'Adolescent', 'rule_applied': 'Age Group Rule ID 318: Prepend capitalized age group to the disease name.'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group Rule ID 289: Prepend capitalized age group to the disease name.'}, {'component': 'Burkitt Lymphoma', 'type': 'Disease', 'normalized_form': 'Burkitt Lymphoma', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}, {'component': 'Leukemia', 'type': 'Disease', 'normalized_form': 'Leukemia', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
213592,MP17: Pediatric Urology: Upper & Lower Urinary Tract,Are pre-operative urine cultures and cystoscopies before ureteral reimplantation clinically useful or cost effective?,,,Pediatric Upper Urinary Tract Disease;;Pediatric Lower Urinary Tract Disease,True,session_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title describes medical procedures ('urine cultures', 'cystoscopies', 'ureteral reimplantation') but does not name a disease or condition. The session title, 'MP17: Pediatric Urology: Upper & Lower Urinary Tract', contains a clear patient subgroup ('Pediatric') and anatomical areas of focus ('Upper & Lower Urinary Tract') within a therapeutic area ('Urology'). According to the single-source principle, the session title is selected as it contains actionable indication components.
2. **Component Identification**: From the session title, the following components were identified: 'Pediatric' (age group), 'Upper Urinary Tract' (anatomical location 1), and 'Lower Urinary Tract' (anatomical location 2).
3. **Rule Retrieval**: The presence of 'Pediatric' prompted the retrieval of rules for the 'Age Group' category to ensure correct formatting.
4. **Rule Application**: The retrieved rules for 'Pediatric' (e.g., Rule ID 295) confirm that it should be used as a prefix for the indication. The phrase 'Upper & Lower Urinary Tract' clearly indicates two separate anatomical regions. To create clinically valid indications from these anatomical sites within a urology context, the general term 'Disease' is appended to each.
5. **Indication Construction**: The components are assembled into two distinct indications: 'Pediatric Upper Urinary Tract Disease' and 'Pediatric Lower Urinary Tract Disease'.
6. **Final Formatting**: As per the generic rules for multiple diseases, the two indications are combined into a single string, separated by ';;'. The final output is formatted in Title Case.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly handle the 'Pediatric' patient subgroup qualifier found in the session title.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule for 'Pediatric' (ID: 295/296)""}, {'component': 'Upper Urinary Tract', 'type': 'Anatomical Location', 'normalized_form': 'Upper Urinary Tract Disease', 'rule_applied': 'Therapeutic Area Fallback/Generalization'}, {'component': 'Lower Urinary Tract', 'type': 'Anatomical Location', 'normalized_form': 'Lower Urinary Tract Disease', 'rule_applied': 'Therapeutic Area Fallback/Generalization'}]",2
180828,Myeloma and Plasma Cell Dyscrasias: Clinical-Prospective Therapeutic Trials: Poster I,Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study,Relapsed;;Refractory;;Multiple Myeloma,Relapsed and/or Refractory Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Multiple Myeloma') and detailed patient subgroup information, making it more precise than the session title.
2.  **Component Identification**: The key components identified in the abstract title were the disease 'Multiple Myeloma' and the patient subgroup descriptors 'Relapsed and/or Refractory' and 'Who Have Received at Least Two Prior Lines of Therapy'.
3.  **Rule Retrieval**: I retrieved rules for 'Occurrence' to handle 'Relapsed and/or Refractory' and for 'Treatment Set-up' to handle 'Prior Lines of Therapy'.
4.  **Rule Application**:
    *   **Occurrence Rule**: The phrase 'Relapsed and/or Refractory' was standardized to 'Relapsed/Refractory' based on common clinical terminology formatting rules, such as the logic found in Rule ID 189 which merges these concepts.
    *   **Treatment Set-up Rule (ID: 207)**: This rule explicitly states that references to 'Prior Lines' of therapy should be excluded from the final indication as they describe treatment history, not a core indication qualifier. Therefore, the entire phrase 'Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor' was removed.
    *   **Generic Rules**: The disease term 'Multiple Myeloma' was already in singular form. The final output was formatted to Title Case.
5.  **Indication Construction**: The standardized patient subgroup 'Relapsed/Refractory' was prepended to the core disease 'Multiple Myeloma' to form the final indication.
6.  **Quality Check**: The final indication adheres to the single-source principle, correctly applies formatting and exclusion rules, and accurately represents the core clinical condition described in the abstract title.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Refractory', 'Relapse'], 'reason': ""To correctly format the 'Relapsed and/or Refractory' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the phrase 'at Least Two Prior Lines of Therapy'.""}]","[{'component': 'Relapsed and/or Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard practice for combining relapsed and refractory states.'}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule for singular form and Title Case.'}, {'component': 'Who Have Received at Least Two Prior Lines of Therapy...', 'type': 'Treatment History', 'normalized_form': '', 'rule_applied': 'Rule ID: 207 - Exclude references to prior lines of therapy.'}]",2
311906,Genetic Predisposition and the Balance Between Infection and Autoimmunity,Q&A,,,Infection;;Autoimmunity,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract_title 'Q&A' contains no medical information. The session_title 'Genetic Predisposition and the Balance Between Infection and Autoimmunity' contains the potential indications 'Infection' and 'Autoimmunity'.
2.  **Select Source**: Based on the Single-Source Extraction Principle, the session_title is selected as it is the only source containing disease terms.
3.  **Identify Components**: The core medical conditions identified are 'Infection' and 'Autoimmunity'. 'Genetic Predisposition' is a patient characteristic that describes the context but does not form part of the standard indication name itself.
4.  **Retrieve Rules**: I checked for rules regarding 'Genetic Origin' to see how to handle 'Genetic Predisposition' but found no specific rules. Therefore, I will rely on the generic rules.
5.  **Apply Rules**: 
    -   **Multiple Diseases Rule**: The title mentions two distinct conditions, 'Infection' and 'Autoimmunity'. They must be extracted as separate indications.
    -   **Separator Rule**: The two indications are separated by ';;'.
    -   **Formatting Rules**: The terms are already in singular form and correctly capitalized (Title Case).
6.  **Construct Indication**: The final generated indication is 'Infection;;Autoimmunity'.
7.  **Quality Check**: The output adheres to all formatting and extraction principles. The source is correctly selected, and multiple diseases are handled appropriately.","[{'category': 'Patient Sub-Group', 'subcategories': ['Genetic Origin'], 'reason': ""To determine how to handle the term 'Genetic Predisposition'.""}]","[{'component': 'Infection', 'type': 'Disease', 'normalized_form': 'Infection', 'rule_applied': 'Generic rule for disease extraction.'}, {'component': 'Autoimmunity', 'type': 'Disease', 'normalized_form': 'Autoimmunity', 'rule_applied': 'Generic rule for disease extraction.'}, {'component': 'Genetic Predisposition', 'type': 'Patient Characteristic', 'normalized_form': 'Genetic Predisposition', 'rule_applied': 'Excluded as it describes the context/risk factor rather than being part of a standard indication name.'}]",2
393826,"Nsclc, Early Stage",Concordance Of Pd-L1 Expression Between Biopsy And Matched Surgical Specimen In Early-Stage Non-Small Cell Lung Cancer: Lc-Scrum-Advantage/Mrd,Early-Stage;;Non-Small Cell Lung Cancer,Early-Stage Non-Small Cell Lung Cancer,Early Stage Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title as it contains a more specific and complete description of the disease and patient subgroup, adhering to the single-source principle.
2. **Component Identification**: The key components identified in the abstract title were 'Early-Stage' (Stage) and 'Non-Small Cell Lung Cancer' (Disease). 'Pd-L1 Expression' was identified as a biomarker, but the title discusses the 'concordance of' expression, making it the subject of the study rather than a defining characteristic of the patient cohort. Therefore, it is excluded from the final indication.
3. **Rule Retrieval**: Rules for 'Stage Onset' were retrieved to handle 'Early-Stage'. Rules for 'Biomarker' were retrieved to evaluate 'Pd-L1 Expression'.
4. **Rule Application**: 
   - The 'Early Stage' rule (ID: 109) was applied, which normalizes 'Early-Stage' to 'Early Stage' (Title Case, no hyphen).
   - The generic singular form rule was applied to 'Lung Cancer', which is already singular.
   - The generic Title Case rule was applied to the entire indication.
   - Procedural terms like 'Biopsy' and 'Surgical Specimen' were excluded as per generic exclusion rules.
5. **Indication Construction**: The normalized stage 'Early Stage' was prepended to the normalized disease 'Non-Small Cell Lung Cancer' to form the final indication.
6. **Quality Check**: The final indication was checked for formatting, accuracy, and adherence to all rules. It correctly represents the patient population described.","[{'category': 'Stage', 'subcategories': ['Stage Onset'], 'reason': ""To correctly format the 'Early-Stage' keyword.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To determine how to handle 'Pd-L1 Expression'.""}]","[{'component': 'Early-Stage', 'type': 'Stage', 'normalized_form': 'Early Stage', 'rule_applied': ""Stage Onset Rule ID: 109 - Normalize to 'Early Stage' (title-case, no hyphen).""}, {'component': 'Non-Small Cell Lung Cancer', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Pd-L1 Expression', 'type': 'Biomarker', 'normalized_form': '', 'rule_applied': 'Excluded as the title describes a study about expression levels, not a pre-defined patient subgroup with a specific PD-L1 status.'}]",2
213605,MP17: Pediatric Urology: Upper & Lower Urinary Tract,Is Excretory Phase Computerized Tomography Important for Evaluation of High Grade Renal Trauma?: Results from the Traumatic Renal Injury Collaboration for Kids (TRICK),Traumatic Renal Injury,Traumatic Renal Injury,High Grade Renal Trauma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a specific, diagnosable condition ('High Grade Renal Trauma'). The session title refers to a broader therapeutic area ('Pediatric Urology') and anatomical regions ('Upper & Lower Urinary Tract') without a specific disease.
2. **Component Identification**: From the abstract title, the core disease identified is 'Renal Trauma' and the grade qualifier is 'High Grade'.
3. **Rule Retrieval**: Rules for the 'Grade' category were retrieved to handle 'High Grade'. Rules for 'Age Group' were also considered due to 'Pediatric' in the session title and 'Kids' in the acronym expansion.
4. **Rule Application**: 
   - The 'High Grade' rule (ID: 115) was applied, which standardizes the format to 'High Grade' and places it before the disease name.
   - The generic rule for Title Case was applied.
   - The generic rule for singular form was applied (though 'Trauma' is already singular).
   - The term 'Pediatric' was not included in the final indication. Although present in the session title and implied in the abstract title's acronym, the Single-Source Extraction Principle dictates that the indication must be built exclusively from the chosen source (the abstract title), which does not explicitly contain the word 'Pediatric'.
5. **Indication Construction**: The components were combined and formatted according to the rules, resulting in 'High Grade Renal Trauma'.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'High Grade' qualifier.""}, {'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To evaluate the term 'Pediatric' from the session title and 'Kids' from the acronym, ultimately excluding it based on the single-source principle.""}]","[{'component': 'High Grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': 'Grade Rule ID: 115'}, {'component': 'Renal Trauma', 'type': 'Disease', 'normalized_form': 'Renal Trauma', 'rule_applied': 'Generic Title Case and Singular Form rules'}]",2
393830,"Nsclc, Early Stage",Real-World Outcomes In Stage I-Iii Resectable Non-Small Cell Lung Cancer (Nsclc): Thassos-Intl Study,Stage I-III;;Resectable;;Non-Small Cell Lung Cancer,Stage I-III Resectable Non-Small Cell Lung Cancer,Resectable Stage I-III Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: Both the session title ('Nsclc, Early Stage') and the abstract title ('Real-World Outcomes In Stage I-Iii Resectable Non-Small Cell Lung Cancer (Nsclc): Thassos-Intl Study') contain a valid disease. The abstract title is more specific and is therefore selected as the source, following the single-source principle.
2. **Identify Components**: The selected abstract title contains the following components: Disease ('Non-Small Cell Lung Cancer (Nsclc)'), Stage ('Stage I-Iii'), and Operative Status ('Resectable'). Study-specific terms like 'Real-World Outcomes' and 'Thassos-Intl Study' are identified for exclusion.
3. **Retrieve Relevant Rules**: To ensure correct formatting, I retrieved rules for staging and resectability. 
   - `get_indication_rules(category=""Stage"", subcategories=[""Stage number""])` was used for 'Stage I-Iii'. Rule ID 91 confirmed that stage ranges should be standardized.
   - `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Resectable""])` was used for 'Resectable'. Rule ID 236 confirmed that 'Resectable' should be included as a prefix.
4. **Apply Rules & Construct Indication**:
   - **Generic Rules**: The disease 'Non-Small Cell Lung Cancer' is already in singular form. Title Case is applied to all components. The parenthetical abbreviation '(Nsclc)' is removed as it's redundant.
   - **Stage Rule**: 'Stage I-Iii' is normalized to 'Stage I-III' for standardized representation, using Roman numerals as is standard for cancer staging.
   - **Treatment Set-up Rule**: 'Resectable' is capitalized and placed at the beginning of the indication.
5. **Final Assembly**: The components are combined in the standard clinical order: [Operative Status] [Stage] [Disease]. This results in 'Resectable Stage I-III Non-Small Cell Lung Cancer'.
6. **Quality Check**: The final indication adheres to all formatting rules, correctly incorporates the patient subgroups from the source title, and excludes non-clinical information.","[{'category': 'Stage', 'subcategories': ['Stage number'], 'reason': ""To correctly format the stage range 'I-Iii'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Resectable'], 'reason': ""To determine how to handle the term 'Resectable'.""}]","[{'component': 'Stage I-Iii', 'type': 'Stage', 'normalized_form': 'Stage I-III', 'rule_applied': 'Stage number rule (ID: 91) for standardizing stage ranges to Roman numerals.'}, {'component': 'Resectable', 'type': 'Operative Status', 'normalized_form': 'Resectable', 'rule_applied': 'Resectable rule (ID: 236) to include as a prefix.'}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic rule to use singular form and remove redundant abbreviations.'}]",2
164457,Society for Benign Prostate Disease,"Welcome and Why SOBPD Should Exist, Who We Are and Our Mission. Society Benefits, Annual meetings",Benign Prostate Disease,Benign Prostatic Hyperplasia,Benign Prostate Disease,True,session_title,"Step 1: The abstract title 'Welcome and Why SOBPD Should Exist, Who We Are and Our Mission. Society Benefits, Annual meetings' does not contain any specific disease or medical condition. 
Step 2: The session title 'Society for Benign Prostate Disease' contains a clear medical indication. 
Step 3: Following the single-source principle, the session title is selected for extraction. 
Step 4: The term 'Benign Prostate Disease' is extracted as the core indication. 
Step 5: Generic rules are applied. The indication is already in Title Case and singular form. The organizational part 'Society for' is excluded as it is not part of the disease name.",[],"[{'component': 'Benign Prostate Disease', 'type': 'Disease', 'normalized_form': 'Benign Prostate Disease', 'rule_applied': 'Generic rules for Title Case and Singular Form.'}]",1
180842,Experimental Transplantation: Basic and Translational: Poster I,The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation,Graft-Versus-Host Disease,Graft-Versus-Host Disease,Gut Graft-Versus-Host Disease,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title 'The Potential Roles of Mucosa-Associated Invariant T Cells in the Pathogenesis of Gut Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplantation' contains a specific disease term. The session title 'Experimental Transplantation: Basic and Translational: Poster I' does not contain a disease. Therefore, the abstract title is selected as the source based on the single-source principle.
2. **Identify Components**: The key components identified in the abstract title are the disease 'Gut Graft-Versus-Host Disease' and a procedural qualifier 'after Hematopoietic Stem Cell Transplantation'.
3. **Retrieve Relevant Rules**: To determine how to handle the procedural qualifier, I retrieved rules for 'Transplant Status' under the 'Treatment Set-up' category.
4. **Apply Rules**: The retrieved rules (e.g., Rule ID 232, 233 for 'Post-Transplant') and the generic exclusion rules state that procedural and temporal qualifiers like 'after...Transplantation' should be excluded from the final indication as they describe a treatment context, not the disease itself.
5. **Construct Indication**: The core disease 'Gut Graft-Versus-Host Disease' is extracted. The procedural context 'after Hematopoietic Stem Cell Transplantation' is excluded. The disease name is already in the correct Title Case and singular form.
6. **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To confirm the handling of the phrase 'after Hematopoietic Stem Cell Transplantation', which represents a post-transplant status.""}]","[{'component': 'Gut Graft-Versus-Host Disease', 'type': 'Disease', 'normalized_form': 'Gut Graft-Versus-Host Disease', 'rule_applied': 'Generic rule: Use Title Case and singular form.'}, {'component': 'after Hematopoietic Stem Cell Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule and specific 'Transplant Status' rules (e.g., Rule ID 232) require excluding post-procedural contexts.""}]",2
262759,"Quality of life, palliative care, ethics and health economics",Health-Related Quality Of Life In Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma Treated With Iberdomide Plus Dexamethasone In A Phase 1B/2A Open-Label Dose Escalation Study,Relapsed;;Refractory;;Multiple Myeloma ,Relapsed/Refractory Multiple Myeloma ,Triple-Class Exposed Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains the specific disease 'Multiple Myeloma', while the session title is generic. Therefore, the abstract title was chosen as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: I identified the core disease 'Multiple Myeloma' and two key patient subgroup descriptors: 'Triple-Class Exposed' (indicating treatment history) and 'Relapsed/Refractory' (indicating disease status).
3.  **Rule Retrieval**: I retrieved rules for 'Occurrence' to correctly handle 'Relapsed/Refractory' and for 'Treatment based' to understand how to process treatment history terms like 'Triple-Class Exposed'.
4.  **Rule Application & Construction**: 
    *   Generic exclusion rules were applied to remove non-diagnostic information such as 'Health-Related Quality Of Life In Patients With', specific drug names ('Iberdomide Plus Dexamethasone'), and study design details ('Phase 1B/2A Open-Label Dose Escalation Study').
    *   The term 'Relapsed/Refractory' is a standard clinical descriptor for disease state and was retained.
    *   'Triple-Class Exposed' is a critical patient subgroup qualifier defining the treatment history and was included.
    *   The components were assembled in a clinically logical order: treatment history, then disease status, then the disease name.
5.  **Formatting**: The final indication was formatted to Title Case and ensured singular form for the disease, resulting in 'Triple-Class Exposed Relapsed/Refractory Multiple Myeloma'.","[{'category': 'Occurrence', 'subcategories': ['Relapsed/Refractory', 'Refractory'], 'reason': ""To correctly handle the 'Relapsed/Refractory' disease status descriptor.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To understand the handling of treatment history descriptors like 'Triple-Class Exposed'.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic singular form rule.'}, {'component': 'Relapsed/Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for retaining standard disease state descriptors.'}, {'component': 'Triple-Class Exposed', 'type': 'Patient Subgroup (Treatment History)', 'normalized_form': 'Triple-Class Exposed', 'rule_applied': 'Treatment based rule for including specific treatment history as a qualifier.'}]",2
148103,Myelodysplastic Syndromes - Biology & Translational Research,Cohesin Mutations Are Associated With A Poor Prognosis Phenotype And A Worse Clinical Outcome In Low-Risk Myelodysplastic Syndromes Patients,Low-Risk;;Myelodysplastic Syndromes,Low-Risk Myelodysplastic Syndrome,Cohesin-Mutated Low-Risk Myelodysplastic Syndrome,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title as it contains a more specific description of the medical indication, including patient subgroups.
2. **Component Identification**: The abstract title contains the core disease 'Myelodysplastic Syndromes', a genetic qualifier 'Cohesin Mutations', and a risk qualifier 'Low-Risk'.
3. **Rule Retrieval**: I retrieved rules for the 'Risk' category to handle 'Low-Risk'. The retrieved rule (ID: 123) confirmed that 'Low-Risk' should be standardized to 'Low-Risk' and prepended to the disease name. I also checked for rules related to 'Gene type' for 'Cohesin Mutations' but found none, so I proceeded with generic formatting rules.
4. **Rule Application & Normalization**:
   - **Disease**: The plural 'Myelodysplastic Syndromes' was converted to its singular form 'Myelodysplastic Syndrome' per generic formatting rules.
   - **Risk Qualifier**: 'Low-Risk' was kept as is, based on the retrieved rule.
   - **Genetic Qualifier**: 'Cohesin Mutations' was converted to the standard adjectival form 'Cohesin-Mutated' to act as a prefix for the indication.
   - **Exclusions**: The phrase 'A Poor Prognosis Phenotype And A Worse Clinical Outcome' and the word 'Patients' were excluded as they describe study outcomes and general population, not the core indication.
5. **Indication Construction**: The identified and normalized components were combined in a clinically logical order (Qualifier + Risk + Disease) to form the final indication: 'Cohesin-Mutated Low-Risk Myelodysplastic Syndrome'.
6. **Final Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form, no trailing spaces) and is built from a single source.","[{'category': 'Risk', 'subcategories': ['Low-Risk'], 'reason': ""To validate the formatting and placement of the 'Low-Risk' qualifier.""}, {'category': 'Gene type', 'subcategories': ['Gene Mutation', 'Gene Mutated', 'Gene Mutant'], 'reason': ""To check for specific rules on how to format the 'Cohesin Mutations' component.""}]","[{'component': 'Myelodysplastic Syndromes', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'Low-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'Low-Risk', 'rule_applied': 'Risk Rule ID: 123'}, {'component': 'Cohesin Mutations', 'type': 'Genetic Qualifier', 'normalized_form': 'Cohesin-Mutated', 'rule_applied': 'Generic Rule: Title Case and standardization to adjectival form.'}]",2
262802,Stem cell transplantation - Clinical,Allogeneic Hematopoietic Stem Transplantation (Hsct) In Patients Over 60 Years. Retrospective Experience Of Two Spanish Centers Between 2015-2020,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title is 'Allogeneic Hematopoietic Stem Transplantation (Hsct) In Patients Over 60 Years. Retrospective Experience Of Two Spanish Centers Between 2015-2020' and the session title is 'Stem cell transplantation - Clinical'.
Step 2: I applied the Single-Source Extraction Principle. Neither title contains a specific disease or disorder. Both titles refer to a medical procedure ('Stem cell transplantation' and 'Allogeneic Hematopoietic Stem Transplantation').
Step 3: The abstract title contains a patient subgroup ('Over 60 Years'). I retrieved rules for the 'Age Group' category to understand how to handle this. Rule ID 303 indicates that 'Above 60' or similar phrases should be normalized to 'Elderly'.
Step 4: However, according to the generic rules, an indication cannot be created from a patient subgroup alone. A disease term must be present in the same source title. Since the abstract title lacks a disease term, it is discarded as a source for the indication, despite containing a patient subgroup.
Step 5: The session title also lacks a disease term. Therefore, no valid medical indication can be extracted from the provided information.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To determine how to handle the phrase 'Over 60 Years' found in the abstract title.""}]","[{'component': 'Allogeneic Hematopoietic Stem Transplantation', 'type': 'Procedure', 'normalized_form': None, 'rule_applied': 'Generic exclusion rule: Procedural/Temporal Qualifiers are excluded as they are not diseases.'}, {'component': 'Over 60 Years', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': ""Age Group rule for 'Above 60' (ID: 303).""}]",2
311960,Ignite Session 1C,"Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity",,,Systemic Autoimmunity,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The `session_title` ('Ignite Session 1C') is generic and contains no medical terms. The `abstract_title` ('Phosphofructokinase P Fine-Tunes T Regulatory Cell Metabolism, Function and Stability in Systemic Autoimmunity') contains the medical condition 'Systemic Autoimmunity'.
2.  **Select Source**: According to the single-source principle, the `abstract_title` is selected as it contains a valid disease term.
3.  **Identify Components**: The core disease component identified is 'Systemic Autoimmunity'. Other terms like 'T Regulatory Cell Metabolism' describe biological processes, not the clinical indication.
4.  **Retrieve Rules**: I retrieved rules for 'Disease Characterisation' to check if 'Systemic' has special handling. No specific rule applied.
5.  **Apply Generic Rules**: I applied the generic rules to the extracted component:
    *   **Casing**: The term 'Systemic Autoimmunity' is already in the correct Title Case.
    *   **Singular Form**: The term is already in its singular form.
    *   **Exclusions**: No sociodemographic, procedural, or other excludable terms are present.
6.  **Construct Indication**: Based on the analysis, the final indication is constructed from the identified component.
7.  **Quality Check**: The final indication 'Systemic Autoimmunity' adheres to all formatting and clinical accuracy requirements.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To verify if the term 'Systemic' requires special handling as a disease characterizer. No specific rule was found to apply.""}]","[{'component': 'Systemic Autoimmunity', 'type': 'Disease', 'normalized_form': 'Systemic Autoimmunity', 'rule_applied': 'Generic rules for casing and singular form.'}]",2
410269,Interventions to Reduce CKD Progression,Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD,Primary Kidney Disease;;CKD,Primary Kidney Disease;;Chronic Kidney Disease,Primary Kidney Disease;;CKD,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Impact of Primary Kidney Disease on the Effects of Empagliflozin in Patients with CKD') was chosen over the session title ('Interventions to Reduce CKD Progression') because it is more specific and contains the core disease terms for the study population, adhering to the single-source principle.
2.  **Component Identification**: The abstract title explicitly mentions two distinct medical conditions: 'Primary Kidney Disease' and 'CKD' (Chronic Kidney Disease).
3.  **Rule Application**: 
    *   **Multiple Diseases Rule**: The generic rule for multiple diseases was applied, which states that if a title mentions multiple distinct diseases, all should be extracted and separated by ';;'. The structure 'Impact of [Disease A] in Patients with [Disease B]' is analogous to the example 'Outcomes in [Disease A] with [Factor B]', leading to the extraction of both conditions.
    *   **Formatting Rules**: Standard formatting rules were applied. 'Primary Kidney Disease' is already in Title Case and singular. 'CKD' is a standard medical acronym and is maintained in its original uppercase form.
    *   **Exclusion Rules**: No terms requiring exclusion (e.g., sociodemographics, procedural qualifiers) were present in the title.
4.  **Indication Construction**: The identified diseases, 'Primary Kidney Disease' and 'CKD', were combined using the ';;' separator to form the final indication.
5.  **Quality Check**: The final output adheres to all formatting and content rules, accurately reflecting the key conditions mentioned in the source title.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': ""To check for specific rules on how to handle two distinct diseases mentioned in the same title. No specific rules were found, so the generic 'Multiple Diseases' rule was applied.""}]","[{'component': 'Primary Kidney Disease', 'type': 'Disease', 'normalized_form': 'Primary Kidney Disease', 'rule_applied': 'Generic Rule: Multiple Diseases'}, {'component': 'CKD', 'type': 'Disease', 'normalized_form': 'CKD', 'rule_applied': 'Generic Rule: Multiple Diseases'}]",2
393888,"Nsclc, Metastatic",Updated Patient-Reported Outcomes From The Crown Study: Analyses In First-Line Alk+ Patients With (W) And Without (W/O) Baseline Brain Metastases (Bms) And W Or W/O Central Nervous System Adverse Events (Cns Aes),First-Line;;Alk+;;Metastatic;;Nsclc,First-Line ALK-Postive Metastatic Non-Small Cell Lung Cancer,Metastatic Non-Small Cell Lung Cancer,True,session_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title does not contain a specific disease name, only a patient subgroup (ALK+). The session title, however, explicitly mentions 'Nsclc, Metastatic'. Following the single-source principle, the session title was chosen as it contains the core disease.
2. **Component Identification**: From the session title 'Nsclc, Metastatic', two components were identified: the disease 'Nsclc' and the occurrence qualifier 'Metastatic'.
3. **Rule Retrieval**: Rules for metastasis-related terms were retrieved to ensure correct formatting. Rules for gene names (ALK+) and line of treatment (First-Line) were also considered to confirm their exclusion since they originate from the non-selected abstract title.
4. **Rule Application & Normalization**:
   - 'Nsclc' is a standard abbreviation for 'Non-Small Cell Lung Cancer' and was expanded and converted to Title Case.
   - The generic rule for singular form was applied, although the term was already singular.
   - The rule for 'Metastatic' (ID: 141) dictates placing it before the disease name.
   - The comma separating the terms in the session title was removed as it is a grammatical separator, not part of the indication.
5. **Indication Construction**: The components were combined in the correct order ('Metastatic' + 'Non-Small Cell Lung Cancer') to form the final indication.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, single source, no excluded terms from the source) and is clinically accurate.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'Metastatic' and its placement relative to the disease.""}, {'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To confirm that 'Alk+' from the abstract title should be ignored based on the single-source principle.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To confirm that 'First-Line' from the abstract title should be ignored based on the single-source principle.""}]","[{'component': 'Nsclc', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'Metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Rule ID 141: Placed as a prefix to the disease name.'}, {'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Ignored due to Single-Source Extraction Principle (component was in abstract_title, but session_title was selected as source).'}, {'component': 'Alk+', 'type': 'Biomarker', 'normalized_form': 'ALK-Positive', 'rule_applied': 'Ignored due to Single-Source Extraction Principle (component was in abstract_title, but session_title was selected as source).'}]",2
148133,Myelodysplastic Syndromes - Clinical,Venetoclax Combined With Azacitidine In The Treatment Of Relapsed/Refractory High-Risk Myelodysplastic Syndromes And Acute Myeloid Leukemia: A Retrospective Single-Center Study,Relapsed;;Refractory;;High-Risk;;Myelodysplastic Syndromes;;Acute Myeloid Leukemia,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory High-Risk Acute Myeloid Leukemia,Relapsed/Refractory High-Risk Myelodysplastic Syndrome;;Relapsed/Refractory Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific diseases ('Myelodysplastic Syndromes', 'Acute Myeloid Leukemia') and is more detailed than the session title, adhering to the single-source principle.
2. **Component Identification**: I identified two distinct diseases: 'Myelodysplastic Syndromes' and 'Acute Myeloid Leukemia'. I also identified the qualifiers 'Relapsed/Refractory' and 'High-Risk'.
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' (specifically 'Recurrent/Refractory') and 'Risk' (specifically 'High-Risk') to ensure correct formatting and application of these qualifiers.
4. **Rule Application**: 
   - **Generic Rules**: The plural 'Syndromes' was converted to its singular form 'Syndrome'. The final output was formatted to Title Case. The two distinct indications are separated by ';;'.
   - **Specific Rules**: The 'Relapsed/Refractory' qualifier applies to both diseases mentioned in the coordinated phrase. The 'High-Risk' qualifier is syntactically linked only to 'Myelodysplastic Syndromes' and was applied accordingly.
5. **Indication Construction**: The components were assembled for each disease. 
   - For the first disease: 'Relapsed/Refractory' + 'High-Risk' + 'Myelodysplastic Syndrome'.
   - For the second disease: 'Relapsed/Refractory' + 'Acute Myeloid Leukemia'.
   - The two resulting indications were combined with the ';;' separator.
6. **Quality Check**: The final output was reviewed to ensure it meets all formatting, clinical accuracy, and exclusion criteria. Treatment names ('Venetoclax', 'Azacitidine') and study descriptors ('Retrospective Single-Center Study') were correctly excluded.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To correctly handle the 'Relapsed/Refractory' disease state qualifier.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly handle the 'High-Risk' patient subgroup qualifier.""}]","[{'component': 'Relapsed/Refractory', 'type': 'Occurrence', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Standard clinical nomenclature for disease state.'}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID: 122 - Standardized to 'High-Risk' and prepended to the associated disease.""}, {'component': 'Myelodysplastic Syndromes', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule: Singular Form.'}, {'component': 'Acute Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case.'}]",2
230055,Breast Cancer-Local/Regional/Adjuvant,Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0.,breast cancer,Breast Cancer,Node-Positive Breast Cancer,True,abstract_title,"Step 1: The abstract title 'Axillary surgery after neoadjuvant chemotherapy in breast cancer patients downstaging from cN+ to ycN0' was chosen as the source because it contains a specific disease and patient subgroup, making it more informative than the session title.
Step 2: The core disease was identified as 'breast cancer'. The patient subgroup was identified by the lymph node status 'cN+', indicating clinically node-positive status before treatment.
Step 3: Relevant rules were retrieved for 'Treatment Set-up' and 'Occurrence' (specifically 'Node Status').
Step 4: The 'Node Status' rule (ID: 191) was applied, which maps 'N+' to the standardized term 'Node-Positive' and places it at the beginning of the indication. Generic rules were applied to convert 'breast cancer' to 'Breast Cancer' (Title Case, Singular). Procedural terms ('Axillary surgery') and treatment timing/context ('after neoadjuvant chemotherapy', 'downstaging from cN+ to ycN0') were excluded as per generic exclusion rules, as they describe the intervention and outcome rather than the core indication.
Step 5: The components were combined to form the final indication: 'Node-Positive Breast Cancer'.","[{'category': 'Treatment Set-up', 'subcategories': ['Treatment Status', 'Operative Status'], 'reason': ""To check rules for handling terms like 'neoadjuvant chemotherapy' and 'surgery'.""}, {'category': 'Occurrence', 'subcategories': ['Node Status'], 'reason': ""To correctly handle and normalize the node status descriptors 'cN+' and 'ycN0'.""}]","[{'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'cN+', 'type': 'Node Status', 'normalized_form': 'Node-Positive', 'rule_applied': 'Occurrence Rule (ID: 191) for Node-Positive status'}, {'component': 'Axillary surgery', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude procedural terms'}, {'component': 'after neoadjuvant chemotherapy', 'type': 'Treatment Timing', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude temporal qualifiers'}]",2
410286,"Kidney Transplantation: Biomarkers, New and Old",Differential cfDNA Methylation in Kidney Allograft Rejection,,,Kidney Allograft Rejection,True,abstract_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Differential cfDNA Methylation in Kidney Allograft Rejection', contains a specific, clinically valid condition.
Step 2: The session title, 'Kidney Transplantation: Biomarkers, New and Old', refers to a procedure ('Kidney Transplantation') rather than a disease. Following the single-source principle, I selected the abstract title as it contains a clear disease term.
Step 3: I identified the core medical condition in the abstract title as 'Kidney Allograft Rejection'.
Step 4: To ensure correct handling of transplant-related terminology, I retrieved rules for the 'Treatment Set-up' category, specifically 'Transplant Status'. The rules indicate that procedural or temporal qualifiers (like 'Post-Transplant') should be excluded. However, 'Kidney Allograft Rejection' is a distinct diagnosis, not a procedural qualifier, so these exclusion rules do not apply. The term 'Allograft' is integral to the indication.
Step 5: I applied the generic formatting rules. I converted the term to Title Case, resulting in 'Kidney Allograft Rejection'. The term is already in its standard singular form.
Step 6: A final quality check confirmed that the extraction adheres to all rules, resulting in a clinically accurate and properly formatted indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify how to handle the term 'Allograft' and ensure it is not an excludable procedural qualifier.""}]","[{'component': 'Kidney Allograft Rejection', 'type': 'Disease', 'normalized_form': 'Kidney Allograft Rejection', 'rule_applied': 'Generic rule: Title Case'}]",2
410288,"Kidney Transplantation: Biomarkers, New and Old",Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection,,,Kidney Transplant T Cell-Mediated Rejection,True,abstract_title,"Step 1: The abstract title 'Elevated Glycolytic Markers in Urinary Extracellular Vesicles in Kidney Transplant T Cell-Mediated Rejection' was chosen as the source because it contains a specific clinical condition, which is preferred over the broader session title 'Kidney Transplantation: Biomarkers, New and Old'.
Step 2: The core clinical condition was identified as 'T Cell-Mediated Rejection'. The context 'Kidney Transplant' is integral to defining this condition, as it specifies the subject of the rejection.
Step 3: Terms such as 'Elevated Glycolytic Markers' and 'in Urinary Extracellular Vesicles' were identified as biomarker and methodology details and were excluded based on the generic exclusion rules for non-diagnostic items.
Step 4: I retrieved rules for 'Transplant Status' to verify how to handle transplant-related terms. The rules suggest excluding temporal or eligibility descriptors (e.g., 'Post-Transplant', 'Transplant-Eligible'). However, in this case, 'Kidney Transplant' is not a simple temporal status but a fundamental part of the disease definition ('rejection of the kidney transplant'). Therefore, it was retained for clinical accuracy.
Step 5: The final indication was constructed by combining the essential components and applying Title Case formatting, resulting in 'Kidney Transplant T Cell-Mediated Rejection'.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine the correct handling of the term 'Kidney Transplant' within the indication.""}]","[{'component': 'Kidney Transplant T Cell-Mediated Rejection', 'type': 'Disease', 'normalized_form': 'Kidney Transplant T Cell-Mediated Rejection', 'rule_applied': 'Generic rule: Retain context when integral to the disease name.'}, {'component': 'Elevated Glycolytic Markers in Urinary Extracellular Vesicles', 'type': 'Biomarker/Methodology', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclude non-diagnostic items.'}]",3
410290,"Kidney Transplantation: Biomarkers, New and Old",Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study,Hypertension ,Hypertension ,Uncontrolled Hypertension;;Graft Failure,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Uncontrolled Hypertension Is Associated with Increased Risk of Graft Failure in Kidney Transplant Recipients: A Nationwide Population-Based Study'. The session title is 'Kidney Transplantation: Biomarkers, New and Old'.
2. **Select Source**: The abstract title contains specific medical conditions ('Uncontrolled Hypertension', 'Graft Failure'), while the session title refers to a procedure ('Kidney Transplantation'). Therefore, the abstract title is selected as the source based on the Single-Source Extraction Principle.
3. **Identify Components**: The abstract title identifies two distinct clinical conditions: 'Uncontrolled Hypertension' and 'Graft Failure'. The patient group is 'Kidney Transplant Recipients'.
4. **Retrieve Relevant Rules**: I retrieved rules for 'Treatment Set-up' with the subcategory 'Transplant Status' to determine how to handle 'Kidney Transplant Recipients'. The rules (e.g., ID 232, 233 for 'Post-Transplant') indicate that procedural and temporal qualifiers defining a patient group should be excluded from the indication itself.
5. **Apply Rules & Construct Indication**:
   - 'Uncontrolled Hypertension' is identified as a primary indication.
   - 'Graft Failure' is also a distinct clinical condition mentioned in the title and is extracted as a second indication.
   - The patient descriptor 'in Kidney Transplant Recipients' is excluded as it describes the context/procedure status of the patient population, not the disease itself, consistent with the retrieved rules and generic exclusion principles.
   - The two indications are formatted in Title Case and separated by ';;' as per formatting rules.
6. **Quality Check**: The final output adheres to all formatting and extraction principles. The indications are clinically valid, sourced from a single title, and correctly formatted.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify the handling of the patient descriptor 'Kidney Transplant Recipients'.""}]","[{'component': 'Uncontrolled Hypertension', 'type': 'Disease', 'normalized_form': 'Uncontrolled Hypertension', 'rule_applied': 'Generic rule: Title Case.'}, {'component': 'Graft Failure', 'type': 'Disease', 'normalized_form': 'Graft Failure', 'rule_applied': 'Generic rule: Title Case.'}, {'component': 'Kidney Transplant Recipients', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': ""Exclusion Rule: Procedural/Temporal Qualifiers. Confirmed by 'Transplant Status' rules.""}]",2
262851,Stem cell transplantation - Clinical,Efficacy And Safety Comparison Of Calcineurin Inhibitors Used For Gvhd Prophylaxis In Hematopoietic Stem Cell Transplantation In Children With Thalassemia,Thalassemia,Thalassemia,Pediatric Thalassemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease term ('Thalassemia'), whereas the session title is procedural ('Stem cell transplantation'). This adheres to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Thalassemia' and the patient subgroup 'Children'.
3. **Rule Retrieval**: Rules for the 'Age Group' category, specifically for 'Pediatric', were retrieved to determine the correct handling of the term 'Children'.
4. **Rule Application**: 
   - The generic exclusion rule was applied to remove procedural context, specifically 'Gvhd Prophylaxis' and 'Hematopoietic Stem Cell Transplantation'.
   - The retrieved 'Age Group' rules (ID 295, 296) mandate normalizing age-related terms like 'Children' to the standard form 'Pediatric' and placing it at the beginning of the indication.
   - The generic casing rule was applied to ensure the final indication is in Title Case.
   - The generic singular form rule was applied, although 'Thalassemia' is already singular.
5. **Indication Construction**: The normalized age group 'Pediatric' was prepended to the disease 'Thalassemia' to form the final indication.
6. **Quality Check**: The final indication 'Pediatric Thalassemia' is clinically accurate, correctly formatted, and free of excluded terms.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To determine the standard representation for the patient subgroup 'Children'.""}]","[{'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group rule (ID 295/296) for normalization of age descriptors.'}, {'component': 'Thalassemia', 'type': 'Disease', 'normalized_form': 'Thalassemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': 'Gvhd Prophylaxis In Hematopoietic Stem Cell Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
213700,"MP22: Trauma/Reconstruction/Diversion: Urethral Reconstruction (including Stricture, Diverticulum) I",How is health-related quality of life affected by salvage cystectomy and urinary diversion as a last-line option for benign disease,,,Trauma;;Urethral Stricture;;Urethral Diverticulum,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains the term ""benign disease"", which is a valid but extremely generic disease category. The session title, ""Trauma/Reconstruction/Diversion: Urethral Reconstruction (including Stricture, Diverticulum) I"", provides multiple specific and clinically valid conditions: ""Trauma"", ""Urethral Stricture"", and ""Urethral Diverticulum"". According to the goal of extracting clinically valid indications, the session title is the superior source in this case.
2.  **Component Identification**: From the session title, three distinct medical conditions were identified: 'Trauma', 'Stricture', and 'Diverticulum'. The anatomical location 'Urethral' is associated with 'Stricture' and 'Diverticulum'. The terms 'Reconstruction' and 'Diversion' are procedural and are excluded based on generic rules.
3.  **Rule Application**: 
    *   The generic rule for multiple diseases was applied, requiring the use of ';;' as a separator.
    *   The generic rule for Title Case was applied to all terms.
    *   The generic rule for singular form was applied (all terms were already singular).
4.  **Indication Construction**: The identified components were combined and formatted. 'Urethral' was prepended to 'Stricture' and 'Diverticulum' as it provides the anatomical context. The final indications are 'Trauma', 'Urethral Stricture', and 'Urethral Diverticulum'.
5.  **Final Output**: The three indications are combined into a single string, separated by ';;', resulting in ""Trauma;;Urethral Stricture;;Urethral Diverticulum"".",[],"[{'component': 'Trauma', 'type': 'Disease', 'normalized_form': 'Trauma', 'rule_applied': 'Generic Title Case rule'}, {'component': 'Urethral Stricture', 'type': 'Disease', 'normalized_form': 'Urethral Stricture', 'rule_applied': 'Generic Title Case rule'}, {'component': 'Urethral Diverticulum', 'type': 'Disease', 'normalized_form': 'Urethral Diverticulum', 'rule_applied': 'Generic Title Case rule'}]",1
180933,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title is 'Screening Chest CT Prior to Allogenic Transplantation - High Rates of Occult Abnormalities' and the session title is 'Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I'.
Step 2: Neither title contains a specific, clinically valid medical indication. The abstract title mentions 'Occult Abnormalities', which is a clinical finding, not a disease. The session title mentions 'Acute Toxicities', which is a complication or adverse effect. Both titles are centered around the procedure 'Allogeneic Transplantation'.
Step 3: I retrieved rules for 'Transplant Status' to confirm how to handle procedure-related terms. The rules confirm that transplant-related descriptors should be excluded as they describe a treatment context, not the disease itself.
Step 4: The generic exclusion rules state that procedural qualifiers (like 'Prior to... Transplantation') and non-diagnostic items (like 'Occult Abnormalities' and 'Acute Toxicities') must be excluded.
Step 5: Since neither title provides a disease term after applying the exclusion rules, no valid indication can be extracted from either source.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': 'To verify that terms related to transplantation are procedural and should be excluded from the final indication.'}]","[{'component': 'Allogenic Transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Procedural/Temporal Qualifiers. Rule ID 230-233 also confirm exclusion of transplant status.'}, {'component': 'Occult Abnormalities', 'type': 'Non-Diagnostic Item', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Non-Diagnostic Items.'}, {'component': 'Acute Toxicities', 'type': 'Non-Diagnostic Item', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Non-Diagnostic Items (Complications or adverse effects).'}]",2
180932,"Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Toxicities: Poster I",The Impact of Letermovir (LTV) Prophylaxis on Early Cytomegalovirus Infection (CMVi) and Outcomes in the Adult Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients with High-Risk Donor Type,Early;;Cytomegalovirus Infection,Early Cytomegalovirus Infection,Adult Early Onset Cytomegalovirus Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific medical condition ('Cytomegalovirus Infection'), whereas the session title is more general.
2. **Component Identification**: The abstract title contains the following components: a disease ('Cytomegalovirus Infection'), an age group ('Adult'), a temporal qualifier ('Early'), and a patient context ('Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients', 'High-Risk Donor Type').
3. **Rule Retrieval**: I retrieved rules for 'Age Group', 'Treatment Set-up', 'Risk', and 'Onset' to handle the identified components.
4. **Rule Application**:
   - **Disease**: 'Cytomegalovirus Infection' was identified as the core disease.
   - **Age Group**: Based on the 'Adult' rule (ID: 289), the term 'Adult' is prepended to the indication.
   - **Onset**: Based on the 'Onset by Time' rule for 'Early' (ID: 266), the term is normalized to 'Early Onset' and prepended to the disease name.
   - **Exclusions**: 
     - The phrase 'Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients' describes a procedural context. The generic rules and the retrieved 'Transplant Status' rules (e.g., ID: 232 for 'Post-Transplant') mandate the exclusion of such procedural qualifiers.
     - 'High-Risk Donor Type' describes a characteristic of the donor, not a direct feature of the patient's disease, and is therefore excluded.
5. **Indication Construction**: The components were combined in the correct order (Age -> Onset -> Disease) and formatted according to generic rules (Title Case, singular form).
6. **Final Indication**: The final generated indication is 'Adult Early Onset Cytomegalovirus Infection'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To handle the 'Adult' patient subgroup.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the 'Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients' context.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To evaluate the 'High-Risk' qualifier.""}, {'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To process the temporal qualifier 'Early'.""}]","[{'component': 'Cytomegalovirus Infection', 'type': 'Disease', 'normalized_form': 'Cytomegalovirus Infection', 'rule_applied': 'Generic disease identification'}, {'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': 'Age Group rule ID: 289'}, {'component': 'Early', 'type': 'Onset Qualifier', 'normalized_form': 'Early Onset', 'rule_applied': 'Onset by Time rule ID: 266'}, {'component': 'Allogeneic Hematopoietic Cell Transplantation (alloHCT) Recipients', 'type': 'Procedural Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural qualifiers and Treatment Set-up rule ID: 232'}, {'component': 'High-Risk Donor Type', 'type': 'Risk Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule - qualifier does not describe the patient's disease.""}]",2
393929,"Nsclc, Metastatic",Real-World Routine Kras Testing Practices In France For Patients (Pts) With Advanced Or Metastatic (Am) Non-Small Cell Lung Cancer (Nsclc): Data From The Esme Cohort,Advanced;;Metastatic;;Non-Small Cell Lung Cancer,Advanced Or Metastatic Non-Small Cell Lung Cancer,Advanced/Metastatic Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it provides more specific and complete information about the patient population, including the disease stage.
2. **Component Identification**: The core components identified in the abstract title are the disease 'Non-Small Cell Lung Cancer (Nsclc)' and the stage/occurrence qualifiers 'Advanced Or Metastatic (Am)'.
3. **Rule Retrieval**: Rules for 'Stage' and 'Occurrence' were retrieved to handle the terms 'Advanced' and 'Metastatic'. The rule for 'Advanced Metastatic' (ID 177) suggests consolidating these terms. While the rule suggests 'Locally Advanced Metastatic', the term 'Locally' is not present in the source text. Therefore, a standard clinical representation 'Advanced/Metastatic' was used to accurately reflect the source 'Advanced Or Metastatic'.
4. **Exclusion Application**: As per generic rules, geographical locations ('France'), patient descriptors ('Pts'), and study methodology terms ('Kras Testing Practices') were excluded from the final indication. The mention of 'Kras' pertains to the testing methodology of the study, not a genetic characteristic of the patient cohort itself, and is therefore correctly excluded.
5. **Indication Construction**: The identified components were combined and formatted according to the generic rules. 'Non-Small Cell Lung Cancer' is already in singular form. The combined phrase was converted to Title Case, resulting in 'Advanced/Metastatic Non-Small Cell Lung Cancer'.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine how to handle the term 'Advanced'.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To determine how to handle the term 'Metastatic' and its combination with 'Advanced'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To confirm that 'Kras Testing Practices' is a methodological term and not a patient subgroup characteristic.""}]","[{'component': 'Advanced Or Metastatic (Am)', 'type': 'Stage/Occurrence', 'normalized_form': 'Advanced/Metastatic', 'rule_applied': ""Rule ID 177 for 'Advanced Metastatic' guided the consolidation of the terms. The output was normalized to the standard clinical shorthand 'Advanced/Metastatic' to accurately represent 'Advanced Or Metastatic'.""}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'Kras Testing Practices', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items and study methodologies. Gene type rules confirmed that this does not describe a specific gene mutation in the patient cohort.'}, {'component': 'France', 'type': 'Region', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic/geographic descriptors.'}]",2
295653,"Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management",Discussion,,,Cancer,True,session_title,"Step 1: The abstract title 'Discussion' contains no medical or disease-related terms, so it is discarded.
Step 2: The session title 'Young Oncologist Forum: Going on a Research Journey: From grant writing, over PhD to team management' is selected as the source.
Step 3: The term 'Oncologist' is identified, which corresponds to the therapeutic area of Oncology.
Step 4: The generic rule for 'Therapeutic Area Fallback' is applied, which states that 'Oncology' should be normalized to the overarching disease 'Cancer'.
Step 5: The final indication is formatted to 'Cancer' following Title Case and singular form rules.",[],"[{'component': 'Oncologist', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",1
328423,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster II,"ASC4START: A Phase IIIb, Open-Label, Randomized Study of Tolerability and Efficacy of Asciminib Versus Nilotinib in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase",Newly Diagnosed;;Philadelphia Chromosome;;Positive;;Chronic Myelogenous Leukemia;;Chronic Phase,Newly Diagnosed Ph-Positive Chronic Myelogenous Leukemia in Chronic Phase,Newly Diagnosed Ph Chromosome-Positive Chronic Myelogenous Leukemia in Chronic Phase,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Chronic Myelogenous Leukemia') and provides more detailed clinical information than the session title, in accordance with the single-source principle.
2. **Component Identification**: I identified four key components in the abstract title: the diagnosis status 'Newly Diagnosed', the chromosomal marker 'Philadelphia Chromosome-Positive', the core disease 'Chronic Myelogenous Leukemia', and the disease stage 'Chronic Phase'.
3. **Rule Retrieval**: I retrieved specific rules for the identified components. 
   - For 'Newly Diagnosed', the rule from the 'Treatment based' category (ID: 193) confirmed it should be used as a prefix.
   - For 'Philadelphia Chromosome-Positive', the rule from the 'Chromosome type' category (ID: 81) dictated its conversion to the standardized abbreviation 'Ph Chromosome-Positive'.
   - For 'Chronic Phase', I determined it was a critical stage descriptor that must be included.
4. **Indication Construction**: I assembled the components in a clinically logical order. The diagnosis status comes first, followed by the genetic marker, the core disease, and finally the stage. The preposition 'in' is kept and lowercased as per generic formatting rules.
5. **Final Formatting and Quality Check**: The final indication was formatted to Title Case, ensuring gene/chromosome abbreviations were preserved. I verified that all generic rules, such as using the singular form for the disease and correct spacing, were applied. The resulting indication is a complete and clinically accurate representation of the patient population described in the title.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To validate the handling of the term 'Newly Diagnosed'.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To find the correct formatting for 'Philadelphia Chromosome-Positive'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine how to handle the 'Chronic Phase' descriptor.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Philadelphia Chromosome-Positive', 'type': 'Chromosome Type', 'normalized_form': 'Ph Chromosome-Positive', 'rule_applied': ""Rule ID: 81 - Convert to the standardized abbreviation 'Ph Chromosome-Positive'.""}, {'component': 'Chronic Myelogenous Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myelogenous Leukemia', 'rule_applied': 'Generic Rule - Title Case and singular form.'}, {'component': 'Chronic Phase', 'type': 'Stage', 'normalized_form': 'in Chronic Phase', 'rule_applied': 'Generic Rule - Include stage information and apply Title Case.'}]",2
410348,COVID-19: A New Understanding and Lessons Learned,Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider,COVID-19,COVID-19 Infection,COVID-19,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Excess Mortality During the COVID-19 Pandemic in a Mid-Sized Dialysis Provider' and the session title is 'COVID-19: A New Understanding and Lessons Learned'.
2.  **Select Source**: Both titles contain the disease term 'COVID-19'. According to the Single-Source Extraction Principle, the abstract title is the preferred source. I will use the abstract title.
3.  **Identify Components**: The key disease component in the abstract title is 'COVID-19'. The phrase 'in a Mid-Sized Dialysis Provider' describes a patient setting based on a medical procedure (dialysis), not a disease itself. 'Excess Mortality' is an outcome, not an indication.
4.  **Apply Rules**: I applied the generic exclusion rules. The procedural context 'Dialysis Provider' is excluded. The outcome 'Excess Mortality' and the epidemiological descriptor 'Pandemic' are also excluded. The disease name 'COVID-19' is already in the correct format and does not need to be changed.
5.  **Construct Indication**: The extracted and cleaned component is 'COVID-19'.
6.  **Quality Check**: The final indication adheres to all formatting and exclusion rules. It is clinically accurate and derived from a single source.",[],"[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic Rule - Disease Identification'}, {'component': 'in a Mid-Sized Dialysis Provider', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule - Exclusion of Procedural/Temporal Qualifiers'}]",1
328431,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Cancer-Related Gene Mutations Drive Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukaemia,Chronic Myeloid Leukaemia,Chronic Myeloid Leukaemia,Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease 'Chronic Myeloid Leukemia'. Following the single-source principle, the abstract title is prioritized.
2.  **Component Identification**: The abstract title contains the disease 'Chronic Myeloid Leukaemia' and two potential qualifiers: 'Cancer-Related Gene Mutations' and 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy'.
3.  **Rule Retrieval**: I retrieved rules for 'Resistance' which confirmed that treatment resistance descriptors should be excluded from the final indication as they represent a treatment response status, not a distinct clinical entity.
4.  **Rule Application**: 
    - The disease term 'Chronic Myeloid Leukaemia' was normalized to the standard American spelling 'Chronic Myeloid Leukemia' and formatted to Title Case.
    - The phrase 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy' was excluded based on the retrieved 'Resistance' rules.
    - The phrase 'Cancer-Related Gene Mutations' is a general descriptor of the cause of resistance, not a specific, standard patient subgroup qualifier. It was excluded to maintain a concise and clinically standard indication.
5.  **Indication Construction**: After applying the rules and exclusions, the core disease 'Chronic Myeloid Leukemia' remains as the final indication.
6.  **Quality Check**: The final output adheres to all formatting and clinical standardization rules.","[{'category': 'Occurrence', 'subcategories': ['Resistance'], 'reason': ""To determine how to handle the phrase 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy'.""}, {'category': 'Gene type', 'subcategories': ['Gene Mutation'], 'reason': ""To check for rules regarding the handling of 'Gene Mutations'.""}]","[{'component': 'Chronic Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form, Spelling Normalization'}, {'component': 'Resistance to the Third-Generation Tyrosine Kinase Inhibitor Therapy', 'type': 'Treatment Resistance', 'normalized_form': '', 'rule_applied': 'Occurrence Rule (ID: 164, 165): Exclude drug/drug class resistance descriptors.'}, {'component': 'Cancer-Related Gene Mutations', 'type': 'General Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclude non-diagnostic, overly general descriptors that do not define a standard clinical subgroup.'}]",2
328439,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster III,Targeted Next-Generation Sequencing Identifies Additional Mutations Other Than BCR-ABL in Chronic Myeloid Leukemia Patients: A Chinese Monocentric Retrospective Study,BCR-ABL;;Chronic Myeloid Leukemia,BCR-ABL-Fusion Chronic Myeloid Leukemia,Chronic Myeloid Leukemia with Additional Mutations Other Than BCR-ABL,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract and session titles contain the disease 'Chronic Myeloid Leukemia'. As per the single-source principle, the abstract title is prioritized as it provides more specific patient details.
2.  **Component Identification**: The abstract title identifies the core disease 'Chronic Myeloid Leukemia' and a specific patient subgroup characterized by 'Additional Mutations Other Than BCR-ABL'. It also contains the sociodemographic descriptor 'Chinese', which must be excluded.
3.  **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under 'Genetic Status' to guide the handling of mutation-defined subgroups. Although no specific rule matched this exact phrase, the general principle is to include clinically relevant genetic descriptors.
4.  **Rule Application & Construction**:
    *   The core disease 'Chronic Myeloid Leukemia' is extracted and formatted in Title Case.
    *   The patient subgroup identifier 'with Additional Mutations Other Than BCR-ABL' is appended to the core disease to accurately define the indication.
    *   The sociodemographic term 'Chinese' is excluded based on the generic exclusion rules.
    *   Study design details ('Monocentric Retrospective Study') are also excluded as they are not part of the medical indication.
5.  **Final Quality Check**: The resulting indication, 'Chronic Myeloid Leukemia with Additional Mutations Other Than BCR-ABL', is clinically accurate, adheres to formatting guidelines (Title Case, singular form), and correctly represents the specific patient population from the selected source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Genetic Status'], 'reason': ""To check for rules on how to handle complex genetic descriptors like 'Additional Mutations Other Than BCR-ABL'.""}]","[{'component': 'Chronic Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Additional Mutations Other Than BCR-ABL', 'type': 'Patient Sub-Group (Genetic Status)', 'normalized_form': 'with Additional Mutations Other Than BCR-ABL', 'rule_applied': 'Generic Rule: Inclusion of clinically relevant patient subgroups'}, {'component': 'Chinese', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of ethnicity'}]",2
180989,Autologous Transplantation: Clinical and Epidemiological: Poster I,Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population,,,,True,none,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Safety of Autologous Hematopoietic Stem Cell Transplantation in Patients over 75 Years Old. Single Center Experience Serving a Minority Population' and the session title is 'Autologous Transplantation: Clinical and Epidemiological: Poster I'.
2.  **Select Source**: Neither the abstract title nor the session title contains a specific disease or disorder. Both refer to a medical procedure ('Autologous Hematopoietic Stem Cell Transplantation' and 'Autologous Transplantation'). The abstract title contains a patient subgroup ('over 75 Years Old') and a sociodemographic descriptor ('Minority Population').
3.  **Identify Components & Retrieve Rules**: 
    *   'over 75 Years Old' was identified as an age-based patient subgroup. I retrieved rules for the 'Age Group' category, which confirmed that such phrases are typically normalized to 'Elderly'.
    *   'Autologous Hematopoietic Stem Cell Transplantation' was identified as a procedure. I retrieved rules for 'Treatment Set-up' which confirmed that transplant-related terms are procedural and should be excluded.
    *   'Minority Population' is a sociodemographic descriptor and must be excluded based on generic rules.
4.  **Apply Rules & Construct Indication**: According to the 'Handling Orphan PSUBs' rule, a patient subgroup cannot form an indication without a core disease term from the same source. Since the abstract title lacks a disease, the patient subgroup 'over 75 Years Old' is discarded. The session title also lacks a disease. Therefore, no valid medical indication can be extracted from either source.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To determine how to handle the patient descriptor 'over 75 Years Old'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To confirm that 'Autologous Hematopoietic Stem Cell Transplantation' is a procedural term to be excluded.""}]","[{'component': 'over 75 Years Old', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': 'Age Group rule for elderly patients.'}, {'component': 'Autologous Hematopoietic Stem Cell Transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural qualifiers.'}, {'component': 'Minority Population', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors.'}]",2
328455,Chronic Myeloid Leukemia: Clinical and Epidemiological: Poster I,Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor,Chronic Myeloid Leukemia;;Intermediate;;High-Risk,Intermediate-Risk High-Risk Chronic Myeloid Leukemia,High-Risk Chronic Myeloid Leukemia;;Intermediate-Risk Chronic Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title as it contains more specific information about the patient subgroup, including disease and risk stratification.
2. **Component Identification**: The key components identified in the abstract title are the disease ""Chronic Myeloid Leukemia"" and the patient subgroups ""Intermediate- or High-Risk"".
3. **Rule Retrieval**: Rules for the 'Risk' category were retrieved to handle the terms ""Intermediate-Risk"" and ""High-Risk"". Specifically, Rule ID 129 for 'Intermediate-Risk' and general rules for 'High-Risk' were applicable.
4. **Rule Application**: The retrieved rules dictate that when multiple risk levels for the same disease are mentioned, they should be extracted as separate indications. The terms ""Intermediate- or High-Risk"" were normalized to ""Intermediate-Risk"" and ""High-Risk"" respectively.
5. **Indication Construction**: Two distinct indications were constructed by prepending the normalized risk qualifiers to the disease name: ""High-Risk Chronic Myeloid Leukemia"" and ""Intermediate-Risk Chronic Myeloid Leukemia"". These were then combined using the required ';;' separator.
6. **Exclusions**: Non-indicative information such as ""Subjects with"", the description of the therapeutic model (""Imatinib Therapy Failure (IMTF) Model""), and the treatment details (""Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor"") were excluded as per generic rules.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Risk Types'], 'reason': ""To correctly handle the 'Intermediate- or High-Risk' qualifiers and understand how to format them as separate indications.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine if 'Initial Therapy' should be included as a 'First-Line' descriptor. The rules helped confirm it should be excluded as it describes the intervention, not the patient population.""}]","[{'component': 'Chronic Myeloid Leukemia', 'type': 'Disease', 'normalized_form': 'Chronic Myeloid Leukemia', 'rule_applied': 'Generic singular form and title case rules.'}, {'component': 'Intermediate- or High-Risk', 'type': 'Risk Stratification', 'normalized_form': 'High-Risk;;Intermediate-Risk', 'rule_applied': 'Rule ID 129 (Risk category), which specifies creating separate indications for each risk level mentioned.'}, {'component': 'Initial Therapy', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers. The term describes the intervention being studied, not a defining characteristic of the patient cohort.'}]",2
262924,Acute lymphoblastic leukemia - Clinical,A Phase 1/2 Study To Evaluate Ponatinib With Chemotherapy In Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Or With T315I Mutation,Relapsed;;Intolerant;;Philadelphia Chromosome;;Positive;;Acute Lymphoblastic Leukemia;;T315I Mutation,Relapsed/Intolerant Ph-Positive T315I Mutated Acute Lymphoblastic Leukemia,Pediatric Relapsed/Refractory Ph Chromosome-Positive Acute Lymphoblastic Leukemia;;Pediatric T315I-Mutated Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains the disease ('Acute Lymphoblastic Leukemia') and is significantly more detailed than the session title, adhering to the single-source principle.
2.  **Component Identification**: The abstract title was parsed to identify key clinical components: 'Pediatric' (Age Group), 'Relapsed/Resistant/Intolerant' (Disease State), 'Philadelphia Chromosome-Positive' (Chromosome Type), 'Acute Lymphoblastic Leukemia' (Disease), and 'T315I Mutation' (Gene Mutation).
3.  **Handling Multiple Indications**: The presence of 'Or' indicates two distinct patient populations, leading to the extraction of two separate indications for the same disease.
4.  **Rule Retrieval and Application**:
    *   **Indication 1**: 'Pediatric Patients With Relapsed/Resistant/Intolerant Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia'
        *   'Pediatric' was retained as the leading qualifier per the 'Age Group' rule (ID: 295).
        *   'Relapsed/Resistant/Intolerant' was normalized to the standard clinical trial terminology 'Relapsed/Refractory' based on 'Occurrence' rules.
        *   'Philadelphia Chromosome-Positive' was standardized to 'Ph Chromosome-Positive' as per the 'Chromosome type' rule (ID: 81).
        *   The disease 'Acute Lymphoblastic Leukemia' was kept in its standard Title Case singular form.
    *   **Indication 2**: '[Pediatric Patients] With T315I Mutation [Acute Lymphoblastic Leukemia]'
        *   The context implies this group is also 'Pediatric' with 'Acute Lymphoblastic Leukemia'.
        *   'T315I Mutation' was normalized to 'T315I-Mutated' following the 'Gene type' rule for mutations (ID: 30), which specifies the '<GENE>-Mutated' format.
5.  **Final Construction**: The normalized components for both indications were assembled in the correct clinical order (Age -> State -> Genetic Marker -> Disease). The two resulting indications were then combined into a single string using the required ';;' separator.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Resistance', 'Relapse'], 'reason': ""To standardize the terms 'Relapsed/Resistant/Intolerant' into a clinically accepted format.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To apply the standard abbreviation and formatting for 'Philadelphia Chromosome-Positive'.""}, {'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'T315I Mutation' into the standard '<GENE>-Mutated' format.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group Rule ID: 295'}, {'component': 'Relapsed/Resistant/Intolerant', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rules for standardizing treatment status.'}, {'component': 'Philadelphia Chromosome-Positive', 'type': 'Chromosome Type', 'normalized_form': 'Ph Chromosome-Positive', 'rule_applied': 'Chromosome type Rule ID: 81'}, {'component': 'T315I Mutation', 'type': 'Gene Mutation', 'normalized_form': 'T315I-Mutated', 'rule_applied': 'Gene type Rule ID: 30'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic formatting rule (Title Case, singular).'}]",2
410383,Kidney Transplantation: New Translational Insights,Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database,,,,True,none,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Outcomes Associated with Sodium-Glucose Cotransporter-2 Inhibitors in Kidney Transplant Recipients: A Real-World Analysis Using a Global Federated Database', and the session title, 'Kidney Transplantation: New Translational Insights', both revolve around the concept of 'Kidney Transplant'.

Step 2: I identified 'Kidney Transplant Recipients' and 'Kidney Transplantation' as the key patient population descriptors.

Step 3: To determine how to handle these terms, I used the `get_indication_rules` tool for the category 'Treatment Set-up' and subcategory 'Transplant Status'.

Step 4: The retrieved rules (e.g., Rule ID 232 for 'Post-Transplant') clearly state that transplant-related statuses should be excluded from the final indication because they describe a procedural or temporal status rather than a distinct clinical disease entity. The generic exclusion rules also state to exclude 'Procedural/Temporal Qualifiers'.

Step 5: Applying this rule, I must exclude 'Kidney Transplant Recipients' from the abstract title and 'Kidney Transplantation' from the session title. After excluding these terms, neither title contains any remaining disease or disorder. Therefore, a valid medical indication cannot be extracted from either source.

Step 6: Since no indication could be formed, the selected source is 'none' and the generated indication is an empty string.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine the correct handling of terms like 'Kidney Transplant Recipients' and 'Kidney Transplantation'.""}]","[{'component': 'Kidney Transplant Recipients', 'type': 'Patient Sub-Group', 'normalized_form': '', 'rule_applied': 'Rule 232 (Post-Transplant) and Generic Exclusion Rule for Procedural/Temporal Qualifiers. The term describes a patient status based on a past procedure and is not a disease.'}, {'component': 'Kidney Transplantation', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Rule 232 (Post-Transplant) and Generic Exclusion Rule for Procedural/Temporal Qualifiers. The term describes a medical procedure, not a disease.'}]",2
148257,Myeloma And Other Monoclonal Gammopathies - Clinical,Overall And Complete Response Rates As Potential Surrogates For Overall Survival In Relapsed Refractory Multiple Myeloma,Relapsed;;Refractory;;Multiple Myeloma,Relapsed Refractory Multiple Myeloma,Relapsed/Refractory Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title contains a specific disease, 'Multiple Myeloma', so it was chosen as the source according to the single-source principle.
2.  **Component Identification**: I identified two key components in the abstract title: the disease 'Multiple Myeloma' and the patient subgroup/disease state 'Relapsed Refractory'.
3.  **Rule Retrieval**: I retrieved rules for the 'Occurrence' category, specifically for 'Recurrent/Refractory' terms, to understand how to format phrases like 'Relapsed Refractory'.
4.  **Rule Application**: 
    *   The retrieved rules guide the normalization of such terms. I standardized 'Relapsed Refractory' to 'Relapsed/Refractory'.
    *   Generic rule for Title Case was applied to the entire indication.
    *   Generic rule for singular form was checked; 'Myeloma' is already singular.
5.  **Indication Construction**: The normalized disease state 'Relapsed/Refractory' was prepended to the disease name 'Multiple Myeloma' to form the final indication.
6.  **Quality Check**: The final indication was checked for compliance with all formatting, exclusion, and clinical accuracy rules. It adheres to the single-source principle, uses correct casing and formatting, and accurately represents the clinical condition described.","[{'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory'], 'reason': ""To determine the correct formatting for the term 'Relapsed Refractory'.""}]","[{'component': 'Relapsed Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': 'Occurrence rule for standardizing recurrent/refractory terms.'}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
295712,"Empowering young cancer nurses academically, clinically and in career progression",The impact of an Education WhatsApp Group to support nurses working in an acute oncology/haematology setting during the Covid-19 pandemic,Covid-19,Covid-19 Infection,Cancer;;Hematologic Malignancy,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains more specific medical terms ('acute oncology/haematology') compared to the session title ('cancer').
Step 2: The term 'oncology/haematology' was identified as representing two distinct therapeutic areas.
Step 3: According to the therapeutic area fallback rule, 'oncology' is mapped to the general disease term 'Cancer'.
Step 4: In the context of an oncology setting, 'haematology' is interpreted as 'Hematologic Malignancy'.
Step 5: The qualifier 'acute' was excluded because it describes the clinical 'setting' rather than being an intrinsic part of the disease name itself, aligning with the principle of excluding non-diagnostic context.
Step 6: The two extracted indications were formatted in Title Case, kept in singular form, and separated by ';;' as per the multiple disease rule.",[],"[{'component': 'oncology', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Therapeutic Area Fallback'}, {'component': 'haematology', 'type': 'Therapeutic Area', 'normalized_form': 'Hematologic Malignancy', 'rule_applied': 'Clinical Interpretation in an Oncology Context'}, {'component': 'acute', 'type': 'Contextual Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Non-Diagnostic Items (describes setting, not disease)'}]",1
230183,Breast Cancer-Metastatic,Treatment of alpelisib induced hyperglycemia with sodium-glucose cotransporter-2 inhibitors: A single institution experience.,hyperglycemia ,Hyperglycemia ,Metastatic Breast Cancer,True,session_title,"Step 1: I analyzed both the abstract and session titles. The abstract title, 'Treatment of alpelisib induced hyperglycemia...', describes a study on managing a treatment side effect (hyperglycemia), not a primary disease indication. The session title, 'Breast Cancer-Metastatic', clearly states a primary disease.
Step 2: Based on the Single-Source Extraction Principle, I selected the session title as it contains the core disease entity.
Step 3: I identified the components in the session title as 'Breast Cancer' (disease) and 'Metastatic' (disease state).
Step 4: I retrieved the specific rule for 'Metastatic' using the get_indication_rules tool, which confirmed the standard format is 'Metastatic <Disease>'.
Step 5: I applied the retrieved rule and the generic formatting rules (Title Case, singular form). The hyphen in 'Breast Cancer-Metastatic' was interpreted as a separator for the qualifier.
Step 6: I constructed the final indication by combining the components according to the rules, resulting in 'Metastatic Breast Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'Metastatic' as a prefix to the disease name.""}]","[{'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic rule: Title Case, Singular form.'}, {'component': 'Metastatic', 'type': 'Disease State', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID 141: Format as 'Metastatic <Primary-Disease-Name>'.""}]",2
230186,Care Delivery and Regulatory Policy,Characteristics and outcomes of COVID-19 in adult cancer patients: Tertiary cancer center experience.,COVID-19;;adult;;cancer,COVID-19 Infection;;Adult Cancer,Adult COVID-19;;Adult Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Characteristics and outcomes of COVID-19 in adult cancer patients: Tertiary cancer center experience.' was chosen as it contains specific medical conditions ('COVID-19', 'cancer'), whereas the session title 'Care Delivery and Regulatory Policy' does not.
2.  **Component Identification**: The abstract title identifies two distinct medical conditions ('COVID-19' and 'cancer') within a specific patient population ('adult cancer patients').
3.  **Rule Retrieval**: Rules for the 'Age Group' category were retrieved to handle the term 'adult'. Rules for 'Patient with two different Disease' were also queried to confirm handling of concurrent conditions.
4.  **Rule Application**:
    *   **Multiple Diseases**: The generic rule for multiple diseases was applied. The title describes a cohort of patients defined by two conditions (cancer and COVID-19). Both are extracted as separate indications, separated by ';;'.
    *   **Age Group**: The retrieved rule for 'Adult' (ID: 289) specifies prefixing the indication with 'Adult'. This prefix is applied to both identified conditions.
    *   **Formatting**: Generic rules were applied to ensure Title Case ('Cancer') and singular form. 'COVID-19' is maintained in its standard uppercase form.
    *   **Exclusion**: The phrase 'Tertiary cancer center experience' describes the study setting and is correctly excluded from the indication.
5.  **Indication Construction**: The components were combined according to the rules: the 'Adult' prefix was added to both 'COVID-19' and 'Cancer', and the two resulting indications were joined with the ';;' separator.
6.  **Final Output**: The final generated indication is 'Adult COVID-19;;Adult Cancer'.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': 'To check for specific rules on handling patients with concurrent diseases like COVID-19 and cancer.'}, {'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'adult' patient subgroup descriptor.""}]","[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic rule for disease identification.'}, {'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': 'adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule (ID: 289) to prefix the indication with 'Adult'.""}]",2
394030,"Nsclc, Metastatic","Harmoni: Randomized, Double-Blind, Multi-Center, Phase III Clinical Study Of Ivonescimab Or Placebo Combined With Pemetrexed And Carboplatin In Patients With Egfr-Mutant Locally Advanced Or Metastatic Non-Squamous Nsclc Who Have Progression Following Egfr-Tki Treatment", Egfr;;Mutant;;Locally Advanced;;Metastatic;;Non-Squamous Nsclc,EGFR-Mutant Locally Advanced Or Metastatic Non-Squamous Non-Small Cell Lung Cancer,EGFR-Mutant Progressive Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen over the session title as it contains a detailed description of the disease and patient population, adhering to the single-source principle.
2.  **Component Identification**: I identified the following key components from the abstract title: 'Egfr-Mutant' (Gene Mutation), 'Locally Advanced Or Metastatic' (Disease Stage/Occurrence), 'Non-Squamous Nsclc' (Disease), and 'Who Have Progression Following Egfr-Tki Treatment' (Progression/Treatment Status).
3.  **Rule Retrieval**: I retrieved rules for 'Gene type', 'Stage', 'Occurrence', and 'Treatment based' to guide the standardization of these components.
4.  **Rule Application & Standardization**:
    *   **Disease Name**: 'Nsclc' was expanded to its full form 'Non-Small Cell Lung Cancer' and standardized to Title Case along with its subtype, resulting in 'Non-Squamous Non-Small Cell Lung Cancer'.
    *   **Gene Mutation**: 'Egfr-Mutant' was standardized to 'EGFR-Mutant', ensuring the gene symbol is in uppercase as per standard convention.
    *   **Stage/Occurrence**: The phrase 'Locally Advanced Or Metastatic' was identified. While Rule 177 suggests consolidating 'advanced' and 'metastatic' into 'Locally Advanced Metastatic', the explicit use of 'or' in a clinical trial title is significant and was retained for precision. The phrase was converted to Title Case: 'Locally Advanced or Metastatic'.
    *   **Progression Status**: The clause 'Who Have Progression Following Egfr-Tki Treatment' clearly defines the disease state. Based on Occurrence Rule 184 ('Progressive'), this was concisely and accurately standardized to the term 'Progressive'.
5.  **Indication Construction**: The standardized components were assembled in a clinically logical order: Gene Mutation -> Progression Status -> Stage -> Disease Name. This resulted in the final indication: 'EGFR-Mutant Progressive Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer'.
6.  **Final Quality Check**: The final indication is fully compliant with all generic rules (Title Case, singular form, no excluded terms) and accurately represents the specific patient population from the source title.","[{'category': 'Gene type', 'subcategories': ['Gene Mutant', 'Gene Mutated'], 'reason': ""To standardize the formatting of 'Egfr-Mutant'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To handle the 'Locally Advanced' component.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Progression-Related'], 'reason': ""To standardize 'Metastatic' and 'Progression Following... Treatment'.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To correctly interpret the patient's treatment history ('Following Egfr-Tki Treatment').""}]","[{'component': 'Egfr-Mutant', 'type': 'Gene Mutation', 'normalized_form': 'EGFR-Mutant', 'rule_applied': 'Generic rule for gene symbol capitalization.'}, {'component': 'Locally Advanced Or Metastatic', 'type': 'Disease Stage/Occurrence', 'normalized_form': 'Locally Advanced or Metastatic', 'rule_applied': ""Occurrence Rule ID 177 (adapted to retain 'or') and Title Case rule.""}, {'component': 'Non-Squamous Nsclc', 'type': 'Disease', 'normalized_form': 'Non-Squamous Non-Small Cell Lung Cancer', 'rule_applied': 'Generic rule for Title Case and abbreviation expansion.'}, {'component': 'Who Have Progression Following Egfr-Tki Treatment', 'type': 'Progression Status', 'normalized_form': 'Progressive', 'rule_applied': ""Occurrence Rule ID 184 ('Progressive') to concisely represent the patient's disease state.""}]",2
394031,"Nsclc, Metastatic",Tropion-Lung07: A Phase III Trial Of Datopotamab Deruxtecan (Dato-Dxd) Plus Pembrolizumab (Pembro) With Or Without Platinum Chemotherapy (Pt-Ct) As First-Line (1L) Therapy In Advanced/Metastatic (Adv/Met) Non-Small Cell Lung Cancer (Nsclc) With Pd-L1 Expression,First-Line;;Advanced;;Metastatic;;Non-Small Cell Lung Cancer,First-Line Advanced/Metastatic Non-Small Cell Lung Cancer,First-Line Advanced Metastatic PD-L1-Positive Non-Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Non-Small Cell Lung Cancer', and provides more detail than the session title, adhering to the single-source principle.
2. **Component Identification**: The following key components were identified in the abstract title: 'First-Line (1L)', 'Advanced/Metastatic (Adv/Met)', 'Non-Small Cell Lung Cancer (Nsclc)', and 'With Pd-L1 Expression'.
3. **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' (specifically 'Line of treatment'), 'Occurrence' (for 'Metastasis-Related Terms' and 'Progression-Related'), and 'Biomarker' to guide normalization.
4. **Component Normalization & Rule Application**:
   - **Line of Treatment**: Based on Treatment Set-up Rule ID 201, '1L' was normalized to 'First-Line'. Rule ID 199 confirmed that 'First-Line' should be retained because it modifies the generic term 'Therapy', not a specific drug.
   - **Disease State**: 'Advanced/Metastatic (Adv/Met)' was combined and normalized to 'Advanced Metastatic', a standard clinical descriptor for this stage of cancer.
   - **Biomarker**: 'With Pd-L1 Expression' was interpreted as a positive biomarker status. Following common clinical terminology patterns (e.g., HER2-Positive), it was normalized to 'PD-L1-Positive'. The casing for 'PD-L1' was standardized to all-caps as per generic rules.
   - **Disease Name**: 'Non-Small Cell Lung Cancer (Nsclc)' was used as the core disease, with the abbreviation removed and Title Case applied.
5. **Final Indication Construction**: The normalized components were assembled in the standard clinical order: Line of Treatment -> Disease State -> Biomarker -> Disease Name. This resulted in the final, clinically precise indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To handle the 'First-Line (1L)' component.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Progression-Related'], 'reason': ""To handle the 'Advanced/Metastatic (Adv/Met)' component.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To find rules for handling the 'Pd-L1 Expression' component.""}]","[{'component': 'First-Line (1L)', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up Rule ID 201'}, {'component': 'Advanced/Metastatic (Adv/Met)', 'type': 'Disease State', 'normalized_form': 'Advanced Metastatic', 'rule_applied': 'Generic normalization for clinical clarity.'}, {'component': 'Non-Small Cell Lung Cancer (Nsclc)', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Generic Rule: Casing and abbreviation removal.'}, {'component': 'With Pd-L1 Expression', 'type': 'Biomarker', 'normalized_form': 'PD-L1-Positive', 'rule_applied': 'Generic Rule: Biomarker casing and standardization to common clinical phrasing.'}]",2
148272,Myeloma And Other Monoclonal Gammopathies - Clinical,Survival And Outcomes Of Newly-Diagnosed Multiple Myeloma Patients Stratified By Transplant Status Diagnosed Between 2007-2018: Real-World Analysis From The Canadian Myeloma Research Group Database,Newly-Diagnosed;;Multiple Myeloma,Newly-Diagnosed Multiple Myeloma,Newly Diagnosed Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Survival And Outcomes Of Newly-Diagnosed Multiple Myeloma Patients...') was chosen as the source because it contains a specific disease term ('Multiple Myeloma'), following the single-source extraction principle which prioritizes the abstract title.
2. **Component Identification**: Key components identified in the abstract title were the disease 'Multiple Myeloma' and the qualifier 'Newly-Diagnosed'. The phrase 'Stratified By Transplant Status' was identified as a methodological descriptor.
3. **Rule Retrieval**: To ensure correct handling of these components, I retrieved rules for 'Diagnosis Status' and 'Transplant Status'.
   - `get_indication_rules(category=""Treatment based"", subcategories=[""Diagnosis Status""])` was called for 'Newly-Diagnosed'.
   - `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Transplant Status""])` was called for 'Transplant Status'.
4. **Rule Application**:
   - The rule for 'Newly Diagnosed' (ID: 193) confirms that it should be included as a prefix to the disease name.
   - The rules for 'Transplant Status' (IDs: 228-233) indicate that such terms should be excluded as they describe procedural suitability or study methodology, not a core part of the clinical indication.
   - Generic rules were applied: 'patients' was converted to singular 'patient' and then removed as it's a population descriptor, not part of the disease name. The disease 'Multiple Myeloma' is already singular. Title Case was applied.
5. **Indication Construction**: The qualifier 'Newly Diagnosed' was combined with the disease 'Multiple Myeloma'. The descriptor 'Transplant Status' was excluded per the rules. The final indication was formatted to 'Newly Diagnosed Multiple Myeloma'.
6. **Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is derived from a single source and correctly excludes non-clinical information.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct formatting and inclusion of the term 'Newly-Diagnosed'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine if 'Transplant Status' should be included in the final indication.""}]","[{'component': 'Newly-Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - 'Newly Diagnosed' should be prefixed to the disease name.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}, {'component': 'Transplant Status', 'type': 'Treatment Status', 'normalized_form': '', 'rule_applied': 'Rule IDs: 228-233 - Transplant status descriptors are excluded as they represent procedural suitability, not a disease state.'}]",3
262962,Acute myeloid leukemia - Clinical,Acute Promyelocytic Leukemia And Thrombosis: How To Identify The High-Risk Patients?,Acute Promyelocytic Leukemia;;Thrombosis,Acute Promyelocytic Leukemia;;Thrombosis,High-Risk Acute Promyelocytic Leukemia;;Thrombosis,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Acute Promyelocytic Leukemia And Thrombosis: How To Identify The High-Risk Patients?') was chosen over the session title ('Acute myeloid leukemia - Clinical') because it is more specific and contains all the necessary components for a detailed indication, adhering to the single-source principle.
2. **Component Identification**: I identified two distinct medical conditions: 'Acute Promyelocytic Leukemia' and 'Thrombosis'. I also identified a patient subgroup qualifier: 'High-Risk'.
3. **Rule Retrieval**: To ensure correct formatting for the risk qualifier, I retrieved rules for the 'Risk' category, specifically for 'High-Risk'.
4. **Rule Application and Construction**:
   - The generic rule for multiple diseases was applied, requiring both 'Acute Promyelocytic Leukemia' and 'Thrombosis' to be extracted and separated by ';;'.
   - The retrieved rule for 'High-Risk' (Rule ID: 122) guided the normalization of 'high-risk' to 'High-Risk' and its placement as a prefix to the primary associated disease.
   - The qualifier 'High-Risk' is contextually linked to the patients with 'Acute Promyelocytic Leukemia', resulting in the combined indication 'High-Risk Acute Promyelocytic Leukemia'.
   - 'Thrombosis' is extracted as a second, separate indication.
5. **Final Formatting**: The final output was formatted using Title Case, singular forms for diseases, and the ';;' separator, with all non-essential terms like 'patients' excluded as per generic rules.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To correctly format and apply the 'High-Risk' patient subgroup qualifier.""}]","[{'component': 'Acute Promyelocytic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Promyelocytic Leukemia', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Thrombosis', 'type': 'Disease', 'normalized_form': 'Thrombosis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'High-Risk', 'type': 'Patient Subgroup (Risk)', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule (ID: 122) for normalization and placement.'}]",2
181043,Health Services Research-Non-Malignant Conditions: Poster I,Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need,,,Non-Malignant Condition,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Integrative Hematology Oncology Fellowship Program: A National Survey Based Analysis of Need' and the session title is 'Health Services Research-Non-Malignant Conditions: Poster I'.
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred if it contains a disease/condition term. The abstract title contains 'Hematology Oncology', which are medical specialties (therapeutic areas), not specific diseases. The rest of the title describes a survey about a fellowship program. Since it lacks a direct disease term, I fall back to the session title.
3.  **Identify Components**: The session title contains the term 'Non-Malignant Conditions'.
4.  **Apply Rules**: I applied the generic rules to this component. The 'Singular Form' rule was used to convert 'Conditions' to 'Condition'. The 'Casing' rule confirmed that 'Non-Malignant Condition' follows Title Case. Methodological terms like 'Health Services Research' and 'Poster I' were excluded.
5.  **Construct Indication**: The identified and normalized component 'Non-Malignant Condition' is the final indication.
6.  **Quality Check**: The final indication is clinically consistent with the session title's context and adheres to all formatting and extraction rules. Using the session title avoids the clinical contradiction of extracting 'Cancer' (from 'Oncology' in the abstract title) for a presentation explicitly categorized under 'Non-Malignant Conditions'.",[],"[{'component': 'Non-Malignant Conditions', 'type': 'Disease Characterisation', 'normalized_form': 'Non-Malignant Condition', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Casing'}]",2
213817,"MP28: Health Services Research: Practice Patterns, Quality of Life and Shared Decision Making III","Burden of depression and anxiety in men with high-risk, intermediate-risk or low-risk prostate cancer",high-risk;;intermediate-risk;;low-risk;;prostate cancer,High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,Depression;;Anxiety;;High-Risk Prostate Cancer;;Intermediate-Risk Prostate Cancer;;Low-Risk Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Burden of depression and anxiety in men with high-risk, intermediate-risk or low-risk prostate cancer') contains specific disease terms ('depression', 'anxiety', 'prostate cancer'), while the session title does not. Therefore, the abstract title was selected as the source, adhering to the single-source principle.
2.  **Component Identification**: The selected title contains multiple medical conditions: 'depression', 'anxiety', and 'prostate cancer'. It also includes risk-based patient subgroups for prostate cancer: 'high-risk', 'intermediate-risk', and 'low-risk'. The gender descriptor 'men' was identified for exclusion.
3.  **Rule Retrieval**: To ensure correct formatting of the risk stratifiers, rules for the 'Risk' category were retrieved using `get_indication_rules(category='Risk', subcategories=['High-Risk', 'Low-Risk', 'Risk Types'])`.
4.  **Rule Application**:
    *   **Generic Exclusion Rule**: The sociodemographic term 'men' was excluded.
    *   **Generic Multiple Disease Rule**: 'Depression', 'Anxiety', and the various forms of 'Prostate Cancer' were identified as distinct indications to be extracted and separated by ';;'.
    *   **Retrieved Risk Rules (ID 122, 123, 129)**: These rules guided the normalization of 'high-risk', 'low-risk', and 'intermediate-risk' to 'High-Risk', 'Low-Risk', and 'Intermediate-Risk' respectively. Rule 129 specifically directs the creation of a separate indication for each risk level when multiple are mentioned for the same disease.
    *   **Generic Formatting Rules**: All terms were converted to Title Case and singular form.
5.  **Indication Construction**: The identified components were combined according to the applied rules. 'Depression' and 'Anxiety' were extracted as standalone indications. The prostate cancer indications were constructed by prepending the normalized risk level to the disease, resulting in three separate indications: 'High-Risk Prostate Cancer', 'Intermediate-Risk Prostate Cancer', and 'Low-Risk Prostate Cancer'.
6.  **Final Output**: All five indications were combined into a single string, delimited by ';;', resulting in the final output.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Low-Risk', 'Risk Types'], 'reason': ""To correctly format the risk stratifiers 'high-risk', 'intermediate-risk', and 'low-risk' found in the abstract title.""}]","[{'component': 'depression', 'type': 'Disease', 'normalized_form': 'Depression', 'rule_applied': 'Generic Title Case Rule'}, {'component': 'anxiety', 'type': 'Disease', 'normalized_form': 'Anxiety', 'rule_applied': 'Generic Title Case Rule'}, {'component': 'high-risk prostate cancer', 'type': 'Disease with Risk Subgroup', 'normalized_form': 'High-Risk Prostate Cancer', 'rule_applied': 'Risk Rule ID 122'}, {'component': 'intermediate-risk prostate cancer', 'type': 'Disease with Risk Subgroup', 'normalized_form': 'Intermediate-Risk Prostate Cancer', 'rule_applied': 'Risk Rule ID 129'}, {'component': 'low-risk prostate cancer', 'type': 'Disease with Risk Subgroup', 'normalized_form': 'Low-Risk Prostate Cancer', 'rule_applied': 'Risk Rule ID 123'}, {'component': 'men', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Gender'}]",2
410433,Coronavirus (COVID-19),Ethical Analysis on Mandating COVID-19 Vaccination Prior to Kidney Transplantation in Brazil,COVID-19,COVID-19 Infection,COVID-19,True,abstract_title,"Step 1: The abstract title 'Ethical Analysis on Mandating COVID-19 Vaccination Prior to Kidney Transplantation in Brazil' was chosen as the primary source because it contains a specific disease term ('COVID-19').
Step 2: The components identified in the title are the disease 'COVID-19' and the procedural context 'Prior to Kidney Transplantation'.
Step 3: I retrieved rules for 'Transplant Status' to confirm that procedural contexts should be excluded. The generic exclusion rules also state that procedural/temporal qualifiers like 'Prior to' and surgery terms like 'Transplantation' should be excluded.
Step 4: The geographic descriptor 'Brazil' is also excluded based on the generic sociodemographic exclusion rules.
Step 5: After applying these exclusions, the only remaining clinically valid medical indication is 'COVID-19'. The formatting is already correct as it is a standard acronym.","[{'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To verify the handling of 'Kidney Transplantation' and confirm its exclusion as a procedural context.""}]","[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic rule: Retain standard disease name.'}, {'component': 'Prior to Kidney Transplantation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers. Confirmed with Transplant Status specific rules.'}, {'component': 'Brazil', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic and geographic descriptors.'}]",2
312133,Ignite Session 8A,Restoration of NAD+ Levels in Rheumatoid Arthritis with NAD+ Boosters as a Novel Therapeutic Strategy to Resolve Acute Inflammation,Rheumatoid Arthritis,Rheumatoid Arthritis,Rheumatoid Arthritis;;Acute Inflammation,True,abstract_title,"Step 1: The abstract title contains disease terms ('Rheumatoid Arthritis', 'Acute Inflammation'), while the session title ('Ignite Session 8A') does not. Therefore, the abstract title was selected as the source.
Step 2: Two distinct medical conditions were identified in the selected title: 'Rheumatoid Arthritis' and 'Acute Inflammation'.
Step 3: The generic rule for multiple diseases was applied, which requires separating distinct conditions with ';;'.
Step 4: The generic rule for 'Acute' was applied. Since 'Acute' is part of the disease name 'Acute Inflammation', it was included.
Step 5: Both indications were formatted to Title Case and singular form as per the generic rules, resulting in 'Rheumatoid Arthritis' and 'Acute Inflammation'.
Step 6: The final indication was constructed by combining the two extracted conditions with the ';;' separator.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct formatting for multiple distinct diseases mentioned in the same title. Although no specific rule was returned, the generic rules provided sufficient guidance.'}]","[{'component': 'Rheumatoid Arthritis', 'type': 'Disease', 'normalized_form': 'Rheumatoid Arthritis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'Acute Inflammation', 'type': 'Disease', 'normalized_form': 'Acute Inflammation', 'rule_applied': 'Generic rule: Title Case, Singular Form, Acute disease characterization'}]",4
148309,Myeloproliferative Neoplasms - Clinical,Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis,Primary;;Myelofibrosis,Primary Myelofibrosis,JAK2 V617F-Mutated Primary Myelofibrosis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Jak2V617F Allele Burden: An Independent Predictor Of Overt Fibrosis In Primary Myelofibrosis') was chosen over the session title ('Myeloproliferative Neoplasms - Clinical') because it contains a more specific disease entity ('Primary Myelofibrosis') and a genetic marker, adhering to the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'Primary Myelofibrosis' and the gene variant 'Jak2V617F'. The term 'Overt Fibrosis' was identified as an outcome being predicted, not a descriptor of the patient population itself, and was therefore excluded from the indication.
3.  **Rule Retrieval**: Rules for 'Gene type' were retrieved to correctly format the 'Jak2V617F' variant. Generic rules for disease characterization were also applied.
4.  **Rule Application and Normalization**:
    *   **Disease Term**: The term 'Primary' was retained as it is an integral part of the disease name 'Primary Myelofibrosis'. The term was converted to Title Case.
    *   **Gene Variant**: Following the pattern from the retrieved 'Gene type' rules (e.g., for 'Gene Mutant' or 'Gene Mutated'), 'Jak2V617F' was normalized to the standard format. The gene symbol 'Jak2' was capitalized to 'JAK2', and the '-Mutated' suffix was added, resulting in 'JAK2 V617F-Mutated'.
5.  **Indication Construction**: The normalized genetic marker was prepended to the disease name to form the final indication.
6.  **Final Formatting**: The final string was checked for compliance with all formatting rules, including Title Case, singular form, and proper spacing, resulting in 'JAK2 V617F-Mutated Primary Myelofibrosis'.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To determine the correct formatting for the gene variant 'Jak2V617F'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding the term 'Overt Fibrosis'.""}]","[{'component': 'Jak2V617F', 'type': 'Gene Variant', 'normalized_form': 'JAK2 V617F-Mutated', 'rule_applied': ""Gene type rule for gene mutations (e.g., ID 31, 32) adapted for a specific variant, requiring capitalization of the gene and addition of a '-Mutated' suffix.""}, {'component': 'Primary Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Primary Myelofibrosis', 'rule_applied': ""Generic rule for 'Primary' to include it when part of a disease name. Title Case and singular form rules also applied.""}, {'component': 'Overt Fibrosis', 'type': 'Disease Outcome', 'normalized_form': '', 'rule_applied': 'Excluded as it describes a predicted outcome within the patient population, not a defining characteristic of the patient subgroup itself.'}]",2
263003,Acute myeloid leukemia - Clinical,Utility Of Flt3 Inhibitors In Patients With Acute Myeloid Leukemia (Aml) And T(6;9)(P22;Q34),Acute Myeloid Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with T(6;9)(P22;Q34),True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract title and session title contain the disease 'Acute Myeloid Leukemia'. The abstract title is chosen as the source because it provides more specific information, namely the chromosomal translocation 'T(6;9)(P22;Q34)', which defines a key patient subgroup. This adheres to the single-source principle, prioritizing the more detailed title.
2.  **Component Identification**: The selected abstract title contains:
    *   Disease: 'Acute Myeloid Leukemia (Aml)'
    *   Patient Subgroup (Genetic Marker): 'T(6;9)(P22;Q34)'
    *   Excluded terms: 'Utility Of Flt3 Inhibitors' (treatment), 'Patients' (generic descriptor).
3.  **Rule Retrieval**: I retrieved rules for 'Chromosome type' to understand how to handle the cytogenetic notation and 'Connectors' to determine how to join the disease and the genetic marker.
4.  **Rule Application**:
    *   The retrieved 'Chromosome type' rules were not directly applicable to this specific translocation format, so the standard cytogenetic nomenclature 'T(6;9)(P22;Q34)' was preserved as it is clinically precise.
    *   The connector 'And' in the title links the disease to the translocation. The most clinically accurate representation is to use 'with' to connect the disease and its defining characteristic.
    *   Generic rules were applied: The redundant abbreviation '(Aml)' was removed. The output was formatted to Title Case, with the preposition 'with' in lower case per casing rules. The disease term 'Leukemia' is already in singular form.
5.  **Indication Construction**: The final indication was constructed by combining the core disease with the specific patient subgroup identifier, resulting in 'Acute Myeloid Leukemia with T(6;9)(P22;Q34)'.
6.  **Quality Check**: The final output was verified for adherence to all formatting, exclusion, and clinical accuracy requirements.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': 'To check for specific formatting rules regarding the chromosomal translocation T(6;9)(P22;Q34).'}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To determine the correct way to handle the word 'And' connecting the disease to the genetic marker.""}]","[{'component': 'Acute Myeloid Leukemia (Aml)', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule: Remove redundant abbreviations.'}, {'component': 'T(6;9)(P22;Q34)', 'type': 'Chromosomal Translocation', 'normalized_form': 'T(6;9)(P22;Q34)', 'rule_applied': 'Preserved standard cytogenetic nomenclature in the absence of a specific transformation rule.'}, {'component': 'With... And', 'type': 'Connector', 'normalized_form': 'with', 'rule_applied': ""Generic rule: Use of 'with' for clinical connection and lowercasing of prepositions.""}]",2
410465,Acute Kidney Injury,A Rare Case of ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,ANCA-Mediated;;Acute Interstitial Nephritis,ANCA-Mediated Acute Interstitial Nephritis,ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('A Rare Case of ANCA-Mediated Acute Interstitial Nephritis Without Glomerulonephritis') was chosen over the session title ('Acute Kidney Injury') because it contains a more specific and detailed disease description, adhering to the single-source principle to use the most informative title.
2.  **Component Identification**: The key components identified in the abstract title are:
    *   Disease: 'Acute Interstitial Nephritis'
    *   Qualifier/Cause: 'ANCA-Mediated'
    *   Negative Finding/Subgroup Definition: 'Without Glomerulonephritis'
    *   Study Descriptor: 'A Rare Case of'
3.  **Rule Application**: 
    *   **Generic Exclusion Rule**: The phrase 'A Rare Case of' was excluded as it describes the nature of the report rather than being part of the clinical indication itself.
    *   **Generic Disease Characterization Rule**: The term 'Acute' was retained as it is an integral part of the disease name 'Acute Interstitial Nephritis'.
    *   **Biomarker/Qualifier Handling**: 'ANCA-Mediated' is a critical descriptor of the disease's etiology and was included. 'ANCA' is maintained in all-caps as it is a standard acronym.
    *   **Subgroup Definition**: The phrase 'Without Glomerulonephritis' is a clinically significant negative finding that defines a specific and important subgroup of this condition, as ANCA-associated diseases often present with glomerulonephritis. Therefore, it was included to ensure clinical accuracy.
4.  **Indication Construction & Formatting**:
    *   The components were combined to form the full indication.
    *   **Title Case Rule**: The final indication was formatted in Title Case, capitalizing each clinically significant word.
    *   **Singular Form Rule**: All disease terms were already in singular form.
    *   The final indication is a single, cohesive entity, so no ';;' separator was needed.","[{'category': 'Biomarker', 'subcategories': ['Biomarker status'], 'reason': ""To check for rules on handling 'ANCA-Mediated' as a potential biomarker.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on handling 'Rare Case' and negative findings like 'Without Glomerulonephritis'.""}]","[{'component': 'ANCA-Mediated Acute Interstitial Nephritis', 'type': 'Disease', 'normalized_form': 'ANCA-Mediated Acute Interstitial Nephritis', 'rule_applied': 'Generic Title Case and Disease Characterization rules.'}, {'component': 'Without Glomerulonephritis', 'type': 'Patient Subgroup (Negative Finding)', 'normalized_form': 'Without Glomerulonephritis', 'rule_applied': 'Retained as a clinically significant descriptor defining the patient subgroup.'}, {'component': 'A Rare Case of', 'type': 'Study Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for non-diagnostic items.'}]",2
295778,Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?,Discussion led by Chair,,,Tumor,True,session_title,"Step 1: The abstract title 'Discussion led by Chair' contains no medical information. The session title 'Young Oncologist Brunch 3: Molecular Tumor Board: A luxury or a necessity?' contains the terms 'Oncologist' and 'Tumor'. Therefore, the session title is selected as the source.
Step 2: The components identified in the session title are 'Young', 'Oncologist', and 'Tumor'.
Step 3: Rules for the 'Age Group' category were retrieved for the term 'Young'. The rules indicate that 'Young' as a standalone descriptor should be excluded unless it is part of a specific phrase like 'Young Adult'. In this context, 'Young' describes the oncologist, not the patient, so it falls under the generic exclusion rule for non-patient descriptors.
Step 4: The term 'Oncologist' points to the therapeutic area of Oncology, which can be mapped to 'Cancer' per generic rules. The title also explicitly contains the disease term 'Tumor'. 'Tumor' is more specific and directly mentioned in the context of the 'Molecular Tumor Board'.
Step 5: The term 'Molecular' describes the type of tumor board (a meeting/methodology) and not the tumor itself, so it is excluded as a procedural/methodological qualifier.
Step 6: Applying the rules, 'Young' and 'Molecular' are excluded. The core disease term 'Tumor' is extracted, converted to Title Case, and is already in singular form. This results in the final indication 'Tumor'.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine how to handle the term 'Young' found in the session title.""}]","[{'component': 'Tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Generic rule: Use specific disease term. Title Case and Singular Form rules applied.'}, {'component': 'Young', 'type': 'Age Group', 'normalized_form': '', 'rule_applied': 'Retrieved rule ID 308 indicates exclusion. Additionally, the term describes the professional, not the patient, and is excluded per generic rules.'}, {'component': 'Oncologist', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': ""Generic rule: Therapeutic Area Fallback. 'Tumor' was chosen as the more specific term present in the title.""}]",2
410466,Acute Kidney Injury,AKI and Spontaneous Rupture of the Urinary Collecting System,AKI,Acute Kidney Injury,Acute Kidney Injury;;Spontaneous Rupture of the Urinary Collecting System,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease terms ('AKI', 'Spontaneous Rupture of the Urinary Collecting System'), making it more informative than the session title.
Step 2: Two distinct medical conditions were identified in the abstract title: 'AKI' and 'Spontaneous Rupture of the Urinary Collecting System'.
Step 3: The abbreviation 'AKI' was expanded to its full, clinically standard form 'Acute Kidney Injury' based on common medical knowledge and the context provided by the session title.
Step 4: The generic rule for multiple diseases was applied, using ';;' as a separator between the two distinct conditions.
Step 5: Title Case formatting was applied to both indications, ensuring short prepositions like 'of' and 'the' remain in lowercase as per the casing rules. The final output is a concatenation of the two normalized indications.",[],"[{'component': 'AKI', 'type': 'Disease', 'normalized_form': 'Acute Kidney Injury', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}, {'component': 'Spontaneous Rupture of the Urinary Collecting System', 'type': 'Disease', 'normalized_form': 'Spontaneous Rupture of the Urinary Collecting System', 'rule_applied': 'Title Case rule.'}]",1
181110,Outcomes Research-Non-Malignant Conditions: Poster I,Sleep Characterization of Adolescent and Young Adult Patients with Sickle Cell Disease Using the Pittsburgh Sleep Quality Index,Adolescent;;Young Adult;;Sickle Cell Disease,Adolescent Young Adult Sickle Cell Disease,Adolescent Sickle Cell Disease;;Young Adult Sickle Cell Disease,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Sleep Characterization of Adolescent and Young Adult Patients with Sickle Cell Disease...') was chosen because it contains a specific disease ('Sickle Cell Disease'), whereas the session title ('Outcomes Research-Non-Malignant Conditions: Poster I') is a broad, non-specific category. This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The selected title contains one disease and two distinct patient subgroups based on age: 
    - Disease: 'Sickle Cell Disease'
    - Age Groups: 'Adolescent' and 'Young Adult'.
3.  **Rule Retrieval**: To ensure correct formatting for the age groups, I retrieved rules for the 'Age Group' category, specifically for 'Adolescent', 'Young', and 'Adult' subcategories.
4.  **Rule Application**: 
    - The generic rule for singular form was applied, though 'Sickle Cell Disease' is already singular.
    - The generic rule for Title Case was applied.
    - The retrieved rules for 'Adolescent' (Rule 318) and 'Young Adult' (Rule 311) confirm they should be used as prefixes to the disease name.
    - The presence of 'and' connecting two distinct patient subgroups ('Adolescent and Young Adult') implies that the study covers both groups. Following the pattern for handling multiple distinct groups (similar to Rule 314 for 'Children/Adolescent'), the indication is split into two, one for each age group, with the core disease duplicated.
5.  **Indication Construction**: The two indications were constructed separately and then combined:
    - Indication 1: 'Adolescent' + 'Sickle Cell Disease' -> 'Adolescent Sickle Cell Disease'
    - Indication 2: 'Young Adult' + 'Sickle Cell Disease' -> 'Young Adult Sickle Cell Disease'
    - The final output was created by joining these with the required ';;' separator.
6.  **Quality Check**: The final indication correctly captures both patient subgroups as separate, standardized indications, adheres to all formatting rules (Title Case, singular, separator), and excludes non-indication elements like 'Patients' and study methodology details.","[{'category': 'Age Group', 'subcategories': ['Adolescent', 'Young', 'Adult'], 'reason': ""To determine the correct formatting for the identified age groups 'Adolescent' and 'Young Adult'.""}]","[{'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic singular form and Title Case rules.'}, {'component': 'Adolescent', 'type': 'Age Group', 'normalized_form': 'Adolescent', 'rule_applied': ""Rule 318: Prepend 'Adolescent' to the disease name.""}, {'component': 'Young Adult', 'type': 'Age Group', 'normalized_form': 'Young Adult', 'rule_applied': ""Rule 311: Prepend 'Young Adult' to the disease name.""}]",2
181112,Outcomes Research-Non-Malignant Conditions: Poster I,Comparison of Clinical and Thrombotic Outcomes in Sars-Cov-2- Pneumonia Versus Other Viral Pneumonia in an Urban Academic Medical Center,Sars-Cov-2- Pneumonia,Sars-Cov-2- Pneumonia,Sars-Cov-2- Pneumonia;;Viral Pneumonia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Comparison of Clinical and Thrombotic Outcomes in Sars-Cov-2- Pneumonia Versus Other Viral Pneumonia in an Urban Academic Medical Center') was chosen as it contains specific disease names, unlike the session title ('Outcomes Research-Non-Malignant Conditions: Poster I') which is too general.
2.  **Component Identification**: The abstract title identifies two distinct medical conditions: 'Sars-Cov-2- Pneumonia' and 'Other Viral Pneumonia'. 'Thrombotic Outcomes' was identified as a study outcome, not a primary indication for a patient cohort.
3.  **Rule Application**: 
    *   **Multiple Diseases Rule**: Both identified diseases were extracted as separate indications, as per the rule to capture all distinct conditions mentioned.
    *   **Separator Rule**: The two indications are separated by ';;'.
    *   **Casing Rule**: The indications were formatted to Title Case. 'Sars-Cov-2' is maintained in its original form.
    *   **Standardization**: 'Other Viral Pneumonia' was simplified to 'Viral Pneumonia' as 'Other' is a comparative term from the study design and not part of the standard indication name.
    *   **Exclusion Rule**: Non-diagnostic and location-based terms like 'Comparison of Clinical and Thrombotic Outcomes' and 'in an Urban Academic Medical Center' were excluded.
4.  **Final Indication Construction**: The processed components were combined to form the final output: 'Sars-Cov-2- Pneumonia;;Viral Pneumonia'.",[],"[{'component': 'Sars-Cov-2- Pneumonia', 'type': 'Disease', 'normalized_form': 'Sars-Cov-2- Pneumonia', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Other Viral Pneumonia', 'type': 'Disease', 'normalized_form': 'Viral Pneumonia', 'rule_applied': ""Generic Casing and Singular Form Rules, and removal of comparative term 'Other'""}]",1
181114,Outcomes Research-Non-Malignant Conditions: Poster I,Venous Thromboembolism Post-COVID-19 Among Individuals with Sickle Cell Disease,Sickle Cell Disease;;Venous Thromboembolism,Sickle Cell Disease;;Venous Thromboembolism,Venous Thromboembolism;;Sickle Cell Disease,True,abstract_title,"Step 1: The abstract title 'Venous Thromboembolism Post-COVID-19 Among Individuals with Sickle Cell Disease' was chosen as the source because it contains specific disease terms, unlike the session title which refers to a general category ('Non-Malignant Conditions').
Step 2: The title identifies three potential conditions: 'Venous Thromboembolism', 'COVID-19', and 'Sickle Cell Disease'.
Step 3: The term 'Post-COVID-19' is identified as a temporal qualifier, describing the timing of the VTE relative to a COVID-19 infection. According to the generic exclusion rules, temporal and procedural qualifiers (like 'post-surgery') should be excluded from the final indication. Therefore, 'Post-COVID-19' is removed.
Step 4: The remaining distinct diseases are 'Venous Thromboembolism' and 'Sickle Cell Disease'. The phrase 'Among Individuals with' indicates that Sickle Cell Disease describes the patient population in which Venous Thromboembolism is being studied. Following the generic rule for multiple diseases (e.g., 'Asthma with Cardiovascular Risk' -> 'Asthma;;Cardiovascular Risk'), both conditions are extracted as separate indications.
Step 5: The indications are formatted according to the rules: Title Case and singular form are already correct. They are separated by the ';;' delimiter, resulting in the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct formatting for co-occurring but distinct diseases mentioned in the title. No specific rules were found, so generic rules were applied.'}]","[{'component': 'Venous Thromboembolism', 'type': 'Disease', 'normalized_form': 'Venous Thromboembolism', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Sickle Cell Disease', 'type': 'Disease', 'normalized_form': 'Sickle Cell Disease', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Post-COVID-19', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Procedural/Temporal Qualifiers'}]",3
164735,The Interplay Between COVID and other Infections,Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19,,,COVID-19;;Infection,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract_title is 'Reduction in Bloodborne Pathogen Splash Exposures After Implementation of Universal Masking and Eye Protection for COVID-19'. The session_title is 'The Interplay Between COVID and other Infections'.
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract_title should be preferred if it contains a disease. The abstract_title mentions 'Bloodborne Pathogen Splash Exposures' and 'COVID-19'. However, 'Exposures' are explicitly listed as an exclusion in the generic rules. The title's focus is on an occupational safety outcome (reduction of exposure) rather than a clinical study of a disease state. The session_title, on the other hand, clearly mentions two disease concepts: 'COVID' and 'Infections'. Therefore, the session_title is selected as the more appropriate source for a clinically valid indication.
3.  **Identify Components**: The selected session_title contains two components: 'COVID' and 'other Infections'.
4.  **Apply Rules & Construct Indication**:
    *   The term 'COVID' is normalized to its standard clinical name, 'COVID-19'.
    *   For 'other Infections', the qualifier 'other' is removed as it is not part of the disease name. The plural 'Infections' is converted to its singular form, 'Infection', per the generic rules.
    *   The two distinct diseases are separated by the ';;' delimiter as required for multiple diseases.
    *   Title Case formatting is applied to both terms.
5.  **Final Indication**: The resulting indication is 'COVID-19;;Infection'.",[],"[{'component': 'COVID', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Standardization of disease name'}, {'component': 'other Infections', 'type': 'Disease', 'normalized_form': 'Infection', 'rule_applied': ""Generic rule: Singular Form; Exclusion of non-clinical qualifier 'other'""}, {'component': 'Bloodborne Pathogen Splash Exposures', 'type': 'Exposure (Excluded)', 'normalized_form': '', 'rule_applied': ""Generic rule: Exclude non-diagnostic items like 'Exposures'""}]",1
295814,Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer,Stepping into the emerging needs in metastatic breast cancer,metastatic;;breast cancer,Metastatic Breast Cancer,Triple-Negative Metastatic Breast Cancer;;HR+/HER2- Metastatic Breast Cancer,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Stepping into the emerging needs in metastatic breast cancer' and the session title is 'Gilead and Kite Oncology - Break Expectations: Novel approaches in triple-negative and HR+/HER2- metastatic breast cancer'.
2. **Select Source**: Both titles contain a disease. The session title provides significantly more specific and clinically relevant information, including key patient subgroups ('triple-negative', 'HR+/HER2-'), which are crucial for a precise medical indication. The abstract title is very general. Therefore, the session title was chosen as the source to generate a higher quality, more specific indication.
3. **Identify Components**: From the session title, I identified the core disease 'breast cancer', the occurrence qualifier 'metastatic', and two distinct patient subgroups: 'triple-negative' and 'HR+/HER2-'. The word 'and' indicates these are two separate populations.
4. **Retrieve Rules**: I retrieved rules for handling metastasis-related terms to confirm the placement and formatting of 'Metastatic'. I also mentally referenced rules for handling biomarker-defined subgroups like 'Triple-Negative' and 'HR+/HER2-'.
5. **Apply Rules & Construct Indication**: 
   - The generic rule for singular form was applied ('cancer' is already singular).
   - The generic rule for Title Case was applied.
   - The rule for multiple distinct patient groups requires separating them with ';;'.
   - The components were assembled into two distinct indications: 'Triple-Negative Metastatic Breast Cancer' and 'HR+/HER2- Metastatic Breast Cancer'.
6. **Final Output**: The two indications are combined with the ';;' separator, resulting in the final generated indication.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic' as a prefix to the disease name.""}]","[{'component': 'triple-negative', 'type': 'Patient Sub-Group (Biomarker)', 'normalized_form': 'Triple-Negative', 'rule_applied': 'Title Case rule'}, {'component': 'HR+/HER2-', 'type': 'Patient Sub-Group (Biomarker)', 'normalized_form': 'HR+/HER2-', 'rule_applied': 'Biomarker formatting rule (preserve case and symbols)'}, {'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': 'Metastasis-Related Terms rule (ID: 141)'}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Title Case rule, Singular form rule'}]",2
377743,Acute lymphoblastic leukemia - Clinical,Inotuzumab Ozogamicin Treatment In Adult Patients With Relapsed Or Refractory Philadelphia Chromosome-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia: A Real-Life French Study,Adult;;Relapsed;;Refractory;;Philadelphia Chromosome-Negative;;Cd22-Positive;;B-Cell Precursor Acute Lymphoblastic Leukemia,Adult Relapsed Or Refractory Ph-Negative Cd22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,Adult Relapsed/Refractory Ph Chromosome-Negative CD22-Positive B-Cell Precursor Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step explanation of your extraction process:
1. **Analyze Input Titles**: The abstract title contains a detailed description of the disease and patient population, making it the preferred source over the more generic session title.
2. **Identify Components**: I identified several key components in the abstract title: 'Adult' (Age Group), 'Relapsed Or Refractory' (Disease State), 'Philadelphia Chromosome-Negative' (Chromosome Type), 'Cd22-Positive' (Biomarker), 'B-Cell Precursor' (Patient Subgroup), and 'Acute Lymphoblastic Leukemia' (Core Disease).
3. **Retrieve Relevant Rules**: I retrieved specific rules for each identified component using the `get_indication_rules` tool to ensure correct normalization and formatting.
4. **Apply Rules**: 
   - 'Adult' is kept as a leading descriptor based on Age Group rules.
   - 'Relapsed Or Refractory' is normalized to 'Relapsed/Refractory' per Occurrence rules.
   - 'Philadelphia Chromosome-Negative' is abbreviated to 'Ph Chromosome-Negative' as per Chromosome type rules.
   - 'Cd22-Positive' is a biomarker that is retained and formatted in Title Case as 'CD22-Positive'.
   - 'B-Cell Precursor' is a specific patient subgroup and is retained.
   - The core disease 'Acute Lymphoblastic Leukemia' is already in singular form and is formatted in Title Case.
   - Generic exclusion rules were applied to remove the treatment name ('Inotuzumab Ozogamicin') and the geographical descriptor ('French').
5. **Construct Indication**: The normalized components were assembled in a clinically logical order, starting with the patient population descriptors followed by the core disease.
6. **Quality Check**: The final indication was reviewed to ensure it adheres to the single-source principle, all formatting rules (Title Case, singular form), and exclusion criteria. The resulting indication is a complete and clinically accurate representation of the patient group from the abstract title.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To correctly format the 'Adult' patient population descriptor.""}, {'category': 'Occurrence', 'subcategories': ['Recurrent/Refractory', 'Relapse'], 'reason': ""To normalize the 'Relapsed Or Refractory' disease state.""}, {'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To handle the 'Philadelphia Chromosome-Negative' descriptor and its standard abbreviation.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To ensure correct formatting of the 'Cd22-Positive' biomarker.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To confirm the inclusion of the 'B-Cell Precursor' patient subgroup.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult'""}, {'component': 'Relapsed Or Refractory', 'type': 'Disease State', 'normalized_form': 'Relapsed/Refractory', 'rule_applied': ""Occurrence rule for 'Recurrent/Refractory'""}, {'component': 'Philadelphia Chromosome-Negative', 'type': 'Chromosome Type', 'normalized_form': 'Ph Chromosome-Negative', 'rule_applied': ""Chromosome type rule for 'Philadelphia Chromosome-Negative'""}, {'component': 'Cd22-Positive', 'type': 'Biomarker', 'normalized_form': 'CD22-Positive', 'rule_applied': 'Generic rule for Title Case and biomarker formatting.'}, {'component': 'B-Cell Precursor', 'type': 'Patient Subgroup', 'normalized_form': 'B-Cell Precursor', 'rule_applied': ""Patient Sub-Group rule for 'B-Cell Precursor'""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}]",2
164756,Updates in Mycobacteria,High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis,Tuberculous meningitis,Tuberculous Meningitis,TB Meningitis,True,abstract_title,"Step 1: The abstract title 'High-Dose Rifampin-containing Regimens for the Treatment of TB Meningitis' was chosen as the source because it contains a specific disease name ('TB Meningitis'), whereas the session title 'Updates in Mycobacteria' refers to a genus of bacteria, which is less specific.
Step 2: The core disease entity was identified as 'TB Meningitis'.
Step 3: The generic exclusion rule was applied to remove treatment-related information ('High-Dose Rifampin-containing Regimens for the Treatment of').
Step 4: The generic formatting rules were applied. The term 'TB Meningitis' is already in singular form. It was converted to Title Case, keeping the acronym 'TB' in its original uppercase form, resulting in 'TB Meningitis'. No specific rules were needed beyond the generic ones.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules regarding disease characterization that might apply to 'TB Meningitis', although none were ultimately applicable.""}]","[{'component': 'TB Meningitis', 'type': 'Disease', 'normalized_form': 'TB Meningitis', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'High-Dose Rifampin-containing Regimens for the Treatment of', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic rule: Exclusion of procedural/temporal qualifiers'}]",2
394135,Palliative Care,Integrated Palliative Care For Patients Referred For Chimeric Antigen Receptor T-Cell (Car-T) Therapy: A Service Evaluation,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title focuses on a type of therapy ('Chimeric Antigen Receptor T-Cell (Car-T) Therapy') and a type of care ('Palliative Care') for an unspecified group of patients. The session title is also a type of care ('Palliative Care'), not a disease. As per the rules, an indication must be a disease or disorder, and since none is explicitly mentioned, no indication can be extracted.",[],"[{'component': 'Chimeric Antigen Receptor T-Cell (Car-T) Therapy', 'type': 'Therapy', 'normalized_form': 'Chimeric Antigen Receptor T-Cell (Car-T) Therapy', 'rule_applied': 'Excluded as it is a treatment modality, not a disease.'}, {'component': 'Palliative Care', 'type': 'Medical Specialty', 'normalized_form': 'Palliative Care', 'rule_applied': 'Excluded as it is a type of care, not a disease.'}]",1
312224,Knowledge Bowl Preliminary Round,Alarcon's NETting Neutrophils,,,,True,none,"The abstract title 'Alarcon's NETting Neutrophils' refers to a biological process involving a type of white blood cell (neutrophils) but does not specify a disease or clinical condition. The session title 'Knowledge Bowl Preliminary Round' is non-medical and does not contain any health-related information. Since neither title contains a clinically valid medical indication, no extraction is possible.",[],[],1
345008,Targeting Replication Stress and the Immune Microenvironment,POLE-specific variant classification strategy is critical for identifying patients who may benefit from immunotherapy,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical disease or disorder. The abstract title mentions a 'POLE-specific variant,' which defines a patient subgroup, but it does not specify the associated disease (e.g., cancer, tumor). According to the 'Single-Source Extraction Principle' and 'Handling Orphan PSUBs' rule, a patient subgroup without a core disease term in the same source title is insufficient to form a valid indication. The session title is also generic, focusing on biological mechanisms rather than a specific disease. Therefore, no indication can be extracted.",[],"[{'component': 'POLE-specific variant', 'type': 'Patient Sub-Group (Genetic)', 'normalized_form': 'POLE Variant', 'rule_applied': 'Handling Orphan PSUBs: This component was identified in the abstract title but could not be used because no corresponding disease term was present in the same title.'}]",2
312263,Moving on Up: Changing How We Define Early Knee OA and Get People Moving,Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field,Osteoarthritis ,Osteoarthritis ,Osteoarthritis;;At-Risk Osteoarthritis,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, ""Biomarker-Based Stratification in Osteoarthritis Patients and in Those at Risk: Advances in the Field"", contains the specific disease term ""Osteoarthritis"". The session title also mentions ""Knee OA"", but per the single-source principle, the abstract title is preferred as it contains a clear disease term.
2.  **Component Identification**: The abstract title identifies two distinct populations related to the same disease:
    *   ""Osteoarthritis Patients"": This directly indicates the disease `Osteoarthritis`.
    *   ""Those at Risk"": This identifies a patient subgroup defined by their risk status for the same disease.
3.  **Rule Retrieval**: I retrieved rules for the 'Risk' category to understand how to handle terms like ""at Risk"". While no specific rule exactly matched the general phrase ""at Risk"", the patterns for other risk types (e.g., High-Risk, Low-Risk) show that the risk qualifier should be prefixed to the disease name.
4.  **Indication Construction**: Based on the identified components and general principles, two separate indications were constructed:
    *   The first indication is the primary disease itself: `Osteoarthritis`.
    *   The second indication combines the risk subgroup with the disease. The phrase ""at Risk"" was normalized to the standardized prefix ""At-Risk"" and combined with the disease to form `At-Risk Osteoarthritis`.
5.  **Formatting and Finalization**: The two distinct indications were formatted according to the generic rules:
    *   **Separator**: The `;;` delimiter is used to separate the two indications.
    *   **Casing**: Both indications are formatted in Title Case.
    *   **Singular Form**: ""Osteoarthritis"" is already in its singular form.
    *   The final combined output is `Osteoarthritis;;At-Risk Osteoarthritis`.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': 'To determine the correct formatting for the patient subgroup ""at Risk"" identified in the abstract title.'}]","[{'component': 'Osteoarthritis Patients', 'type': 'Disease', 'normalized_form': 'Osteoarthritis', 'rule_applied': 'Generic rule: Singular Form, Title Case.'}, {'component': 'Those at Risk', 'type': 'Patient Subgroup (Risk)', 'normalized_form': 'At-Risk Osteoarthritis', 'rule_applied': 'General principle from Risk rules: Prefix the risk status to the disease name. The risk is implicitly for Osteoarthritis, the main subject of the title.'}]",2
230348,Central Nervous System Tumors,"Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma.",Central Nervous System Tumors;;grade 2;;3 ,Grade 2 Grade 3 Central Nervous System Tumor,Grade II Glioma;;Grade III Glioma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Compliance, adverse events and quality of life of patients in a phase 3 study comparing temozolomide with PCV as adjuvant chemotherapy in grade 2 and 3 glioma.') was chosen over the session title ('Central Nervous System Tumors') because it contains a specific disease with qualifiers ('grade 2 and 3 glioma'), adhering to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title are the disease 'glioma' and the grade qualifiers 'grade 2 and 3'.
3. **Rule Retrieval**: The `get_indication_rules` tool was used for the 'Grade' category to understand how to handle numeric grades. Rule ID 119 (for Grade 2) and similar rules for other grades confirmed that Arabic numerals should be converted to Roman numerals (2 -> II, 3 -> III) and that multiple grades mentioned together should be split into separate indications.
4. **Rule Application**: 
   - The phrase 'grade 2 and 3 glioma' was identified as representing two distinct clinical indications.
   - The indications were separated: 'grade 2 glioma' and 'grade 3 glioma'.
   - The generic rule for singular form was applied, but 'glioma' is already singular.
   - The generic rule for Title Case was applied to capitalize 'Glioma'.
   - The retrieved grade-specific rules were applied to convert Arabic numerals to Roman numerals, resulting in 'Grade II' and 'Grade III'.
   - The multiple disease rule was applied to join the two final indications with the ';;' separator.
5. **Indication Construction**: The components were assembled into the final string: 'Grade II Glioma;;Grade III Glioma'.
6. **Quality Check**: The final output was verified for adherence to all formatting, exclusion, and content rules. It correctly captures the two distinct patient subgroups mentioned in the source title.","[{'category': 'Grade', 'subcategories': ['Grade', 'Grade group number', 'Grade number'], 'reason': ""To determine the correct formatting for 'grade 2 and 3'.""}]","[{'component': 'grade 2 glioma', 'type': 'Disease with Grade', 'normalized_form': 'Grade II Glioma', 'rule_applied': ""Grade number rule (convert to Roman numeral); Title Case rule; Multiple disease rule (split from 'and 3').""}, {'component': 'grade 3 glioma', 'type': 'Disease with Grade', 'normalized_form': 'Grade III Glioma', 'rule_applied': ""Grade number rule (convert to Roman numeral); Title Case rule; Multiple disease rule (split from '2 and').""}]",2
148434,Stem Cell Transplantation - Clinical,Minimal Residual Disease Monitoring And Preemptive Immunotherapies For Frequent 11Q23 Rearranged Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation,11Q23;;Rearranged;;Acute Leukemia,11Q23 Rearranged Acute Leukemia,11q23-Rearranged Acute Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Minimal Residual Disease Monitoring And Preemptive Immunotherapies For Frequent 11Q23 Rearranged Acute Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation' was chosen because it contains a specific disease ('Acute Leukemia'), whereas the session title is a general procedural category.
2. **Component Identification**: The key components identified in the abstract title are the disease 'Acute Leukemia' and the chromosomal alteration '11Q23 Rearranged'. The phrase 'After Allogeneic Hematopoietic Stem Cell Transplantation' was identified as a treatment context.
3. **Rule Retrieval**: I retrieved rules for 'Chromosome type' to understand how to handle '11Q23 Rearranged' and for 'Treatment Set-up' (specifically 'Transplant Status') to handle the post-transplantation context.
4. **Rule Application**:
   - **Generic Exclusion Rule**: The terms 'Minimal Residual Disease Monitoring' and 'Preemptive Immunotherapies' are procedural/methodological and were excluded.
   - **Treatment Set-up Rule**: The retrieved rules for 'Transplant Status' (e.g., Rule ID 232, 233 for 'Post-Transplant') mandate the exclusion of temporal treatment statuses. 'After Allogeneic Hematopoietic Stem Cell Transplantation' falls into this category and was therefore excluded.
   - **Chromosome Type**: While no specific rule dictated the exact formatting for '11Q23 Rearranged', it is a critical clinical descriptor defining a specific subtype of leukemia. It was retained as a qualifier.
   - **Generic Formatting Rule**: The disease term 'Acute Leukemia' is already singular and was converted to Title Case. The qualifier '11Q23 Rearranged' was standardized to '11q23-Rearranged' for clarity and common clinical notation, prepending it to the disease name.
   - The term 'Frequent' was excluded as it describes the incidence of the rearrangement rather than being a standard clinical qualifier for the disease itself.
5. **Indication Construction**: The final indication was constructed by combining the standardized chromosomal qualifier with the disease name, resulting in '11q23-Rearranged Acute Leukemia'.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To determine the correct formatting and inclusion of the '11Q23 Rearranged' chromosomal alteration.""}, {'category': 'Treatment Set-up', 'subcategories': ['Transplant Status'], 'reason': ""To determine how to handle the phrase 'After Allogeneic Hematopoietic Stem Cell Transplantation'.""}]","[{'component': 'Acute Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': '11Q23 Rearranged', 'type': 'Chromosomal Alteration', 'normalized_form': '11q23-Rearranged', 'rule_applied': 'Standard clinical formatting for chromosomal alterations; prepended to the disease name.'}, {'component': 'After Allogeneic Hematopoietic Stem Cell Transplantation', 'type': 'Procedural/Temporal Qualifier', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule; Treatment Set-up Rule ID 232/233 for 'Post-Transplant' context.""}, {'component': 'Minimal Residual Disease Monitoring And Preemptive Immunotherapies', 'type': 'Procedural/Methodological Term', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for non-diagnostic items.'}, {'component': 'Frequent', 'type': 'Non-Clinical Qualifier', 'normalized_form': '', 'rule_applied': 'Excluded as it is not a standard clinical descriptor for an indication.'}]",2
230358,Central Nervous System Tumors,Assessment of neurocognitive functions using ACE-III scale in patients with high-grade glioma receiving adjuvant chemoradiation.,high-grade;;glioma,High-Grade Glioma,High Grade Glioma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific disease term, 'glioma', compared to the broader 'Central Nervous System Tumors'.
2. **Component Identification**: The key components identified in the abstract title were 'high-grade' (a tumor grade) and 'glioma' (the disease).
3. **Rule Retrieval**: Rules for the 'Grade' category were retrieved to correctly format 'high-grade'. Rules for 'Treatment Set-up' were retrieved to determine if 'receiving adjuvant chemoradiation' should be included.
4. **Rule Application**: 
   - The specific rule for 'High Grade' (ID: 115) was applied, standardizing 'high-grade' to 'High Grade' (Title Case, no hyphen).
   - The generic rule for singularization was applied to 'glioma' (which was already singular).
   - The generic exclusion rule for procedural/temporal qualifiers was applied to 'receiving adjuvant chemoradiation', leading to its exclusion from the final indication.
5. **Indication Construction**: The standardized components were combined to form the final indication 'High Grade Glioma'.
6. **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form) and accurately represents the core clinical condition described in the source title.","[{'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To correctly format the 'high-grade' descriptor.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To verify whether the treatment context 'receiving adjuvant chemoradiation' should be part of the indication.""}]","[{'component': 'high-grade', 'type': 'Grade', 'normalized_form': 'High Grade', 'rule_applied': ""Grade rule (ID: 115) requires standardizing to 'High Grade' with no hyphen.""}, {'component': 'glioma', 'type': 'Disease', 'normalized_form': 'Glioma', 'rule_applied': 'Generic rule: Use singular form for disease names.'}, {'component': 'receiving adjuvant chemoradiation', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': ""Generic exclusion rule: Exclude procedural/temporal qualifiers like 'receiving'.""}]",2
230361,Central Nervous System Tumors,The effects of vascular endothelial cells on regulating post-irradiation microglia phenotype in irradiation-induced brain injury.,brain injury,Brain Injury,Central Nervous System Tumor,True,session_title,"Step 1: The abstract title mentions 'irradiation-induced brain injury'. This is a complication or adverse effect resulting from a procedure (irradiation) and not a primary disease. According to the exclusion rules, complications should be excluded. Therefore, the abstract title does not contain a valid primary indication.
Step 2: The session title, 'Central Nervous System Tumors', contains a clear and valid disease category. Based on the Single-Source Extraction Principle, I will use the session title as the source since the abstract title lacks a valid primary disease.
Step 3: I identified the disease term 'Central Nervous System Tumors' from the session title.
Step 4: I applied the generic rule for singular form, converting 'Tumors' to 'Tumor'.
Step 5: The final indication is constructed as 'Central Nervous System Tumor', adhering to Title Case and singular form rules.",[],"[{'component': 'Central Nervous System Tumors', 'type': 'Disease', 'normalized_form': 'Central Nervous System Tumor', 'rule_applied': 'Generic Rule: Singular Form'}]",1
181219,Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II,Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice,Acquired;;Congenital;;Immunodeficiency Disorders,Acquired Immunodeficiency Disorder;;Congenital Immunodeficiency Disorder,Acquired/Congenital Immunodeficiency Disorder,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'Chronically Elevated Interleukin-6 Disturbs the Coagulation Cascade in Mice', describes a physiological process in a preclinical model and does not contain a valid human medical indication. The session title, 'Lymphocytes and Acquired or Congenital Immunodeficiency Disorders: Poster II', contains clear disease terms.
2.  **Principle Adherence**: Following the single-source principle, the session title was chosen for extraction.
3.  **Component Identification**: The core components identified in the session title are the diseases 'Acquired Immunodeficiency Disorders' and 'Congenital Immunodeficiency Disorders', connected by the word 'or'.
4.  **Rule Retrieval**: The presence of the connector 'or' prompted the retrieval of rules for 'Occurrence' -> 'Connectors'.
5.  **Rule Application**: Rule ID 146 for the connector 'or' was applied, which specifies replacing 'or' with a '/' to merge the descriptors. The generic rule for converting plural disease names to singular was also applied ('Disorders' -> 'Disorder').
6.  **Indication Construction**: The descriptors 'Acquired' and 'Congenital' were combined using '/', and then prepended to the singular, title-cased disease name, resulting in 'Acquired/Congenital Immunodeficiency Disorder'.
7.  **Exclusion**: Non-disease terms like 'Lymphocytes' and metadata 'Poster II' were correctly excluded.","[{'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To correctly handle the 'or' connector between 'Acquired' and 'Congenital'.""}]","[{'component': 'Acquired or Congenital Immunodeficiency Disorders', 'type': 'Disease', 'normalized_form': 'Acquired/Congenital Immunodeficiency Disorder', 'rule_applied': ""Connector rule (ID 146) to replace 'or' with '/'; Generic rule for singular form ('Disorders' -> 'Disorder'); Generic rule for Title Case.""}]",2
328676,Myelodysplastic Syndromes - Clinical and Epidemiological: Poster I,The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study,Myelodysplastic Syndrome,Myelodysplastic Syndrome,Cerebrovascular Accident;;Myelodysplastic Syndrome,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study') was chosen as it contains specific disease terms, which is preferred over the session title according to the single-source principle.
2.  **Component Identification**: Two distinct medical conditions were identified in the abstract title: 'Cerebrovascular Accident' and 'Myelodysplastic Syndrome'.
3.  **Rule Application**: The generic rule for 'MULTIPLE DISEASES' was applied. This rule states that when multiple distinct diseases are mentioned, both should be extracted and separated by a double semicolon (';;').
4.  **Exclusion Rules**: Sociodemographic and procedural qualifiers such as 'in the United States' and 'A Nationwide Population-Based Study' were excluded as per the generic exclusion rules.
5.  **Formatting Rules**: The extracted indications were checked for formatting. Both 'Cerebrovascular Accident' and 'Myelodysplastic Syndrome' are already in singular form and appropriate Title Case.
6.  **Final Construction**: The two identified and normalized indications were combined using the ';;' separator to form the final output.",[],"[{'component': 'Cerebrovascular Accident', 'type': 'Disease', 'normalized_form': 'Cerebrovascular Accident', 'rule_applied': 'Generic Rule - Multiple Diseases'}, {'component': 'Myelodysplastic Syndrome', 'type': 'Disease', 'normalized_form': 'Myelodysplastic Syndrome', 'rule_applied': 'Generic Rule - Multiple Diseases'}]",3
295920,Oligometastatic disease and oligoprogression in breast cancer,Systemic therapeutic options,Oligometastatic disease;;breast cancer,Oligometastatic Disease;;Breast Cancer,Oligometastatic Breast Cancer;;Oligoprogressive Breast Cancer,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract_title ('Systemic therapeutic options') contains no disease term, only a treatment modality. The session_title ('Oligometastatic disease and oligoprogression in breast cancer') contains the disease 'breast cancer' and relevant clinical qualifiers. Therefore, the session_title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: The session_title contains one primary disease, 'breast cancer', and two distinct clinical states: 'Oligometastatic' and 'oligoprogression'.
3.  **Rule Retrieval**: To correctly format the clinical state qualifiers, rules were retrieved for 'Metastasis-Related Terms' and 'Progression-Related' from the 'Occurrence' category.
4.  **Rule Application**: 
    - The rule for 'Oligometastatic' (ID: 156) instructs to construct the indication as 'Oligometastatic <Disease>'. Applying this to 'breast cancer' yields 'Oligometastatic Breast Cancer'.
    - The term 'oligoprogression' is the noun form of the state described by the 'Oligoprogressive' rule (ID: 157). This rule guides the normalization of the term to the adjectival form 'Oligoprogressive' placed before the disease name. This results in 'Oligoprogressive Breast Cancer'.
    - The generic rule for multiple diseases was applied, using ';;' to separate the two distinct indications.
    - Generic formatting rules (Title Case, singular form) were applied to both indications.
5.  **Final Indication Construction**: The two extracted indications were combined into the final string: 'Oligometastatic Breast Cancer;;Oligoprogressive Breast Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Progression-Related'], 'reason': ""To handle the formatting of 'Oligometastatic' and 'oligoprogression' qualifiers.""}]","[{'component': 'Oligometastatic disease', 'type': 'Disease with Occurrence Qualifier', 'normalized_form': 'Oligometastatic Breast Cancer', 'rule_applied': ""Occurrence rule for 'Oligometastatic' (ID: 156) combined with the core disease 'Breast Cancer'.""}, {'component': 'oligoprogression in breast cancer', 'type': 'Disease with Progression Qualifier', 'normalized_form': 'Oligoprogressive Breast Cancer', 'rule_applied': ""Occurrence rule for 'Oligoprogressive' (ID: 157) applied to normalize 'oligoprogression' and combine it with 'Breast Cancer'.""}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Title Case and singular form rules.'}]",2
263162,"Enzymopathies, membranopathies and other anemias",The Value Of Anemia For Organ Damage Evaluation In Systemic Sclerosis Patients:A Multi-Center Retrospective Study,Systemic Sclerosis,Systemic Sclerosis,Anemia;;Systemic Sclerosis,True,abstract_title,"Step 1: The abstract title contains specific disease terms ('Anemia', 'Systemic Sclerosis'), so it is selected as the source over the session title, following the single-source extraction principle.
Step 2: Two distinct medical conditions were identified in the abstract title: 'Anemia' and 'Systemic Sclerosis'.
Step 3: According to the generic rule for multiple diseases, when a title mentions more than one distinct disease, all should be extracted and separated by ';;'.
Step 4: The terms were checked against formatting rules. Both 'Anemia' and 'Systemic Sclerosis' are already in singular form and correctly capitalized (Title Case).
Step 5: Exclusion rules were applied. The phrase 'A Multi-Center Retrospective Study' describes the study methodology and is excluded. 'Organ Damage Evaluation' is a procedural context and not part of the core indication, so it is also excluded.
Step 6: The final indications are combined using the ';;' separator, resulting in 'Anemia;;Systemic Sclerosis'.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': 'To confirm the correct procedure for handling titles that mention two distinct diseases.'}]","[{'component': 'Anemia', 'type': 'Disease', 'normalized_form': 'Anemia', 'rule_applied': 'Generic rule for multiple diseases'}, {'component': 'Systemic Sclerosis', 'type': 'Disease', 'normalized_form': 'Systemic Sclerosis', 'rule_applied': 'Generic rule for multiple diseases'}]",2
263163,"Enzymopathies, membranopathies and other anemias",Clinical Characteristics And Risk Factors Of Anemia In Patients With Systemic Sclerosis From The Pkuph-Ssc Cohort,Systemic Sclerosis,Systemic Sclerosis,Anemia;;Systemic Sclerosis,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Clinical Characteristics And Risk Factors Of Anemia In Patients With Systemic Sclerosis From The Pkuph-Ssc Cohort' was chosen over the session title because it contains more specific disease information, adhering to the single-source principle.
2. **Component Identification**: The abstract title identifies two distinct medical conditions: 'Anemia' and 'Systemic Sclerosis'. The phrase 'Anemia In Patients With Systemic Sclerosis' indicates these are co-occurring conditions.
3. **Rule Application**: The generic rule for 'Multiple Diseases' was applied, which requires extracting all distinct diseases and separating them with ';;'. The terms 'Anemia' and 'Systemic Sclerosis' were already in singular form and proper Title Case.
4. **Exclusion Application**: Non-diagnostic phrases such as 'Clinical Characteristics And Risk Factors Of', 'In Patients With', and 'From The Pkuph-Ssc Cohort' were excluded as per the generic exclusion rules.
5. **Indication Construction**: The two identified and normalized disease terms were combined using the ';;' separator to form the final indication: 'Anemia;;Systemic Sclerosis'.",[],"[{'component': 'Anemia', 'type': 'Disease', 'normalized_form': 'Anemia', 'rule_applied': 'Generic rule for Multiple Diseases'}, {'component': 'Systemic Sclerosis', 'type': 'Disease', 'normalized_form': 'Systemic Sclerosis', 'rule_applied': 'Generic rule for Multiple Diseases'}]",3
214013,MP38: Sexual Function/Dysfunction: Basic Research & Pathophysiology,"Vascular, Neurologic and Hormonal Abnormalities in Men with Persistent Sexual Dysfunction after Discontinuation of Finasteride",Sexual Dysfunction,Sexual Dysfunction,Persistent Sexual Dysfunction,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific and complete medical condition ('Persistent Sexual Dysfunction'). The session title ('Sexual Function/Dysfunction') is broader.
2. **Component Identification**: The abstract title contains the core condition 'Persistent Sexual Dysfunction'. It also mentions 'Vascular, Neurologic and Hormonal Abnormalities', the patient group 'Men', and the context 'after Discontinuation of Finasteride'.
3. **Rule Application & Refinement**:
   - The primary indication is identified as 'Persistent Sexual Dysfunction'. The term 'Persistent' is a clinically relevant descriptor and is retained.
   - 'Vascular, Neurologic and Hormonal Abnormalities' are interpreted as findings or characteristics being studied within the patient group, not as separate, co-primary indications. The title structure 'A, B, and C in patients with D' suggests D is the core indication.
   - 'Men' is excluded based on the generic rule to remove sociodemographic (gender) descriptors.
   - 'after Discontinuation of Finasteride' is excluded as it's a procedural/temporal qualifier, specifying the context of the condition's onset, not defining the indication itself.
4. **Final Formatting**: The extracted indication 'Persistent Sexual Dysfunction' is already in singular form and is formatted using Title Case.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease characterization keywords like 'Persistent'. No specific rule was found for this term, so standard clinical interpretation was applied.""}]","[{'component': 'Persistent Sexual Dysfunction', 'type': 'Disease', 'normalized_form': 'Persistent Sexual Dysfunction', 'rule_applied': 'Generic rule: Retain clinically relevant disease descriptors. Formatting rule: Title Case.'}, {'component': 'Vascular, Neurologic and Hormonal Abnormalities', 'type': 'Clinical Finding', 'normalized_form': 'N/A', 'rule_applied': 'These were identified as findings within the patient group, not as the primary indication, and were therefore not extracted.'}, {'component': 'Men', 'type': 'Gender', 'normalized_form': 'N/A', 'rule_applied': 'Generic Exclusion Rule: Exclude sociodemographic descriptors.'}, {'component': 'after Discontinuation of Finasteride', 'type': 'Temporal Qualifier', 'normalized_form': 'N/A', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}]",2
312328,Pediatric Thieves Market Poster,A Perplexing Situation,,,,True,none,"Neither the abstract title ('A Perplexing Situation') nor the session title ('Pediatric Thieves Market Poster') contains a recognizable medical disease or condition. The abstract title is generic and non-clinical. The session title contains the patient subgroup 'Pediatric', but it is an orphan subgroup without an associated disease, and 'Thieves Market Poster' is not a medical term. According to the single-source principle and the rule for handling orphan patient subgroups, no indication can be extracted.",[],"[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Orphan PSUB rule: A patient subgroup without an associated disease cannot form an indication.'}]",1
345103,Cancer-associated Inflammation and Microbiome,Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions,renal cell carcinoma,Renal Cell Carcinoma,Primary Renal Cell Carcinoma;;Bone Metastatic Lesion,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Single-cell analysis of immune and stroma cell remodeling in renal cell carcinoma primary tumors and bone metastatic lesions') was chosen as it contains specific disease terms ('renal cell carcinoma', 'bone metastatic lesions'), which is preferred over the more general session title ('Cancer-associated Inflammation and Microbiome').
2. **Component Identification**: The abstract title explicitly mentions two distinct clinical entities being analyzed: 'renal cell carcinoma primary tumors' and 'bone metastatic lesions'. The conjunction 'and' separates them, indicating they should be treated as separate indications.
3. **Rule Retrieval**: To correctly handle the term 'metastatic', I retrieved rules for the 'Occurrence' category, specifically for 'Metastasis-Related Terms'.
4. **Indication 1 Construction**: For 'renal cell carcinoma primary tumors':
   - The disease is 'renal cell carcinoma'.
   - The qualifier 'primary' is included as it specifies the nature of the tumor, distinguishing it from metastatic sites.
   - The plural 'tumors' was converted to its singular form 'Tumor' as per generic formatting rules.
   - Applying Title Case results in 'Primary Renal Cell Carcinoma'.
5. **Indication 2 Construction**: For 'bone metastatic lesions':
   - This describes a secondary disease site. The term 'metastatic' is a key descriptor.
   - The plural 'lesions' was converted to its singular form 'Lesion'.
   - Applying Title Case results in 'Bone Metastatic Lesion'.
6. **Final Assembly**: The two distinct indications were combined using the required ';;' separator, resulting in the final output.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic lesions' and understand its clinical context.""}]","[{'component': 'renal cell carcinoma primary tumors', 'type': 'Disease', 'normalized_form': 'Primary Renal Cell Carcinoma', 'rule_applied': 'Generic Rule: Singular Form (tumors -> Tumor); Generic Rule: Title Case; Generic Rule: Primary (included as it specifies tumor origin).'}, {'component': 'bone metastatic lesions', 'type': 'Disease', 'normalized_form': 'Bone Metastatic Lesion', 'rule_applied': 'Generic Rule: Singular Form (lesions -> Lesion); Generic Rule: Title Case; Occurrence Rule (Metastatic).'}]",2
312341,Pediatric Thieves Market Poster,"Red but White, Itchy but Painful, Controlled yet Uncontrolled",,,,True,none,"Neither the abstract title nor the session title contains a clinically valid medical indication. The abstract title lists symptoms ('Red', 'White', 'Itchy', 'Painful') and states ('Controlled', 'Uncontrolled') but does not name a specific disease. The session title contains an age group ('Pediatric') but 'Thieves Market Poster' is not a recognized medical condition. According to the rules, if no disease term is present, no indication can be extracted.",[],"[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Generic Rule - An indication must be built from a title containing a disease term. 'Pediatric' is a patient subgroup, but no disease is present in the session title.""}, {'component': 'Red, White, Itchy, Painful', 'type': 'Symptoms', 'normalized_form': '', 'rule_applied': 'Exclusion Rule - Isolated symptoms are not extracted as indications.'}]",1
328738,Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II,The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge,CLL,Chronic Lymphocytic Leukemia,COVID-19;;Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title 'The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge' was chosen as the source because it contains specific disease terms ('Covid-19', 'CLL'), following the single-source principle.
Step 2: Two distinct diseases were identified in the title: 'Covid-19' and 'CLL'.
Step 3: The abbreviation 'CLL' was expanded to 'Chronic Lymphocytic Leukemia' based on common medical knowledge and confirmed by its presence in the session title.
Step 4: The generic rule for multiple diseases was applied, which requires separating each distinct disease with a ';;' delimiter.
Step 5: The generic casing rules were applied. 'COVID-19' is maintained in its standard uppercase format as a proper noun/acronym, and 'Chronic Lymphocytic Leukemia' is formatted in Title Case.
Step 6: The final indication was constructed by combining the two normalized disease terms, resulting in 'COVID-19;;Chronic Lymphocytic Leukemia'.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct formatting for a title mentioning two distinct diseases (COVID-19 and CLL).'}]","[{'component': 'Covid-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic Casing Rule for proper nouns/acronyms.'}, {'component': 'CLL', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Abbreviation expansion and Generic Title Case Rule.'}]",2
410659,Geriatric Nephrology,External Validation of a Risk Prediction Tool in Determining Early Death Among Elderly Patients Initiated on Dialysis,,,Geriatric Kidney Disease,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title, 'External Validation of a Risk Prediction Tool in Determining Early Death Among Elderly Patients Initiated on Dialysis', lacks a specific disease. 'Early Death' is an outcome, and 'Initiated on Dialysis' is a procedural qualifier, which should be excluded per generic rules. Therefore, I defaulted to the session title.
2.  **Component Identification (Session Title)**: The session title is 'Geriatric Nephrology'. I identified two components: 'Geriatric' (an age group) and 'Nephrology' (a therapeutic area).
3.  **Rule Retrieval**: I retrieved rules for the 'Age Group' category, specifically for 'Elderly' and 'Geriatric'. Rule ID 320 and 321 state that 'Geriatric' should be used as a capitalized prefix for the identified disease.
4.  **Rule Application**: 
    -   I applied the 'Therapeutic Area Fallback' generic rule to convert the therapeutic area 'Nephrology' into a standard disease term, 'Kidney Disease'.
    -   I applied the retrieved 'Geriatric' age group rule (ID 320/321) to prepend 'Geriatric' to the disease name.
5.  **Indication Construction**: Combining the components according to the rules resulted in 'Geriatric Kidney Disease'.
6.  **Final Quality Check**: The final indication adheres to all formatting rules: it is in Title Case, uses the singular form, and contains no excluded terms.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To handle the terms 'Geriatric' from the session title and 'Elderly' from the abstract title.""}]","[{'component': 'Geriatric', 'type': 'Age Group', 'normalized_form': 'Geriatric', 'rule_applied': ""Age Group Rule ID 320/321: Use 'Geriatric' as a prefix.""}, {'component': 'Nephrology', 'type': 'Therapeutic Area', 'normalized_form': 'Kidney Disease', 'rule_applied': 'Generic Rule: Therapeutic Area Fallback.'}]",2
263205,Indolent and mantle-cell non-Hodgkin lymphoma - Clinical,First-Line Treatment In Advanced Stage Folicular Lymphoma: A Single-Center Experience With R-Chop Vs Bendamustine-Rituximab.,First-Line;;Advanced Stage;;Folicular Lymphoma,First-Line Advanced Stage Folicular Lymphoma,First-Line Advanced Stage Follicular Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'First-Line Treatment In Advanced Stage Folicular Lymphoma: A Single-Center Experience With R-Chop Vs Bendamustine-Rituximab.' was chosen as it contains a specific disease ('Folicular Lymphoma'), following the single-source principle which prioritizes the abstract title.
2. **Component Identification**: The key components identified in the abstract title were 'First-Line' (line of treatment), 'Advanced Stage' (disease stage), and 'Folicular Lymphoma' (the core disease).
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Line of treatment' from the 'Treatment Set-up' category and for 'Stage Type' from the 'Stage' category.
4. **Rule Application**: 
   - Based on the 'Line of treatment' rules (specifically Rule ID 199 and 200), 'First-Line' was retained because it was followed by the generic word 'Treatment' and not a specific drug name. It was normalized to 'First-Line' and placed at the beginning of the indication.
   - 'Advanced Stage' was identified as a clinically significant stage descriptor and was retained and converted to Title Case.
   - 'Folicular Lymphoma' was already in the correct singular and Title Case format.
   - Specific drug names ('R-Chop', 'Bendamustine-Rituximab') and study-specific text ('A Single-Center Experience With') were excluded as per generic exclusion rules.
5. **Indication Construction**: The identified and normalized components were combined in a clinically standard order (Line -> Stage -> Disease) to form the final indication: 'First-Line Advanced Stage Follicular Lymphoma'.
6. **Quality Check**: The final output was verified against all generic rules, ensuring correct casing, singular form, and exclusion of non-indication elements.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine how to handle the 'First-Line' descriptor.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules regarding the 'Advanced Stage' descriptor.""}]","[{'component': 'First-Line', 'type': 'Line of Treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up, Line of treatment, Rule ID 200'}, {'component': 'Advanced Stage', 'type': 'Stage', 'normalized_form': 'Advanced Stage', 'rule_applied': 'Generic Rule: Title Case'}, {'component': 'Folicular Lymphoma', 'type': 'Disease', 'normalized_form': 'Follicular Lymphoma', 'rule_applied': 'Generic Rule: Singular Form, Title Case'}]",2
295985,Novartis - Evidence-Based Practice in HR+/HER2 Advanced Breast Cancer: Illuminating the Treatment Path for Patients,Welcome and Introduction,HR+;;HER2;;Advanced;;Breast Cancer,HR-Positive HER2 Advanced Breast Cancer,HR+/HER2- Advanced Breast Cancer,True,session_title,"Step 1: The abstract title 'Welcome and Introduction' contains no medical information. The session title 'Novartis - Evidence-Based Practice in HR+/HER2 Advanced Breast Cancer: Illuminating the Treatment Path for Patients' contains a clear disease and patient subgroup. Therefore, the session title was selected as the source based on the Single-Source Extraction Principle.
Step 2: The following components were identified in the session title: 'HR+' (Hormone Receptor-Positive), 'HER2' (HER2-Negative), 'Advanced' (Stage), and 'Breast Cancer' (Disease).
Step 3: Rules for 'Hormone status', 'Biomarker', and 'Stage' were retrieved to ensure correct formatting and inclusion.
Step 4: The generic rules for casing and singular form were applied. 'Breast Cancer' is already singular and in Title Case. The identified components were combined in the standard clinical order: patient subgroup (biomarkers), then stage, then the disease name. The notation 'HR+/HER2-' is a standard, clinically recognized format for this specific breast cancer subtype and was retained for accuracy. The non-diagnostic parts of the title, such as 'Novartis - Evidence-Based Practice' and 'Illuminating the Treatment Path for Patients', were excluded.
Step 5: The final indication was constructed by combining the normalized components, resulting in 'HR+/HER2- Advanced Breast Cancer'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Hormone status'], 'reason': ""To check for rules regarding the formatting of hormone receptor status like 'HR+'.""}, {'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To find rules for handling biomarker status, specifically 'HER2-'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To ensure the correct application of the stage descriptor 'Advanced'.""}]","[{'component': 'HR+', 'type': 'Hormone Status', 'normalized_form': 'HR+', 'rule_applied': 'Standard clinical abbreviation retained for accuracy.'}, {'component': 'HER2', 'type': 'Biomarker', 'normalized_form': 'HER2-', 'rule_applied': ""Standard clinical abbreviation retained for accuracy; unicode character '' normalized to hyphen '-'.""}, {'component': 'Advanced', 'type': 'Stage', 'normalized_form': 'Advanced', 'rule_applied': 'Generic Title Case rule.'}, {'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Title Case and Singular Form rules.'}]",2
394296,Prostate Cancer,Impact Of Intensified Androgen Deprivation Therapy (Adti) In The Metastatic Castration-Sensitive Prostate Cancer (Mcspc) Setting On Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Disease Characteristics And Survival Outcomes,Metastatic;;Castration-Sensitive Prostate Cancer,Metastatic Castration-Sensitive Prostate Cancer,Metastatic Castration-Sensitive Prostate Cancer;;Metastatic Castration-Resistant Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title contains specific disease entities ('Metastatic Castration-Sensitive Prostate Cancer' and 'Metastatic Castration-Resistant Prostate Cancer'), while the session title is more general ('Prostate Cancer'). Based on the Single-Source Extraction Principle, the abstract title is selected as the source.
2.  **Identify Components**: The abstract title clearly mentions two distinct clinical indications: 'Metastatic Castration-Sensitive Prostate Cancer (Mcspc)' and 'Metastatic Castration-Resistant Prostate Cancer (Mcrpc)'. Both are valid and separate indications.
3.  **Retrieve Relevant Rules**: To ensure correct formatting, I retrieved rules for 'Metastasis-Related Terms' and 'Resistance' under the 'Occurrence' category, and for 'Hormone status' under 'Patient Sub-Group'.
4.  **Apply Rules**: 
    *   The rule for 'Metastatic' (ID: 141) confirms the standard format 'Metastatic <Disease>', which is already present in the title.
    *   No specific rules were found for 'Castration-Sensitive' or 'Castration-Resistant', so I proceeded with generic rules. These terms are standard clinical descriptors defining the disease state and are not excluded.
    *   The generic rule for multiple diseases is applied, requiring the use of ';;' as a separator.
    *   The generic rule for Title Case is applied to each component of the indications.
    *   The generic rule for singular form is applied; 'Cancer' is already singular.
5.  **Construct Indication**: The two identified indications are formatted and combined using the ';;' separator.
6.  **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies both distinct patient populations mentioned in the source title, uses the correct separator, and follows Title Case conventions.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms', 'Resistance'], 'reason': ""To verify the formatting for 'Metastatic' and check for any rules regarding 'Resistant' in the context of 'Castration-Resistant'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Hormone status'], 'reason': ""To check for specific rules related to hormone status terms like 'Castration-Sensitive' and 'Castration-Resistant'.""}]","[{'component': 'Metastatic Castration-Sensitive Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Metastatic Castration-Sensitive Prostate Cancer', 'rule_applied': ""Generic Title Case and Singular Form rules. Occurrence rule for 'Metastatic'.""}, {'component': 'Metastatic Castration-Resistant Prostate Cancer', 'type': 'Disease', 'normalized_form': 'Metastatic Castration-Resistant Prostate Cancer', 'rule_applied': ""Generic Title Case and Singular Form rules. Occurrence rule for 'Metastatic'.""}]",2
345147,Innovative Approaches for Tumor Profiling and Data Analysis 1,Evaluation of a 293 gene oncology-focused exome sequencing panel for screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing,ovarian cancer,Ovarian Cancer,BRCA-Mutated Ovarian Cancer,True,abstract_title,"Step 1: The abstract title contains the specific disease 'ovarian cancer', while the session title has the less specific term 'Tumor'. Therefore, the abstract title is selected as the source based on the Single-Source Extraction Principle.
Step 2: The key components identified in the abstract title are 'ovarian cancer' (disease) and 'BRCA mutations' (patient subgroup).
Step 3: A query was made to `get_indication_rules` for 'Gene Mutation' to find the correct formatting for 'BRCA mutations'. Although no specific rule was returned, standard clinical nomenclature conventions are applied.
Step 4: The generic rules are applied. 'ovarian cancer' is converted to 'Ovarian Cancer' (Title Case, singular). 'BRCA mutations' is normalized to 'BRCA-Mutated' to act as a standard clinical qualifier. The procedural context ('screening', 'prerequisite for autologous cellular immunotherapy manufacturing') is excluded as per the generic exclusion rules.
Step 5: The components are combined, with the patient subgroup qualifier preceding the disease, resulting in 'BRCA-Mutated Ovarian Cancer'.
Step 6: A final quality check confirms adherence to all formatting, exclusion, and single-source rules.","[{'category': 'Gene type', 'subcategories': ['Gene Mutation', 'Gene Mutant', 'Gene Mutated'], 'reason': ""To determine the correct formatting for 'BRCA mutations'.""}]","[{'component': 'ovarian cancer', 'type': 'Disease', 'normalized_form': 'Ovarian Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'BRCA mutations', 'type': 'Gene Mutation', 'normalized_form': 'BRCA-Mutated', 'rule_applied': ""Standard clinical nomenclature for gene mutations (e.g., 'Gene-Mutated')""}, {'component': 'screening of ovarian cancer patients for BRCA mutations as a prerequisite for autologous cellular immunotherapy manufacturing', 'type': 'Procedural Context', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of Procedural/Temporal Qualifiers'}]",2
148549,Transfusion Medicine,Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain,,,Red Blood Cell Autoantibody;;Thrombotic Risk,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Evaluation Of Red Blood Cell Autoantibodies And Associated Thrombotic Risk In A Tertiary Care Centre In Spain') contains specific medical conditions, while the session title ('Transfusion Medicine') is a broad therapeutic area. Therefore, the abstract title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: Two distinct medical concepts were identified in the abstract title: 'Red Blood Cell Autoantibodies' and 'Thrombotic Risk'. The conjunction 'And Associated' links them as separate entities for evaluation.
3.  **Rule Retrieval**: I retrieved rules for the 'Risk' category to correctly handle 'Thrombotic Risk'. While no specific rule matched 'Thrombotic Risk', the generic rule for multiple diseases (e.g., 'Cardiovascular Risk') indicates that it should be treated as a standalone indication.
4.  **Rule Application & Normalization**:
    *   **Multiple Diseases**: The two identified concepts are treated as separate indications, to be joined by ';;'.
    *   **Singular Form**: The plural term 'Autoantibodies' was converted to its singular form 'Autoantibody' as per generic formatting rules.
    *   **Title Case**: Both indications were formatted to Title Case: 'Red Blood Cell Autoantibody' and 'Thrombotic Risk'.
    *   **Exclusion**: Non-diagnostic and geographic information ('Evaluation Of', 'In A Tertiary Care Centre In Spain') was excluded.
5.  **Indication Construction**: The normalized components were combined to form the final output: `Red Blood Cell Autoantibody;;Thrombotic Risk`.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To check for specific rules on how to format 'Thrombotic Risk'.""}]","[{'component': 'Red Blood Cell Autoantibodies', 'type': 'Disease', 'normalized_form': 'Red Blood Cell Autoantibody', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Title Case'}, {'component': 'Thrombotic Risk', 'type': 'Disease', 'normalized_form': 'Thrombotic Risk', 'rule_applied': 'Generic Rule: Multiple Diseases; Generic Rule: Title Case'}]",2
263238,Infections in hematology (incl. supportive care/therapy),Protection Of Patients With Hematologic Malignancy From Severe Infection During Pandemia: Estonian Two Centres Experience,Hematologic Malignancy,Hematologic Malignancy,Hematologic Malignancy;;Severe Infection,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Hematologic Malignancy', 'Severe Infection'), which is preferred over the broader session title ('Infections in hematology') per the single-source principle.
2. **Component Identification**: Two distinct medical conditions were identified in the abstract title: 'Hematologic Malignancy' and 'Severe Infection'.
3. **Rule Application (Generic)**:
   - **Multiple Diseases Rule**: The presence of two distinct conditions requires them to be extracted as separate indications, delimited by ';;'.
   - **Formatting Rules**: Both terms were converted to Title Case and confirmed to be in singular form.
   - **Exclusion Rules**: Non-diagnostic and contextual phrases such as 'Protection Of Patients', 'During Pandemia', and 'Estonian Two Centres Experience' were excluded as per the generic rules.
4. **Indication Construction**: The two normalized disease terms were combined using the ';;' separator to form the final output.
5. **Quality Check**: The final indication adheres to all formatting, separation, and content rules. It accurately reflects the core clinical conditions mentioned in the source title.",[],"[{'component': 'Hematologic Malignancy', 'type': 'Disease', 'normalized_form': 'Hematologic Malignancy', 'rule_applied': 'Generic Casing and Singular Form Rules'}, {'component': 'Severe Infection', 'type': 'Disease', 'normalized_form': 'Severe Infection', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
410696,Glomerular Diseases,Late-Onset Lupus Nephritis Presenting as Acute Decompensated Heart Failure,Late-Onset;;Lupus Nephritis,Late-Onset Lupus Nephritis,Late Onset Lupus Nephritis;;Acute Decompensated Heart Failure,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Late-Onset Lupus Nephritis Presenting as Acute Decompensated Heart Failure' was chosen as it contains specific disease terms, which is preferred over the broader session title 'Glomerular Diseases' according to the single-source principle.
2. **Component Identification**: The abstract title identifies two distinct clinical conditions: 'Late-Onset Lupus Nephritis' and 'Acute Decompensated Heart Failure'. The phrase 'Presenting as' links them as separate entities.
3. **Rule Retrieval**: I retrieved rules for 'Onset' to handle 'Late-Onset' and for 'Patient with two different Disease' to confirm how to handle the two conditions. The 'Onset' rules confirmed the formatting for 'Late Onset', and the generic rules for multiple diseases were applied in the absence of a specific rule for the 'Presenting as' scenario.
4. **Rule Application**: 
   - **Multiple Diseases**: The generic rule was applied to extract both distinct diseases, separated by ';;'.
   - **Onset Rule (ID 287)**: The specific rule for 'Late Onset' was applied, standardizing 'Late-Onset' to 'Late Onset' (Title Case, no hyphen).
   - **Disease Characterization (Acute)**: The generic rule for 'Acute' was applied, retaining it as it is an integral part of the disease name 'Acute Decompensated Heart Failure'.
   - **Formatting**: All terms were converted to Title Case and singular form as required.
5. **Indication Construction**: The two processed components were combined to form the final indication: 'Late Onset Lupus Nephritis' and 'Acute Decompensated Heart Failure', joined by ';;'.
6. **Quality Check**: The final output was verified against all generic and specific rules, ensuring compliance with formatting, single-source principle, and clinical accuracy.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To correctly format the 'Late-Onset' qualifier.""}, {'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check for specific rules on how to handle two diseases linked by 'Presenting as'. No specific rules were found, so generic rules were applied.""}]","[{'component': 'Late-Onset Lupus Nephritis', 'type': 'Disease with Onset Qualifier', 'normalized_form': 'Late Onset Lupus Nephritis', 'rule_applied': ""Onset by Time rule for 'Late Onset' (ID 287) and Generic Casing/Singular rules.""}, {'component': 'Acute Decompensated Heart Failure', 'type': 'Disease', 'normalized_form': 'Acute Decompensated Heart Failure', 'rule_applied': ""Generic rule for 'Acute' and Generic Casing/Singular rules.""}]",2
345167,Cancer Cachexia,Integrin-mediated lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia,cancer;;associated;;cachexia,Cancer-Associated Cachexia,Pancreatic Cancer;;Cancer-Associated Cachexia,True,abstract_title,"Step 1: The abstract title was selected as the source because it contains more specific disease information ('pancreatic cancer', 'cancer-associated cachexia') than the session title ('Cancer Cachexia').
Step 2: The abstract title identifies two distinct but related clinical conditions: 'pancreatic cancer' and 'cancer-associated cachexia'.
Step 3: According to the generic rule for multiple diseases, both conditions must be extracted as separate indications.
Step 4: The terms were normalized according to formatting rules: 'pancreatic cancer' becomes 'Pancreatic Cancer' (Title Case) and 'cancer-associated cachexia' becomes 'Cancer-Associated Cachexia' (Title Case).
Step 5: The two normalized indications are joined using the required ';;' separator, resulting in the final output.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct way to handle the presence of both pancreatic cancer and cachexia in the title.'}]","[{'component': 'pancreatic cancer', 'type': 'Disease', 'normalized_form': 'Pancreatic Cancer', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'cancer-associated cachexia', 'type': 'Disease', 'normalized_form': 'Cancer-Associated Cachexia', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Multiple Diseases'}]",2
263249,Lymphoma Biology & Translational Research,Tp53 Gene Mutation Diversity In Russian Patients With B-Cell Lymphomas,B-Cell Lymphomas,B-Cell Lymphoma,Tp53-Mutated B-Cell Lymphoma,True,abstract_title,"Step 1: The abstract title 'Tp53 Gene Mutation Diversity In Russian Patients With B-Cell Lymphomas' was chosen as the source because it contains a specific disease ('B-Cell Lymphomas'), which is more precise than the session title's broader term ('Lymphoma').
Step 2: The components identified in the abstract title were 'Tp53 Gene Mutation' (gene mutation), 'Russian Patients' (sociodemographic descriptor), and 'B-Cell Lymphomas' (disease).
Step 3: Rules for 'Gene Name' and 'Patient Sub-Group' were retrieved to handle 'Tp53' and 'B-Cell' respectively.
Step 4: The generic sociodemographic exclusion rule was applied to remove 'Russian Patients'. The retrieved 'Gene Name' rule (ID: 27) guided the formatting of 'Tp53 Gene Mutation' into 'Tp53-Mutated'. The generic singularization rule was applied to convert 'Lymphomas' to 'Lymphoma'. The 'B-Cell' qualifier was retained as it is an integral part of the disease name.
Step 5: The components were combined and formatted according to Title Case rules, resulting in the final indication 'Tp53-Mutated B-Cell Lymphoma'.","[{'category': 'Gene Name', 'subcategories': ['Gene Name'], 'reason': ""To determine how to handle the gene 'Tp53' and its qualifier 'Mutation'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct handling of the 'B-Cell' qualifier for the lymphoma.""}]","[{'component': 'Tp53 Gene Mutation', 'type': 'Gene Mutation', 'normalized_form': 'Tp53-Mutated', 'rule_applied': ""Gene Name Rule ID: 27 requires combining the gene symbol with its qualifier, formatted as '<GeneSymbol>-<Qualifier>'.""}, {'component': 'B-Cell Lymphomas', 'type': 'Disease', 'normalized_form': 'B-Cell Lymphoma', 'rule_applied': ""Generic rule for singular form was applied ('Lymphomas' -> 'Lymphoma'). 'B-Cell' is retained as an essential disease specifier.""}, {'component': 'Russian Patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity/region was applied.'}]",3
263250,Lymphoma Biology & Translational Research,"Surgical Specimens Of Indolent And Aggressive B-Nhls Show Differences In Their Flow-Cytometry Profile Of Ploidy, Proliferating Fraction And Proportion Of Tumor-Associated Myeloid And T-Cell Subsets",Indolent;;Aggressive;;B-Nhls,Indolent Aggressive B-cell non-Hodgkin lymphoma,Indolent B-Cell Non-Hodgkin's Lymphoma;;Aggressive B-Cell Non-Hodgkin's Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains specific disease terms ('Indolent And Aggressive B-Nhls'), which is more precise than the broader term 'Lymphoma' in the session title. This adheres to the Single-Source Extraction Principle.
2. **Component Identification**: The key components identified in the abstract title were the disease 'B-Nhls' and its characterizations 'Indolent' and 'Aggressive'.
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to understand how to handle descriptors like 'Indolent' and 'Aggressive'. While no specific rule existed for these exact terms, the general principle is to include clinically significant descriptors that define a patient subgroup.
4. **Rule Application and Normalization**:
   - **Multiple Indications**: 'Indolent' and 'Aggressive' describe distinct clinical behaviors of the lymphoma, so they were treated as separate indications.
   - **Abbreviation Expansion**: The abbreviation 'B-Nhls' was expanded to its full clinical term 'B-Cell Non-Hodgkin's Lymphoma'.
   - **Singular Form**: The plural 'Lymphomas' (implied by 'B-Nhls') was converted to the singular 'Lymphoma' as per generic formatting rules.
   - **Casing**: The final indications were formatted in Title Case.
   - **Separator**: The two distinct indications were separated by the required ';;' delimiter.
5. **Indication Construction**: The normalized components were combined to form two clinically distinct indications: 'Indolent B-Cell Non-Hodgkin's Lymphoma' and 'Aggressive B-Cell Non-Hodgkin's Lymphoma'.
6. **Quality Check**: The final output was reviewed to ensure it is clinically accurate, follows all formatting rules, and adheres to the single-source principle. All methodological terms like 'Surgical Specimens' and 'Flow-Cytometry' were correctly excluded.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules on handling disease characterization keywords like 'Indolent' and 'Aggressive'.""}]","[{'component': 'Indolent B-Nhls', 'type': 'Disease', 'normalized_form': ""Indolent B-Cell Non-Hodgkin's Lymphoma"", 'rule_applied': ""Generic rule: Singular form, Title Case, Abbreviation Expansion. 'Indolent' is a clinically significant descriptor and was retained.""}, {'component': 'Aggressive B-Nhls', 'type': 'Disease', 'normalized_form': ""Aggressive B-Cell Non-Hodgkin's Lymphoma"", 'rule_applied': ""Generic rule: Singular form, Title Case, Abbreviation Expansion. 'Aggressive' is a clinically significant descriptor and was retained.""}]",2
148578,Acute Lymphoblastic Leukemia - Clinical,L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia,Children;;Acute Pancreatitis;;Acute Lymphoblastic Leukemia,Childhood Acute Pancreatitis;;Acute Lymphoblastic Leukemia,Childhood Acute Pancreatitis;;Childhood Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('L-Asparaginase Associated Acute Pancreatitis In Children With Acute Lymphoblastic Leukemia') was chosen over the session title ('Acute Lymphoblastic Leukemia - Clinical') because it is more specific and contains more detailed information, including multiple conditions and a patient subgroup, adhering to the 'Abstract Title first' principle.

2. **Component Identification**: The abstract title contains two distinct medical conditions: 'Acute Pancreatitis' and 'Acute Lymphoblastic Leukemia'. It also identifies a patient subgroup: 'Children'. The phrase 'L-Asparaginase Associated' is identified as a descriptor for Acute Pancreatitis.

3. **Rule Retrieval & Application**:
   - **Age Group**: Rules for 'Childhood' were retrieved using `get_indication_rules(category=""Age Group"", subcategories=[""Childhood""])`. Rule ID 294 directs the replacement of 'Children' with the prefix 'Childhood' before the associated disease name.
   - **Multiple Diseases**: The generic rules for multiple diseases were applied, requiring the extraction of all distinct conditions and separating them with ';;'.
   - **Exclusion Rule**: The descriptor 'L-Asparaginase Associated' indicates that the pancreatitis is a complication or adverse effect of a treatment. According to the generic exclusion rules, 'Complications or adverse effects' should be excluded from the final indication. Therefore, this phrase was removed.

4. **Indication Construction**:
   - The patient subgroup 'Children' is linked to the patients who have Acute Lymphoblastic Leukemia, and the pancreatitis occurs within this group. Therefore, the 'Childhood' qualifier applies to both conditions.
   - 'Acute Pancreatitis' combined with the age qualifier becomes 'Childhood Acute Pancreatitis'.
   - 'Acute Lymphoblastic Leukemia' combined with the age qualifier becomes 'Childhood Acute Lymphoblastic Leukemia'.
   - The two indications are combined using the ';;' separator.

5. **Final Quality Check**: The final output `Childhood Acute Pancreatitis;;Childhood Acute Lymphoblastic Leukemia` adheres to all formatting rules (Title Case, singular form, no trailing spaces) and accurately reflects the clinically valid indications present in the source title after applying the necessary rules.","[{'category': 'Age Group', 'subcategories': ['Childhood'], 'reason': ""To handle the 'Children' patient subgroup.""}, {'category': 'Patient with two different Disease', 'subcategories': None, 'reason': 'To check for specific rules on handling multiple diseases, though a tool error occurred and generic rules were used instead.'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine if 'L-Asparaginase Associated' is a valid clinical qualifier.""}]","[{'component': 'Acute Pancreatitis', 'type': 'Disease', 'normalized_form': 'Acute Pancreatitis', 'rule_applied': 'Generic disease identification.'}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic disease identification.'}, {'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Childhood', 'rule_applied': ""Age Group Rule ID 294: Replace 'Children' with 'Childhood' and prepend to the disease name.""}, {'component': 'L-Asparaginase Associated', 'type': 'Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}]",2
410725,"Health Maintenance, Nutrition, and Metabolism",Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis,,,End-Stage Renal Disease;;Complex Congenital Heart Disease,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Intradialytic Amino Acids Improved Malnutrition Markers in ESRD with Complex Congenital Heart Disease on Peritoneal Dialysis') was chosen over the session title ('Health Maintenance, Nutrition, and Metabolism') because it contains specific disease terms, adhering to the single-source principle.
2. **Component Identification**: Two distinct diseases were identified in the abstract title: 'ESRD' and 'Complex Congenital Heart Disease'. The term 'with' connects them, indicating a patient population with both conditions.
3. **Rule Application (Generic)**:
   - **Multiple Diseases**: The generic rule for multiple diseases was applied, requiring both conditions to be extracted and separated by ';;'.
   - **Standardization**: 'ESRD' was expanded to its full standard name 'End-Stage Renal Disease'.
   - **Exclusion**: The procedural qualifier 'on Peritoneal Dialysis' and the non-diagnostic term 'Malnutrition Markers' were excluded as per generic exclusion rules.
   - **Formatting**: Both indications were converted to Title Case and singular form.
4. **Rule Retrieval (Tool-based)**:
   - A rule check for 'Patient with two different Disease' was performed, but no specific rules were found, defaulting to the generic separator rule.
   - A rule check for 'Disease Characterisation' was done for the term 'Complex'. No specific rule exists, so the clinically significant descriptor 'Complex' was retained.
   - A rule check for 'Genetic Origin' was done for 'Congenital'. No specific rule exists, so this standard medical term, being part of the disease name, was retained.
5. **Indication Construction**: The two standardized disease names were combined using the ';;' separator, resulting in the final indication.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To determine the correct formatting for a title describing patients with two concurrent diseases (ESRD and Heart Disease).'}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for specific rules on handling the qualifier 'Complex'.""}, {'category': 'Occurrence', 'subcategories': ['Genetic Origin'], 'reason': ""To check for specific rules on handling the qualifier 'Congenital'.""}]","[{'component': 'ESRD', 'type': 'Disease', 'normalized_form': 'End-Stage Renal Disease', 'rule_applied': 'Standard medical acronym expansion and Title Case rule.'}, {'component': 'Complex Congenital Heart Disease', 'type': 'Disease', 'normalized_form': 'Complex Congenital Heart Disease', 'rule_applied': ""Title Case and singular form rules. 'Complex' and 'Congenital' were retained as they are clinically significant parts of the disease name.""}, {'component': 'on Peritoneal Dialysis', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/treatment context.'}]",2
312429,Review Course,Wrap-Up,,,,True,none,"Neither the abstract title ('Wrap-Up') nor the session title ('Review Course') contains any specific disease, disorder, or therapeutic area. Both titles are generic and describe the nature of the presentation rather than a clinical subject. Therefore, no medical indication can be extracted.",[],[],1
296059,"Breast cancer, early stage","Cosmesis (CA), late effects (LE) and Patient reported outcome measures (PROM) in high risk breast cancer (BC) treated with hypo-fractionated radiotherapy (RT): real world outcome from a developing country.",high risk;;breast cancer ,High Risk Breast Cancer ,High-Risk Breast Cancer,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease, 'breast cancer', along with a patient subgroup qualifier, 'high risk'. The session title also contains 'Breast cancer' but the abstract title is more specific.
Step 2: The core disease 'breast cancer' was identified. Per generic rules, it was converted to singular and Title Case, resulting in 'Breast Cancer'.
Step 3: The qualifier 'high risk' was identified. The `get_indication_rules` tool was used for the 'Risk' category.
Step 4: Rule ID 122 for 'High-Risk' was applied, which standardizes 'high risk' to 'High-Risk' and places it before the disease name.
Step 5: Other elements in the title such as 'Cosmesis (CA)', 'late effects (LE)', 'Patient reported outcome measures (PROM)', treatment details ('hypo-fractionated radiotherapy'), and geographic descriptors ('developing country') were excluded as per generic exclusion rules.
Step 6: The final indication was constructed by combining the normalized risk qualifier and the disease: 'High-Risk Breast Cancer'.","[{'category': 'Risk', 'subcategories': ['High-Risk', 'Risk Types'], 'reason': ""To correctly format the 'high risk' patient subgroup qualifier.""}]","[{'component': 'high risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID 122: Normalize 'high risk' to 'High-Risk' and prepend to the disease.""}, {'component': 'breast cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Rule: Convert to singular form and Title Case.'}]",2
296071,Melanoma and other skin tumours,Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: a phase II clinical trial (NeoBCC),primary;;basal cell carcinoma,Primary Basal Cell Carcinoma,Unresectable Primary Basal Cell Carcinoma,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('primary basal cell carcinoma'), which is preferred over the broader categories in the session title ('Melanoma and other skin tumours').
Step 2: The core disease was identified as 'primary basal cell carcinoma'. The qualifier 'difficult to resect' was also identified.
Step 3: Rules for resectability were retrieved using `get_indication_rules(category='Treatment Set-up', subcategories=['Resectable', 'Unresectable'])` to understand how to handle terms related to surgical status.
Step 4: The phrase 'difficult to resect' is a clinical descriptor indicating that the tumor is not easily removable. Based on the retrieved rules for 'Unresectable' and 'Non-Resectable', this term was normalized to the standard clinical qualifier 'Unresectable'.
Step 5: The generic rule for 'Primary' was applied, keeping it as part of the disease name. The generic rules for Title Case and singular form were applied to format the final indication.
Step 6: The components were combined to form the final indication: 'Unresectable Primary Basal Cell Carcinoma'.","[{'category': 'Treatment Set-up', 'subcategories': ['Resectable', 'Unresectable'], 'reason': ""To determine the correct handling and normalization of the phrase 'difficult to resect'.""}]","[{'component': 'difficult to resect', 'type': 'Resectability Status', 'normalized_form': 'Unresectable', 'rule_applied': ""Normalization based on retrieved 'Unresectable' rules (e.g., Rule ID 245), as 'difficult to resect' implies a state of unresectability.""}, {'component': 'primary basal cell carcinoma', 'type': 'Disease', 'normalized_form': 'Primary Basal Cell Carcinoma', 'rule_applied': ""Generic rule for 'Primary' and generic formatting rules (Title Case, Singular Form).""}]",2
394376,Renal Cancer,Adjuvant Everolimus (Eve) In Patients (Pts) With Completely Resected Very High-Risk Renal Cell Cancer (Rcc) And Clear Cell Histology: Results From The Phase Iii Swog S0931 (Everest) Trial,Resected;;Very High-Risk;;Renal Cell Cancer,Resected Very High-Risk Renal Cell Cancer,Very High-Risk Clear Cell Renal Cell Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen over the session title because it contains a more specific and detailed description of the medical indication, including risk level and histology, which aligns with the Single-Source Extraction Principle.

2. **Component Identification**: I identified the following key components in the abstract title: 
   - Disease: 'Renal Cell Cancer (Rcc)'
   - Risk Qualifier: 'Very High-Risk'
   - Histology/Subtype: 'Clear Cell Histology'
   - Treatment/Procedural Context: 'Adjuvant', 'Completely Resected'

3. **Rule Retrieval**: I retrieved rules for 'Treatment Set-up' (Operative Status), 'Risk' (Risk Types), and 'Patient Sub-Group' (Disease Characterisation) to guide the extraction.

4. **Rule Application and Component Normalization**:
   - **Disease**: 'Renal Cell Cancer' was kept as the core disease, and the abbreviation '(Rcc)' was removed. The term is already in singular form.
   - **Risk Qualifier**: Based on the pattern from retrieved 'Risk Types' rules, 'Very High-Risk' was identified as a critical patient subgroup qualifier and was prepended to the disease name. It was formatted in Title Case.
   - **Histology/Subtype**: 'Clear Cell' is a crucial histological subtype of Renal Cell Cancer. The term 'Histology' was dropped as it is descriptive of the analysis type, not the disease itself. 'Clear Cell' was included in the indication.
   - **Exclusions**: Following generic exclusion rules and the patterns in the retrieved 'Treatment Set-up' rules (e.g., for 'Post Operative'), the terms 'Adjuvant' (treatment timing) and 'Completely Resected' (procedural status) were excluded as they describe the treatment context rather than defining the core indication.

5. **Indication Construction**: The identified and normalized components were assembled in the standard clinical order: [Risk] [Histology/Subtype] [Disease]. This resulted in 'Very High-Risk Clear Cell Renal Cell Cancer'.

6. **Final Quality Check**: The final indication was reviewed for compliance with all formatting rules (Title Case, singular form, no extra spaces) and clinical accuracy. The result is a concise, standardized, and clinically valid medical indication.","[{'category': 'Treatment Set-up', 'subcategories': ['Operative Status', 'Treatment Modality'], 'reason': ""To determine how to handle the term 'Completely Resected' and 'Adjuvant'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format and include the 'Very High-Risk' qualifier.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To determine how to handle the 'Clear Cell Histology' descriptor.""}]","[{'component': 'Renal Cell Cancer', 'type': 'Disease', 'normalized_form': 'Renal Cell Cancer', 'rule_applied': 'Generic singular form and Title Case rule.'}, {'component': 'Very High-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'Very High-Risk', 'rule_applied': 'Risk category rule pattern for prepending risk status.'}, {'component': 'Clear Cell Histology', 'type': 'Disease Subtype', 'normalized_form': 'Clear Cell', 'rule_applied': ""Patient Sub-Group rule pattern to include clinically significant subtypes and exclude descriptive terms like 'Histology'.""}, {'component': 'Adjuvant', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}, {'component': 'Completely Resected', 'type': 'Operative Status', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers, supported by Treatment Set-up rule patterns.'}]",2
230538,Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology,Comparative oncology analysis using genomic profiling of canine cancers by tissue and liquid biopsy testing reveals actionable somatic alterations with orthologs in human cancers.,cancers,Cancer,Tumor,True,session_title,"Step-by-step extraction process:
1.  **Analyze Titles**: The abstract title mentions ""canine cancers"" and ""human cancers"". The session title mentions ""Tumor"".
2.  **Select Source**: According to the Single-Source Extraction Principle, the abstract title is preferred if it contains a disease. However, the primary focus of the abstract title is on ""canine cancers,"" which is not a human medical indication. The mention of ""human cancers"" is secondary and for comparative purposes. Therefore, the abstract title is not a suitable source for a clinically valid human indication.
3.  **Fallback to Session Title**: The session title, ""Developmental Therapeutics-Molecularly Targeted Agents and Tumor Biology"", contains the valid disease term ""Tumor"".
4.  **Extract and Normalize**: The term ""Tumor"" is extracted from the session title. It is already in singular form and Title Case, adhering to the generic rules.
5.  **Final Indication**: The final generated indication is ""Tumor"".",[],"[{'component': 'canine cancers', 'type': 'Disease', 'normalized_form': 'Canine Cancer', 'rule_applied': 'Excluded as it is a non-human (veterinary) indication.'}, {'component': 'human cancers', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Not selected as it was mentioned in a comparative context, not as the primary disease of study.'}, {'component': 'Tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': 'Extracted from the session title as the primary source was unsuitable. Generic formatting rules applied.'}]",1
345226,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies",Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses,,,Cancer,True,session_title,"Step 1: The abstract title 'Extracellular vesicles (EV) - mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses' does not contain a specific disease or condition. It describes a biological process and study methodology.
Step 2: The session title 'Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies' contains the term 'Anticancer', which points to the therapeutic area of Oncology.
Step 3: According to the Single-Source Extraction Principle, the session title is used as a fallback. 
Step 4: The generic rule for 'Therapeutic Area Fallback' is applied, which states that 'Oncology' or related terms should be mapped to the overarching disease 'Cancer'. The other terms in the title refer to treatment modalities and are excluded.
Step 5: The final indication is standardized to 'Cancer' in Title Case and singular form.",[],"[{'component': 'Anticancer', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",1
197778,Mitochondrial Interventions: Small Molecule and Gene Therapy (Mitochondrial Interventions: Small Molecule and Gene Therapy),Mitochondrial Interventions: Small Molecule and Gene Therapy,,,,True,none,"Both the abstract title and the session title describe therapeutic modalities ('Small Molecule and Gene Therapy') and a biological target ('Mitochondrial Interventions'), but they do not name a specific disease, disorder, or clinical condition. According to the extraction rules, an indication must be a clinically valid medical condition. Since no disease is mentioned, a valid indication cannot be extracted from the provided text.",[],[],1
296082,"NSCLC, metastatic",A multicenter study of incidence of drug-induced lung disease in first-line osimertinib therapy and continuation of osimertinib administration,lung disease,Lung Disease,Metastatic Non-Small Cell Lung Cancer,True,session_title,"Step 1: The abstract title focuses on a complication ('drug-induced lung disease'), while the session title ('NSCLC, metastatic') clearly identifies the primary disease and its stage. Therefore, the session title was chosen as the source based on the Single-Source Extraction Principle.
Step 2: The components identified in the session title are the disease 'NSCLC' and the occurrence qualifier 'metastatic'.
Step 3: To ensure correct formatting for the qualifier, rules for 'Metastasis-Related Terms' were retrieved using the `get_indication_rules` tool.
Step 4: The retrieved rule (ID: 141) for 'Metastatic' dictates the format 'Metastatic <Primary-Disease-Name>'. The acronym 'NSCLC' was expanded to its full, standardized form 'Non-Small Cell Lung Cancer' for clinical clarity.
Step 5: The components were combined and formatted according to the rules, resulting in the final indication 'Metastatic Non-Small Cell Lung Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To correctly format the term 'metastatic' as a prefix to the disease.""}]","[{'component': 'NSCLC', 'type': 'Disease', 'normalized_form': 'Non-Small Cell Lung Cancer', 'rule_applied': 'Standardization of medical acronyms for clarity.'}, {'component': 'metastatic', 'type': 'Occurrence', 'normalized_form': 'Metastatic', 'rule_applied': ""Rule ID: 141 - Format as 'Metastatic <Primary-Disease-Name>'.""}]",2
345240,"Oncolytic Viruses, Anticancer Vaccines, and Other Immunomodulatory Therapies","CRB-601, an avb8 blocking antibody, prevents activation of TGFb and exhibits anti-tumor activity associated with immune cell remodeling of the tumor microenvironment",,,Tumor,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains the disease-related term ""anti-tumor"", while the session title only lists therapy types.
Step 2: The component ""anti-tumor activity"" was identified in the abstract title.
Step 3: Generic rules were applied. The prefix ""anti-"" was removed, and the term ""tumor"" was converted to Title Case and singular form, resulting in ""Tumor"".
Step 4: No other patient subgroups, stages, or qualifiers were mentioned in the title, so the final indication is the standalone disease term.",[],"[{'component': 'anti-tumor', 'type': 'Disease', 'normalized_form': 'Tumor', 'rule_applied': ""Generic rule: Convert to singular form and Title Case. Removed 'anti-' prefix as it describes activity against the disease.""}]",1
263328,Myeloma and other monoclonal gammopathies - Clinical,Opportunities Of Therapy In Patients With Newly Diagnosed Multiple Myeloma With Dialysis-Dependent Renal Impairment,Newly Diagnosed;;Multiple Myeloma,Newly Diagnosed Multiple Myeloma,Newly Diagnosed Multiple Myeloma with Dialysis-Dependent Renal Impairment,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Opportunities Of Therapy In Patients With Newly Diagnosed Multiple Myeloma With Dialysis-Dependent Renal Impairment') was chosen over the session title ('Myeloma and other monoclonal gammopathies - Clinical') because it contains a more specific and detailed description of the patient population and disease state, adhering to the single-source principle.
2. **Component Identification**: I identified three key components in the abstract title:
    - Diagnosis Status: 'Newly Diagnosed'
    - Core Disease: 'Multiple Myeloma'
    - Patient Subgroup: 'With Dialysis-Dependent Renal Impairment'
3. **Rule Retrieval**: I retrieved rules for 'Diagnosis Status' (specifically 'Newly Diagnosed') which confirmed that this term should be prefixed to the disease name. I also checked rules for patient subgroups and connectors to guide the inclusion of the renal impairment detail.
4. **Rule Application and Construction**:
    - The rule for 'Newly Diagnosed' (ID: 193) was applied, placing it at the beginning of the indication.
    - The core disease 'Multiple Myeloma' was kept as is, already in correct singular and Title Case format.
    - The patient subgroup 'With Dialysis-Dependent Renal Impairment' is a clinically significant descriptor that defines a specific, high-risk patient population in the context of Multiple Myeloma. It was included to maintain clinical accuracy.
    - Generic formatting rules were applied: Title Case for all significant words, with the preposition 'with' in lower case as per the guidelines.
5. **Final Quality Check**: The final indication was reviewed to ensure it is concise, clinically accurate, correctly formatted, and derived from a single source. The resulting indication accurately reflects the patient population described in the abstract title.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To verify the correct handling and formatting of the term 'Newly Diagnosed'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding specific patient conditions like 'Renal Impairment' or 'Dialysis-Dependent'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To determine the standard formatting for the connector 'With' when linking a disease to a patient characteristic.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule - Use singular form and Title Case.'}, {'component': 'With Dialysis-Dependent Renal Impairment', 'type': 'Patient Subgroup', 'normalized_form': 'with Dialysis-Dependent Renal Impairment', 'rule_applied': ""Generic Rule - Include clinically valid patient subgroups and use lower case for prepositions like 'with'.""}]",2
296096,SCLC,"DeLLphi-303: phase 1b first-line combination study of tarlatamab, a DLL3-targeting half-life extended bispecific T-cell engager (HLE BiTE), with carboplatin, etoposide, and PD-L1 inhibition in extensive stage small cell lung cancer (ES-SCLC)",extensive stage;;small cell lung cancer ,Extensive Stage Small Cell Lung Cancer ,First-Line Extensive Stage Small Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease and patient population description ('extensive stage small cell lung cancer'), which is more detailed than the session title ('SCLC'). The Single-Source Extraction Principle mandates using the more informative title.
2. **Component Identification**: I identified three key components in the abstract title: the treatment line ('first-line'), the disease stage ('extensive stage'), and the disease itself ('small cell lung cancer').
3. **Rule Retrieval**: To ensure correct formatting, I retrieved rules for 'Stage' and 'Treatment Set-up'.
   - For 'extensive stage', I used `get_indication_rules(category=""Stage"", subcategories=[""Stage Type""])`.
   - For 'first-line', I used `get_indication_rules(category=""Treatment Set-up"", subcategories=[""Line of treatment""])`.
4. **Rule Application**:
   - **Disease Normalization**: Applied generic rules to convert 'small cell lung cancer' to 'Small Cell Lung Cancer' (Title Case, singular form).
   - **Stage Rule**: Based on the retrieved rule (ID: 99), 'extensive stage' was normalized to 'Extensive Stage' and placed before the disease name.
   - **Treatment Line Rule**: Based on the retrieved rule (ID: 200), 'first-line' was normalized to 'First-Line' and placed at the beginning of the indication, as it describes the patient population setting.
5. **Indication Construction**: The components were assembled in the standard order: Treatment Line -> Stage -> Disease. This resulted in 'First-Line Extensive Stage Small Cell Lung Cancer'.
6. **Final Quality Check**: The final indication adheres to all formatting rules (Title Case, singular, no excluded terms) and accurately represents the patient population described in the abstract title.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To correctly format the 'extensive stage' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly format the 'first-line' component.""}]","[{'component': 'first-line', 'type': 'Line of treatment', 'normalized_form': 'First-Line', 'rule_applied': 'Treatment Set-up Rule ID: 200'}, {'component': 'extensive stage', 'type': 'Stage', 'normalized_form': 'Extensive Stage', 'rule_applied': 'Stage Rule ID: 99'}, {'component': 'small cell lung cancer', 'type': 'Disease', 'normalized_form': 'Small Cell Lung Cancer', 'rule_applied': 'Generic Casing and Singular Form Rules'}]",2
165030,The Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology - Controversies in Pediatric Infection Prevention,To See or Not To See: COVID-19 Visitor Restrictions in Pediatric Healthcare Settings,COVID-19,COVID-19 Infection,Pediatric COVID-19,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the abstract title ('To See or Not To See: COVID-19 Visitor Restrictions in Pediatric Healthcare Settings') and the session title ('The Tiny but Fierce Beasts of COVID-19 & Healthcare Epidemiology - Controversies in Pediatric Infection Prevention') contain the disease term 'COVID-19' and the patient subgroup 'Pediatric'.
2.  **Select Source**: According to the single-source principle, the abstract title is preferred as it contains a clear disease term. I selected the abstract title as the source.
3.  **Identify Components**: From the abstract title, I identified the disease 'COVID-19' and the patient subgroup 'Pediatric'. Other terms like 'Visitor Restrictions' and 'Healthcare Settings' are non-diagnostic and marked for exclusion.
4.  **Retrieve Rules**: I retrieved rules for the 'Age Group' category with the subcategory 'Pediatric' to ensure correct formatting.
5.  **Apply Rules**: The retrieved rules (e.g., Rule ID 295, 296) confirm that 'Pediatric' should be used as a singular, title-cased prefix to the disease name. Generic rules for exclusion were applied to remove non-diagnostic information.
6.  **Construct Indication**: The patient subgroup 'Pediatric' was prepended to the disease 'COVID-19' as per the retrieved rules.
7.  **Quality Check**: The final indication 'Pediatric COVID-19' adheres to all formatting (Title Case, singular form) and exclusion rules. It correctly combines the patient subgroup with the disease from a single source.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To correctly format the 'Pediatric' patient subgroup qualifier.""}]","[{'component': 'COVID-19', 'type': 'Disease', 'normalized_form': 'COVID-19', 'rule_applied': 'Generic disease identification.'}, {'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Rule ID 296: Place 'Pediatric' as the first word of the indication.""}]",2
148651,Aggressive Non-Hodgkin Lymphoma - Clinical,"Front-Mind: A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy And Safety Of R-Chop + Tafasitamab + Lenalidomide Vs R-Chop Alone For Newly-Diagnosed High-Risk Dlbcl",Newly-Diagnosed;;High-Risk;;Dlbcl,Newly-Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Dlbcl') and detailed patient subgroup information ('Newly-Diagnosed High-Risk'), making it more informative than the session title.
2. **Component Identification**: I identified three key components in the abstract title: the diagnosis status 'Newly-Diagnosed', the risk level 'High-Risk', and the disease abbreviation 'Dlbcl'.
3. **Rule Retrieval**: I retrieved rules for 'Diagnosis Status' and 'Risk' to ensure correct formatting. The rule for 'Newly Diagnosed' (ID: 193) confirms it should be used as a prefix. The rules for 'High-Risk' (e.g., ID: 122) confirm its placement before the disease.
4. **Component Normalization & Application of Generic Rules**:
   - 'Newly-Diagnosed' was normalized to 'Newly Diagnosed' as per the retrieved rule and Title Case generic rule.
   - 'High-Risk' was kept as is, following standard formatting for risk qualifiers.
   - 'Dlbcl' is a standard medical abbreviation that was expanded to its full, clinically accurate name: 'Diffuse Large B-Cell Lymphoma'.
   - Generic rules for Title Casing and singular form were applied.
5. **Indication Construction**: The normalized components were assembled in a clinically logical order: Diagnosis Status -> Risk -> Disease Name. This resulted in the final indication: 'Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma'.
6. **Quality Check**: The final indication adheres to all formatting rules, accurately reflects the patient population from the source title, and excludes irrelevant study design details.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To validate the formatting and placement of the 'Newly-Diagnosed' keyword.""}, {'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To ensure the correct formatting and inclusion of the 'High-Risk' qualifier.""}]","[{'component': 'Newly-Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Rule ID: 122 - Standardize risk level and attach to the associated disease.'}, {'component': 'Dlbcl', 'type': 'Disease', 'normalized_form': 'Diffuse Large B-Cell Lymphoma', 'rule_applied': 'Standard medical abbreviation expansion and Title Case rule.'}]",2
148656,Bleeding Disorders (Congenital And Acquired),Inhibitors In Mild Haemophilia A: Experience Of A Single Spanish Center,Mild;;Haemophilia A,Mild Haemophilia A,Mild Haemophilia A With Inhibitors,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title 'Inhibitors In Mild Haemophilia A: Experience Of A Single Spanish Center' was chosen as the source because it contains a specific disease ('Haemophilia A'), which is preferred over the broader category in the session title ('Bleeding Disorders').
2. **Component Identification**: The selected title contains three key clinical components: the disease 'Haemophilia A', the severity 'Mild', and the patient subgroup descriptor 'Inhibitors'. The phrase 'Experience Of A Single Spanish Center' was identified as non-clinical context (study methodology and geography) and marked for exclusion per generic rules.
3. **Rule Retrieval**: I retrieved rules for 'Patient Sub-Group' with subcategories 'Severity' and 'Disease Characterisation' to guide the handling of 'Mild' and 'Inhibitors'. Although no specific rule for 'Mild' was found, the general principle of prepending severity descriptors to the disease name was applied.
4. **Component Normalization & Application of Rules**:
   - **Disease**: 'Haemophilia A' is a standard medical term and was kept as is, formatted in Title Case.
   - **Severity**: 'Mild' was identified as a direct modifier of the disease and prepended to it, resulting in 'Mild Haemophilia A'.
   - **Patient Subgroup**: 'Inhibitors' in the context of haemophilia is a critical clinical specifier defining a patient subgroup. The phrase 'Inhibitors In' was standardized to the more common clinical phrasing 'With Inhibitors' to create a clear and standard indication.
   - **Exclusions**: The geographic descriptor 'Spanish' and the methodological phrase 'Experience Of A Single Center' were excluded based on generic rules.
5. **Final Construction**: The normalized components were combined in the standard order of [Severity] [Disease] [Subgroup] to form the final indication: 'Mild Haemophilia A With Inhibitors'. This indication is clinically precise, follows all formatting rules, and is derived solely from the selected source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Severity', 'Disease Characterisation'], 'reason': ""To check for rules on handling severity keywords like 'Mild' and other disease characteristics like the presence of inhibitors.""}]","[{'component': 'Mild', 'type': 'Severity', 'normalized_form': 'Mild', 'rule_applied': 'General principle for severity descriptors: prepend to the disease name.'}, {'component': 'Haemophilia A', 'type': 'Disease', 'normalized_form': 'Haemophilia A', 'rule_applied': 'Generic Rule: Title Case formatting.'}, {'component': 'Inhibitors', 'type': 'Patient Subgroup', 'normalized_form': 'With Inhibitors', 'rule_applied': ""Standardization of clinical phrasing for patient subgroups. 'Inhibitors in' was converted to the standard 'With Inhibitors'.""}, {'component': 'Spanish Center', 'type': 'Geographic/Study Info', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude geographic and sociodemographic descriptors.'}]",2
230598,Gastrointestinal Cancer-Colorectal and Anal,Clinical and prognostic features of BRAF V600E-mutant resectable colorectal cancer: A single-center retrospective analysis of Chinese patients.,BRAF V600E-mutant;;resectable;;colorectal cancer,BRAF V600E-mutated Resectable Colorectal Cancer,Resectable BRAF V600E-Mutated Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the primary source because it contains a specific disease term ('colorectal cancer'), following the single-source extraction principle.
2. **Component Identification**: The key components identified in the abstract title were 'BRAF V600E-mutant', 'resectable', and 'colorectal cancer'. The sociodemographic descriptor 'Chinese patients' was also identified for exclusion.
3. **Rule Retrieval**: To ensure correct formatting, rules were retrieved for gene mutations ('Gene type') and resectability status ('Treatment Set-up').
4. **Rule Application**:
   - **Generic Exclusion Rule**: The term 'Chinese patients' was excluded as it is an ethnicity-based descriptor.
   - **Gene Type Rule (ID: 31)**: The phrase 'BRAF V600E-mutant' was normalized to 'BRAF V600E-Mutated' by replacing 'mutant' with '-Mutated'.
   - **Treatment Set-up Rule (ID: 236)**: The term 'resectable' was identified as a patient subgroup qualifier and capitalized to 'Resectable'.
   - **Generic Formatting Rules**: The disease 'colorectal cancer' was converted to singular Title Case 'Colorectal Cancer'.
5. **Indication Construction**: The normalized components were assembled in the standard clinical order: [Operative Status] [Gene Status] [Disease]. This resulted in 'Resectable BRAF V600E-Mutated Colorectal Cancer'.
6. **Quality Check**: The final indication was verified against all formatting, casing, and exclusion rules. It adheres to the single-source principle and accurately represents the clinical information in the title.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'BRAF V600E-mutant' component.""}, {'category': 'Treatment Set-up', 'subcategories': ['Resectable'], 'reason': ""To handle the 'resectable' patient subgroup descriptor.""}]","[{'component': 'BRAF V600E-mutant', 'type': 'Gene Mutation', 'normalized_form': 'BRAF V600E-Mutated', 'rule_applied': ""Gene type rule (ID: 31) for 'Gene Mutant' keyword.""}, {'component': 'resectable', 'type': 'Operative Status', 'normalized_form': 'Resectable', 'rule_applied': ""Treatment Set-up rule (ID: 236) for 'Resectable' keyword.""}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic rules for Title Case and singular form.'}, {'component': 'Chinese patients', 'type': 'Sociodemographic', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for ethnicity.'}]",2
378058,You have a new match! Pairing treatments and patients together for optimal treatment in chronic lymphocytic leukaemia (CLL),Tailoring treatment in CLL: Selecting the right treatment and duration for the right patient in relapse setting,CLL,Chronic Lymphocytic Leukemia,Relapsed Chronic Lymphocytic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains both a disease term (CLL) and a specific patient subgroup ('relapse setting'), making it more informative than the session title.
Step 2: The components identified were the disease 'CLL' and the patient status 'relapse setting'.
Step 3: Rules for handling relapse-related terms were retrieved using the `get_indication_rules` tool for the 'Occurrence' category. Rule 144 (Relapsed) indicates that terms like 'relapsed' should be standardized to 'Relapsed' and placed before the disease name.
Step 4: The abbreviation 'CLL' was expanded to 'Chronic Lymphocytic Leukemia' based on the session title's full name. The term 'relapse setting' was normalized to the standard qualifier 'Relapsed' as per the retrieved rules.
Step 5: The components were combined and formatted according to generic rules. 'Relapsed' was placed before the disease, and the entire indication was converted to Title Case, resulting in 'Relapsed Chronic Lymphocytic Leukemia'.","[{'category': 'Occurrence', 'subcategories': ['Relapse', 'Recurrence-Related Terms'], 'reason': ""To determine the correct formatting for the term 'relapse setting'.""}]","[{'component': 'CLL', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Expanded abbreviation based on session title context.'}, {'component': 'relapse setting', 'type': 'Occurrence', 'normalized_form': 'Relapsed', 'rule_applied': ""Rule 144: Standardized term to 'Relapsed' and positioned it as a prefix to the disease.""}]",2
279755,Jazz Pharmaceuticals: Should we expect long term survival in high-risk Acute Myeloid Leukaemia (AML)?,How should Measurable Residual Disease (MRD) assessment inform treatment decisions?,high-risk;;Acute Myeloid Leukaemia,High-Risk Acute Myeloid Leukemia,High-Risk Acute Myeloid Leukaemia,True,session_title,"Step 1: The abstract title 'How should Measurable Residual Disease (MRD) assessment inform treatment decisions?' lacks a specific disease, as MRD is a measure of disease burden, not the disease itself. The session title 'Jazz Pharmaceuticals: Should we expect long term survival in high-risk Acute Myeloid Leukaemia (AML)?' clearly contains the disease 'Acute Myeloid Leukaemia'. Therefore, the session title was chosen as the source based on the single-source principle.
Step 2: Components identified in the session title are the disease 'Acute Myeloid Leukaemia' and the risk qualifier 'high-risk'.
Step 3: The `get_indication_rules` tool was used for the 'Risk' category to ensure correct formatting of 'high-risk'.
Step 4: The retrieved rule (ID: 122) confirmed that 'high-risk' should be normalized to 'High-Risk' and prepended to the disease name.
Step 5: Applying generic rules, the disease name was kept in singular form and Title Case. The company name 'Jazz Pharmaceuticals' and the context 'long term survival' were excluded.
Step 6: The final indication was constructed by combining the normalized risk qualifier and the disease name, resulting in 'High-Risk Acute Myeloid Leukaemia'.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To verify the correct formatting and placement of the 'high-risk' qualifier.""}]","[{'component': 'high-risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID: 122 - Normalize 'high-risk' to 'High-Risk' and place it before the disease name.""}, {'component': 'Acute Myeloid Leukaemia', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukaemia', 'rule_applied': 'Generic Rule - Use Title Case and singular form.'}]",2
181452,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",Updated Results of a Phase II Study of Ponatinib and Blinatumomab for Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia,Philadelphia Chromosome;;Positive;;Acute Lymphoblastic Leukemia,Ph-Positive Acute Lymphoblastic Leukemia,Ph Chromosome-Positive Acute Lymphoblastic Leukemia,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease ('Acute Lymphoblastic Leukemia') and is more detailed than the session title, adhering to the single-source principle.
Step 2: The components identified in the abstract title are the disease 'Acute Lymphoblastic Leukemia' and the genetic marker 'Philadelphia Chromosome-Positive'.
Step 3: The `get_indication_rules` tool was used for the category 'Chromosome type' to find the correct formatting for 'Philadelphia Chromosome-Positive'.
Step 4: Rule ID 81 was applied, which standardizes 'Philadelphia Chromosome-Positive' to 'Ph Chromosome-Positive'. Generic rules for singularization and title case were also applied. The term 'Patients with' was excluded as it is a general descriptor.
Step 5: The standardized genetic marker was combined with the disease name to form the final indication.
Step 6: A quality check confirmed that all rules were followed, including single-source selection, correct formatting, and exclusion of non-indication elements.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To correctly format the 'Philadelphia Chromosome-Positive' genetic marker.""}]","[{'component': 'Philadelphia Chromosome-Positive', 'type': 'Genetic Marker', 'normalized_form': 'Ph Chromosome-Positive', 'rule_applied': ""Rule ID 81: Convert 'Philadelphia Chromosome-Positive' to the standardized abbreviation 'Ph Chromosome-Positive'.""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Use singular form and Title Case.'}]",2
181453,"Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II",A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia,Measurable Residual Disease-Positive;;B-Cell Acute Lymphoblastic Leukemia,MRD-Positive B-Cell Acute Lymphoblastic Leukemia,Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease, 'Acute Lymphoblastic Leukemia', which is more detailed than the session title. The single-source principle dictates using the abstract title.
2. **Component Identification**: The abstract title contains the core disease 'Acute Lymphoblastic Leukemia' and two key patient subgroup qualifiers: 'Measurable Residual Disease-Positive' and 'B-Cell'.
3. **Rule Retrieval**: Rules for 'Patient Sub-Group' were retrieved, specifically for 'B-Cell Precursor' and 'Disease Characterisation', to validate the inclusion of these qualifiers.
4. **Rule Application**: 
   - The rule for 'B-Cell Precursor' (ID 420) confirms that 'B-Cell' should be retained as it forms a recognized disease subtype when combined with the core disease.
   - 'Measurable Residual Disease-Positive' is a critical clinical descriptor defining a specific patient population for treatment and is not listed under any exclusion rules. Therefore, it must be included.
   - Generic rules were applied: The final indication was converted to Title Case, and non-clinical text like 'A Phase II Study of...' was excluded.
5. **Indication Construction**: The components were combined in the correct clinical order: the disease status qualifier, followed by the cell type, and then the core disease name.
6. **Final Quality Check**: The resulting indication is clinically precise, adheres to all formatting rules, and is derived from a single source.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease status qualifiers like 'Measurable Residual Disease-Positive'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['B-Cell Precursor'], 'reason': ""To verify the correct handling of the 'B-Cell' qualifier for Acute Lymphoblastic Leukemia.""}]","[{'component': 'Measurable Residual Disease-Positive', 'type': 'Patient Sub-Group (Disease Status)', 'normalized_form': 'Measurable Residual Disease-Positive', 'rule_applied': 'General inclusion principle for clinically significant patient subgroups not explicitly excluded.'}, {'component': 'B-Cell', 'type': 'Patient Sub-Group (Cell Type)', 'normalized_form': 'B-Cell', 'rule_applied': ""Rule ID 420: Retain 'B-Cell Precursor' (and by extension, 'B-Cell') when it is part of a formal disease name.""}, {'component': 'Acute Lymphoblastic Leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule: Use singular form and Title Case.'}]",2
263373,Myeloproliferative neoplasms - Clinical,"Primary Myelofibrosis In Young Patients <=50 Years: Clinicopathological Characteristics, Genetic Landscape And Disease Outcome. A Single Center Experience",Primary Myelofibrosis;;Young,Adult Primary Myelofibrosis,Primary Myelofibrosis,True,abstract_title,"Step 1: The abstract title 'Primary Myelofibrosis In Young Patients <=50 Years...' was selected as the source because it contains a specific disease term, 'Primary Myelofibrosis', making it more suitable than the broader session title 'Myeloproliferative neoplasms - Clinical'.
Step 2: The components identified in the abstract title are the disease 'Primary Myelofibrosis' and the patient subgroup 'Young Patients <=50 Years'.
Step 3: The `get_indication_rules` tool was used for the category 'Age Group' and subcategory 'Young' to determine how to handle the patient descriptor.
Step 4: The retrieved rules (e.g., ID 308) state that non-quantified age descriptors like 'Young' should be excluded from the final indication to maintain standardization. The generic rule for 'Primary' confirms its inclusion as it is part of the disease name.
Step 5: The indication was constructed by taking the core disease 'Primary Myelofibrosis' and excluding the age-related patient subgroup as per the rules.
Step 6: A quality check confirmed that the single-source principle was followed, formatting is correct (Title Case, singular), and excluded elements were properly removed, resulting in a clinically accurate indication.","[{'category': 'Age Group', 'subcategories': ['Young'], 'reason': ""To determine the correct handling of the term 'Young Patients' found in the abstract title.""}]","[{'component': 'Primary Myelofibrosis', 'type': 'Disease', 'normalized_form': 'Primary Myelofibrosis', 'rule_applied': ""Generic rule for 'Primary' - include when part of the disease name.""}, {'component': 'Young Patients <=50 Years', 'type': 'Age Group', 'normalized_form': '', 'rule_applied': ""Age Group rule (ID: 308) - Exclude non-standard age descriptors like 'Young'.""}]",2
279766,Takeda: Long term proteasome inhibition for multiple myeloma in the era of COVID,Current challenges for patient management, COVID;;multiple myeloma, COVID;;Multiple Myeloma,Multiple Myeloma,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title ('Current challenges for patient management') contains no disease term. The session title ('Takeda: Long term proteasome inhibition for multiple myeloma in the era of COVID') contains the disease term 'multiple myeloma'.
2. **Select Source**: Based on the Single-Source Extraction Principle, the session title is selected as it is the only one containing a disease.
3. **Identify Components**: The core disease component identified is 'multiple myeloma'. Other phrases like 'Long term proteasome inhibition' (a treatment modality) and 'in the era of COVID' (a temporal context) are identified for exclusion.
4. **Retrieve Rules**: No specific category rules were needed for this straightforward extraction, but I performed a proactive check on 'Disease State/Severity' to ensure no qualifiers were missed. The primary rules applied are the generic ones.
5. **Apply Rules & Construct Indication**: 
   - The disease term 'multiple myeloma' is extracted.
   - The generic Title Case rule is applied, converting it to 'Multiple Myeloma'.
   - The generic Singular Form rule is applied, but 'myeloma' is already singular.
   - The generic Exclusion Rule is applied to remove the company name ('Takeda'), the treatment description ('Long term proteasome inhibition'), and the temporal context ('in the era of COVID').
6. **Quality Check**: The final indication 'Multiple Myeloma' is clinically accurate, correctly formatted, and adheres to all rules.","[{'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': 'Proactively checked for any disease state keywords in the title, although none were present.'}]","[{'component': 'multiple myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Singular Form'}, {'component': 'Long term proteasome inhibition', 'type': 'Treatment Modality', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of procedural/temporal qualifiers'}, {'component': 'in the era of COVID', 'type': 'Temporal Context', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of non-diagnostic items'}]",2
214230,MP50: Kidney Cancer: Localized: Surgical Therapy III,Implications of Positive Surgical Margins following Robotic Partial Nephrectomy,Kidney Cancer,Kidney Cancer,Localized Kidney Cancer,True,session_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The session title is 'MP50: Kidney Cancer: Localized: Surgical Therapy III' and the abstract title is 'Implications of Positive Surgical Margins following Robotic Partial Nephrectomy'.
2. **Select Source**: The session title contains the explicit disease term 'Kidney Cancer'. The abstract title describes a surgical procedure and its outcome but does not name the underlying disease. Based on the single-source principle, the session title is selected as it contains the disease term.
3. **Identify Components**: From the session title, the core disease is 'Kidney Cancer' and a disease qualifier is 'Localized'. 'MP50' and 'Surgical Therapy III' are metadata and procedural context, which should be excluded.
4. **Retrieve Rules**: I retrieved rules for the 'Stage' category to see if 'Localized' had a specific rule. No specific rule was found for 'Localized', so I proceeded with generic rules.
5. **Apply Rules**: The generic rules for formatting and exclusion are applied. 'Kidney Cancer' is already in singular form and Title Case. 'Localized' is a standard clinical descriptor for the stage of a cancer and is included. The procedural context 'Surgical Therapy' is excluded as per the generic exclusion rules.
6. **Construct Indication**: The qualifier 'Localized' is combined with the disease 'Kidney Cancer' to form the final indication.
7. **Quality Check**: The final indication 'Localized Kidney Cancer' is clinically accurate, follows all formatting rules, and adheres to the single-source principle.","[{'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for specific rules governing the term 'Localized' as a disease stage descriptor.""}]","[{'component': 'Kidney Cancer', 'type': 'Disease', 'normalized_form': 'Kidney Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Localized', 'type': 'Stage Qualifier', 'normalized_form': 'Localized', 'rule_applied': 'Generic Rule: Disease Characterization'}, {'component': 'Surgical Therapy III', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Rule: Exclusion of procedural terms'}]",2
230619,Gastrointestinal Cancer-Colorectal and Anal,Modifiable and non-modifiable risk factors associated with early-onset colorectal cancer: Analysis of the National Health Interview Survey.,early-onset;;colorectal cancer,Early-Onset Colorectal Cancer,Early Onset Colorectal Cancer,True,abstract_title,"Step 1: The abstract title 'Modifiable and non-modifiable risk factors associated with early-onset colorectal cancer: Analysis of the National Health Interview Survey.' was chosen as the source because it contains a specific disease, which is preferred over the session title.
Step 2: The components identified in the title were 'early-onset' (an onset qualifier) and 'colorectal cancer' (the disease). The phrases 'Modifiable and non-modifiable risk factors' and 'Analysis of the National Health Interview Survey' were identified as study methodology and excluded.
Step 3: The `get_indication_rules` tool was used for the category 'Onset' and subcategory 'Onset by Time' to handle the 'early-onset' term.
Step 4: The retrieved rules (e.g., Rule ID 265) specify normalizing 'early-onset' to 'Early Onset' and prepending it to the disease name. Generic rules for Title Case and singular form were also applied.
Step 5: The components were combined according to the rules, resulting in 'Early Onset' + 'Colorectal Cancer'.
Step 6: A final quality check confirmed adherence to all formatting and extraction principles, leading to the final indication 'Early Onset Colorectal Cancer'.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To correctly handle the 'early-onset' qualifier.""}]","[{'component': 'early-onset', 'type': 'Onset Qualifier', 'normalized_form': 'Early Onset', 'rule_applied': ""Onset by Time Rule ID 265: Standardize to capitalized, space-separated form 'Early Onset'.""}, {'component': 'colorectal cancer', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Casing Rule: Apply Title Case.'}]",2
296164,Colorectal cancer,Assessing nivolumab in class II expressing microsatellite stable (pMMR) colorectal cancer (CRC): Results of the ANICCA-Class II trial,microsatellite stable;;pMMR;;Colorectal cancer,Microsatellite Stable pMMR Colorectal cancer,Class II Expressing Microsatellite Stable Colorectal Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains the disease ('colorectal cancer') and specific patient subgroup information ('class II expressing', 'microsatellite stable (pMMR)'), making it more detailed than the session title.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'colorectal cancer (CRC)', and two patient subgroup descriptors: 'class II expressing' and 'microsatellite stable (pMMR)'.
3.  **Rule Retrieval**: I initiated a search for rules related to biomarkers to correctly format 'microsatellite stable (pMMR)'. Although the retrieved rules for 'Biomarker' were not directly applicable to 'microsatellite stable', I proceeded using general knowledge and standard formatting rules.
4.  **Rule Application & Normalization**:
    *   **Disease**: 'colorectal cancer (CRC)' was normalized to 'Colorectal Cancer' using Title Case and singular form rules.
    *   **Biomarker 1**: 'microsatellite stable (pMMR)' was normalized to 'Microsatellite Stable'. 'pMMR' (proficient Mismatch Repair) is a synonym for Microsatellite Stable, so the full, more common term was used.
    *   **Biomarker 2**: 'class II expressing' was normalized to 'Class II Expressing' using Title Case.
5.  **Indication Construction**: The normalized components were combined in the order they appeared in the title to form a single, specific indication. The qualifiers describe a single patient cohort and are therefore prepended to the disease name.
6.  **Quality Check**: The final indication adheres to all formatting rules (Title Case, singular form), follows the single-source principle, and accurately represents the specific patient population described in the abstract title.","[{'category': 'Biomarker', 'subcategories': ['Biomarker'], 'reason': ""To check for specific formatting rules for biomarkers like 'microsatellite stable (pMMR)'.""}]","[{'component': 'colorectal cancer (CRC)', 'type': 'Disease', 'normalized_form': 'Colorectal Cancer', 'rule_applied': 'Generic Rule: Title Case, Singular Form, and removal of abbreviation.'}, {'component': 'class II expressing', 'type': 'Biomarker', 'normalized_form': 'Class II Expressing', 'rule_applied': 'Generic Rule: Title Case.'}, {'component': 'microsatellite stable (pMMR)', 'type': 'Biomarker', 'normalized_form': 'Microsatellite Stable', 'rule_applied': 'Normalization based on clinical terminology, where pMMR is equivalent to Microsatellite Stable. Generic Title Case rule applied.'}]",2
197861,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",Prenatal Cannabis Exposure and Outcomes during Middle Childhood,Prenatal;;Cannabis Exposure,Prenatal Cannabis Exposure,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title, 'Prenatal Cannabis Exposure and Outcomes during Middle Childhood', describes an exposure and a patient age group, but not a disease. According to the generic exclusion rules, exposures are not considered valid indications. The session title, 'Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes', similarly lists an exposure and broad categories of outcomes, not a specific disorder. Therefore, no indication can be extracted.",[],"[{'component': 'Prenatal Cannabis Exposure', 'type': 'Exposure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude exposures.'}, {'component': 'Neurocognitive and Mental Health Outcomes', 'type': 'Outcome Category', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items. This is a broad category of outcomes, not a specific disease.'}]",1
197863,"Cannabis, Developmental periods, Neurocognitive and Mental Health Outcomes",Differential Effects of Adolescent versus Early Adult Cannabis Initiation on Longitudinal Brain Development: Evidence for Adolescence as a Period of Vulnerability,,,,True,none,"Neither the abstract title nor the session title contains a specific, clinically valid medical indication. The abstract title focuses on 'longitudinal brain development,' which is a physiological process, not a disease. The session title lists broad topics including 'Neurocognitive and Mental Health Outcomes,' which is a high-level category of outcomes rather than a specific, diagnosable disorder. According to the exclusion rules, physiologic processes and non-diagnostic items are not to be extracted as indications. Therefore, no valid indication can be generated from the provided text.",[],"[{'component': 'longitudinal brain development', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Exclusion of Non-Diagnostic Items'}, {'component': 'Neurocognitive and Mental Health Outcomes', 'type': 'Outcome Category', 'normalized_form': '', 'rule_applied': 'Exclusion of Non-Diagnostic Items'}]",1
148704,Chronic Lymphocytic Leukemia And Related Disorders - Clinical,Subcutaneous Immunoglobulins Use In Immunodeficiency Secondary To Chronic Lymphocytic Leukaemia: Monocentric Experience In Covid-19 Era,Chronic Lymphocytic Leukaemia,Chronic Lymphocytic Leukaemia,Immunodeficiency;;Chronic Lymphocytic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains specific disease terms ('Immunodeficiency', 'Chronic Lymphocytic Leukaemia'), making it the preferred source over the session title.
2. **Component Identification**: The abstract title identifies two distinct medical conditions: 'Immunodeficiency' and 'Chronic Lymphocytic Leukaemia'. The phrase 'Secondary To' connects them.
3. **Rule Application**: 
   - According to the generic exclusion rules, phrases like 'secondary to' must be excluded. This means the relationship between the two diseases is not part of the final indication.
   - The 'Multiple Diseases' rule is applied, which requires extracting all distinct diseases and separating them with ';;'.
   - The term 'Leukaemia' was normalized to the standard American spelling 'Leukemia'.
   - Title Case and singular form rules were applied to both conditions.
4. **Indication Construction**: The two extracted and normalized diseases, 'Immunodeficiency' and 'Chronic Lymphocytic Leukemia', are formatted as two separate indications joined by the ';;' delimiter.
5. **Final Output**: The resulting indication is 'Immunodeficiency;;Chronic Lymphocytic Leukemia', accurately reflecting the two distinct clinical entities mentioned in the source title while adhering to all formatting and exclusion rules.","[{'category': 'Patient with two different Disease', 'subcategories': [], 'reason': ""To check for rules on how to handle indications where one disease is secondary to another. No specific rules were found, so the generic rule for excluding 'secondary to' was applied.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To check for rules on handling connectors between disease states, although 'Secondary To' was ultimately handled by a generic exclusion rule.""}]","[{'component': 'Immunodeficiency', 'type': 'Disease', 'normalized_form': 'Immunodeficiency', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}, {'component': 'Chronic Lymphocytic Leukaemia', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Generic Rule: Title Case, Singular Form, Spelling Normalization'}, {'component': 'Secondary To', 'type': 'Connector', 'normalized_form': '', 'rule_applied': ""Generic Exclusion Rule: Exclude 'secondary to' phrases""}]",2
197874,Cell-Type Specific Molecular Biology of Addiction,Neuron Subtype Specific Molecular Mechanisms in Fentanyl Abstinence,,,Addiction,True,session_title,"The abstract title, 'Neuron Subtype Specific Molecular Mechanisms in Fentanyl Abstinence', describes a biological mechanism and a state (abstinence) rather than a core disease. The session title, 'Cell-Type Specific Molecular Biology of Addiction', contains the clinically valid medical indication 'Addiction'. Following the single-source principle, the session title was chosen. The descriptive terms 'Cell-Type Specific Molecular Biology' were excluded as they relate to research methodology, not the disease itself. The final indication was formatted to Title Case.",[],"[{'component': 'Addiction', 'type': 'Disease', 'normalized_form': 'Addiction', 'rule_applied': 'Generic exclusion of non-diagnostic items; Title Case formatting.'}, {'component': 'Fentanyl Abstinence', 'type': 'State/Process', 'normalized_form': '', 'rule_applied': 'Excluded as it is a state/process, not a primary disease.'}]",1
148732,"Enzymopathies, Membranopathies And Other Anemias",Diagnostic Importance Of Bone Marrow Aspiration In Children With Anemia Of Unknown Etiology,Children;;Anemia ,Childhood Anemia,Pediatric Anemia Of Unknown Etiology,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Diagnostic Importance Of Bone Marrow Aspiration In Children With Anemia Of Unknown Etiology') contains a specific disease ('Anemia Of Unknown Etiology') and is therefore selected over the session title, following the single-source principle.
2.  **Component Identification**: The abstract title contains the disease 'Anemia Of Unknown Etiology' and the patient subgroup 'Children'. The phrase 'Bone Marrow Aspiration' is identified as a diagnostic procedure and is marked for exclusion.
3.  **Rule Retrieval**: To correctly handle the age group 'Children', I retrieved rules for the 'Age Group' category, specifically for 'Pediatric', as 'Children' is a synonym. The retrieved rules (e.g., ID 295, 296) confirm that age-group qualifiers like 'Pediatric' should be prepended to the indication.
4.  **Rule Application and Normalization**:
    *   The patient subgroup 'Children' is normalized to the standard medical term 'Pediatric'.
    *   The procedural term 'Bone Marrow Aspiration' is excluded as per the generic exclusion rules.
    *   The disease term 'Anemia Of Unknown Etiology' is retained.
    *   Generic formatting rules are applied: Title Case is used, and the disease is already in singular form.
5.  **Indication Construction**: The normalized age-group qualifier 'Pediatric' is placed at the beginning of the indication, resulting in 'Pediatric Anemia Of Unknown Etiology'.
6.  **Quality Check**: The final indication is derived from a single source, correctly formatted, includes the relevant patient subgroup, and excludes non-diagnostic information.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To determine the correct formatting for the age group 'Children', which normalizes to 'Pediatric'.""}]","[{'component': 'Children', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': ""Age Group rule (ID: 295, 296) - Normalize 'Children' to 'Pediatric' and place it as a prefix.""}, {'component': 'Anemia Of Unknown Etiology', 'type': 'Disease', 'normalized_form': 'Anemia Of Unknown Etiology', 'rule_applied': 'Generic Rule - Retain disease name and apply Title Case.'}, {'component': 'Bone Marrow Aspiration', 'type': 'Procedure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude procedural/diagnostic terms.'}]",2
181511,"Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster II",Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML,AML,Acute Myeloid Leukemia,ALK Fusion-Positive Monosomy 7 Acute Myeloid Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Functional Consequence and Therapeutic Targeting of Cryptic ALK Fusions (ALKfus) in Monosomy7 AML' was chosen as it contains a specific disease (AML) and patient subgroups, making it more informative than the session title.
2.  **Component Identification**: I identified three key components in the abstract title:
    *   Disease: 'AML'
    *   Gene Alteration: 'ALK Fusions (ALKfus)'
    *   Chromosomal Abnormality: 'Monosomy7'
3.  **Rule Retrieval**: I performed a search for specific rules related to 'Gene Fusions' and 'Monosomy' but found no specific rules. Therefore, I proceeded using the generic rules.
4.  **Rule Application and Normalization**:
    *   **Disease Name**: Expanded the abbreviation 'AML' to its full form, 'Acute Myeloid Leukemia', per standard practice.
    *   **Gene Alteration**: Converted 'ALK Fusions' to the singular 'ALK Fusion' and then to the standard adjectival form 'ALK Fusion-Positive' to accurately describe the patient subgroup being targeted.
    *   **Chromosomal Abnormality**: Normalized 'Monosomy7' to 'Monosomy 7' by adding a space for clarity and standardization.
    *   **Casing**: Applied Title Case to the entire indication.
5.  **Indication Construction**: The normalized components were combined in the order of [Gene Alteration] [Chromosomal Abnormality] [Disease Name] to form the final, clinically precise indication: 'ALK Fusion-Positive Monosomy 7 Acute Myeloid Leukemia'.
6.  **Final Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements, including the single-source principle, singularization, and proper casing.","[{'category': 'Gene type', 'subcategories': ['Gene Fusions'], 'reason': ""To check for specific formatting rules for gene fusions like 'ALK Fusions'.""}, {'category': 'Chromosome type', 'subcategories': ['Monosomy'], 'reason': ""To check for specific formatting rules for chromosomal abnormalities like 'Monosomy7'.""}]","[{'component': 'ALK Fusions', 'type': 'Gene Fusion', 'normalized_form': 'ALK Fusion-Positive', 'rule_applied': ""Generic rule: Convert to singular and use standard '-Positive' suffix for patient subgroup characterization.""}, {'component': 'Monosomy7', 'type': 'Chromosomal Abnormality', 'normalized_form': 'Monosomy 7', 'rule_applied': 'Generic rule: Standardize formatting for readability.'}, {'component': 'AML', 'type': 'Disease', 'normalized_form': 'Acute Myeloid Leukemia', 'rule_applied': 'Generic rule: Expand common medical abbreviations.'}]",2
165128,Adult Vaccines,Modeled Impact of the COVID-19 Pandemic and Associated Reduced Adult Vaccinations on Herpes Zoster in the United States,Herpes Zoster,Herpes Zoster Infection,Adult Herpes Zoster,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains a specific disease term, 'Herpes Zoster', while the session title 'Adult Vaccines' is a therapeutic area, not a specific indication.
Step 2: The disease 'Herpes Zoster' was identified. The term 'Adult' was identified as a patient subgroup qualifier.
Step 3: Rules for the 'Age Group' category, specifically for 'Adult', were retrieved to ensure correct formatting. The rules confirm that 'Adult' should be used as a capitalized prefix.
Step 4: Generic rules were applied. The disease term was converted to Title Case ('Herpes Zoster'). The geographic location 'United States' and contextual information like 'COVID-19 Pandemic' and 'Reduced Adult Vaccinations' were excluded as per the exclusion rules.
Step 5: The final indication was constructed by combining the patient subgroup with the disease, resulting in 'Adult Herpes Zoster'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To confirm the correct formatting for the 'Adult' patient subgroup.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' (ID: 289)""}, {'component': 'Herpes Zoster', 'type': 'Disease', 'normalized_form': 'Herpes Zoster', 'rule_applied': 'Generic rule for Title Case and Singular Form'}]",2
296202,Basic Science,Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA),extensive;;small-cell lung cancer,Extensive Stage Small-Cell Lung Cancer,Extensive Small-Cell Lung Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The `abstract_title` ('Gene expression profile (GEP) of extensive small-cell lung cancer (eSCLC) patients (pts) receiving first-line platinum-etoposide plus atezolizumab (PEA)') was chosen as it contains a specific disease ('small-cell lung cancer'), whereas the `session_title` ('Basic Science') is too generic.
2.  **Component Identification**: The key components identified in the abstract title are the disease 'small-cell lung cancer', the disease state 'extensive', and the treatment line 'first-line'.
3.  **Rule Retrieval**: Rules for 'Occurrence' (Disease State/Severity) and 'Treatment Set-up' (Line of treatment) were retrieved to handle 'extensive' and 'first-line' respectively.
4.  **Rule Application**:
    *   **Disease State**: 'extensive' is a standard clinical descriptor for the stage of small-cell lung cancer. It is retained and capitalized.
    *   **Treatment Line**: The term 'first-line' is followed by specific drug names ('platinum-etoposide plus atezolizumab'). According to the retrieved rule (ID: 199 for Treatment Set-up), line-of-treatment descriptors should be excluded when they describe the study treatment rather than defining the patient population. Therefore, 'first-line' was excluded.
    *   **Generic Rules**: The disease term was converted to Title Case and singular form (already singular). The standard hyphenation for 'Small-Cell' was applied. Non-diagnostic information such as 'Gene expression profile (GEP)', 'patients (pts)', and specific drug names were excluded.
5.  **Indication Construction**: The retained components 'Extensive' and 'Small-Cell Lung Cancer' were combined to form the final indication, resulting in 'Extensive Small-Cell Lung Cancer'.","[{'category': 'Occurrence', 'subcategories': ['Disease State/Severity'], 'reason': ""To determine how to handle the disease qualifier 'extensive'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine whether to include or exclude the 'first-line' descriptor.""}]","[{'component': 'extensive small-cell lung cancer', 'type': 'Disease', 'normalized_form': 'Extensive Small-Cell Lung Cancer', 'rule_applied': ""Generic Title Case and singular form rules. 'Extensive' is retained as a standard disease stage qualifier.""}, {'component': 'first-line', 'type': 'Line of treatment', 'normalized_form': '', 'rule_applied': 'Treatment Set-up Rule ID: 199 - Exclude line-of-treatment when followed by a specific drug/regimen name.'}, {'component': 'patients (pts)', 'type': 'Patient Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude non-diagnostic items.'}, {'component': 'platinum-etoposide plus atezolizumab (PEA)', 'type': 'Treatment', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule - Exclude specific treatment names.'}]",2
148747,Hodgkin Lymphoma - Clinical,Prognostic Factors Of Worse Survival In Newly Diagnosed Advanced-Stage Hodgkin Lymphoma In Taiwan: A Nationwide Retrospective Study,Newly Diagnosed;;Advanced-Stage;;Hodgkin Lymphoma,Newly Diagnosed Advanced-Stage Hodgkin Lymphoma,Newly Diagnosed Advanced Stage Hodgkin Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title ('Prognostic Factors Of Worse Survival In Newly Diagnosed Advanced-Stage Hodgkin Lymphoma In Taiwan: A Nationwide Retrospective Study') was chosen over the session title ('Hodgkin Lymphoma - Clinical') because it is more specific and contains a clear disease entity with patient subgroups, adhering to the single-source principle.
2. **Component Identification**: The key clinical components identified in the abstract title were 'Newly Diagnosed', 'Advanced-Stage', and 'Hodgkin Lymphoma'. The geographic location 'In Taiwan' and the study type 'A Nationwide Retrospective Study' were identified for exclusion.
3. **Rule Retrieval**: To ensure correct formatting, rules for 'Diagnosis Status' (for 'Newly Diagnosed') and 'Stage Type' (for 'Advanced-Stage') were retrieved using the `get_indication_rules` tool.
4. **Rule Application**: 
   - The rule for 'Newly Diagnosed' (ID: 193) confirms it should be used as a prefix to the disease name.
   - The general principle for staging terms like 'Advanced-Stage' is to place them before the disease name and normalize formatting. 'Advanced-Stage' was converted to 'Advanced Stage'.
   - The generic exclusion rule was applied to remove the geographic descriptor 'In Taiwan'.
   - The generic singular form and Title Case rules were applied to the entire indication.
5. **Indication Construction**: The identified components were assembled in a clinically logical order: Diagnosis Status -> Stage -> Disease. This resulted in 'Newly Diagnosed' + 'Advanced Stage' + 'Hodgkin Lymphoma'.
6. **Final Quality Check**: The final indication was reviewed to ensure it met all formatting and clinical accuracy requirements. It is a single, concise indication derived from the selected source, with all rules correctly applied.","[{'category': 'Treatment based', 'subcategories': ['Diagnosis Status'], 'reason': ""To validate the handling of the term 'Newly Diagnosed'.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To determine the correct formatting and placement of 'Advanced-Stage'.""}]","[{'component': 'Newly Diagnosed', 'type': 'Diagnosis Status', 'normalized_form': 'Newly Diagnosed', 'rule_applied': ""Rule ID: 193 - Prefix 'Newly Diagnosed' to the disease phrase.""}, {'component': 'Advanced-Stage', 'type': 'Stage', 'normalized_form': 'Advanced Stage', 'rule_applied': 'Generic stage rule - Normalize hyphenation and place before the disease name.'}, {'component': 'Hodgkin Lymphoma', 'type': 'Disease', 'normalized_form': 'Hodgkin Lymphoma', 'rule_applied': 'Generic rule - Use singular form and Title Case.'}, {'component': 'In Taiwan', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic/geographic descriptors.'}]",2
312583,Detection/Diagnosis: Detection/Diagnosis - Other,Improving The Performance Of Early Breast Cancer Diagnosis By A Model Combining Breast Ultrasound With Methylation Markers In Non-Invasive Circulating Tumor Dna,Early;;Breast Cancer,Early Breast Cancer,Breast Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('Improving The Performance Of Early Breast Cancer Diagnosis...') contains the specific disease term 'Breast Cancer', while the session title is generic. Therefore, the abstract title was selected as the source based on the Single-Source Extraction Principle.
2.  **Component Identification**: The key components identified in the abstract title are 'Early' and 'Breast Cancer'. Other terms like 'Diagnosis', 'Ultrasound', and 'Methylation Markers' are related to methodology and are excluded.
3.  **Rule Retrieval**: To correctly handle the term 'Early', I retrieved rules for the 'Onset' category, specifically 'Onset by Time'.
4.  **Rule Application**: The retrieved rules (e.g., Rule 267, 268) specify that 'Early' should be excluded if it modifies a non-disease concept like 'detection' or 'diagnosis'. In the phrase 'Early Breast Cancer Diagnosis', 'Early' modifies 'Diagnosis'. Therefore, 'Early' is not part of the indication and must be excluded.
5.  **Indication Construction**: The remaining disease term is 'Breast Cancer'. Generic rules are applied: the term is already in singular form and Title Case.
6.  **Final Output**: The final, standardized indication is 'Breast Cancer'.","[{'category': 'Onset', 'subcategories': ['Onset by Time'], 'reason': ""To determine how to handle the keyword 'Early' and verify if it applies to the disease onset or the diagnosis timing.""}]","[{'component': 'Early', 'type': 'Temporal Qualifier', 'normalized_form': '', 'rule_applied': ""Onset by Time rule (e.g., ID 267, 268) - Exclude 'Early' when it modifies non-disease concepts like 'diagnosis'.""}, {'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic rule - Use singular form and Title Case.'}]",2
378125,Adult acute lymphoblastic leukemia (EWALL),The US experience in ALL,ALL,Acute Lymphoblastic Leukemia,Adult Acute Lymphoblastic Leukemia,True,session_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'The US experience in ALL' and the session title is 'Adult acute lymphoblastic leukemia (EWALL)'.
2.  **Select Source**: Both titles contain a disease term ('ALL' and 'acute lymphoblastic leukemia'). The session title is more specific as it includes the patient subgroup 'Adult'. Therefore, the session title is selected as the source based on the single-source principle, prioritizing the more descriptive title.
3.  **Identify Components**: From the session title, the components are 'Adult' (age group) and 'acute lymphoblastic leukemia' (disease). The acronym '(EWALL)' is identified as a probable study group name and marked for exclusion.
4.  **Retrieve Rules**: To ensure correct formatting for the age group, I retrieved rules for the 'Age Group' category, specifically for the 'Adult' subcategory. The rules confirm that 'Adult' should be used as a capitalized prefix.
5.  **Apply Generic Rules**: 
    - **Casing**: 'acute lymphoblastic leukemia' is converted to Title Case: 'Acute Lymphoblastic Leukemia'.
    - **Singular Form**: The disease is already in singular form.
    - **Exclusion**: The acronym '(EWALL)' is excluded as it is not part of the clinical indication.
6.  **Construct Indication**: The components are combined according to the rules: the age group 'Adult' is prefixed to the disease 'Acute Lymphoblastic Leukemia'.
7.  **Final Output**: The final generated indication is 'Adult Acute Lymphoblastic Leukemia'.","[{'category': 'Age Group', 'subcategories': ['Adult'], 'reason': ""To validate the correct formatting and placement of the 'Adult' patient subgroup descriptor.""}]","[{'component': 'Adult', 'type': 'Age Group', 'normalized_form': 'Adult', 'rule_applied': ""Age Group rule for 'Adult' requires it to be a capitalized prefix.""}, {'component': 'acute lymphoblastic leukemia', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': '(EWALL)', 'type': 'Other', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for non-diagnostic items like study group names.'}]",2
165143,Adult Vaccines,Immunologic Hyporesponsiveness with Subsequent Dosing of Meningococcal Vaccines: Re-Evaluating the Current Paradigm,,,Meningococcal Disease,True,abstract_title,"Step 1: The abstract title contains a specific disease context ('Meningococcal Vaccines'), while the session title ('Adult Vaccines') is a broad therapeutic area. Therefore, the abstract title is selected as the source.
Step 2: The term 'Meningococcal Vaccines' directly implies the indication is the prevention of the disease caused by meningococcus, which is 'Meningococcal Disease'.
Step 3: The term 'Immunologic Hyporesponsiveness' is identified as a physiologic process or a response to the vaccine, not the primary disease indication itself. According to the generic exclusion rules, physiologic processes are excluded.
Step 4: The phrase 'Subsequent Dosing' is a procedural/temporal qualifier and is excluded based on generic rules.
Step 5: The final indication is constructed by taking the core disease, applying Title Case, and ensuring it is in singular form, resulting in 'Meningococcal Disease'.",[],"[{'component': 'Meningococcal Vaccines', 'type': 'Disease', 'normalized_form': 'Meningococcal Disease', 'rule_applied': 'Generic rule: Extracted core disease from vaccine context.'}, {'component': 'Immunologic Hyporesponsiveness', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic items and physiologic processes.'}]",1
279835,Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe,RWD of CAR T-cell therapy in older adults: The UK experience,,,Older Adult Hematologic Malignancy,True,session_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title ('RWD of CAR T-cell therapy in older adults: The UK experience') does not contain a specific disease or a therapeutic area, only a patient subgroup ('older adults'). The session title ('Aging and Hematology: Real-world evidence of CAR T-cell therapy in older adults in Europe') contains the therapeutic area 'Hematology' and the same patient subgroup. According to the single-source principle, the session title is selected as it contains a disease-related term, whereas the abstract title does not.
2.  **Component Identification**: From the session title, two key components were identified: the patient subgroup 'older adults' and the therapeutic area 'Hematology'.
3.  **Rule Retrieval**: To standardize the patient subgroup, rules for age groups were retrieved using `get_indication_rules(category=""Age Group"", subcategories=[""Elderly""])`.
4.  **Rule Application**: 
    *   **Patient Subgroup**: Based on the retrieved rules (specifically Rule ID 331 for 'Older adult'), the term 'older adults' is normalized to the singular, title-case form 'Older Adult'.
    *   **Therapeutic Area**: The generic 'Therapeutic Area Fallback' rule is applied. 'Hematology' is a therapeutic area, and in the context of CAR T-cell therapy, it refers to cancers of the blood. It is mapped to the standard overarching disease term 'Hematologic Malignancy'.
    *   **Exclusion**: The geographic descriptor 'Europe' is excluded as per the generic exclusion rules.
5.  **Indication Construction**: The normalized patient subgroup is prepended to the standardized disease term, resulting in 'Older Adult Hematologic Malignancy'.
6.  **Formatting**: The final indication is formatted in Title Case and singular form as required.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To handle the normalization of the patient subgroup 'older adults'.""}]","[{'component': 'older adults', 'type': 'Age Group', 'normalized_form': 'Older Adult', 'rule_applied': ""Age Group rule for 'Older adult' (ID: 331) - Normalize to singular, title-case form.""}, {'component': 'Hematology', 'type': 'Therapeutic Area', 'normalized_form': 'Hematologic Malignancy', 'rule_applied': 'Generic rule: Therapeutic Area Fallback.'}]",2
378147,Diagnosis in hematological diseases: Morphology and flow cytometry: 2.0 diagnostics in hematology: The role of artificial intelligence,AI approach for advanced analysis of flow-cytometryc data,,,Hematological Disease,True,session_title,"Step 1: The abstract title 'AI approach for advanced analysis of flow-cytometryc data' does not contain a specific disease or condition. 
Step 2: The session title 'Diagnosis in hematological diseases: Morphology and flow cytometry: 2.0 diagnostics in hematology: The role of artificial intelligence' contains the term 'hematological diseases'.
Step 3: Following the single-source principle, the session title is selected as it is the only source containing a disease term.
Step 4: The term 'hematological diseases' is extracted. 
Step 5: Applying the generic rules, the plural 'diseases' is converted to the singular 'Disease', and Title Case is applied, resulting in 'Hematological Disease'. The surrounding text describes diagnostic methods and topics, not the core indication, and is therefore excluded.",[],"[{'component': 'hematological diseases', 'type': 'Disease', 'normalized_form': 'Hematological Disease', 'rule_applied': 'Generic rule: Singular Form; Generic rule: Casing'}]",1
410917,"AI, Digital Health, Data Science - I",Integrating Electronic Health Data Records to Develop and Validate a Predictive Model of Hospital-Acquired AKI in Non-Critically Ill Patients,AKI,Acute Kidney Injury,Hospital-Acquired Acute Kidney Injury,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The `session_title` ('AI, Digital Health, Data Science - I') contains no medical terms. The `abstract_title` ('Integrating Electronic Health Data Records to Develop and Validate a Predictive Model of Hospital-Acquired AKI in Non-Critically Ill Patients') contains the medical condition 'Hospital-Acquired AKI'.
2. **Select Source**: Based on the Single-Source Extraction Principle, the `abstract_title` is selected as it contains the disease term.
3. **Identify Components**: The key components identified in the abstract title are 'Hospital-Acquired AKI' (disease) and 'Non-Critically Ill Patients' (patient subgroup).
4. **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' under the 'Disease Characterisation' subcategory to understand how to handle qualifiers like 'Hospital-Acquired' and 'Non-Critically Ill'. While no specific rule matched these exact terms, the general principles of clinical validity were applied.
5. **Apply Rules & Construct Indication**:
   - **Disease Term**: 'AKI' is expanded to its full form 'Acute Kidney Injury'.
   - **Qualifier**: 'Hospital-Acquired' is a clinically significant qualifier that specifies the origin of the condition and is retained.
   - **Patient Subgroup**: 'Non-Critically Ill' is a general descriptor of the patient's overall state, not a specific characteristic of the disease itself. Similar to excluding terms like 'pre-hospital' or sociodemographic data, this is considered a study population descriptor rather than a core part of the indication and is therefore excluded.
   - **Formatting**: The final indication is converted to Title Case and singular form as per generic rules.
6. **Final Indication**: Combining the components results in 'Hospital-Acquired Acute Kidney Injury'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for rules regarding disease qualifiers like 'Hospital-Acquired' and patient state descriptors like 'Non-Critically Ill'.""}]","[{'component': 'Hospital-Acquired AKI', 'type': 'Disease', 'normalized_form': 'Hospital-Acquired Acute Kidney Injury', 'rule_applied': ""Generic rule: Expand acronyms. Retained 'Hospital-Acquired' as a clinically significant qualifier.""}, {'component': 'Non-Critically Ill Patients', 'type': 'Patient Subgroup', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Excluded as it describes the general patient state rather than a specific, defining characteristic of the disease indication.'}]",2
197935,Poster Session I (In-Person),No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers,,,,True,none,"Step 1: The session title 'Poster Session I (In-Person)' is generic and contains no medical information. The abstract title 'No Signs of Neurodegenerative Effects in 15q11.2 BP1-BP2 Copy Number Variant Carriers' was selected for analysis.
Step 2: The abstract title identifies a patient subgroup, '15q11.2 BP1-BP2 Copy Number Variant Carriers', which is a genetic characteristic, not a disease. The main finding is the *absence* of a condition ('No Signs of Neurodegenerative Effects').
Step 3: I retrieved rules for 'Chromosome type' to understand how to handle the copy number variant. The rules suggest that chromosomal alterations without a specific disease context are generally excluded.
Step 4: A medical indication must be a clinically valid disease or disorder. The title explicitly states the absence of neurodegenerative effects, and the carrier status itself is not a disease. Therefore, no valid medical indication can be extracted.","[{'category': 'Chromosome type', 'subcategories': ['Chromosome type'], 'reason': ""To determine how to handle the '15q11.2 BP1-BP2 Copy Number Variant'.""}]","[{'component': 'Neurodegenerative Effects', 'type': 'Potential Disease', 'normalized_form': None, 'rule_applied': ""The title states 'No Signs of', negating the presence of this condition, making it invalid as an indication.""}, {'component': '15q11.2 BP1-BP2 Copy Number Variant Carriers', 'type': 'Patient Subgroup', 'normalized_form': None, 'rule_applied': ""This describes a genetic carrier status, not a disease or disorder. Per 'Chromosome type' rules, such genetic markers without a specific disease are not considered a valid indication.""}]",2
230706,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary","Tislelizumab versus chemotherapy as second-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC, RATIONALE 302): Impact on health-related quality of life (HRQoL).",second-line;;advanced;;metastatic;;esophageal squamous cell carcinoma,Second-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma,Second-Line Advanced Metastatic Esophageal Squamous Cell Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('esophageal squamous cell carcinoma'), whereas the session title contains broader categories. This adheres to the Single-Source Extraction Principle.
2.  **Component Identification**: The key components identified in the abstract title were 'second-line' (treatment line), 'advanced or metastatic' (stage/occurrence), and 'esophageal squamous cell carcinoma' (disease).
3.  **Rule Retrieval**: I retrieved rules for 'Line of treatment', 'Stage Type', and 'Metastasis-Related Terms' to handle the identified components.
4.  **Rule Application**:
    *   **Treatment Line**: Based on Treatment Set-up Rule ID 199, 'second-line' was retained because it is followed by the word 'treatment'. Rule ID 202 was then applied to normalize it to 'Second-Line'.
    *   **Stage/Occurrence**: The terms 'advanced' and 'metastatic' were identified as disease state descriptors. Following the pattern of Occurrence Rule ID 177, which consolidates similar terms (e.g., 'locally advanced, or metastatic' into 'Locally Advanced Metastatic'), I combined 'advanced or metastatic' into the standardized phrase 'Advanced Metastatic'.
    *   **Disease Name**: The disease 'esophageal squamous cell carcinoma' was standardized to 'Esophageal Squamous Cell Carcinoma' by applying the generic Title Case and singular form rules.
5.  **Indication Construction**: The normalized components were assembled in the standard order: Line of Treatment + Stage/Occurrence + Disease Name.
6.  **Final Indication**: The final constructed indication is 'Second-Line Advanced Metastatic Esophageal Squamous Cell Carcinoma'.","[{'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To correctly handle the 'second-line' descriptor.""}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To handle the 'advanced' stage descriptor.""}, {'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To handle the 'metastatic' occurrence descriptor and its combination with 'advanced'.""}]","[{'component': 'second-line', 'type': 'Line of Treatment', 'normalized_form': 'Second-Line', 'rule_applied': 'Treatment Set-up Rule ID 202'}, {'component': 'advanced or metastatic', 'type': 'Stage/Occurrence', 'normalized_form': 'Advanced Metastatic', 'rule_applied': 'Occurrence Rule ID 177 (by pattern)'}, {'component': 'esophageal squamous cell carcinoma', 'type': 'Disease', 'normalized_form': 'Esophageal Squamous Cell Carcinoma', 'rule_applied': 'Generic Rule: Title Case, Singular Form'}]",2
329014,Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster III,Hypercalcemia in Individuals with Monoclonal Gammopathy of Undetermined Significance: Results from the Istopmm Study,Monoclonal Gammopathy,Monoclonal Gammopathy,Hypercalcemia;;Monoclonal Gammopathy of Undetermined Significance,True,abstract_title,"Step 1: The abstract title was chosen as the source because it contains specific disease terms ('Hypercalcemia', 'Monoclonal Gammopathy of Undetermined Significance'), following the single-source extraction principle.
Step 2: Two distinct clinical conditions were identified in the title: 'Hypercalcemia' and 'Monoclonal Gammopathy of Undetermined Significance'. The phrase 'in Individuals with' indicates these are concurrent conditions within the study population.
Step 3: The generic rule for handling multiple diseases was applied, which requires separating each distinct indication with a double semicolon ';;'.
Step 4: All components were formatted according to the generic rules: Title Case was maintained, and the terms were already in singular form. Non-diagnostic phrases like 'in Individuals with' and 'Results from the Istopmm Study' were excluded.
Step 5: The final indication was constructed by combining the two identified conditions, separated by ';;'.",[],"[{'component': 'Hypercalcemia', 'type': 'Disease', 'normalized_form': 'Hypercalcemia', 'rule_applied': 'Generic rule for disease identification and Title Case.'}, {'component': 'Monoclonal Gammopathy of Undetermined Significance', 'type': 'Disease', 'normalized_form': 'Monoclonal Gammopathy of Undetermined Significance', 'rule_applied': 'Generic rule for disease identification and Title Case.'}]",2
197955,Poster Session I (In-Person),Mutations in Kalrn Disrupt Gamma-Band Oscillations in the Auditory Cortex of Adult Mice,,,,True,none,"The abstract title describes a preclinical study in mice ('Adult Mice') and focuses on a physiological process ('Gamma-Band Oscillations') rather than a specific human disease. The session title is purely logistical and contains no medical information. According to the guidelines, indications must be clinically valid medical conditions in humans. Therefore, no indication can be extracted.",[],"[{'component': 'Adult Mice', 'type': 'Subject', 'normalized_form': 'Adult Mice', 'rule_applied': 'Exclusion of non-human subjects for clinical indications.'}, {'component': 'Gamma-Band Oscillations', 'type': 'Physiologic Process', 'normalized_form': 'Gamma-Band Oscillations', 'rule_applied': 'Exclusion of non-diagnostic items and physiologic processes.'}]",1
181581,"Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II","Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma",High-Risk;;Elderly;;Mantle Cell Lymphoma,High-Risk Elderly Mantle Cell Lymphoma,Elderly High-Risk Mantle Cell Lymphoma,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Mantle Cell Lymphoma'), adhering to the single-source principle. The session title was disregarded.
2. **Component Identification**: From the abstract title, the following components were identified: the disease 'Mantle Cell Lymphoma', the age group 'Elderly', and the risk stratification 'High-Risk'. The treatment information ('Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC)') and the term 'Patients' were identified for exclusion.
3. **Rule Retrieval**: To ensure correct formatting and standardization, rules were retrieved for the identified patient subgroups. Specifically, `get_indication_rules` was called for the 'Risk' category (subcategory 'High-Risk') and the 'Age Group' category (subcategory 'Elderly').
4. **Rule Application**: 
   - The generic rule for singular form was applied, though 'Mantle Cell Lymphoma' is already singular.
   - The generic rule for Title Case was applied to all components.
   - The retrieved 'Age Group' rules (e.g., ID 299) confirmed that 'Elderly' should be standardized and placed at the beginning of the indication.
   - The retrieved 'Risk' rules (e.g., ID 122) confirmed that 'High-Risk' should be standardized and prepended to the disease name.
5. **Indication Construction**: The components were assembled in the standard order: Age Group -> Risk -> Disease. This resulted in 'Elderly' + 'High-Risk' + 'Mantle Cell Lymphoma'.
6. **Final Quality Check**: The final indication 'Elderly High-Risk Mantle Cell Lymphoma' was checked for compliance with all formatting rules (Title Case, no trailing spaces, no excluded terms), resulting in the final output.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the formatting and placement of the 'High-Risk' qualifier.""}, {'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To validate the formatting and placement of the 'Elderly' patient subgroup.""}]","[{'component': 'Mantle Cell Lymphoma', 'type': 'Disease', 'normalized_form': 'Mantle Cell Lymphoma', 'rule_applied': 'Generic rule: Title Case, Singular Form'}, {'component': 'High-Risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule ID 122: Standardize and attach to the disease name.'}, {'component': 'Elderly', 'type': 'Age Group', 'normalized_form': 'Elderly', 'rule_applied': 'Age Group rule ID 299: Standardize and place at the beginning of the indication.'}]",2
148814,Myelodysplastic Syndromes - Clinical,A Phase 3 Study Of The Efficacy And Safety Of Luspatercept Versus Epoetin Alfa For The Treatment Of Anemia Due To Lower-Risk Mds In Esa-Naive Patients Requiring Rbc Transfusions (The Commands Trial),Lower-Risk;;Mds,Low-Risk Myelodysplastic Syndrome,ESA-Naive Anemia due to Lower-Risk Myelodysplastic Syndrome Requiring RBC Transfusions,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains specific disease and patient subgroup information ('Anemia Due To Lower-Risk Mds', 'Esa-Naive Patients Requiring Rbc Transfusions'), which is more detailed than the session title ('Myelodysplastic Syndromes - Clinical').

2.  **Component Identification**: I identified the following key components from the abstract title:
    *   Core Condition: 'Anemia'
    *   Underlying Disease: 'Lower-Risk Mds'
    *   Patient Treatment Status: 'Esa-Naive'
    *   Patient Subgroup: 'Requiring Rbc Transfusions'

3.  **Rule Retrieval**: I mentally reviewed the rules for handling risk, treatment status, and multiple conditions.
    *   **Risk**: The term 'Lower-Risk' needs to be standardized in Title Case with a hyphen.
    *   **Treatment Status**: 'Esa-Naive' is a critical descriptor of treatment history and should be placed at the beginning of the indication. 'ESA' is an acronym and should be capitalized.
    *   **Disease Normalization**: 'Mds' is a standard abbreviation for Myelodysplastic Syndromes. It should be expanded and converted to singular Title Case: 'Myelodysplastic Syndrome'.
    *   **Patient Subgroup**: 'Requiring Rbc Transfusions' is a key clinical characteristic defining the patient population and must be included.

4.  **Indication Construction**: I assembled the components based on clinical and grammatical conventions:
    *   The primary condition being treated is 'Anemia'. The cause is 'Lower-Risk Mds'. The title explicitly links them with 'Due To'.
    *   The patient population is defined by being 'Esa-Naive' and 'Requiring Rbc Transfusions'.
    *   I started with the treatment status 'ESA-Naive' as it's a primary qualifier.
    *   I then constructed the core indication 'Anemia due to Lower-Risk Myelodysplastic Syndrome'.
    *   Finally, I appended the patient characteristic 'Requiring RBC Transfusions' to complete the description.

5.  **Final Formatting**: I applied the generic formatting rules:
    *   **Title Case**: Capitalized all significant words (e.g., 'Anemia', 'Myelodysplastic Syndrome'). Short prepositions like 'due to' are in lower case.
    *   **Acronyms**: Kept 'ESA' and 'RBC' in their original all-caps form.
    *   **Singular Form**: Used 'Syndrome' instead of 'Syndromes'.
    *   **Spacing**: Ensured single spaces between all words.

The final indication accurately and concisely captures all the specific clinical details from the source title.","[{'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format the 'Lower-Risk' descriptor.""}, {'category': 'Treatment based', 'subcategories': ['Treatment Status'], 'reason': ""To handle the 'Esa-Naive' patient status correctly.""}, {'category': 'Patient with two different Disease', 'subcategories': ['General'], 'reason': ""To determine how to handle 'Anemia Due To... Mds'.""}]","[{'component': 'Anemia', 'type': 'Condition', 'normalized_form': 'Anemia', 'rule_applied': 'Generic Casing Rule'}, {'component': 'Lower-Risk Mds', 'type': 'Disease with Risk', 'normalized_form': 'Lower-Risk Myelodysplastic Syndrome', 'rule_applied': 'Risk Types rule, Singular Form rule, Abbreviation Expansion'}, {'component': 'Esa-Naive', 'type': 'Treatment Status', 'normalized_form': 'ESA-Naive', 'rule_applied': 'Treatment Status rule, Acronym Casing'}, {'component': 'Requiring Rbc Transfusions', 'type': 'Patient Subgroup', 'normalized_form': 'Requiring RBC Transfusions', 'rule_applied': 'Generic Casing Rule, Acronym Casing'}]",2
394576,Supportive Care,Prevention Of Taxane Chemotherapy Induced Nail Changes And Peripheral Neuropathy By Application Of Extremity Cooling: A Prospective Single Center Study With Intrapatient Comparison,Peripheral Neuropathy,Peripheral Neuropathy,,True,none,"Step 1: The abstract title was selected as the primary source because it contains specific medical terms, unlike the generic session title ""Supportive Care"".
Step 2: The abstract title mentions ""Taxane Chemotherapy Induced Nail Changes"" and ""Taxane Chemotherapy Induced Peripheral Neuropathy"". These are identified as complications or adverse effects resulting from a treatment (chemotherapy).
Step 3: According to the generic exclusion rules, 'Complications or adverse effects' should always be excluded from the final indication. The focus of the study is on preventing these side effects, which falls under supportive care, rather than treating a primary disease.
Step 4: Since the only potential conditions mentioned in the title are excluded by the rules, and the session title is too broad, no valid medical indication can be extracted.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': 'Initial check to see if treatment-induced conditions are handled as a specific patient subgroup. The retrieved rules did not apply, reinforcing the decision to use the generic exclusion rule.'}]","[{'component': 'Taxane Chemotherapy Induced Nail Changes', 'type': 'Adverse Effect', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}, {'component': 'Taxane Chemotherapy Induced Peripheral Neuropathy', 'type': 'Adverse Effect', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude complications or adverse effects.'}]",3
394584,Supportive Care,Initial Geriatric Assessment And Chemotherapy Tolerability Treatment In Brazilian Patients With Malignant Neoplasm Of The Digestive System.,Malignant;;Neoplasm,Malignant Neoplasm,Geriatric Malignant Neoplasm of the Digestive System,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as it contains a specific disease ('Malignant Neoplasm Of The Digestive System'), whereas the session title ('Supportive Care') is a general therapeutic area.
2. **Component Identification**: The key components identified in the abstract title were the disease 'Malignant Neoplasm Of The Digestive System' and the patient subgroup 'Geriatric'. The descriptor 'Brazilian Patients' was also identified.
3. **Rule Retrieval**: Rules for the 'Age Group' category were retrieved to handle the term 'Geriatric'.
4. **Rule Application**:
   - **Generic Exclusion Rule**: The sociodemographic descriptor 'Brazilian' was excluded as per the generic rules.
   - **Generic Formatting Rule**: The disease name was converted to Title Case, with prepositions like 'of' and 'the' remaining in lowercase.
   - **Age Group Rule (Geriatric)**: Based on the retrieved rules (e.g., ID 320), 'Geriatric' was identified as an age-group qualifier and prepended to the disease name.
   - **Exclusion of Non-Diagnostic Items**: The phrases 'Initial Geriatric Assessment' and 'Chemotherapy Tolerability Treatment' were excluded as they describe study methodology and procedures, not the core indication.
5. **Indication Construction**: The components were combined according to the rules, resulting in 'Geriatric' + 'Malignant Neoplasm of the Digestive System'.
6. **Final Quality Check**: The final indication adheres to all formatting and clinical accuracy requirements. It is singular, in Title Case, and correctly includes the patient subgroup while excluding non-essential information.","[{'category': 'Age Group', 'subcategories': ['Elderly'], 'reason': ""To correctly handle the patient descriptor 'Geriatric'.""}]","[{'component': 'Geriatric', 'type': 'Age Group', 'normalized_form': 'Geriatric', 'rule_applied': ""Age Group rule for 'Geriatric' (ID: 320, 321)""}, {'component': 'Malignant Neoplasm Of The Digestive System', 'type': 'Disease', 'normalized_form': 'Malignant Neoplasm of the Digestive System', 'rule_applied': 'Generic Casing Rule'}, {'component': 'Brazilian Patients', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule for Ethnicity/Region'}]",2
263513,From biology to preclinical models in ALL,Ubtf-Atxn7L3 Gene Fusion Due To 17Q21.31 Deletion Defines Novel High-Risk All Subtype Amenable To Mrd-Based Treatment Intensification,High-Risk;;All,High-Risk Acute Lymphoblastic Leukemia,Ubtf-Atxn7L3 Fusion-Positive High-Risk Acute Lymphoblastic Leukemia,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title was chosen as it contains a specific disease ('All') and detailed patient subgroup information, making it superior to the more general session title, in accordance with the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were 'Ubtf-Atxn7L3 Gene Fusion', '17Q21.31 Deletion', 'High-Risk', and 'All'.
3.  **Rule Retrieval**: I retrieved rules for the 'High-Risk' category, which confirmed that 'High-Risk' should be normalized to title case and prepended to the disease name.
4.  **Component Normalization and Application**:
    *   **Disease**: The abbreviation 'All' was expanded to its full, clinically standard name 'Acute Lymphoblastic Leukemia' and converted to singular form.
    *   **Risk**: Based on the retrieved rules and generic formatting, 'High-Risk' was kept as a prefix to the disease.
    *   **Genetic Marker**: The title states that the 'Ubtf-Atxn7L3 Gene Fusion' *defines* the subtype. This is the most critical patient subgroup characteristic. I formatted this using the standard convention '-Positive' to create 'Ubtf-Atxn7L3 Fusion-Positive'. The underlying cause ('17Q21.31 Deletion') was excluded to maintain conciseness, as the gene fusion is the direct defining feature of the subtype.
5.  **Exclusions**: The term 'Novel' was excluded as it describes the research finding, not the clinical condition. The phrase 'Amenable To Mrd-Based Treatment Intensification' was excluded as it describes a procedural/methodological context, not the indication itself.
6.  **Final Construction**: The normalized components were assembled in the standard order (genetic marker -> risk level -> disease) to form the final indication: 'Ubtf-Atxn7L3 Fusion-Positive High-Risk Acute Lymphoblastic Leukemia'. This indication is clinically precise, follows all formatting rules, and accurately reflects the specific disease subtype described in the source title.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the formatting and placement of the 'High-Risk' qualifier.""}]","[{'component': 'Ubtf-Atxn7L3 Gene Fusion', 'type': 'Gene Fusion', 'normalized_form': 'Ubtf-Atxn7L3 Fusion-Positive', 'rule_applied': 'Standard clinical formatting for genetic markers defining a subtype.'}, {'component': 'High-Risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule ID 122: Normalize and attach to the disease entity.'}, {'component': 'All', 'type': 'Disease', 'normalized_form': 'Acute Lymphoblastic Leukemia', 'rule_applied': 'Generic Rule: Abbreviation expansion and singular form.'}]",3
345435,Tumor Organoids for Therapeutic Testing,Cellos: High-throughput deconvolution of 3D organoid dynamics at cellular resolution for cancer pharmacology,,,Cancer,True,abstract_title,"Step 1: The abstract title contains the term 'cancer', which is a valid disease. According to the single-source principle, the abstract title is prioritized over the session title.
Step 2: The relevant phrase in the abstract title is 'cancer pharmacology'. The term 'pharmacology' describes a field of study, not a patient or disease characteristic, and is therefore excluded.
Step 3: The core disease term 'cancer' is extracted.
Step 4: Applying the generic formatting rules, 'cancer' is converted to Title Case, resulting in 'Cancer'. The term is already in singular form. This aligns with the Therapeutic Area Fallback rule where 'Oncology' maps to 'Cancer'.",[],"[{'component': 'cancer', 'type': 'Disease', 'normalized_form': 'Cancer', 'rule_applied': 'Generic Rule: Title Case; Generic Rule: Therapeutic Area Fallback'}]",1
230744,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers.,cancer-associated;;thrombosis;;biliary tract cancers,Cancer-Associated Thrombosis;;Biliary Tract Cancer,Biliary Tract Cancer;;Cancer-Associated Thrombosis,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: Both the abstract title and session title contain disease terms. According to the single-source extraction principle, the abstract title is the preferred source.
2.  **Select Source**: The abstract title, ""Genomic determinants and clinical relevance of cancer-associated thrombosis in biliary tract cancers,"" was selected.
3.  **Identify Components**: The title contains two distinct medical conditions: ""cancer-associated thrombosis"" and ""biliary tract cancers"".
4.  **Retrieve Rules**: I checked for rules regarding multiple diseases. The generic rules specify that multiple distinct diseases should be extracted and separated by ';;'.
5.  **Apply Rules & Construct Indication**:
    *   The term ""biliary tract cancers"" was normalized. The plural ""cancers"" was converted to the singular ""Cancer"" and Title Case was applied, resulting in ""Biliary Tract Cancer"".
    *   The term ""cancer-associated thrombosis"" was normalized by applying Title Case, resulting in ""Cancer-Associated Thrombosis"".
    *   The two indications were combined using the ';;' separator as per the generic rule for multiple diseases.
6.  **Quality Check**: The final indication adheres to all formatting and content rules. It correctly identifies both clinical conditions mentioned in the source title and excludes non-diagnostic terms like ""Genomic determinants"" and ""clinical relevance"".","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To confirm the correct procedure for handling two distinct diseases mentioned in the same title.'}]","[{'component': 'biliary tract cancers', 'type': 'Disease', 'normalized_form': 'Biliary Tract Cancer', 'rule_applied': 'Generic Rule: Singular Form; Generic Rule: Casing Rules'}, {'component': 'cancer-associated thrombosis', 'type': 'Disease', 'normalized_form': 'Cancer-Associated Thrombosis', 'rule_applied': 'Generic Rule: Casing Rules'}]",2
197976,Poster Session I (In-Person),Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma,Trauma,Trauma,,True,none,"Step 1: The abstract title was selected as the potential source because the session title is generic ('Poster Session I (In-Person)') and contains no medical terms.
Step 2: The abstract title 'Early-Life Trauma Exposure: The Role of vmPFC in Resilience to Trauma' was analyzed. The key term identified was 'Trauma'.
Step 3: The term 'Trauma' in this context refers to 'Trauma Exposure', which is an event or an exposure, and 'Resilience to Trauma', which is a physiological process. According to the generic exclusion rules, exposures and physiologic processes are not considered clinically valid medical indications.
Step 4: The title does not specify a diagnosable disorder resulting from trauma (e.g., Post-Traumatic Stress Disorder). Therefore, a specific, clinically valid indication cannot be extracted.
Step 5: Since neither the abstract title nor the session title provides a valid medical indication, the generated indication is empty.","[{'category': 'Onset', 'subcategories': ['Onset by Age'], 'reason': ""To check for rules on handling 'Early-Life' as a potential onset qualifier.""}]","[{'component': 'Trauma Exposure', 'type': 'Exposure', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude exposures.'}, {'component': 'Resilience to Trauma', 'type': 'Physiologic Process', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude physiologic processes.'}]",2
296288,"Head and neck cancer, excluding thyroid",Real World Evidence of First-line Cetuximab (CX) plus Paclitaxel (PX) in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),Recurrent;;Metastatic;;Squamous Cell Carcinoma of the Head and Neck,Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,True,abstract_title,"Step-by-step extraction process:
1. **Source Selection**: The abstract title was chosen as the source because it contains a specific disease ('Squamous Cell Carcinoma of the Head and Neck'), which is more precise than the broader category in the session title ('Head and neck cancer').
2. **Component Identification**: I identified the following components in the abstract title: the disease 'Squamous Cell Carcinoma of the Head and Neck', the occurrence qualifiers 'Recurrent or Metastatic', and the treatment context 'First-line'.
3. **Rule Retrieval**: I retrieved rules for 'Occurrence' and 'Treatment Set-up'.
4. **Rule Application and Construction**:
   - **Disease**: The disease name 'Squamous Cell Carcinoma of the Head and Neck' was normalized to Title Case.
   - **Occurrence Qualifiers**: The phrase 'Recurrent or Metastatic' was normalized to 'Recurrent/Metastatic' based on standard rules for combining disease state qualifiers (e.g., Rule ID 139).
   - **Treatment Context**: The term 'First-line' was identified. According to the retrieved 'Line of treatment' rules (e.g., Rule ID 199), line-of-treatment descriptors must be excluded when they are immediately followed by a specific drug name. In the title, 'First-line' is followed by 'Cetuximab (CX) plus Paclitaxel (PX)', so it was excluded from the final indication.
   - **Assembly**: The normalized components were combined to form the final indication.
5. **Quality Check**: The final indication was checked against all generic rules. It adheres to the single-source principle, uses Title Case, is in singular form, and correctly excludes the treatment-line descriptor. The result is a clinically accurate and well-formatted indication.","[{'category': 'Occurrence', 'subcategories': ['Recurrence-Related Terms', 'Metastasis-Related Terms', 'Recurrent/Refractory'], 'reason': ""To handle the terms 'Recurrent or Metastatic' and format them correctly.""}, {'category': 'Treatment Set-up', 'subcategories': ['Line of treatment'], 'reason': ""To determine whether to include or exclude the 'First-line' descriptor.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check for any specific rules related to 'Squamous Cell Carcinoma'.""}]","[{'component': 'Recurrent or Metastatic', 'type': 'Occurrence', 'normalized_form': 'Recurrent/Metastatic', 'rule_applied': ""Occurrence rule (ID 139) for concatenating multiple qualifiers with a '/'.""}, {'component': 'Squamous Cell Carcinoma of the Head and Neck', 'type': 'Disease', 'normalized_form': 'Squamous Cell Carcinoma of the Head and Neck', 'rule_applied': 'Generic rule for Title Case.'}, {'component': 'First-line', 'type': 'Line of Treatment', 'normalized_form': '', 'rule_applied': 'Treatment Set-up rule (ID 199) to exclude line-of-treatment when followed by a specific drug name.'}]",2
230749,"Gastrointestinal Cancer-Gastroesophageal, Pancreatic, and Hepatobiliary",Clinical utility of immunotherapy hyperprogressive genes in hepatocellular carcinoma patients.,hepatocellular carcinoma,Hepatocellular Carcinoma,Hyperprogressive Hepatocellular Carcinoma,True,abstract_title,"Step 1: The abstract title contains a specific disease ('hepatocellular carcinoma'), so it is selected as the source over the more general session title, following the single-source principle.
Step 2: The components identified in the abstract title are the disease 'hepatocellular carcinoma' and the qualifier 'hyperprogressive'.
Step 3: To correctly format the qualifier, I retrieved rules for disease progression by calling `get_indication_rules(category='Occurrence', subcategories=['Progression-Related'])`. While no specific rule for 'hyperprogressive' exists, the rules for similar terms like 'Progressive' and 'Oligoprogressive' indicate that such qualifiers should be prepended to the disease name in Title Case.
Step 4: Applying this pattern and the generic rules, 'hyperprogressive' is normalized to 'Hyperprogressive', and 'hepatocellular carcinoma' is converted to 'Hepatocellular Carcinoma'. The term 'patients' is excluded as per generic rules.
Step 5: The final indication is constructed by combining the normalized qualifier and the disease name.
Step 6: A quality check confirms the indication adheres to all formatting and clinical accuracy requirements.","[{'category': 'Occurrence', 'subcategories': ['Progression-Related'], 'reason': ""To determine the correct formatting for the term 'hyperprogressive' by checking rules for similar progression-related keywords.""}]","[{'component': 'hyperprogressive', 'type': 'Disease Qualifier', 'normalized_form': 'Hyperprogressive', 'rule_applied': ""Analogy from Progression-Related rules (e.g., 'Progressive' rule ID: 184) and Title Case rule.""}, {'component': 'hepatocellular carcinoma', 'type': 'Disease', 'normalized_form': 'Hepatocellular Carcinoma', 'rule_applied': 'Title Case rule and Singular Form rule (already singular).'}]",2
279909,Pediatric hematology: Immunodeficiency-related lymphoproliferative disorders,Classification of immunodeficiency-related lymphoproliferative disorders,immunodeficiency-related lymphoproliferative disorders,Immunodeficiency-Related Lymphoproliferative Disorder,Pediatric Immunodeficiency-Related Lymphoproliferative Disorder,True,session_title,"Step-by-step extraction process:
1. **Analyze Titles**: Both the abstract and session titles contain the disease term 'Immunodeficiency-related lymphoproliferative disorders'. The session title also includes the patient subgroup 'Pediatric'.
2. **Select Source**: Based on the Single-Source Extraction Principle, the session title is chosen as it provides a more specific and complete indication by including the patient subgroup.
3. **Identify Components**: The selected source contains the disease 'Immunodeficiency-related lymphoproliferative disorders' and the age group 'Pediatric'.
4. **Retrieve Rules**: The `get_indication_rules` tool was used for the 'Age Group' category with the subcategory 'Pediatric' to ensure correct formatting.
5. **Apply Rules**: 
   - The retrieved rule (ID: 295) confirms that 'Pediatric' should be used as a prefix.
   - The generic rule for singular form was applied, converting 'disorders' to 'Disorder'.
   - The generic rule for Title Case was applied to the entire indication.
   - The term 'hematology' is a broad therapeutic area and is excluded in favor of the more specific disease name.
6. **Construct Indication**: The components were combined according to the rules, resulting in 'Pediatric Immunodeficiency-Related Lymphoproliferative Disorder'.
7. **Quality Check**: The final indication was verified against all formatting, inclusion, and exclusion criteria.","[{'category': 'Age Group', 'subcategories': ['Pediatric'], 'reason': ""To confirm the correct formatting and placement of the 'Pediatric' age group qualifier.""}]","[{'component': 'Pediatric', 'type': 'Age Group', 'normalized_form': 'Pediatric', 'rule_applied': 'Age Group Rule ID: 295'}, {'component': 'Immunodeficiency-related lymphoproliferative disorders', 'type': 'Disease', 'normalized_form': 'Immunodeficiency-Related Lymphoproliferative Disorder', 'rule_applied': 'Generic Singular Form Rule, Generic Title Case Rule'}]",2
378207,Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden,Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL,CLL,Chronic Lymphocytic Leukemia,Infection;;Chronic Lymphocytic Leukemia,True,abstract_title,"Step-by-step extraction process:
1. **Analyze Input Titles**: The abstract title is 'Interactive Panel Discussion: Challenging Cases Involving Infections Associated with CLL' and the session title is 'Interactive Session: Chronic Lymphocytic Leukemia (CLL) and Beyond - Management of the Infection Burden'.
2. **Select Source**: Both titles contain disease terms. According to the single-source principle, the abstract title is the preferred source. It contains 'Infections' and 'CLL'.
3. **Identify Components**: The abstract title identifies two distinct clinical conditions: 'Infections' and 'CLL'. The phrase 'Associated with' links them, indicating co-occurrence.
4. **Retrieve Relevant Rules**: I retrieved rules for 'Patient with two different Disease' to understand how to handle co-occurring conditions and 'Occurrence' for connector words. The retrieved rules did not specifically cover 'Associated with', so I fell back to the generic rule for multiple diseases.
5. **Apply Rules**:
   - **Generic Rule (Multiple Diseases)**: The title mentions two distinct conditions, 'Infections' and 'CLL'. They must be extracted as separate indications, delimited by ';;'.
   - **Generic Rule (Singular Form)**: The plural 'Infections' is converted to its singular form, 'Infection'.
   - **Generic Rule (Casing)**: All terms are converted to Title Case.
   - **Standardization**: The abbreviation 'CLL' is expanded to its full name, 'Chronic Lymphocytic Leukemia', for clinical clarity. This is supported by the context from the session title.
6. **Construct Indication**: The identified and normalized components are combined using the ';;' separator, resulting in 'Infection;;Chronic Lymphocytic Leukemia'.
7. **Quality Check**: The final output adheres to all formatting and content rules. It correctly identifies both clinical conditions from the chosen source, uses the correct separator, and applies proper casing and singularization.","[{'category': 'Patient with two different Disease', 'subcategories': [''], 'reason': ""To check for rules on how to handle two diseases mentioned together, linked by 'Associated with'.""}, {'category': 'Occurrence', 'subcategories': ['Connectors'], 'reason': ""To check if 'Associated with' is a standard connector with specific formatting rules.""}]","[{'component': 'Infections', 'type': 'Disease', 'normalized_form': 'Infection', 'rule_applied': 'Generic Rule: Singular Form'}, {'component': 'CLL', 'type': 'Disease', 'normalized_form': 'Chronic Lymphocytic Leukemia', 'rule_applied': 'Standardization of abbreviation to full disease name.'}, {'component': 'Associated with', 'type': 'Connector', 'normalized_form': ';;', 'rule_applied': ""Generic Rule: Multiple Diseases - indicates two separate conditions to be delimited by ';;'.""}]",3
394614,Supportive Care,"Mortality Within 30 Days After Last Dose Of Intravenous Systemic Anti-Cancer Therapy: Single-Center, One-Year, Retrospective Analysis",,,Cancer,True,abstract_title,"Step 1: The abstract title contains the term 'Anti-Cancer Therapy', which points to a disease context, while the session title 'Supportive Care' does not specify a disease. Therefore, the abstract title is selected as the source.
Step 2: The term 'Anti-Cancer Therapy' implies the therapeutic area is Oncology. According to the generic rules (Therapeutic Area Fallback), when a specific disease is not named, the overarching disease for Oncology should be used.
Step 3: The generic rule states 'Oncology' -> 'Cancer'.
Step 4: All other parts of the title, such as 'Mortality Within 30 Days After Last Dose', describe study outcomes or methodology and are excluded as per the exclusion rules.
Step 5: The final indication is formatted to Title Case and singular, resulting in 'Cancer'.",[],"[{'component': 'Anti-Cancer Therapy', 'type': 'Therapeutic Area', 'normalized_form': 'Cancer', 'rule_applied': 'Therapeutic Area Fallback'}]",3
214394,MP58: Prostate Cancer: Detection & Screening VII,ATM mutations are associated with high-risk architectural features in men with familial prostate cancer,familial;;prostate cancer,Familial Prostate Cancer ,Familial ATM-Mutated High-Risk Prostate Cancer,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: Both the abstract and session titles mention 'Prostate Cancer'. The abstract title is more specific, containing details about gene mutations, risk, and patient subgroups, so it was chosen as the source based on the single-source principle.
2.  **Component Identification**: The key components identified in the abstract title were 'ATM mutations' (gene mutation), 'high-risk' (risk stratification), 'familial' (patient subgroup), and 'prostate cancer' (disease). The term 'men' was identified as a sociodemographic descriptor to be excluded.
3.  **Rule Retrieval**: I retrieved rules for 'Gene type' to handle 'ATM mutations', 'Risk' for 'high-risk', and 'Patient Sub-Group' for 'familial'.
4.  **Rule Application**: 
    *   **Exclusion Rule**: The gender descriptor 'men' was removed.
    *   **Gene Type Rule**: 'ATM mutations' was normalized to 'ATM-Mutated' based on the retrieved rule for gene mutations.
    *   **Risk Rule**: 'high-risk' was normalized to 'High-Risk'.
    *   **Patient Subgroup Rule**: 'familial' was normalized to 'Familial' and identified as a primary qualifier.
    *   **Formatting Rules**: The final indication was converted to Title Case and singular form.
5.  **Indication Construction**: The normalized components were combined in a clinically logical order: Patient Subgroup -> Gene Mutation -> Risk -> Disease. This resulted in 'Familial ATM-Mutated High-Risk Prostate Cancer'. The phrasing of the title suggests these are all characteristics of the patient population being studied.
6.  **Quality Check**: The final indication was reviewed to ensure it adheres to all formatting, inclusion, and exclusion criteria, resulting in a high-confidence, clinically valid indication.","[{'category': 'Gene type', 'subcategories': ['Gene type'], 'reason': ""To correctly format the 'ATM mutations' component.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To correctly format the 'high-risk' component.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Familial'], 'reason': ""To correctly format the 'familial' component.""}]","[{'component': 'ATM mutations', 'type': 'Gene Mutation', 'normalized_form': 'ATM-Mutated', 'rule_applied': ""Gene type rule for 'Gene Mutation' (ID: 30)""}, {'component': 'high-risk', 'type': 'Risk', 'normalized_form': 'High-Risk', 'rule_applied': 'Risk rule for standardizing risk levels.'}, {'component': 'familial', 'type': 'Patient Sub-Group', 'normalized_form': 'Familial', 'rule_applied': ""Patient Sub-Group rule for 'Familial' (ID: 392)""}, {'component': 'prostate cancer', 'type': 'Disease', 'normalized_form': 'Prostate Cancer', 'rule_applied': 'Generic rule for Title Case and singular form.'}, {'component': 'men', 'type': 'Sociodemographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for gender.'}]",2
394619,Supportive Care,Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors,Advanced;;High Grade;;Ovarian Carcinoma,Advanced High Grade Ovarian Carcinoma,Venous Thromboembolism;;Advanced High Grade Ovarian Carcinoma,True,abstract_title,"Step-by-step extraction process:
1.  **Source Selection**: The abstract title 'Venous Thromboembolism (Vte) In Patients With Advanced High Grade Ovarian Carcinoma (Ahgoc) Receiving Parp Inhibitors' was chosen over the session title 'Supportive Care' because it contains specific disease terms, adhering to the single-source principle.
2.  **Component Identification**: The abstract title identifies two distinct medical conditions: 'Venous Thromboembolism' and 'Advanced High Grade Ovarian Carcinoma'. The phrase 'In Patients With' indicates these are comorbidities.
3.  **Rule Retrieval**: I retrieved rules for 'Patient with two different Disease', 'Stage', 'Grade', and 'Treatment Set-up'.
4.  **Rule Application**: 
    *   **Multiple Diseases**: The generic rule for multiple diseases was applied, requiring both conditions to be extracted and separated by ';;'.
    *   **Grade**: The specific rule for 'High Grade' (ID: 115) confirmed it should be normalized to 'High Grade' and placed before the disease name.
    *   **Stage**: 'Advanced' was kept as a standard clinical qualifier for the carcinoma.
    *   **Exclusion**: The phrase 'Receiving Parp Inhibitors' was excluded as it describes a procedural/temporal treatment context, which is a standard exclusion criterion.
    *   **Formatting**: Abbreviations (Vte, Ahgoc) were removed, and the final output was formatted to Title Case and singular form as required.
5.  **Indication Construction**: The first indication was normalized to 'Venous Thromboembolism'. The second indication was constructed by combining the stage ('Advanced'), grade ('High Grade'), and disease ('Ovarian Carcinoma') to form 'Advanced High Grade Ovarian Carcinoma'. The two indications were then combined with the ';;' separator.
6.  **Final Quality Check**: The final output was reviewed for compliance with all formatting, accuracy, and completeness rules.","[{'category': 'Patient with two different Disease', 'subcategories': ['Patient with two different Disease'], 'reason': 'To handle the comorbidity context of VTE in patients with ovarian cancer.'}, {'category': 'Stage', 'subcategories': ['Stage Type'], 'reason': ""To check for rules regarding the term 'Advanced'.""}, {'category': 'Grade', 'subcategories': ['Grade'], 'reason': ""To apply the correct formatting for 'High Grade'.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To confirm the exclusion of 'Receiving Parp Inhibitors'.""}]","[{'component': 'Venous Thromboembolism (Vte)', 'type': 'Disease', 'normalized_form': 'Venous Thromboembolism', 'rule_applied': 'Generic rule: Remove abbreviations and apply Title Case.'}, {'component': 'Advanced High Grade Ovarian Carcinoma (Ahgoc)', 'type': 'Disease', 'normalized_form': 'Advanced High Grade Ovarian Carcinoma', 'rule_applied': ""Combination of generic rules (Title Case, remove abbreviation) and specific rule for 'High Grade' (ID: 115).""}, {'component': 'Receiving Parp Inhibitors', 'type': 'Treatment Context', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for procedural/temporal qualifiers.'}]",2
148877,Myeloma And Other Monoclonal Gammopathies - Clinical,Analysis Of Delay In The Diagnosis Of Multiple Myeloma In A Sanitary Region Of Southern Spain.,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step 1: The abstract title contains a specific disease term, 'Multiple Myeloma', so it is selected as the primary source over the session title, which contains broader terms ('Myeloma', 'Monoclonal Gammopathies').
Step 2: The disease term 'Multiple Myeloma' was identified in the abstract title.
Step 3: Generic exclusion rules were applied. The geographic descriptor 'Southern Spain' was identified and excluded from the final indication.
Step 4: Generic formatting rules were applied. The indication 'Multiple Myeloma' is already in the correct Title Case and singular form. No changes were needed.
Step 5: The final indication was constructed as 'Multiple Myeloma'.",[],"[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Casing and Singular Form rules'}, {'component': 'Southern Spain', 'type': 'Geographic Descriptor', 'normalized_form': '', 'rule_applied': 'Generic Sociodemographic Exclusion rule'}]",1
198028,Poster Session I (In-Person),Exposure to Prenatal Stress Induces Sex-Specific Vulnerability to Psychopathologic Domains in Adolescent Rats,,,,True,none,"The abstract title describes a study conducted in ""Adolescent Rats"", which is an animal model. Medical indications must be for human diseases. Additionally, ""Psychopathologic Domains"" is a broad, non-specific category rather than a clinically valid indication. The term ""Sex-Specific"" is a gender descriptor and is excluded by generic rules. The session title does not contain any disease information. Therefore, no valid indication can be extracted.","[{'category': 'Age Group', 'subcategories': ['Adolescent'], 'reason': ""To check rules for the keyword 'Adolescent'.""}, {'category': 'Risk', 'subcategories': ['Risk Types'], 'reason': ""To check rules for the keyword 'Vulnerability'.""}, {'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check rules for the keyword 'Psychopathologic'.""}]","[{'component': 'Adolescent Rats', 'type': 'Animal Model', 'normalized_form': '', 'rule_applied': 'Exclusion of non-human studies. A medical indication must be for a human disease.'}, {'component': 'Sex-Specific', 'type': 'Gender Descriptor', 'normalized_form': '', 'rule_applied': 'Generic exclusion rule for sociodemographic descriptors (gender).'}, {'component': 'Psychopathologic Domains', 'type': 'Non-Specific Disease Category', 'normalized_form': '', 'rule_applied': 'Exclusion of non-diagnostic items. The term is too broad and not a clinically valid indication.'}]",2
279967,Janssen: Immunotherapy: evolution or revolution in the cure of multiple myeloma,How will we treat high-risk multiple myeloma in the future?,high-risk;;multiple myeloma,High-Risk Multiple Myeloma,High-Risk Multiple Myeloma,True,abstract_title,"Step 1: The abstract title 'How will we treat high-risk multiple myeloma in the future?' was chosen as the source because it contains a specific disease and patient subgroup, making it more informative than the session title.
Step 2: The components identified in the abstract title were the disease 'multiple myeloma' and the risk qualifier 'high-risk'.
Step 3: The `get_indication_rules` tool was used for the category 'Risk' and subcategory 'High-Risk' to ensure correct formatting.
Step 4: The retrieved rule (ID: 122) confirmed that 'high-risk' should be normalized to 'High-Risk' and prepended to the disease name. Generic rules for Title Case ('Multiple Myeloma') and singular form were also applied.
Step 5: The components were combined to form the final indication 'High-Risk Multiple Myeloma'.
Step 6: A quality check confirmed adherence to all formatting, exclusion, and single-source principles.","[{'category': 'Risk', 'subcategories': ['High-Risk'], 'reason': ""To validate the correct formatting and placement of the 'high-risk' qualifier.""}]","[{'component': 'high-risk', 'type': 'Risk Qualifier', 'normalized_form': 'High-Risk', 'rule_applied': ""Rule ID 122: Normalize 'high-risk' to 'High-Risk'.""}, {'component': 'multiple myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic Rule: Apply Title Case to disease names.'}]",2
312718,Treatment - Types And Sites Of Breast Cancer: Brain Metastases,Efficacy And Safety Of Pyrotinib-Based Therapy In The Treatment Of Her2-Positive Breast Cancer Patients With Brain Metastases:A Multi-Center Real-World Study,Her2;;Positive;;Breast Cancer;;Brain Metastases,Brain Metastasis;;Her2-Positive Breast Cancer,HER2-Positive Breast Cancer with Brain Metastasis,True,abstract_title,"The extraction process followed these steps:
1. **Source Selection**: The 'abstract_title' was chosen over the 'session_title' as it provides a more detailed and specific description of the medical indication.
2. **Component Identification**: The key clinical components identified in the abstract title were 'Her2-Positive', 'Breast Cancer', and 'Brain Metastases'.
3. **Rule Application and Normalization**:
   - **Biomarker**: 'Her2-Positive' was identified as a biomarker. The standard format for gene symbols/biomarkers is all-caps, so it was normalized to 'HER2-Positive'.
   - **Disease**: 'Breast Cancer' is the core disease and is already in the correct singular, Title Case format.
   - **Metastasis**: 'Brain Metastases' describes a specific patient subgroup. The generic rule for singularization was applied, converting 'Metastases' to 'Metastasis'.
4. **Indication Construction**: The components were combined to form a single, clinically precise indication. The phrase 'Patients With' explicitly links the brain metastasis to the primary breast cancer, defining a specific patient population rather than two separate diseases. The final indication is structured as '[Biomarker] [Disease] with [Metastatic Site]'.
5. **Exclusions**: Non-clinical terms such as 'Efficacy And Safety', 'Pyrotinib-Based Therapy', 'Treatment Of', and 'Multi-Center Real-World Study' were excluded as per the generic rules.","[{'category': 'Occurrence', 'subcategories': ['Metastasis-Related Terms'], 'reason': ""To understand how to handle terms related to metastasis, which guided the decision to treat 'Brain Metastases' as a characteristic of the primary cancer.""}]","[{'component': 'Her2-Positive', 'type': 'Biomarker', 'normalized_form': 'HER2-Positive', 'rule_applied': 'Generic Casing Rule for Biomarkers'}, {'component': 'Breast Cancer', 'type': 'Disease', 'normalized_form': 'Breast Cancer', 'rule_applied': 'Generic Formatting Rule (Title Case, Singular)'}, {'component': 'Brain Metastases', 'type': 'Patient Subgroup (Metastasis)', 'normalized_form': 'Brain Metastasis', 'rule_applied': 'Generic Singular Form Rule'}]",4
329101,Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II,Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance,Multiple Myeloma,Multiple Myeloma,Multiple Myeloma,True,abstract_title,"Step-by-step extraction process:
1.  **Analyze Input Titles**: The abstract title is 'Free from Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal Residual Disease (MRD)-Driven Discontinuation of Maintenance'. The session title is 'Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster II'.
2.  **Select Source**: The abstract title contains the specific disease 'Multiple Myeloma'. According to the single-source principle, the abstract title is preferred and will be used exclusively.
3.  **Identify Components**: The core disease identified is 'Multiple Myeloma'. Other phrases include 'Free from Maintenance Drug Therapy', 'Minimal Residual Disease (MRD)-Driven', and 'Discontinuation of Maintenance'.
4.  **Retrieve Rules**: I retrieved rules for 'Patient Sub-Group' and 'Treatment Set-up' to determine how to handle the identified components.
5.  **Apply Rules**: 
    *   The core disease 'Multiple Myeloma' is kept. It is already in singular form and Title Case.
    *   'Free from Maintenance Drug Therapy' and 'Discontinuation of Maintenance' are procedural/temporal qualifiers describing the study's intervention, not the patient's baseline indication. Based on the generic exclusion rules, these are removed.
    *   'Minimal Residual Disease (MRD)-Driven' describes the methodology used to guide treatment decisions within the trial. It is not a standard patient subgroup that defines the indication itself. No specific rule mandates its inclusion, so it is excluded under the generic rule for non-diagnostic/methodological items.
6.  **Construct Indication**: After excluding the non-indication components, the only remaining element is the core disease.
7.  **Final Indication**: The final generated indication is 'Multiple Myeloma'.","[{'category': 'Patient Sub-Group', 'subcategories': ['Disease Characterisation'], 'reason': ""To check if 'Minimal Residual Disease (MRD)-Driven' is a standard patient subgroup.""}, {'category': 'Treatment Set-up', 'subcategories': ['Treatment Status'], 'reason': ""To verify how to handle terms like 'Free from Maintenance Drug Therapy' and 'Discontinuation of Maintenance'.""}]","[{'component': 'Multiple Myeloma', 'type': 'Disease', 'normalized_form': 'Multiple Myeloma', 'rule_applied': 'Generic rule: Identify core disease.'}, {'component': 'Free from Maintenance Drug Therapy', 'type': 'Procedural Qualifier', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude procedural/temporal qualifiers.'}, {'component': 'Minimal Residual Disease (MRD)-Driven', 'type': 'Study Methodology', 'normalized_form': '', 'rule_applied': 'Generic Exclusion Rule: Exclude non-diagnostic/methodological items.'}]",2
